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Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) 
play a central role in the promotion of longitudinal skeletal growth. The 
anabolic effects of these hormones involve many organ systems, including 
stimulation of protein synthesis and inhibition of protein catabolism, 
and regulation of lipolysis. Furthermore, GH and IGF-1 are involved in 
bone remodeling and muscle growth, but they also exert effects on joints. 
Several studies showed evidence for the involvement of GH and IGF-1 in 
longevity and ageing, suggesting that optimizing the GH / IGF-1 axis is of 
importance to promote healthy ageing in the general population. 
In this thesis, firstly, the long-term consequences of (transient) GH 
excess on bone and joints were studied in patients with biochemically 
controlled acromegaly. Secondly, the role of the GH / IGF-1 axis was 
investigated in patients with primary osteoarthritis (OA) having serum 
IGF-1 levels within the normal range. Finally, the long-term effects of 
recombinant human GH (rhGH) replacement in adult GH deficient 
(GHD) patients were studied, focusing on the cardiovascular consequences 
and the effects on bone metabolism.
GH physiology and regulation
GH is a single chain polypeptide hormone that is synthesized, stored, 
and secreted by somatotrope cells in the pituitary gland. In plasma, GH 
circulates freely or is bound to GH-binding protein (GHBP). GH is 
cleared via renal and hepatic mechanisms.
Control of GH secretion is regulated at the hypothalamic and the 
pituitary level by the interaction of stimulatory and inhibitory hormones, 
resulting in a diurnal and pulsatile secretion pattern. GH is especially 
released during sleep, stress and exercise (1;2). In addition, GH secretion 
is enhanced by thyroxin, sex steroids, cortisol, amino acids and fasting. 
GH secretion is inhibited by meals, glucose, free fatty acids, glucocorticoid 
excess and adiposity. GH secretion is highest in the late puberty; thereafter 
there is an age-dependent decline of GH production and –secretion. 
Estrogen affects GH action at the level of GH receptor (GHR) expression 
and signaling. It was shown that estrogens inhibit the JAK/STAT pathway 
and the activator of transcription signaling by GH via the induction of a 
cytokine suppressor (3), resulting in a higher GH/IGF-1 ratio in females 
when compared to males. Therefore, premenopausal women have higher 
ambulant GH levels than men; this difference disappears after menopause 
(4;5).
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Figure 1. Regulation of the GH / IGF-1 axis (Adapted from Pollak et al. Nat Rev Cancer 2004; 
4(7): 505-518) 
 
Hypothalamic Growth Hormone-Releasing Hormone (GHRH) 
stimulates GH gene transcription, GH cell proliferation and GH release. 
The hypothalamic inhibitory hormone somatostatin (SMS) acts via the 
binding to SMS receptors, and inhibits GH release from the secretory 
granules in the somatotropes and also inhibits GHRH release. In addition, 
there is a negative feedback loop of GH at the hypothalamic level, and of 
IGF-1 both at the level of the hypothalamus and the pituitary.
GH stimulates the production of IGF-1 in many organs, especially 
in the liver, which, in turn, mediates its effects primarily by the IGF-1 
receptor type 1 (6). IGF-1 is an important growth-promoting polypeptide 
with structural and functional homology to pro-insulin. IGF-1 mediates 
the effects of GH at tissue level and is a key factor for longitudinal skeletal 
growth (7). Serum IGF-1 concentrations reflect the GH concentrations 
over 24 hours. IGF-1 binding proteins regulate the bioavailability of 
IGF-1. Serum IGF-1 concentrations in adulthood decrease progressively 
with age and are influenced by many other factors, such as BMI (8;9). 
GH function
The primary effect of GH is the promotion of longitudinal skeletal 
growth. GH exerts its effects on the growth plate predominantly through 
stimulation of IGF-1 secretion (6). The anabolic actions of GH and 
IGF-1 involve many organ systems, including stimulation of protein 
synthesis and inhibition of protein catabolism, and regulation of lipolysis. 
Furthermore, GH is involved in bone remodeling, muscle growth, and 
immunomodulation. GH antagonizes the actions of insulin, resulting in 
glucose intolerance and hyperinsulinaemia. In contrast, IGF-1 has insulin-
like effects by enhancing peripheral glucose uptake. 
GHR and d3-GHR polymorphism 
Effects of GH on target tissues are mediated by the dimeric GH receptor 
(GHR). Three variants of the GHR that differ in the presence or absence of 
exon 3 (GHRfl-fl homodimer, GHRfl-d3 heterodimer, and GHRd3-d3 homodimer) 
are commonly seen in the general population (10). The function of exon 3 
is unknown, although the deletion is in close proximity to the GH binding 
site (11). The loss of exon 3 results in a truncated receptor. This truncation 
appears to have little effect on the receptor, since GHRfl-d3 and GHRd3-d3 
are stable, functional receptors with no significant differences in binding 
activity or internalization when compared to GHRfl-fl. However, the presence 
of at least one d3-allele is associated with increased GH responsiveness by 
enhanced signal transduction (12;13), which was shown to have functional 
consequences in various clinical conditions. This is illustrated in children with 
growth failure by increased growth velocity after recombinant human GH 
(rhGH) administration, and in acromegaly, a rare endocrine syndrome due 
to pathological GH oversecretion, in which d3-carriers showed an increased 
biochemical disease activity and worse clinical outcome (12;14-16). 
Effects of  GH and IGF-1 on carti lage and bone 
UNDERLYING MECHANISMS: GH and IGF-1 are important regulators 
of bone homeostasis, and play a central role in the achievement of normal 
longitudinal bone growth and bone mass. Although GH may act directly 
on skeletal cells, most of its effects are mediated by IGF-1, which is present 
in the systematic circulation and is synthesized by peripheral tissues and 
acts at later stages of chondrocyte maturation (17;18). Longitudinal bone 
growth is determined by chondrocyte proliferation and differentiation 
in the epiphyseal growth plate of long bones, resulting in endochondral 
bone formation. Within the growth plate, chondrocyte proliferation, 
hypertrophy and differentiation result in chondrogenesis. The newly 
formed cartilage is invaded by blood vessels, and it is modeled into bone 
trabeculae. This endochondral ossification process is regulated by genetic 
and hormonal factors, the cellular environment, and nutrition (19). GH 
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is a main stimulator of chondrocyte proliferation in the growth plate, and, 
to a lesser extent, of ECM secretion and the hypertrophic switch of post-
proliferative chondrocytes. These effects are predominantly mediated via 
the secretion of IGF-1.
In addition to the effects on longitudinal growth, GH and IGF-1 are 
anabolic hormones and have the potential to regulate bone modeling 
and remodeling (Figure 2). GH stimulates the proliferation of cells of 
the osteoblastic lineage, although IGF-1 is required for selected anabolic 
effects of GH in osteoblasts (20;21). GH also stimulates the expression of 
bone morphogenetic proteins, which are important for the differentiation 
of osteoblasts and for bone formation (22). Bone remodeling is a 
temporary regulated process of coordinated bone resorption and bone 
formation carried out in microscopic basis multicellular units (23;24). 
There, multinucleated osteoclasts are attracted to specific sites to resorb 
bone. When resorption is completed, there is a reversal period and 
mononuclear osteoblasts are attracted to fill the cavity with newly 
synthesized matrix. This is followed by a resting phase. Bone remodeling 
is essential to maintain calcium homeostasis and to remove potentially 
damaged bone. Critical to these events are the receptor activator of 
nuclear factor kB ligand (RANK-L) and its decoy receptor osteoprotegerin 
(25;26). RANK-L is synthesized by osteoblastic stromal cells and induces 
osteoclast formation. Osteoprotegerin binds RANK-L and competes 
with the RANK-L receptor, therefore impairing osteoclastogenesis. 
IGF-1 induces RANK-L synthesis (27;28), whereas the induction of 
osteoprotegerin by GH may temper these effects (29). The fact that IGF-1 
has a dual role enhancing bone formation and bone resorption may 
explain why it has modest effects on BMD. 
Bone modeling occurs especially during growth, and is often regulated 
by mechanical forces, serving to maintain bone shape and mass. GH and 
IGF-1 exert their anabolic actions on trabecular and cortical bone, and 
are important for the acquisition of bone mass during adolescence and 
possibly for the maintenance of skeletal architecture during adult life. Late 
adolescence and early adulthood are critical periods for the acquisition 
of bone mass, and the achievement of peak bone mass (30;31), being an 
essential determinant of future risk of osteoporosis (30). 
 
Figure 2. The effects of GH and IGF-1 on bone (Adapted from Giustina et al. End Rev 2008 
(5):535-559)
FGF, Fibroblast growth factor; E2, estradiol; OPG, osteoprotegerin
Acromegaly 
Acromegaly is a rare endocrine disease in which patients have elevated 
GH and IGF-1 concentrations, caused by a pituitary adenoma in most 
cases (32). The clinical characteristics of acromegaly were first described 
by Pierre Marie in 1886 (33). Prevalence of acromegaly is 60 – 70 cases 
per million and incidence is 3 – 4 cases per million a year (34;35), but the 
disease is likely to be under diagnosed. 
Pathogenesis and Anatomy 
Both GH and GHRH hypersecretion can induce acromegaly. Pituitary 
GH-secreting adenomas are responsible for 98% of the acromegaly 
cases (36). In a minority of these (~1%), GHRH secreting bronchial 
or gastrointestinal carcinoid tumors cause secondary somatotrope 
hyperplasia, and consequently, acromegaly. 
The pituitary gland lies within the sella turcica, close to the 
hypothalamus and the optic chiasm and is connected to the hypothalamus 
via the pituitary stalk (Figure 3). The pituitary gland consists of 
the anterior lobe (adenohypophysis, 80%) and the posterior lobe 
(neurohypophysis, 20%). The cell types in the anterior lobe are the 
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somatotropes (50%), which produce GH, lactotropes (20%) which 
produce prolactin, corticotropes (10%) which produce adenocorticotrope 
hormone (ACTH), thyrotropes (10%) producing thyroid-stimulating 
hormone (TSH) and gonadotropes (10%), which produce follicle-
stimulating hormone (FSH) and luteinizing hormone (LH). Most 
GH-producing pituitary tumors produce only GH, while mixed GH 
and prolactin production is present in 30% of cases. A minority of GH-
producing tumors also produces TSH or α-subunits. 
Pituitary tumors can be staged according to the Hardy-Wilson 
classification that is based on the grade of sella turcica enlargement and 
invasion (0-IV), and the presence of supra- and parasellar extension (A-E) 
(Figure 4). Most GH-producing microadenomas (defined as diameter 
<1cm) and macroadenomas (defined as diameter >1cm) with suprasellar 
extension have a reasonable chance of surgical cure, whereas chance of 
surgical cure is low in tumors invading the sellar floor or those with 
parasellar extension.  
 
Figure 3. Localization of the pituitary gland (Adapted from Gray’s Anatomy of the Human Body)
 
Figure 4. Hardy-Wilson classification of pituitary tumors (Adapted from Schutte et al. NTvNN 
2003(104);99-104)
Clinical signs and symptoms
 Due to the insidious clinical manifestation of GH excess, acromegaly is a 
disease with a typical delayed diagnosis, approximately 10 years from the 
onset of symptoms (37;38). Symptoms associated with acromegaly can 
be subdivided in symptoms related to GH hypersecretion, those related 
to either hyperprolactinaemia or hypopituitarism, and local mass effects 
related to tumor size.  
Changes in appearance derive from skeletal growth and soft-tissue 
enlargement. Facial changes include enlarged lips and nose, and 
macroglossia, which can cause excessive snoring and obstructive sleep 
apnea. In addition, frontal skull bossing and cranial ridges, mandibular 
overgrowth with prognatism, maxillary widening with teeth separation, 
jaw malocclusion, and overbite are frequently seen. Furthermore, ring 
and shoe sizes increase over time (38). Skin thickening is noticed mainly 
in the face, hands and feet. Hypertrophy of sebaceous and sweat glands 
with concomitant hypersecretion result in an oily and sweaty skin. Other 
clinical features are a low voice, tiredness, paresthaesias, and hirsutism. 
Arthropathy (i.e. pain, stiffness and functional limitations of the joints) 
is one of the presenting symptoms at diagnosis in 50 – 70% of patients, 
and is also frequently observed in patients after cure of acromegaly (See 
Thesis M.J.E. Wassenaar, Acromegaly: irreversible consequences). The stature 
of the patient is characterized by kyphoscoliosis, and increased weight 
(39). Many patients suffer from carpal tunnel syndrome. In addition, 
prevalence of vertebral fractures, especially the wedge type, is high, despite 
normal bone mineral density (BMD) (40-42). 
Important cardiovascular and metabolic manifestations of acromegaly 
include cardiomyopathy, valvular abnormalities, hypertension, diabetes 
mellitus type 2 (DM2), and an impaired glucose tolerance (43-46), which 
predominantly account for the 2 – 3 fold increased mortality risk in 
active acromegalics (47-51). In addition, the prevalence of malignancies, 
specifically of the gastro-intestinal tract, is increased (49). 
Hyperprolactinaemia is present in approximately 30% of patients, 
either due to compression of the pituitary stalk by a macroadenoma with 
suprasellar extension or due to combined secretion of GH and prolactin 
(52). In patients with macroadenomas, hypopituitarism occurs in 
approximately 40% of patients by mass compression of normal pituitary 
tissue. This results in amenorrhea or impotence, or secondary thyroid or 
adrenal failure (53-55). Other local tumor effects include headache, visual 
field defects with typical (bitemporal) hemianopsia, and sporadically 
dysfunction of cerebral nerves.     
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DIAGNOSIS: Most acromegaly patients have elevated basal plasma GH 
and IGF-1 levels, although high GH concentrations can also be found in 
healthy subjects due to the episodic nature of GH secretion. Therefore, 
the diagnosis of acromegaly has to be confirmed by a glucose tolerance test 
(GTT), being the golden standard for the diagnosis of endogenous GH 
excess. In healthy controls, an oral glucose load of 75 grams suppresses 
serum GH to very low levels. In contrast, in active acromegaly, serum 
GH concentrations are insufficiently suppressed after glucose loading. 
In patients with uncontrolled DM or liver / renal diseases, in patients 
receiving estrogens, pregnant patients and during late adolescence, 
GTT outcome is unreliable (36). In the Leiden University Medical 
Center (LUMC), the normal GH suppression after GTT is <1mU/l (or 
<0.38µg/l), measured by IFMA, a highly sensitive assay for the 22 kDa 
protein (Wallac, Turku, Finland). 
MR imaging of the pituitary with contrast enhancement, is the most 
sensitive method for the visualization of a pituitary adenoma (2mm 
detection limits). In addition, MRI can visualize tumor dimensions, 
invasiveness and the relation to the optic chiasm. In the few cases with 
an extra-pituitary GH source, CT or MRI (or both) can be performed to 
localize the ectopic GH source (56). 
Treatment
Acromegaly treatment should aim at (1) relief of the symptoms of GH 
excess and mass effects of the pituitary tumor, (2) metabolic restoration, 
(3) reduction of the increased mortality risk and (4) improvement of the 
impaired QoL associated with active acromegaly. Several treatment options 
for acromegaly are currently available (57). 
Surgery
 Pituitary surgery is performed via the transsphenoidal route. Via the 
vestibulum nasi, and through the sphenoid sinus and the sellar floor. 
After opening of the basal dura mater, the tumor is selectively removed 
under microscopical guidance. The procedure is associated with a very 
low mortality and morbidity. Complications include meningitis and 
cerebrospinal fluid leaks (<1%), transient diabetes insipidus and (partial) 
hypopituitarism (<10%). After selective and complete tumor removal, 
GH secretion is reported to normalize completely (58-62). The success 
rate of surgery is 50 – 65% and is largely affected by the experience 
of the neurosurgeon and the tumor size (63). Microadenoma removal 
is successful in most cases (80 – 90%), but complete tumor removal 
becomes more difficult with increasing size and expansion of the adenoma. 
Non-invasive macroadenomas have surgical success rates of 40 – 60%, 
but removal of adenomas with parasellar invasion and growth into the 
sellar floor is successful only in 20 – 40% of cases. Repeat surgery is 
less successful than primary surgery (64). During prolonged follow-up, 
recurrence rate of acromegaly is 6 – 19% after surgery (47;65).
Radiotherapy 
Conventional radiotherapy is usually given in a total dose of approximately 
40 Gray (Gy) in at least 20 fractions. After radiotherapy, a 50% decline 
in GH levels was observed in the majority of patients within 2 years, 
and a 75% decline after 5 years (66-71). Remission rates of radiotherapy 
are dependent on the pre-irradiation serum GH concentration, and 
are, thus, positively affected by prior surgical debulking. The incidence 
of hypopituitarism increases with the time after radiotherapy, up to 
50 – 75% after long-term follow-up; however, lower incidence rates 
were reported with lower radiation doses (72). Optic nerve damage 
and secondary carcinogenesis are very rare (<2% within 20 years) (73). 
Following radiotherapy, recurrences are rarely observed. 
Other irradiation techniques are proton-beam irradiation and 
stereotactic radiosurgery (gamma knife) (74). With radiosurgery, a high 
single dose is administered at the stereotactically mapped region, resulting 
in precise ablation of the tumor and a lower dose on the surrounding 
tissue. Previous studies showed that after radiosurgery, GH decline is faster 
with a lower incidence of hypopituitarism in the short-term compared 
to conventional techniques (75). However, long-term data are currently 
unavailable (76;77).  
Medical treatment
SOMATOSTATIN ANALOGUES: Somatostatin (SMS) analogues have been 
the most important medical therapy for acromegaly for more than 15 
years (78). The currently used analogues, octreotide and lanreotide, inhibit 
GH secretion via the SMS receptor subtypes 2 and 5 (79)Somatostatin. 
Initially, SMS analogues were administered sc in a three-times-daily 
regimen or continuously infused sc by pump infusion. The introduction 
of long-acting release forms using monthly intramuscularly injectable 
microspheres of octreotide, the 1 – 2 weekly injections with lanreotide SR, 
and the more recent sc injection formula lanreotide Autogel for monthly 
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use has improved the treatment results and facilitated the use of these 
agents (80). Few side effects are observed, including bile stone formation, 
inhibition of insulin secretion (and therefore deterioration of glucose 
tolerance in a minority of patients), and gastro-intestinal complaints. 
These side effects are most importantly explained by the physiological 
actions of SMS.
Reduction of GH and IGF-1 levels during treatment with SMS 
analogues is observed in many patients, in which octreotide sensitivity 
and pre-treatment serum GH concentrations are predictive. In 20 – 50% 
of patients, SMS treatment results in reduction of tumor volume (80); 
however, pre-surgical medical treatment did not improve surgical outcome 
(81;82). SMS analogues have profound effects on clinical symptoms 
associated with active acromegaly, but, despite long-term stringent 
biochemical control of GH excess, subtle abnormalities in GH secretion 
persist (58). Recent studies indicate the potential biological relevance of 
these findings: impaired QoL and diastolic heart function when compared 
to surgically cured acromegaly patients (83;84). 
PEGVISOMANT: Pegvisomant is a GH analogue that antagonizes GH 
at the GHR site, blocking endogenous GH binding to its receptor and 
thereby blocking IGF-1 production (2). Although GH concentration 
increases, serum IGF-1 is effectively reduced in almost all patients (IGF-1 
normalization in 97% after 12 months (85)) with clinical effect. With 
respect to side effects, a major concern of Pegvisomant treatment is the 
growth of the pituitary adenoma due to disrupted feedback systems, which 
is in the short-term, however, only observed in a very small number of 
patients. Yearly monitoring of the adenoma size with MRI is advisable 
(85). In addition, monitoring of liver function is required, since during 
Pegvisomant therapy liver function abnormalities can develop. 
DOPAMINE AGONISTS: Dopamine agonists reduce GH secretion in a 
minority of patients (<20%) via an unknown mechanism (86;87), and are 
given orally in one or two weekly doses. Treatment response is better in 
patients with a mixed GH / prolactin producing adenoma. A minority of 
patients shows some tumor regression (20 – 50%) during therapy. Adverse 
effects are headache, dizziness and nausea. In 30 – 40% of patients who 
were not biochemically controlled by SMS analogue mono-therapy, 
co-treatment with cabergoline may be able to normalize serum IGF-1 
concentrations, irrespective of prolactin concentrations (88). 
Def inition of  disease control / disease remission
Biochemical criteria are largely dependent on the GH assay used, and, 
therefore, reference values should be determined in each laboratory. Nadir 
GH levels should be <1 µg/l, preferably <0.4 µg/l, in the 2 hours after 75 
gram oral glucose load during the GTT (36). Age- and gender-adjusted 
serum IGF-1 levels should be within normal ranges. Since IGF-1 has a 
long half-life and stable serum levels, it allows for assessment of disease 
activity. In this respect, several influencing factors such as age and blood 
glucose levels should be taken into account in the interpretation of IGF-1 
concentrations (89). 
A random (mean) serum GH concentration is also frequently used in 
the evaluation of disease activity in treated acromegaly. However, due to 
the pulsatile nature of GH secretion, a single high GH concentration does 
not always indicate active disease. Mean GH concentrations <2.5 µg/l are 
used in many studies as supportive marker of disease control. However, in 
30% of patients, a discrepancy between abnormal GH levels but normal 
serum IGF-1 levels is encountered (90).
The Leiden Acromegaly cohort
From 1977 onwards, all acromegaly patients that have been treated in 
the Leiden University Medical Center (LUMC), being a tertial referral 
center with dedicated pituitary surgeons, were collected in a database. 
In these patients, referred to as the Leiden Acromegaly cohort, detailed 
yearly follow-up was performed from the onset of acromegaly treatment 
over a long time period, enabling to assess the long-term outcome after 
acromegaly treatment. 
The first treatment option in the majority of patients was 
transsphenoidal surgery performed by a single specialized neurosurgeon. 
If necessary, adjuvant treatment consisted of radiotherapy (prior to 1985) 
or SMS analogs (from 1985 onwards). From 1998, some patients received 
depot formulations of long-acting SMS analogs as primary treatment. 
Since 2003, Pegvisomant was available for treatment-resistant acromegaly. 
This treatment approach resulted in early postoperative control in 66% 
and late control in 90% of patients (91). Surgery results, using strict 
criteria of remission, were excellent in these patients with a recurrence in 
19% of patients after achievement of postoperative remission. About 40% 
of patients remained in remission after only surgical intervention, even 
after more than 15 years of follow-up (65). 
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After establishment of disease control, biochemical analyses for follow-up 
were performed on a yearly basis by oral glucose tolerance tests (expect 
in medically treated patients), measurement of serum GH and IGF-1 
concentrations and evaluation of other pituitary functions.
Late ef fects of  acromegaly
Following appropriate treatment with surgery, radiotherapy and/or 
pharmacological therapy, many systemic co morbid conditions improve 
considerably (92). Unfortunately, despite biochemical control, it has 
become apparent that patients experience many manifestations of 
acromegaly during prolonged follow-up. The Center for Endocrine 
Tumors Leiden (CETL) of the LUMC has extensively reported on the 
Leiden Acromegaly cohort (as described above), showing that treated 
acromegaly patients suffer from a high prevalence of late effects of 
transient GH excess (see Thesis N.R. Biermasz, Acromegaly: Treatment 
and Follow-up / see Thesis M.J.E. Wassenaar, Acromegaly: Irreversible 
consequences). We observed a decreased (diastolic) heart function (84), 
more cardiac valve abnormalities (93), an increased prevalence of colonic 
diverticula (94), and also that patients suffered from severe skeletal 
manifestations, reflected in joints and bone as arthropathy and vertebral 
fractures (95;96). These late effects, which are hypothesized to be specific 
for previous GH-excess, significantly affect QoL and mortality (97;98). 
In this respect, two of the most prevalent and invalidating 
complications of acromegaly are arthropathy and vertebral fractures, which 
will be discussed below in more detail. The course of these complications 
during prolonged follow-up and potential (modifiable) risk factors for 
poor outcome are currently unknown.
Primary osteoarthritis
Osteoarthritis (OA) is a heterogeneous disease affecting the entire joint, 
and is characterized by gradual progressive loss of articular cartilage 
combined with increased metabolic activity in both the subchondral bone 
and bone at the joint margins. Soft tissue structures in and around the 
joint are also often affected. These include the synovium that may show 
signs of inflammation, the peri-articular ligaments, which are often lax, 
and bridging muscles, which become weak (99). OA most commonly 
involves the hand, knee, hip, first metatarsophalangeal (MTP) joints and 
facet joints in the spine. Disc degeneration of the spine, considered as an 
OA subtype, is also very common. 
OA has a multifactorial etiology, in which systemic and genetic risk 
factors determine an individual’s susceptibility for the impact of local 
biochemical risk factors. Well-known systemic factors include age and 
female sex. To date, it is unknown whether relatively high circulating GH 
and / or IGF-1 concentrations render patients more susceptible to primary 
OA. The exact pathogenesis of OA remains to be elucidated, but genetic 
influences contribute considerably to OA development and are most likely 
of a polygenic nature with modest effect sizes (99). Genetic factors play 
especially a role in generalized, hand, hip and spine OA developing at 
middle age and in OA developing before the age of 30 (100).
Epidemiology
OA is the most prevalent joint disorder in the world. In the Western 
world, OA ranks fourth in health impact among women and eighth 
in men (101). Symptomatic OA affects approximately 12% of persons 
between 25 and 75 years of age in the United States of America (U.S.A.) 
(102). Radiographic OA is even more common. In the Rotterdam Study, 
a population-based study amongst 917 women between 55 – 70 years of 
age, the prevalence of radiographic OA was 21% in the knee, 10% in the 
hip and 69% in the hand (103). OA is more common in women than in 
men, and prevalence and incidence increase with increasing age (99), with 
a peak onset between 50 – 60 years. 
Symptoms and signs of  OA
OA is one of the leading causes of disability in general population, 
resulting in substantial medical and social costs. From a clinical 
perspective, the most common and dominant symptom occurring in OA 
is joint pain, typically exacerbated by joint use and relieved by rest. The 
origin of joint pain is thought to be due to stimulation of pain receptors 
in the synovium, subchondral bone, as witnessed by associations between 
bone marrow lesions and joint pain, and surrounding tissues, such as 
periost, entheses and tendons (104). Other OA-related symptoms include 
morning stiffness and joint stiffening after a period of inactivity. The range 
of joint motion is often restricted and, in severe cases, the integrity of the 
joint may become disrupted, resulting in joint instability and functional 
limitations. 
Assessment of structural abnormalities in affected joints can be done 
radiographically (105). Typical radiographic features of OA are the 
presence of osteophytes (i.e. bony enlargements) on the joint margins, 
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joint space narrowing, subchondral sclerosis and cysts, and an altered 
shape of the bone ends (Figure 5) (101;106). There are several radiographic 
scoring methods available that are validated for the use in primary OA 
(research), including the classifications according to Kellgren & Lawrence 
and the Osteoarthritis Research Society International (OARSI) atlas 
(107;108). Radiographic deformities are not clearly related to clinical 
symptoms.
Figure 5. Radiographic features of osteoarthritis in the knee joint in a characteristic patient with 
primary OA (left) and acromegaly (right)
Left: Arthritic joint with typical structural features for patients with primary OA: both osteophytosis 
and severe joint space narrowing are shown, indicating cartilage loss. 
Right: A characteristic arthritic joint of an acromegaly patient is shown, with significant 
osteophytosis, but widened joint spaces, reflecting cartilage preservation / hypertrophy. 
Treatment
At present, there is no medical treatment available to prevent OA onset 
or to cure or delay the structural disease progression. Currently, OA 
treatment remains symptomatic, aiming to control pain and maintain 
or improve joint function. In case of persisting severe joint problems, 
replacement surgery can be taken into consideration (i.e. total knee or hip 
prosthesis). 
Assessment of  disease outcome in OA / Def inition of  OA 
progression: 
Different outcome measures can be used when assessing the change of 
OA over time. The change may be defined based upon the evaluation of 
symptoms (clinically) or structural abnormalities (radiographically). In the 
evaluation of OA symptoms, several domains can be considered, including 
pain, function, inflammation, range of motion, or QoL. Currently, 
conventional radiography is still the recommended imaging modality 
for the structural assessment of OA. Outcome measures should be valid, 
reliable and sensitive to change over time.
CLINICAL OUTCOME: With respect to the evaluation of changes in pain 
and joint function, several instruments are currently available. Depending 
on the joint site, pain can be evaluated by the use of a visual analog scale 
(VAS) or using the pain subscales of standardized questionnaires with 
questions concerning pain, such as the self-administered Western Ontario 
McMaster University (WOMAC) Index for lower limb OA (109) and 
Australian / Canadian (AUSCAN) Index for hand OA (110). Instruments 
measuring function outcome include the function subscales of the 
WOMAC and AUSCAN questionnaires. These instruments have been 
validated and shown to be reliable for the use in primary OA.
RADIOGRAPHIC OUTCOME: For changes in structural joint damage, 
experts in the field of primary OA have recommended individual 
radiographic features to be recorded as radiographic outcome. Comparing 
the severity of these individual OA features between at least two different 
time points assesses radiographic progression. Various methods or 
instruments are available for the assessment of radiographic outcomes.
Radiographic outcomes for hand OA are the changes in joint space 
narrowing and osteophytes, for example assessed by the use of the OARSI 
atlas (107). Also for the knee and hip, standardized atlases can be used for 
semi-quantification of osteophytes and joint space narrowing in each joint 
compartment (111). In addition, joint space width can be assessed in mm, 
using manual or semi-automatic computerized methods. Radiographic 
scoring of the spine can be assessed using the Kellgren & Lawrence score 
or according to the Lane atlas (112). Radiographic progression has to be 
defined by the change above the smallest detectable change (SDC), which 
reflects the change above measurement error (113). 
For the assessment of radiographic progression, radiographs can 
be read by different reading procedures with different reading orders. 
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Radiographs can be scored either in an unpaired order or paired, with 
or without knowledge of their chronological sequence (114). There are 
advantages and disadvantages for each of these methods. Paired scoring 
in chronological order probably provides the most information to the 
reader, having greatest sensitivity (114). However, this may also introduce 
bias as the observer may expect progression over time, which results in 
overestimation of progression. Unpaired scoring is unbiased, but probably 
more prone to measurement error, which may be so large that the signal is 
lost in the noise. New, more sensitive imaging tools, such as MR imaging, 
may be useful to monitor progression of the degenerative OA processes. 
Pathophysiology of acromegalic arthropathy  
(See Thesis M.J .E . Wassenaar : Acromegaly: 
 Irreversible consequences)
Currently, the pathogenesis of acromegalic arthropathy is not 
fully understood. There are some similarities with primary OA. It 
is hypothesized that there are two phases in the pathogenesis of 
acromegalic arthropathy. First, elevated GH and IGF-1 levels induce 
cartilage hypertrophy and laxity of the peri-articular ligaments, leading 
to thickening of the cartilage lining and congestion of the joint space 
resulting in a limited range of motion. In this phase, radiographic 
abnormalities include joint space widening and peri-articular soft tissue 
hypertrophy. This early stage is thought to be at least partially reversible by 
adequate treatment (115). However, when GH excess persists, the disease 
acquires the features of a degenerative joint disease. The altered joint 
geometry results in repeat intra-articular trauma and exuberant reparative 
reactions, which lead to scar, cyst, and osteophyte formation with further 
deterioration of joint architecture. In addition, there is evidence for direct 
effects of GH and IGF-1 on bone (17).
Prevalence of acromegalic arthropathy is high in both active and 
controlled acromegaly, affecting weight and non-weight bearing joints 
(116). Despite long-term disease control, prevalence was 4 – 12 fold 
increased when compared to general population (95). Interestingly, the 
pattern of radiographic abnormalities differed from that in primary OA: 
in acromegaly especially osteophytosis was seen, with few joint space 
narrowing, indicating that GH excess is specifically involved in bone 
formation, but may protect against cartilage loss (96). Elevated GH / 
IGF-1 activity was associated with the onset of acromegalic arthropathy. 
Especially patients with high IGF-1 levels at the time of diagnosis and 
carriers of the common d3-GHR polymorphism, which is associated 
with an enhanced GH responsiveness, were at increased risk to develop 
secondary arthropathy (117;118). The disease course of acromegalic 
arthropathy in treated patients during long-term follow-up is unknown. 
In addition, information on risk factors for poor OA outcome is currently 
lacking. At present, there are no acromegaly-specific scoring methods 
for arthropathy available. In addition, no imaging studies of this unique 
phenotype of secondary OA with pathological cartilage hypertrophy have 
been performed, except for a single group that used ultrasonography 
(119;120). In this respect, MR imaging could be of interest by giving 
additional information to plain films by direct visualization of cartilage, 
enabling assessment of cartilage defects, thickness and quality, but also 
by accurate visualization of other structural abnormalities of subchondral 
bone such as osteophytes, cysts and bone marrow edema. 
Involvement of  the GH/IGF-1 axis in (primary) OA
Next to the evidence for involvement of the GH/IGF-1 axis in 
acromegalic arthropathy, there are several other lines of research suggesting 
a role of the somatotropic axis in (primary) OA. First, IGF-1 has been 
shown to enhance chondrocyte proliferation as well as proteoglycan and 
collagen synthesis, both in vivo and in vitro (121). This results in increased 
cartilage formation and laxity of peri-articular ligaments. Second, IGF-1 
is involved in the initiation and regulation of osteophyte development 
at the joint periphery(122). Third, genetic functional variations of GH/
IGF-1 genes are associated with symptomatic or radiographic OA in 
patients with primary OA (123-125). This is further supported by genetic 
evidence for association of several genetic variants that were all involved in 
the endochondral ossification, pointing towards an important role for this 
process in OA pathogenesis (126).
Endochondral ossification is the main process in longitudinal skeletal 
growth (being a primary function of GH and IGF-1), and involves the 
replacement of a cartilage model by bone tissue. The main player in this 
process is the chondrocyte, of which a complex network of circulating 
hormones, growth factors and ECM components tightly regulates its 
behavior. The importance of the interactions between these factors is 
illustrated by the effects of mutations in humans or mice in the genes 
encoding a number of the proteins involved in cartilage morphogenesis. 
In this respect, GH is a main stimulator of chondrocyte proliferation 
in the growth plate, and, in a lesser extent, of ECM secretion and the 
hypertrophic switch of post-proliferative chondrocytes. GH exerts its 
effects on the growth plate predominantly through IGF-1 stimulation 
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(127;128). Chondrocytes in OA cartilage share a fair amount of their 
expressed genes with those expressed in the terminal layer of the growth 
plate (125). It is therefore possible that genes involved in skeletal 
morphogenesis early in life determining joint shape, might play a late 
acting deleterious role towards OA onset and progression. Therefore, next 
to the other lines of evidence, this underlines the hypothesis that the GH / 
IGF-1 axis is indeed involved in the pathophysiology of OA (onset). 
Adult Growth Hormone Def iciency (GHD)
GHD in adults can occur as a consequence of various pathological 
processes in the pituitary and hypothalamic region, of which pituitary 
adenomas and their treatment are most common. Because the majority of 
cells in the anterior pituitary (60%) are somatotrophs, in general, the GH 
axis is the first to be affected, followed by failure of the LH / FSH, ACTH 
and TSH secretion. 
Clinical signs and symptoms
GHD in adults is a well-recognized and clinical condition (129), and is 
characterized by an adverse body composition (i.e. increased body fat and 
decreased lean body mass (LBM)), decreased bone mass and turnover and 
increased fracture rate, impaired cardiac function and muscle weakness 
(130). In addition, adult GHD is associated with an adverse cardiovascular 
lipid profile: increased serum total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C) and triglycerides (TG), in combination 
with decreased high-density lipoprotein cholesterol (HDL-C) levels. 
The majority of patients with GHD have multiple pituitary hormone 
deficiencies, and despite adequate hormonal substitution therapy, life 
expectancy is reduced in patients with hypopituitarism during adulthood 
(131;132). Therefore, it is postulated that GHD might be, at least in part, 
a good explanation for the observed negative cardiovascular effects in these 
patients.
In addition, from the patient’s perspective, one of the most important 
impairments is the decline in health-related QoL. Adults with GHD 
frequently complain of lack of energy, fatigue, social isolation, disturbed 
emotional reactions and social behavior, poor general health, lack of self-
control, anxiety, decreased vitality, mood and sense of well-being as well as 
problems with sexual relationships (133-138).
Diagnosis of  GHD
GHD evaluation should only be performed in patients with a high a priori 
risk for GHD, for example patients with known pituitary disease or GHD 
during childhood. Due to considerable overlap of IGF-1 concentrations 
and mean 24-h GH concentrations between healthy subjects and GHD 
patients, the diagnosis of GHD has to be confirmed by a stimulation test 
(139). Diagnosis should be based on the combination of documented 
pituitary or hypothalamic disease and a decreased GH response to 
insulin-induced hypoglycaemia during an insulin-tolerance test (ITT) 
or Growth Hormone Releasing Hormone-Arginine (GHRH/Arg) test in 
case of contra-indications for ITT, according to current guidelines (severe 
GHD defined as a GH peak response <3 µg/l, glucose nadir <2.2 mmol/l) 
(140;141). 
Recombinant human GH (rhGH) treatment 
The treatment of adult patients with rhGH is available since the early 
1990s. In the short-term (follow-up up to 2 years), rhGH replacement 
therapy was shown to improve the lipid profile (i.e. decrease in plasma 
LDL-C and TC levels), diastolic blood pressure (DBP) and body 
composition (i.e. decrease in fat mass and increase in LBM) (142). In 
addition, short-term positive effects were reported on left ventricular 
mass and interventricular septum thickness without changing diastolic 
function (143). On the other hand, rhGH replacement therapy was shown 
to increase fasting glucose and insulin levels (142). In selected patients, 
rhGH replacement therapy was shown to have favorable effects on QoL 
and well-being (144;145); however, the effect on several QoL subscales 
was limited (146), probably due to the complex pathology in these 
patients with possible direct treatment effects (i.e. cranial radiotherapy) 
and failure of multiple pituitary axes and difficulty with measuring QoL. 
The beneficial metabolic effects of rhGH replacement were reported 
to be sustained for at least 5 years of treatment; however, data on longer 
follow-up duration are scarce. In addition, initial treatment strategies with 
rhGH in GHD adults were weight-based regimes, adapted from treatment 
of children with GHD. However, this resulted frequently in supra-
physiological substitution and this treatment regime was subsequently 
abandoned during long-term studies. The Growth Hormone Research 
Society recommended titrating rhGH replacement dose individually, with 
the aim to reach IGF-1 levels within the normal age- and sex-adjusted 
range.
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With respect to cardiovascular disease, a direct improvement of several 
cardiovascular parameters was seen within the first treatment year, which 
was reported to be sustained during longer rhGH treatment, suggesting 
ongoing beneficial effects even beyond 5 years (147;148). However, overall 
cardiovascular risk profile, as reflected by prevalence of the metabolic 
syndrome (MS), appeared still to be increased when compared to general 
population, without any effect of 5 years of rhGH treatment (141). 
At present, it is unknown whether rhGH therapy favorably affects the 
incidence of cardiovascular events, including cardiovascular death. With 
respect to bone, rhGH replacement therapy increases bone remodeling, 
indicated by an increase of biochemical markers of both bone formation 
and resorption. This results in an initial decline in BMD, followed by a 
significant increase, reaching a plateau phase after 5 to 7 years of treatment 
(149-151). Currently, long-term fracture data are unavailable. In addition, 
there are no available studies among GHD adults assessing the effects of 
GHD or rhGH treatment on joints, or, more specifically, the prevalence of 
arthropathy.
rhGH replacement therapy in adults in general is considered to be 
safe. Recently, overall mortality rate was reported not to be different 
between treated GHD patients and the background population, neither 
in malignancy-related mortality (152). However, an increased risk in 
cardiovascular death was observed in rhGH-treated women (152). This 
increased cardiovascular mortality, however, is not clearly explained. In 
children, long-term safety data have shown an increased incidence in 
cardiovascular disease and bone tumor-related mortality (153). Since 
untreated GHD is also associated with an increased mortality (131;132), 
the net beneficial effects of rhGH supplementation on firm end points, 
such as mortality, should be questioned. In addition, patient characteristics 
and approach to rhGH supplementation change over time (154). These 
recent findings emphasize the necessity of ongoing monitoring and to 
critically evaluate long-term efficacy and safety data with respect to rhGH 
use in adult patients with GHD.
OUTLINE OF THIS THESIS
In this thesis, a number of observations are described in acromegaly 
patients with cured or biochemically well-controlled disease during long-
term follow-up. These observations focus on the long-term consequences 
of the disease on joints and bone. In addition, we investigated the role 
of the Growth Hormone (GH) / Insulin-like Growth Factor-1 (IGF-1) 
axis, including the possible effect of the exon 3 deleted GH receptor (d3-
GHR) polymorphism, in patients with primary osteoarthritis (OA) that 
have serum IGF-1 levels within the normal range. Finally, we studied the 
long-term consequences of recombinant human GH (rhGH) replacement 
in GH Deficient (GHD) adults, focusing on the cardiovascular effects and 
the effects on bone in comparison to healthy controls.
Part A. Long-term effects of acromegaly on joints 
and bone
Part A describes the long-term effects of acromegaly on joints and bone 
in a well-characterized cohort of controlled acromegaly patients, who 
were in remission for a mean duration of 17 years. We especially focused 
on the course of arthropathy and vertebral fractures over time in treated 
patients and risk factors for poor outcome. In order to address these 
questions, we performed a prospective 2.5-year follow-up study. 
Arthropathy is one of the most common complications of acromegaly, 
significantly impairing QoL. We previously showed in a well-characterized 
cohort of treated acromegaly patients, that the prevalence of arthropathy 
was high despite biochemical control. GH / IGF-1 activity at diagnosis 
was shown to be related to the presence of radiographic OA many years 
later. Although acromegalic arthropathy shares features with primary OA, 
radiographic features significantly differ. Severe osteophytosis is seen, but 
joint spaces are widened rather than narrowed in patients with long-term 
controlled acromegaly. At present, the prognosis and determinants of 
acromegalic arthropathy during prolonged follow-up are unknown. It 
is unclear whether cartilage hypertrophy and osteophytosis are stable in 
these patients or whether these patients experience a gradually ongoing 
deterioration. In Chapter 2, we investigated the radiographic course of 
arthropathy in a cohort of long-term controlled acromegaly patients in 
a prospective follow-up study. In addition, determinants of radiographic 
outcome were assessed. In Chapter 3, the clinical course of arthropathy 
was assessed by the use of validated questionnaires on self-reported 
joint pain, stiffness and function, by structured physical examination 
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and performance tests. Risk factors for poor clinical outcome were also 
assessed. In addition, we related clinical progression to radiographic 
change over time. In Chapter 4, we further characterized acromegalic 
joints by Magnetic Resonance Imaging (MRI) scans of the knee. We chose 
for this imaging modality since MRI may give additional information 
to plain films, especially on cartilage defects, but also onother structural 
abnormalities such as osteophytes, cysts, bone marrow edema, effusion 
and meniscus degeneration. Comparisons were made between patients 
with active acromegaly, medically treated patients and acromegaly patients 
cured by surgery and/or additional radiotherapy. In addition, primary OA 
patients were included as controls in order to differentiate which structural 
abnormalities observed with MRI were acromegaly-specific. Chapter 5 
focuses on the process of joint space narrowing, which is an infrequent 
finding in patients with acromegalic arthropathy. It is unknown whether 
joint space narrowing is the end-stage of acromegalic arthropathy or 
whether this feature develops independently of acromegaly. Risk factors 
for joint space narrowing and the relationship to clinical symptoms were 
studied. 
Next to the high prevalence of arthropathy, patients with acromegaly, 
regardless of disease activity, suffer from a high prevalence of vertebral 
fractures. Bone mineral density (BMD) in these patientsis frequently 
normal, indicating that BMD most likely is not a good predictor of 
fracture risk in this form of secondary osteoporosis. To date, it is unclear 
whether patients in long-term remission have a persistent, irreversible 
increased risk of future fractures, or whether GH/IGF-1 control reduces 
the fracture risk to normal, despite presence of prevalent vertebral 
fractures. In view of the excess mortality and significant morbidity 
associated with VFs, insight in VF progression in acromegaly is of 
paramount clinical significance. In Chapter 6, the disease course of 
vertebral fractures and potential determinants for progression were studied 
in treated acromegaly patients, in a 2.5-year prospective follow-up study. 
In a subgroup, we also assessed the relationship between progression of 
vertebral fractures and BMD changes. 
Part B. The role of the GH / IGF-1 axis in primary 
osteoarthritis
Part B describes studies on the involvement of the GH / IGF-1 axis in 
the development and progression of primary OA. Several lines of research 
suggest a role of the GH / IGF-1 axis in OA pathogenesis. First, IGF-1 
has been shown to enhance chondrocyte proliferation and proteoglycan 
and collagen synthesis by chondrocytes in normal cartilage, both in vivo 
and in vitro, also during cytokine exposure. These anabolic and protecting 
properties make IGF-1 an obvious candidate for a major role in cartilage 
repair. Second, in acromegalic disease, we found further evidence for an 
association between the activity of the GH/IGF-1 axis and the risk of 
secondary OA. Prevalence and severity of arthropathy worsen with the 
duration of uncontrolled acromegaly, and pre-treatment IGF-1 levels 
predict radiographic OA in a dose-dependent manner. Finally, previous 
studies showed that genes regulating formation, degradation and repair of 
articular cartilage and subchondral bone remodelling may be involved in 
OA pathogenesis.
In this context, in Chapter 7, we summarized the evidence for a 
role of serum IGF-1 concentrations in primary OA by conducting a 
systematic review. We also addressed the association between several 
IGF-1 gene polymorphisms and the onset and progression of primary 
OA. In this literature review, we found inconsistent results among 
epidemiological studies investigating serum IGF-1 in relation to primary 
OA. Overall, there was no evidence supporting an association between 
serum IGF-1 and primary OA. However, sample sizes were small and in 
most studies, sex and BMI, both important factors for the interpretation 
of IGF-1 levels, were not taken into account. Furthermore, only one 
study had a longitudinal design. In order to gain more insight into the 
pathophysiology of primary OA, taking into account factors influencing 
IGF-1 concentrations (i.e. age, sex, BMI), we studied serum IGF-1 
concentrations in relation to primary OA onset and progression in 
Chapter 8. We used a well-characterized cohort of patients with familial 
generalized OA from the Genetics osteoARthritis and Progression (GARP) 
Study, in which serum IGF-1 levels were within the normal range. In 
addition, we studied the interaction with a common polymorphism of the 
GHR, called exon 3 deletion (d3-GHR), in relation to OA progression.  
This d3-GHR polymorphism is associated with an enhanced GH 
responsiveness, and, therefore, with increased activity of the GH / IGF-1 
axis. Previously, in acromegaly patients, the d3-GHR polymorphism 
was reported to be associated with the presence and the severity of 
radiographic arthropathy. The association with primary OA, however, 
has never been studied. To further explore the role of the GH/IGF-1 axis 
in primary OA, in Chapter 9 we studied the association between the 
d3-GHR polymorphism and symptomatic OA in patients with primary 
familial OA at multiple joint sites from the GARP Study in comparison 
to healthy controls. We used a single nucleotide polymorphism (SNP, 
rs4590183) being in full linkage disequilibrium (LD) as a proxy for the 
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d3-GHR polymorphism, and tested this SNP in two additional OA 
cohorts and in patients with acromegalic arthropathy for replication. The 
results were pooled in a genetic meta-analysis. 
Part C. Long-term outcome of recombinant human 
GH (rhGH) therapy in GH def icient (GHD) adults
This part of the thesis addresses the long-term effects of rhGH therapy 
in adult patients with GHD. The beneficial effects of short-term rhGH 
therapy (up to 2 years) in GHD adults are well-documented, and include 
improvement of the lipid profile, body composition and cardiac function. 
In selected patients, also positive effects on QoL and general well-being 
were described. These effects were reported to be sustained for the first 5 
years of rhGH treatment; however, data with longer follow-up duration 
are scarce. 
In Chapter 10, we systematically reviewed the effects of rhGH therapy 
in GHD adults during prolonged follow-up (at least 5 years) on 
biochemical and anthropometric parameters, QoL, bone metabolism, 
muscle strength, serious adverse events (SAEs) and mortality. In Chapter 
11, we evaluated biochemical and anthropometric parameters in a large 
cohort of GHD adults after rhGH treatment for at least 10 years. In 
addition, the prevalence of the metabolic syndrome (MS) was studied to 
assess the overall cardiovascular risk, and we calculated the incidence of 
major cardiovascular events during long-term rhGH supplementation. 
Chapter 12 describes differences in the metabolic prolife between 
middle-aged GHD patients after chronic rhGH replacement, and healthy 
control subjects. The data from healthy controls were obtained from the 
Leiderdorp (reference) cohort of the Nederlandse Epidemiologie van 
Obesitas (NEO) Study, which we were able to match for age, sex, and also 
BMI. Finally, in Chapter 13, we studied the effects of long-term rhGH 
replacement (defined as at least 5 years) on BMD, using dual energy X-ray 
absorptiometry (DEXA), and bone metabolism in middle-aged GHD 
adults. In addition, we studied the incidence of (non-vertebral) fractures 
during chronic rhGH supplementation.
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ABSTRACT
OBJECTIVE: Arthropathy is an invalidating complication of acromegaly, of 
which the prognosis and determinants are currently unknown in treated 
acromegaly. Therefore, the objective of the present study was to investigate 
radiographic progression of arthropathy over a mean follow-up period of 
2.6 years and determinants of outcome in patients with long-term well-
controlled acromegaly. 
DESIGN: Prospective follow-up study
METHODS: In a prospective cohort study we studied 58 patients (mean 
age 62 years, women 41%) with controlled acromegaly for a mean of 
17.6 years. Radiographic progression of joint disease was defined by the 
Osteoarthritis Research Society International (OARSI) classification as a 
1-point increase in joint space narrowing (JSN) or osteophyte scores on 
radiographs of the hands, knees, and hips obtained at the first study visit 
and after 2.6 years. Potential risk factors for progression were assessed. 
RESULTS: Progression of osteophytes and JSN was observed in 72% and 
74% of patients, respectively. Higher age predisposed for osteophyte 
progression. Patients with biochemical control by somatostatin (SMS) 
analogs had more progression of osteophytosis than surgically cured 
patients (OR=18.9, p=0.025), independently of age, sex, BMI, baseline 
insulin-like growth factor-1 (IGF-1) SDS and exon 3 deletion of the 
GHR. This was also evident for JSN progression, as were higher age and 
higher baseline IGF-1 SDS. 
CONCLUSIONS: Acromegalic patients have progressive JSN and 
osteophytosis, despite long-term biochemical control. Parameters reflecting 
GH/IGF-1 activity were associated with progressive joint disease. 
Remarkably, biochemical control by SMS analogs was associated with 
more progression than surgical cure. Although the present study is not 
a randomized controlled trial, this may indicate insufficient GH control 
according to current criteria and the need of more aggressive therapy. 
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INTRODUCTION
Acromegaly is a chronic, progressive disease, caused by a growth hormone 
(GH)-producing pituitary adenoma, resulting in elevated GH and insulin-
like growth factor-1 (IGF-1) concentrations. Available treatments are 
transsphenoidal surgery (TPS), radiotherapy and medical therapy with 
somatostatin (SMS) analogs and Pegvisomant. In acromegaly, the risk 
to develop secondary osteoarthritis (OA) is increased. However, little is 
known on the pathophysiology of acromegalic joint disease or the role of 
the GH/IGF-I system in primary OA (1).
In a well-characterized cohort patients with long-term disease control, 
we recently observed a 4- to 12-fold increased prevalence of arthropathy at 
young ages, leading to limited physical functioning and psychological well-
being (2;3). Interestingly, the distribution of radiological abnormalities, 
such as osteophytes and joint space narrowing (JSN), differed from 
primary OA. In acromegaly, GH hypersecretion results in a characteristic 
radiographic OA phenotype with severe osteophytosis, but wide joint 
spaces (4), indicating that cartilage hypertrophy is maintained despite 
long-term remission. This observation indicates that transient GH/IGF-1 
excess is mainly involved in bone formation resulting in osteophytosis, 
but may protect against cartilage loss (4). We recently documented a 
predictive role for pre-treatment IGF-1 levels on radiographic appearance 
of OA in acromegaly, in a dose-dependent manner (5). In addition, we 
found that patients with a common GH receptor polymorphism, exon 3 
deletion (d3-GHR) which results in enhanced GH responsiveness, had an 
increased prevalence of irreversible complications of acromegaly, such as 
radiographic OA, dolichocolon and adenomatous colonic polyps (6;7).
These observations were obtained in a cross-sectional study. At present, 
the disease course of OA during prolonged follow-up in patients with 
long-term biochemical control of acromegaly is unknown. It is unclear 
whether cartilage hypertrophy is permanent and stable in these patients 
or whether deterioration occurs in hypertrophied cartilage. Therefore, 
we designed a prospective follow-up study during 2.6 years to assess the 
course of acromegalic arthropathy, and to identify potential risk factors. 
MATERIALS AND METHODS
Study design and patient selection
PATIENTS: All consecutive patients with acromegaly, who were referred 
to the Leiden University Medical Center, are collected in a database. In 
the baseline study (2007), 89 patients in long-term biochemical remission 
were included (2). All 89 patients were invited for a follow-up study visit 
(2010), of which 58 consented to participate. Thirty-one (35%) declined 
to consent, with not OA-related health problems (N=16), travel distance 
(N=6), and lack of time (N=4) as most frequent reasons. Demographic 
and disease characteristics did not statistically differ between included and 
non-included patients (data not shown), except for a higher number of 
females among non-consenters (p=0.025) (2;3).
Detailed yearly follow-up was performed from the onset of acromegaly 
treatment. The first treatment option in the majority of patients was TPS 
performed by a single specialized neurosurgeon. If necessary, adjuvant 
treatment consisted of radiotherapy (prior to 1985) or SMS analogs (from 
1985 onwards). From 1998, some patients received depot formulations of 
long-acting SMS analogs as primary treatment. Since 2003, Pegvisomant 
was available for treatment-resistant acromegaly. 
Disease activity was assessed yearly by oral glucose tolerance tests (except 
in medically treated patients), fasting serum GH and IGF-1 levels. Remission 
of acromegaly was defined as a normal glucose-suppressed serum GH <1.25 
(RIA assay until 1992) or 0.38µg/l (immunofluorometric assay (IFMA) from 
1992 onwards), serum GH levels of <1.9µg/l (all years), and normal IGF-1 
levels for age (from 1986 onwards) (8-10). Patients not meeting these criteria 
were offered additional treatment. 
Hypopituitarism was supplemented with thyroxine, hydrocortisone, 
testosterone, and estrogens (only in pre-menopausal women) according to the 
following definitions (11). Estrogen deficiency in women was present in case 
of LH/FSH deficiency in premenopausal women with prolonged amenorrea 
>1 year without adequate replacement therapy or by a low serum oestradiol 
concentration of <70nmol/l and all postmenopausal women. In men, LH/
FSH deficiency was defined as testosterone level below the reference range 
(8.0nmol/l). TSH deficiency was defined as a free thyroxine level below the 
reference range (<10pmol/l). ACTH deficiency was defined as an insufficient 
increase of cortisol (peak <0.55µmol/l) after corticotrophin releasing hormone 
test or insulin tolerance test. GH deficiency was not routinely assessed. 
The Medical Ethics Committee approved the study protocol, and all 
subjects gave written consent. 
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PROTOCOL: Fifty-eight patients were seen at the outpatient clinic for 
two study visits with a 2.6-year interval. The baseline assessment was 
performed between September and December 2007, the follow-up visit 
between March and September 2010. At baseline, patients had a mean 
duration of remission of 15.0 years. All patients completed a standardized 
questionnaire concerning demographic data and medical history. 
Treatment and patient characteristics were derived from patient records. At 
both time points, conventional radiographs were obtained, according to a 
standardized protocol (see below). Blood samples were taken in the post-
absorptive states to assess actual GH and IGF-1 concentrations.  
Study parameters
PARAMETERS OF ACROMEGALIC DISEASE: Duration of active disease 
was estimated using the start of symptoms and signs to the date of 
normalization of serum IGF-1 concentration after treatment. Duration 
of remission was calculated from the date of biochemical remission until 
the start of the present study. Cure of acromegaly was defined by normal 
glucose-suppressed GH levels and IGF-1 levels for age after surgery and/
or irradiation. Biochemical control of acromegaly was defined by normal 
serum IGF-1 levels for age during SMS analog treatment. Both cured and 
biochemically controlled patients were referred to as ‘in remission’.
ASSAYS: Serum GH was measured with a sensitive IFMA (Wallac, Turku, 
Finland), specific for the 22 kDA GH protein (detection limit: 0.01µg/l, 
interassay coefficient of variation (CV): 1.6-8.4% of 0.01-15.38µg/l) from 
1992 onwards. For the conversion of µg/l to mU/l, multiply by 2.6. Before 
1992, GH was measured by RIA (Biolab, Serona, Coissins, Switzerland), 
detection limit: 0.5mU/l, with an interassay CV <5%; for the conversion 
of µg/l to mU/l, multiply by 2.
From 1986 to 2005, serum IGF-1 concentrations were determined 
by RIA (Incstar, Stillwater, MN) with a detection limit of 1.5 nmol/L 
and an interassay CV less than 11%. IGF-1 is expressed as SD score for 
age- and gender-related normal levels determined in the same laboratory 
(12). From 2005, serum IGF-1 concentrations (nmol/l) were measured 
using an immunometric technique on an Immulite 2500 system (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). The intra-assay variations 
at mean plasma levels of 8 and 75nmol/l were 5.0 and 7.5%, respectively. 
IGF-1 levels were expressed as SDS (normal range -2 to +2 SDS), using 
lambda-mu-sigma smoothed reference curves based on 906 controls 
(13;14).  
DNA COLLECTION AND GENETIC ANALYSIS: DNA extraction 
was done 6-8 weeks after blood collection (8ml) at the baseline visit. 
DNA concentrations and purity (OD 260/280) were determined 
spectophotometrically using the nanodrop (Isogen, IJsselstein, The 
Netherlands). The d3-GHR polymorphism was detected as described 
previously (15). Both heterozygotes and homozygotes for the d3-GHR 
allele were referred to as d3 carriers.
RADIOGRAPHIC PROTOCOL: Conventional radiographs of the 
hands (dorsovolar), knees (posterior-anterior (PA), in weight-bearing/
semi-flexed and lateral) and hips (PA, supine) were obtained from all 
participating patients, employing a standardized protocol with a fixed 
film-focus distance and fixed joint position. Knee radiographs were made 
in fixed-flexion (16). Radiographic examinations at both study visits were 
performed by a single experienced radiographer.
ASSESSMENT OF RADIOGRAPHIC OA PROGRESSION: For a semi-
quantitative assessment of radiographic OA severity, radiographs were 
graded on a scale of 0-3 for JSN and osteophytes, using the Osteoarthritis 
Research Society (OARSI) atlas (17). In the hands, distal interphalangeal 
(DIP), proximal interphalangeal (PIP), metacarpophalangeal (MCP), 
first interphalangeal (IP), and first carpometacarpal (CMC1) joints 
were scored. All radiographs were scored by a single experienced reader 
(K.M.J.A. Claessen), blinded for patient characteristics. Radiographs 
of the same patient from both time points were assessed together in 
chronological order; this was previously demonstrated to be the most 
sensitive method to change, when assessing radiographic progression in 
primary OA (18).
THE JSN AND OSTEOPHYTE SCORES OF THE FOLLOWING JOINT 
GROUPS WERE ANALYZED IN COMBINATION: hands (DIPs, 
PIPs, MCPs, IPs, CMC1s), knees (medial and lateral tibiofemoral (TF) 
compartments) and hips. Total scores were calculated by adding left and right 
sites. The maximum total JSN score was 108 for a patient: 90 in the hands, 
6 in the hips and 12 in the knees. The maximum total osteophyte score was 
120 for a patient: 90 in the hands, 6 in the hips and 24 in the knees. In joint-
specific analyses, left and right joints were analyzed independently. 
The reproducibility for JSN and osteophytes, depicted by the intra-
class correlation coefficient (ICC), was very good. ICCs for JSN and 
osteophytes were respectively 0.98 and 0.98 in the hands, 1.00 and 0.99 in 
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the knee, 0.98 and 1.00 in the hip. The reproducibility was based on the 
repeat reading of 15 randomly selected radiographs.
DEFINITION OF RADIOGRAPHIC OA PROGRESSION: Radiographic 
progression was defined both at patient level, including all hand, hip and 
knee joints, and at the specific joint level. Radiographic progression was 
only defined in patients and joints, respectively, with existing OA features 
(osteophytes and/or JSN) at baseline. Radiological progression was the 
change in JSN or osteophyte scores after 2.6 years above the smallest 
detectable change (SDC, 0.85 and 0.57 respectively), and was therefore 
defined by at least a 1-score increase in JSN or osteophyte total scores (19). 
Also at joint site level, SDC was used to assess radiographic change above 
measurement error (SDCs for osteophytes and JSN: knee, both 0.3; hip, 
both 0.4; hands, 0.8 and 0.4, resp.). Therefore, radiographic progression 
was defined as at least a 1-score increase in JSN or osteophyte scores at the 
specific joint. 
Knees and hips without radiological end-stage disease (grade 3) in 
terms of JSN or osteophytes at the first study visit, which received hip 
or knee prosthesis during follow-up, were considered to have progressive 
JSN and osteophytosis in that particular joint. In addition, patients with 
end-stage OA or joint prostheses at baseline that were unable to further 
progress, were considered to have progressive disease in terms of JSN and 
osteophytes in their respective joints.
Statistical analysis
SPSS for Windows, version 17.0 (SPSS Inc.,Chicago,IL,USA), was used 
for data analysis. Data are presented as mean±SD, unless otherwise stated. 
To evaluate the magnitude of the changes observed during 2.6years, 
standardised response means (SRM) were calculated as the mean change 
between both study visits divided by the SD of change (20). Spearman 
rank correlations were used to correlate initial severity of radiographic 
OA with progression scores. The relationship between duration of SMS 
therapy and severity of arthropathy was studied with linear regression 
analysis with osteophyte/JSN scores as dependent variable, and duration 
of SMS treatment as independent variable, adjusted for age. Duration 
of SMS therapy was subdivided into 4 groups: (1) no SMS treatment, 
(2) <5years SMS treatment, (3) 5-10years SMS treatment, (4) >10years 
SMS treatment. Logistic regression analyses were performed to investigate 
risk factors for progression at patient level, with radiographic outcome as 
dependent variable. Crude and adjusted odds ratios (OR) were calculated, 
with adjustments for age, sex, BMI. Additional adjustments for baseline 
IGF1 SDS were performed when studying acromegaly cure vs. control. 
At joint site level, left and right joints were analyzed independently. Risk 
factor analysis was performed by generalized estimating equations (GEE) 
analysis to account for intra-patient effects, with corrections for age, sex, 
BMI, and baseline IGF1 SDS when appropriate.  
RESULTS
Patient description
In total, 58 patients with long-term remission of acromegaly were studied 
in the present longitudinal study. Mean interval between both study visits 
was 2.6 years (range 2.3-2.9). Patient characteristics are shown in Table 1. 
Mean age was 61.8±10.9 years and 41% were women. The patients were 
in remission for a mean duration of 17.6±7.2 years (minimum 2 years) 
and mean actual IGF-1 SDS was 0.51±1.51. There were no recurrences 
during longitudinal follow-up. Remission was achieved by surgery, if 
necessary, followed by radiotherapy in 40 patients (69%). The other 18 
patients (31%) were treated during the observation period with either 
primary and/or postoperative long-acting SMS analogs (mean duration 
105 months, range 21-191). Only one patient was co-treated with 
Pegvisomant. At the first study visit, two patients had knee prostheses, and 
one patient had bilateral hip prostheses for end-stage OA.
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Table 1. Clinical characteristics of  58 patients with acromegaly
Clinical characteristics Patients (N=58)
Age (years) 61.8 (10.9)
Sex, female (n (%)) 24 (41)
BMI (kg/m2) 28.9 (4.5)








  Surgery only
  Surgery + RT   
  SMS analogues 
    Primary
    Following surgery *
    Following RT







Disease duration (years) 9.2 (8.1)
Duration of remission (years) 17.6 (7.2)







  Corticotrope failure
  Thyreotrope failure
  Gonadotrope failure
     Males
     Pre-menopausal







d3-GHR carrier (n (%)) 21 (36.2)
ROA at baseline, (n (%))
  Patient level, n=58
        OP
        JSN
        OP and/or JSN 
  Knee, N=116
        OP
        JSN







Clinical characteristics Patients (N=58)
 Hip, N=116
        OP
        JSN
        OP and/or JSN
  Hand, N=116
        OP
        JSN







Values are means (SD) unless stated otherwise. 
GH, growth hormone; IGF-1, insulin-like growth factor 1; BMI, body mass index; RT, radiotherapy; 
SMS, somatostatin (analogs); GHD, growth hormone deficiency; d3-GHR, exon 3 deletion of the 
GHR polymorphism; ROA, radiographic osteoarthritis, defined as Osteoarthritis Research Society 
International (OARSI) score ≥1; OP, osteophytes; JSN, joint space narrowing; N=number of joints. *, 
one patient is co-treated with Pegvisomant.
Table 2. Values at baseline and follow-up, after additional 
2.6 years of  follow-up, and change scores in 58 patients (116 
joints) with acromegaly
Joint site                 Baseline             Follow-up        Change*            P value        SRM
Patient level 
OP, range 0-120 












OP, range 0-24 












OP, range 0-6 












OP, range 0-90 











Data are shown as mean (SD). *, mean change (SD) over 2.6 years.
SRM, standardised response mean; OP, osteophytes; JSN, joint space narrowing.
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Radiographic progression of osteophytes and JSN
Total scores of osteophytes and JSN deteriorated over time (Table 
2), reflected in mean changes of total scores of 2.0±1.9 and 1.7±1.7, 
respectively. Radiographic progression of osteophytes and JSN at any 
joint site was present in 42 (72%) and 43 (74%) patients, respectively. 
Progression of osteophytosis was highest in the knee (31%), with slightly 
lower percentages in the hands (28%), and hip (26%). JSN progression 
occurred most often in the hands (40%), followed by the knee (23%), 
and hip (15%). During follow-up, two patients received unilateral knee 
prosthesis and one patient underwent unilateral hip replacement.
There was a distinct relationship between the severity of radiographic 
arthropathy features at baseline and the degree of increase in radiographic 
scoring over 2.6 years. The baseline severity of JSN correlated moderately 
with JSN progression over 2.6 years (Spearman rank correlation coefficient 
r=0.5, p<0.001); the baseline severity of osteophytosis correlated with both 
osteophyte and JSN progression (r=0.3, p<0.05 and r=0.5, p<0.001).  
Risk factors for radiographic progression of 
arthropathy 
PATIENT LEVEL: JSN progression was associated with higher age (p=0.01), 
but not with sex and baseline IGF-1 SDS. There was a difference between 
surgically cured patients and those controlled with SMS analogs (Table 3). 
Patients with biochemical control by SMS analogs had a 9.0-fold increased 
risk to develop osteophyte progression compared with patients cured by 
surgery or additional radiotherapy (OR=12.3, p=0.032, independently of 
age, sex, BMI and baseline IGF-1 SDS). This risk was even more increased 
after additional correction for d3-GHR polymorphism (OR=18.9, 
p=0.025). When comparing patient characteristics between SMS-treated 
and surgically cured patients, medically treated patients had a longer 
history of active disease (p=0.01) and higher IGF-1 SDS, both at baseline 
and follow-up (p=0.08 and p=0.07, respectively), albeit in the normal 
range (Table 4). Pre-treatment GH/IGF-1 levels, duration of remission 
and prevalence of hypopituitarism were not different between both groups. 
Duration of SMS treatment was moderately correlated with the severity 
of arthropathy, especially osteophytosis (r=0.35, p<0.01), with highest 
correlation in the hip (r=0.5, p<0.001 for both osteophytosis and JSN). 
Upon further investigation, we found a clear dose-response relationship 
between duration of SMS treatment and severity of arthropathy, especially 
with osteophytosis (β=3.029, p=0.025, adjusted for age and baseline 
IGF-1 SD scores, Figure 1). After stratification for joints, the strongest 
relationship was found for the hip (β=1.235, p<0.001 and β=0.691, 
p<0.001 for osteophytes and JSN, respectively), followed by osteophytosis 
in the hand (β=0.708, p=0.014).
Table 3. Risk factors for radiographic progression of  
acromegalic arthropathy at patient level, in 58 patients

















































Risk factors were analyzed with binary logistic regression analysis with OA progression as 
dependent variable. Baseline IGF-1 SDS were IGF-1 SD scores at the time of the first joint 
evaluation in 2007. Disease cure is defined as normal glucose-suppressed GH levels and IGF-1 
levels for age after surgery and/or irradiation. Adjusted odds ratios were adjusted for age, sex and 
BMI. Additional adjustments were made for baseline IGF-1 SDS and d3-GHR polymorphism in the 
analysis on controlled vs. cured acromegaly disease. 
CI, confidence interval; JSN, joint space narrowing; BMI, body mass index; d3-GHR, exon 3 deletion 
of the GHR polymorphism. NA, not applicable. *, p<0.05. 
JOINT S ITE LEVEL: Risk factors for progression of arthropathy were also 
studied for the specific joint sites, because their effect may differ between 
various sites (21) (Table 5, Figure 2). At the first study visit, 97 knees 
(84%), 84 hips (72%) and 104 (90%) hands showed radiographic OA 
features (Table 1), and were hence included in the present analysis. All 
analyses were adjusted for age, sex and BMI; analyses on acromegaly cure 
vs. medically control were also corrected for baseline IGF-1 SDS. 
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Knee: Higher baseline IGF-1 SDS was associated with JSN progression. 
Furthermore, SMS analog-treated patients had a 3.5-fold increased risk to 
develop JSN progression compared to surgically cured patients (p=0.02). 
d3-GHR polymorphism predisposed for osteophyte progression (OR=3.6, 
p=0.01). This could not be demonstrated for female sex or baseline IGF-1 
SDS. 
Hip: Risk factors for JSN progression were higher age (OR=1.1, 
p=0.047) and higher baseline IGF-1 SD levels. In addition, SMS analog 
treatment was associated with JSN progression (OR=5.6, p=0.016), 
irrespective of adjustment of IGF-1 SDS (OR=4.3, p=0.045); a trend was 
demonstrated for osteophyte progression (OR=2.9, p=0.06). 
Hands: Both JSN and osteophyte progression were seen more 
frequently in older patients (p<0.001 and p=0.02, respectively). SMS-
treated patients showed 4.2 times more osteophyte progression compared 
with surgically cured patients (p=0.01). In addition, longer duration of 
active disease was associated with osteophyte progression. 
Figure 1: Dose-response relationship between duration of SMS therapy and severity of 
osteophytosis (at patient level), adjusted for age and baseline IGF-1 SD levels. 
Mean osteophyte and JSN scores (±SEM) of both study visits were shown for patients treated 
by TPS and/or RT versus patients treated by SMS analogs. The left symbol (circle) of each pair 
represents the baseline OP/JSN score; the right one (square) represents the score after 2.6 years 
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Table 4. Characteristics of  acromegalic patients with cured 
acromegaly (N=40) versus SMS-treated patients (N=18)





Age (years) 62.0 (10.6) 62.0 (11.4) 0.99
Sex, female (%) 40% 41% 0.94












Estimated disease duration (years) 7.5 (7.6) 14.3 (7.5) 0.01*



























Hypopituitarism (%) 38% 29% 0.56
Values are means (SD) unless stated otherwise. Disease cure is defined as normal glucose-
suppressed GH levels and IGF-1 levels for age after surgery and/or irradiation. Data are shown as 
mean (SD), unless mentioned otherwise. *, p<0.05.
GH, growth hormone; IGF-1, insulin-like growth factor-1; BMI, body mass index. 
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Table 5. Risk factor analysis for progression of  osteophytosis 
and JSN in joint-specif ic analyses of  the knee, hip and hands 
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Data were presented as adjusted odds ratio with 95% confidence intervals (adjusted OR, 95% 
CI). Left and right joints were analyzed independently. Risk factors were analyzed by Generalized 
Estimating Equations (GEE) analysis to adjust for the intra-patient effect. Additional adjustments 
were made for age, sex, BMI, intra-patient effect and baseline IGF-1 SD scores, when appropriate.
CI, confidence interval; OP, osteophytosis; JSN, joint space narrowing; BMI, body mass index; d3-
GHR, exon 3 deletion of the GHR polymorphism. *, p<0.05. 
Figure 2: Mean osteophyte and JSN scores at baseline and follow-up, respectively, for 
acromegaly patients treated by surgery and/or radiotherapy versus patients treated by SMS 
analogs. 
Mean osteophyte and JSN scores (±SEM) of both study visits were shown for patients treated 
by TPS and/or RT versus patients treated by SMS analogs. The left symbol (circle) of each pair 
represents the baseline OP/JSN score; the right one (square) represents the score after 2.6 years 





This prospective study is the first to document that radiological features 
of acromegalic arthropathy progresses despite long-term biochemical 
remission of acromegaly, even in a relatively short follow-up period of 2.6 
years and at all measured joint sites. Thus, it appears to be a progressive 
joint disease that is not merely halted or reversed by control of acromegaly. 
Remarkably, biochemical control by SMS analogs was associated with 
increased progression of radiological features of acromegalic arthropathy.
We previously demonstrated in a cross-sectional study that late effects 
of acromegaly on joints are striking, despite long-term disease control. 
The OA prevalence in these patients is much higher at all joint sites 
compared with the general population, and is associated with impaired 
quality of life (QoL) (2;3). Risk factors for radiographic OA in patients 
with long-term controlled acromegaly are high pre-treatment IGF-1 
levels (5) and presence of d3-GHR polymorphism (6;7). In the present 
study, we observed progression of radiographic OA features in patients 
who were considered strictly controlled with medical therapy according 
to current guidelines. Several parameters reflecting GH/IGF-1 activity 
appear to predispose for progression. This finding may indicate that joints 
are a sensitive target organ to monitor GH/IGF-1 and could be used as 
biomarker to evaluate ongoing disease activity. 
Several issues have to be considered with respect to the pathophysiology 
of progressive acromegalic osteoarthropathy. Progression of acromegalic 
arthropathy has probably a multifactorial pathophysiology, as known 
for primary OA. Traditionally, early-stage acromegalic arthropathy was 
considered to be driven by elevated IGF-1 levels, partially reversible after 
adequate treatment, and subsequently by mechanical changes. In later 
stages, acromegalic arthropathy was thought to act via one final common 
pathway with primary OA (1;22-24), indicating the same factors to be 
involved in progression. In accordance, we demonstrated that common 
risk factors for primary OA development, such as higher age, apply for 
patients with long-term controlled acromegaly (1;25-28). However, several 
parameters reflecting GH/IGF-1 activity appeared to influence progression 
of acromegalic arthropathy in the present study. Therefore, also the late 
stage of arthropathy might be mediated by the actual activity of the GH/
IGF-I axis. First, IGF-1 SD concentrations measured at the baseline study 
visit were within the normal range in all patients, but, were associated 
with OA progression in knee and hip. Moreover, the functional d3-GHR 
polymorphism predicted osteophyte progression in the knee. In addition, 
medically well-controlled patients showed more radiographic progression 
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compared with surgically cured patients. In previous studies, GH secretion 
was found to be persistently abnormal during treatment with SMS 
analogs, despite appropriate biochemical control according to current 
criteria (29-32). Although disease history and treatment characteristics 
were not completely comparable between SMS-treated and surgically 
cured patients, the present study supports the hypothesis of suboptimal 
GH control in SMS-treated patients. 
The classification of the radiographic changes of acromegalic 
arthropathy, which differs from those of primary OA, is subject to 
debate. Secondary OA in long-term controlled acromegaly presents 
with a characteristic phenotype of severe osteophytosis, frequently with 
extremely wide joint spaces, which is a well-known characteristic of active 
acromegalic disease (4). At present, no acromegalic-specific classification 
system for arthropathy exists, and primary OA scales are used, although 
with these scales joint space widening cannot be evaluated. Therefore, 
a main feature of acromegalic arthropathy is not taken into account. 
Because of the discrepancy between osteophyte severity and the lack of 
JSN, we preferred to use the OARSI atlas for grading radiographic OA 
with individual scores for osteophytes and JSN, and not a global OA 
scoring system such as Kellgren-Lawrence (33). However, it is difficult to 
define pathological JSN progression in acromegaly. To date, it is unknown 
whether joint space regression is a degenerative osteoarthritic feature or 
a reflection of ongoing normalization of hypertrophied cartilage after 
remission induction. Some short-term ultrasonography studies showed 
reduced joint space thickness after biochemical control (22;23). However, 
the fact that we also demonstrated osteophyte progression supports the 
hypothesis that in the present study joint space reduction is a pathological 
phenomenon. Future research, possibly with magnetic resonance imaging 
(MRI), is required on the regression of hypertrophied cartilage to normal 
thickness.
The most remarkable manifestation in our study is the increased 
progression of radiographic OA in medically treated patients, 
demonstrated in individual patients and in joint-specific analyses. In 
previous studies, differential effects on QoL and diastolic heart function 
were documented in patients with biochemical control by SMS analogs 
vs patients with surgical cure of acromegaly (29;34). This notion of 
inappropriate control of GH secretion by SMS analogs is supported 
by persistent abnormalities in GH secretion in these patients, despite 
clinically normal GH/IGF-1 levels (30). Recently, Neggers et al. 
hypothesized that in certain patients SMS analogs may normalize serum 
IGF-1 by a GH-independent factor that induces hepatic GH resistance, 
which itself decreases hepatic IGF-1 production. Therefore, the reduction 
in circulating IGF-1 during SMS treatment does not necessarily imply 
disease control in peripheral tissues (extra-hepatic acromegaly) (35). 
Probably, SMS-treated patients might benefit from more aggressive 
disease control than obtained by applying current criteria. SMS analogs-
Pegvisomant combination therapy was reported to have positive effects on 
QoL, especially on the physical dimension (31). Further studies have to 
confirm whether addition of Pegvisomant optimalizes disease control and 
therefore improves joint symptoms. 
An alternative explanation for increased OA progression in SMS-
treated patients may be a direct IGF-1-independent effect of SMS analogs 
on joint structure. There is evidence for direct local effects of SMS on 
cartilage, which are mostly inhibitive (36-39). In addition, SMS receptors 
were demonstrated in bone cells, which may mediate direct effects on 
the bone (40). Further studies are needed to confirm the physiological 
significance of SMS in chondrocyte and osteoblast growth regulation, with 
a view to articular effects of long-term SMS use in acromegaly. Another 
explanation is a generally less favourable previous course of acromegaly 
in SMS-treated patients (i.e. longer active disease duration or more severe 
acromegaly disease), which might result in more progressive disease. 
However, most previous studies failed to demonstrate a relationship 
between duration of active disease and arthropathy (8;22;41;42).
The degree of progression in primary OA varies considerably, 
depending on OA subtype, the radiographic protocol and the scoring 
method of progression. Therefore, the progression percentages observed in 
our study could not simply be compared with other studies investigating 
radiographic OA progression. A prospective study with the same 
radiographic protocol is the Genetics, ARthrosis and Progression (GARP) 
Study, involving patients with primary generalized OA (43). However, in 
this study progression was scored according to a different protocol and 
by another team of observers, resulting in unknown variation. The results 
from our study suggest more progression in acromegaly patients than in 
the GARP cohort (44;45). However, due to the different study design, no 
firm conclusions can be drawn. 
Studies investigating OA progression over 2-3 years in the general 
population are scarce; most studies had longer follow-up. In several 
studies on hand OA, no significant change was demonstrated over 2 years 
(27;46-48). In the Rotterdam Study, radiographic OA progression was 
seen in 11.4% of the knees and 10.4% in the hips after 6.6 years follow-
up, indicating lower percentages after 2-3 years (49). Although study 
designs are not fully comparable, the OA progression rate in acromegaly is 
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suggested to be much higher than in general population.
Some potential limitations of the present study have to be addressed. 
The first concerns the possibility of bias due to differences between 
consenters and non-consenters for follow-up. However, demographic and 
disease-specific characteristics did not differ, except for higher percentage 
females in non-consenters. We expect that this sex difference is a random 
finding and is, therefore, unlikely to affect the outcome. Second, paired 
scoring for progression with the films in chronological order may possibly 
have led to overestimation of progression when compared to paired 
scoring with films blinded for time sequence (18). However, because we 
were (a priori) especially interested in risk factors for progression, any 
misclassification of progression would have been non-differential, and, 
furthermore, radiographs of both cured and SMS-treated patients were 
scored in the same manner. Third, the maximal obtainable osteophyte/
JSN scores in the hands were higher than in the hips or knees. It is very 
difficult to weight the responses in different joint sites and it is not clear if 
progression in one additional hand joint is as significant as one additional 
knee joint. Another limitation is the relatively short duration of additional 
follow-up after initial joint evaluation. Nonetheless, clear and multiple 
indications in different joint systems were obtained for progressive joint 
disease.  In addition, in the present study we were especially interested in 
short-to-midterm follow-up, because we expected more differentiation in 
OA progression and, therefore, more possibilities to study risk factors.
In conclusion, our study indicates that many patients with long-
term controlled acromegaly suffer from radiographic progression of 
acromegalic arthropathy, already within only 2.6 years of follow-up. 
Therefore, acromegalic arthropathy is a progressive joint disease that is 
not merely halted or reversed by biochemical disease control. Remarkably, 
biochemical control by SMS analogs was associated with increased 
radiographic progression of acromegalic arthropathy. However, since 
our study is not a randomized controlled trial, additional studies with 
longer follow-up duration are required to explore whether more aggressive 
treatment might be beneficial to improve the ultimate outcome of 
acromegalic arthropathy.
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ABSTRACT
OBJECTIVE: Arthropathy is an invalidating complication of acromegaly. 
This arthropathy deteriorates radiographically despite long-term 
disease control. However, the clinical course and its relationship to the 
radiographic course are currently unknown. We aimed to investigate the 
clinical course of arthropathy during follow-up and its relationship to 
radiographic progression in long-term controlled acromegaly patients. 
DESIGN: Prospective follow-up study.
METHODS: We studied 58 patients (mean age 62 years, women 41%) 
with controlled acromegaly for a mean of 17.6 years. Clinical progression 
of joint disease was defined at baseline and after 2.6 years, by the Western 
Ontario McMaster Universities Osteoarthritis Index (WOMAC) and 
Australian/Canadian Osteoarthritis Index (AUSCAN) questionnaires 
for lower limb and hand OA, respectively, and performance tests. 
Potential risk factors for progression were assessed. The clinical course of 
arthropathy was related to the radiographic course.
RESULTS: On average, hand and lower limb function deteriorated during 
follow-up, despite large interindividual variations. Joint pain was stable 
over time. High levels of pain and functional impairment at baseline were 
related to clinical progression of hand pain and functional limitations. 
High baseline BMI was a risk factor for functional deterioration in the 
lower limb. The changes in symptoms and radiographic progression during 
follow-up were not related.
CONCLUSIONS: In treated acromegaly patients, joint function 
deteriorates during prolonged follow-up, despite biochemical disease 
control, although there was interindividual variation. Clinical and 
radiographic course of arthropathy were not related. Therefore, in clinical 
practice, a combination of clinical and radiographic assessment is necessary 
to evaluate the course of acromegalic arthropathy. 
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INTRODUCTION
In active acromegaly, patients have pathologically high growth hormone 
(GH) and insulin-like growth hormone-1 (IGF-1) levels, caused by a 
GH-producing pituitary adenoma in most cases. The increased GH/IGF-1 
activity is associated with a variety of complaints, increased morbidity 
and mortality, resulting in reduced quality of life (QoL). Reversal of GH 
excess ameliorates clinical symptoms and life expectancy. However, other 
acromegalic features persist due to irreversible changes, for instance in 
bone and cartilage (1). 
One of the most invalidating complications of acromegaly, which is 
at least partially irreversible, is arthropathy (2). Joint-related complaints, 
such as pain, stiffness or functional limitations, present at very young 
ages, frequently in combination with typical radiological abnormalities 
(3). Both weight and non-weight bearing joints are affected. Remarkably, 
even after long-term remission of acromegaly, the prevalence of clinical 
and radiographic osteoarthritis (OA) is persistently high, up to 12-fold 
higher compared to that in the general population (4). The presence of 
joint problems is associated with a considerable impairment of physical 
functioning and psychological well-being, reducing QoL (5). 
Recently, arthropathy was reported to progress radiographically 
in acromegaly patients, even despite biochemical disease control (6). 
However, at present the clinical disease course of arthropathy during 
prolonged follow-up has not been studied. The determinants of outcome 
are not fully elucidated. Knowledge on these topics provides more insight 
in the pathophysiological processes that play a role in chronic acromegalic 
arthropathy. In addition, the knowledge of modifiable determinants can 
lead to new-targeted therapies. 
Therefore, we designed a prospective follow-up study to assess the 
clinical course of acromegalic arthropathy and to identify risk factors for 
clinical progression. Furthermore, we aimed to evaluate the clinical OA 
course in relation to radiographic disease progression in order to propose a 
clinically useful tool to score arthropathy in acromegaly. 
PATIENTS AND METHODS
Study design and patient selection
PATIENTS: All consecutive patients with acromegaly, who were referred 
to the Leiden University Medical Center for treatment from 1977 
onwards, are collected in a database. In 2007, 89 acromegaly patients 
with long-term biochemical remission for a mean of 15.0 years (range 
2.0-31.0 years) were assessed in a cross-sectional study (baseline visit) (4). 
All patients were re-invited in 2010 for a follow-up visit, of which 58 
consented to participate. Thirty-one (35%) declined to participate, with 
health problems not related to OA (N=16) and travel distance (N=6) 
as most frequent reasons. There were no differences in demographic 
and acromegalic disease characteristics, nor in (radiographic) severity of 
arthropathy between patients participating in the follow-up study and 
those who did not (data not shown), except for more females among non-
participators (p=0.025) (4;5). 
Detailed yearly biochemical and clinical follow-up had been performed 
from the onset of acromegaly treatment. From 1977 onwards, the first 
treatment option in the majority of patients was transsphenoidal surgery 
(TPS) performed by a single specialized neurosurgeon. If necessary, 
adjuvant treatment consisted of radiotherapy (prior to 1985) or SMS 
analogs (from 1985 onwards). From 1998, in some patients, primary 
treatment consisted of depot formulations of long-acting SMS analogs. 
This treatment approach resulted in early postoperative control in 66% 
and late control in more than 90% of the patients (7). From 2003, 
Pegvisomant was available for treatment-resistant acromegaly. 
Disease activity was assessed yearly by oral glucose tolerance tests 
(except in medically-treated patients), fasting serum GH and IGF-1 levels. 
Remission was defined as a normal glucose-suppressed serum GH<1.25 
(RIA assay until 1992) or 0.38µg/l (immunofluorometric assay (IFMA) 
from 1992 onwards), serum GH levels of <1.9µg/L (all years), and normal 
IGF-1 levels for age (from 1986 onwards) (1;8;9). Patients not meeting 
these criteria were offered additional treatment.
Hypopituitarism was supplemented with estrogens/testosterone, 
thyroxine, hydrocortisone according to the following definitions (1;8;10). 
Estrogen deficiency in women was present in case of LH/FSH deficiency 
in premenopausal women with prolonged amenorrea >1 year without 
adequate replacement therapy or by low serum oestradiol concentration of 
<70nmol/l and all postmenopausal women. In men, LH/FSH deficiency 
was defined as testosterone level <8.0nmol/l. Thyroid stimulating hormone 
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(TSH) deficiency was defined as a free thyroxine level below the reference 
range (<10pmol/l). Adrenocorticotrophic hormone (ACTH) deficiency 
was defined as an insufficient increase of cortisol (peak <0.55µmol/l) 
after corticotrophin releasing hormone test or insulin tolerance test. GH 
deficiency was not routinely assessed.
The Medical Ethics Committee approved the study protocol, and all 
subjects gave written consent for their participation.
STUDY DESIGN: Patients were included for baseline cross-sectional 
assessment between September and December 2007. Between March and 
September 2010 participants who consented for a follow-up evaluation 
were assessed. At both study visits, patients completed standardized 
questionnaires (vide infra), conventional radiographs of hands, hips 
and knees were obtained in all patients (vide infra), and blood samples 
were taken in the post-absorptive state to assess actual GH and IGF-1 
concentrations. 
Study parameters
QUESTIONNAIRES: A standardized questionnaire was completed 
concerning demographic data, medical history and symptoms and signs 
of OA. Self-reported pain, stiffness and functional limitations were 
assessed with the corresponding subscales of the Australian/Canadian 
Osteoarthritis Hand Index (AUSCAN) and Western Ontario McMaster 
Universities Osteoarthritis Index (WOMAC), assessing the hand and 
lower limb (knee and hip together), respectively (11;12). Samples of 
questions include: pain during rest, pain during walking stairs, pain which 
disturbs sleep, pain during sitting, stiffness after a time of inactivity, 
problems with bending, problems with pulling on socks, problems with 
opening of a cooking-pot, and problems when picking up heavy things. 
Using the AUSCAN, items are rated on a 5-point Likert scale ranging 
from 0 (none) to 4 (extreme), using a 48-h time frame, total scores 
ranging from 0 to 20, 0 to 4 and 0 to 36, for pain, stiffness and function, 
respectively. WOMAC scores on the subscales pain, stiffness and function 
range from 0 to 100, using a 100mm visual analogue scale (VAS) format. 
Higher scores indicate worse outcome.
PERFORMANCE TESTS: Cylinder and pinch grip strength of both 
hands was assessed using a cylinder and pinch grip meter, respectively, in 
kilograms (13;14). 
RADIOGRAPHIC PROTOCOL AND RADIOGRAPHIC SCORING: 
Conventional radiographs of the hands (dorsovolar), knees (posterior-
anterior (PA), in weight-bearing/semi-flexed and lateral) and hips (PA, 
supine) were obtained by a single experienced radiographer, according to 
a standardized protocol (15). These radiographic data have been recently 
published (6).
Radiographs were scored paired in chronological order blinded 
for patient characteristics by a single trained reader (K.C.), using the 
Osteoarthritis Research Society (OARSI) atlas (16). Osteophytes and 
JSN were graded 0-3 in the hands (distal interphalangeal (DIP), proximal 
interphalangeal (PIP), metacarpophalangeal (MCP), first interphalangeal 
(IP), and first carpometacarpal (CMC1) joints), knees (medial and lateral 
tibiofemoral) and hips. Total scores were calculated by adding left and 
right sites, with maximum scores ranging from 0 to 108 for JSN and from 
0 to 120 for osteophytes. Intra-class correlation coefficients (ICCs) for 
intra-reader reproducibility based on 15 randomly selected radiographs, 
were 0.98 and 0.98 in the hands, 1.00 and 0.99 in the knee, 0.98 and 
1.00 in the hip, for JSN and osteophytes respectively. 
DEFINITION OF CLINICAL PROGRESSION: Clinical relevant change in 
hand OA was evaluated by the minimum clinically important improvement 
(MCII) of 1.49 and 1.25 for pain and function, respectively (17). Those with 
a change on AUSCAN pain and function below -1.49 and -1.25, respectively, 
were classified as improved. Patients with change on AUSCAN pain and 
function above 1.49 and 1.25, respectively, were classified as deteriorated. 
Clinical progression of lower limb OA was defined as an increase in 
self-reported (WOMAC) pain, stiffness or functional limitations above the 
predefined minimum perceptible clinical improvement (MPCI). MPCI was 
originally developed as threshold value to define treatment response in OA. 
Threshold values were 9.7 for WOMAC pain, 10.0 for WOMAC stiffness 
and 9.3 for WOMAC function (18). These threshold values with negative sign 
were used to define clinical improvement.
DEFINITION OF RADIOGRAPHIC PROGRESSION: For osteophytes and 
JSN the smallest detectable change (SDC) was used to assess change over 
2.6 years above the measurement error (0.85 and 0.57 resp.), and therefore, 
radiographic progression was defined as ≥1-score increase in JSN or osteophyte 
total scores (19). At joint site level, radiographic progression was defined as 
≥1-score increase in JSN or osteophyte score at the specific site (SDCs for 
osteophytes and JSN: knee, both 0.3; hip, both 0.4; hands, 0.8 and 0.4, resp.), 
only in those joints with baseline features of radiographic OA. 
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PARAMETERS OF ACROMEGALIC DISEASE: Active disease duration 
was estimated using the start of symptoms and signs to the date of serum 
IGF-1 normalization after treatment. Duration of remission was calculated 
from the date of biochemical remission until the start of the present study. 
Cure of acromegaly was defined by normal glucose-suppressed GH levels 
and IGF-1 levels for age after surgery and/or irradiation. Biochemical 
acromegaly control was defined by normal serum IGF-1 levels for age 
during SMS analog treatment. Both cured and biochemically controlled 
patients were referred to as ‘in remission’.
BIOCHEMICAL PARAMETERS: Serum GH was measured with a sensitive 
IFMA (Wallac, Turku, Finland), specific for the 22kDA GH protein, 
calibrated against World Health Organisation International Reference 
Preparation (WHO IRP) 80/505 (detection limit: 0.01µg/l, interassay 
coefficient of variation (CV): 1.6-8.4% of 0.01-15.38µg/l) from 1992 
onwards. For the conversion of µg/l to mU/l, multiply by 2.6. Before 
1992, GH was measured by RIA (Biolab, Serona, Coissins, Switzerland), 
calibrated against WHO IRP 66/21 (detection limit: 0.5mU/l, with an 
interassay CV<5%; for the conversion of µg/l to mU/l, multiply by 2). 
Serum IGF-1 concentrations (nmol/l) were measured using an 
immunometric technique on an Immulite 2500 system (Diagnostic 
Products Corporation, Los Angeles, CA, USA). The intra-assay 
variations at mean plasma levels of 8 and 75nmol/l were 5.0 and 7.5%, 
respectively. IGF-1 levels were expressed as SD score, using lambda-mu-
sigma smoothed reference curves based on measurements in 906 healthy 
individuals (20;21). 
Statistical analysis
SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA), was used 
for data analysis. Mean changes with 95% confidence intervals (CI) for 
the pain, stiffness and function subscales of the AUSCAN and WOMAC 
questionnaires, hand grip strength, and osteophytes and JSN were 
calculated. Cumulative probability plots were used to visualise changes in 
AUSCAN and WOMAC pain and function, respectively. 
Binary logistic regression analyses were used to evaluate determinants 
for clinical OA progression with respect to pain and function, for the hand 
and lower limb, with clinical progression as dependent variable. Age, sex, 
BMI, acromegalic-specific parameters (i.e. type of treatment, baseline 
IGF-1 SDS, active disease duration), baseline self-reported pain and 
function scores, and structural abnormalities at baseline (osteophytes/JSN) 
were studied. Adjustments were made for the use of pain medication. 
The association between clinical change and radiographic progression 
of OA was assessed by estimating mean differences between patients 
with and without radiographic progression, using Independent T-tests. 
ANCOVA analyses were performed to adjust for age, sex, BMI, baseline 
total AUSCAN and WOMAC scores for hand and lower limb OA, 
respectively, and baseline osteophytes and JSN, with radiographic 
progression as dependent variable.
RESULTS
Patient description
Fifty-eight patients with long-term remission of acromegaly were included 
and followed for a mean of 2.6 years (range 2.3-2.9 years). Patient 
characteristics are shown in Table 1. Mean age was 61.8±10.9 years and 
41% were women. Patients were in remission for a mean of 17.6±7.2 
years (minimum 2 years) and mean actual IGF-1 SDS was 0.51±1.51. 
No recurrences occurred during longitudinal follow-up. In 40 patients 
(69%) remission was achieved by surgery, and, if necessary, by additional 
radiotherapy. The other 18 patients (31%) were treated during the 
observation period by either primary and/or postoperative long-acting 
SMS analogs. One patient was co-treated with Pegvisomant. Any pituitary 
deficiency was present in 20 patients (35%). 
At baseline, structural abnormalities on radiographs were highly 
prevalent. In the knee, osteophytes and JSN were present in 78% and 
31% of patients, respectively; in the hip, prevalence of osteophytes and 
JSN was 72% and 14%, respectively, and in the hands 84% and 70%, 
respectively.
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Clinical course of acromegalic arthropathy over 2.6 
years
Self-reported pain and disabil ity
HANDS: Mean self-reported pain did not significantly change over time 
(Table 2). However, there was a great variation on the individual level, as 
depicted in a cumulative probability plot (Figure 1A). Clinically relevant 
increase in pain was found in 15 patients (27%), whereas 6 patients (10%) 
reported less pain. With respect to change in functional limitations, 26 
patients (45%) reported more functional limitations and 4 patients (7%) 
improved (Figure 1A). Mean AUSCAN function scores deteriorated 
significantly over time (p<0.001) with a mean change (2.6±4.8) above 
the clinically relevant deterioration threshold (i.e. 1.25), although there 
was large individual variety. Especially on the questions regarding muscle 
power and fine motor control, patients reported worse scores over time.
LOWER LIMB: WOMAC stiffness and function scores, not pain scores, 
deteriorated significantly over time (Table 2). Patients deteriorated 
especially on the following items: descending stairs, putting on and taking 
off socks, rising from bed and getting in/out bath. As shown in Figure 
1B, clinically relevant progression was shown in 27 patients (47%), based 
on changes in WOMAC pain (N=12), stiffness (N=21) or function 
scores (N=10) above the MCPI. Twenty-one patients improved, based 
on changes in WOMAC pain (N=9), stiffness (N=9) or function score 
(N=14) below the MCPI. 
AUSCAN and WOMAC change scores of pain, stiffness and function 
subscales were not significantly different between younger (<45 years) and 
older (≥65 years) patients, nor between males and females (data not shown). 
Also when the clinical course of arthropathy was only assessed in patients 
with radiographic presence of OA at baseline, we found similar heterogeneous 
clinical changes during follow-up (both for AUSCAN and WOMAC). 
At baseline and follow-up 6 (10.3%) and 7 (12.1%) patients used 
medication for joint symptoms, respectively. Non-steroidal anti-
inflammatory drugs (NSAIDs) and paracetamol were most frequently 
used: at baseline by 8.6% and 1.7% of the patients, respectively, and at 
follow-up by 3.4% and 8.6%, resp. Joint surgery was performed in 4 
patients (6.9%) (knee surgery N=3, hip surgery N=1).During follow-up, 3 
patients (5.2%) received a joint replacement (2 knees, 1 hip). In the small 
subgroup of patients with joint prostheses, pain did not change over time, 
and function scores improved in 1 patient.
Performance tests (Table 2)
Cylinder grip strength decreased over 2.6 years (p=0.052), especially in the 
right hand (p=0.021), which was the dominant hand in 83% of patients. 
In addition, pinch grip strength deteriorated considerably, with a mean 
decrease of 2.5±2.2 kilograms (p<0.001).
Figure 1A
Figure 1B
Cumulative probability plots of change in self-reported pain and functional limitations of 
the hand (A) and lower limb (B), respectively, over 2.6 years in 58 patients with long-term 
controlled acromegaly.
A. Change in self-reported pain and functional limitations in the hand. The horizontal lines 
represent the cut-off for deterioration and improvement based on the minimum clinically important 
improvement. Patients above the upper horizontal line have deterioration of pain or functional 
limitations. Patients below the lower dotted line have improvement of pain or functional limitations.
B. Change in self-reported pain and functional limitations in the lower limb. The horizontal line 
above is the line set at minimal perceptible clinical improvement (MCPI) score which is used as 
the cut-off to define clinical progression, and the horizontal line below is the line set to define 
improvement. 
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Table 1. Clinical characteristics of  58 patients with 
acromegaly
Clinical characteristics Patients (N=58)
Age (years) 61.8 (10.9)
Sex, female (n (%)) 24 (41.4)
BMI (kg/m2) 28.9 (4.5)
Treatment (n (%))
  Surgery only
  Surgery + RT   
  SMS analogues 
        Primary
        Following surgery *
        Following RT







Disease duration (years) 9.2 (8.1)
Duration of remission (years) 17.6 (7.2)







  Corticotrope failure
  Thyreotrope failure
  Gonadotrope failure
     Males
     Pre-menopausal







Values are means (SD) unless stated otherwise. 
GH, growth hormone; IGF-1, insulin-like growth factor 1; BMI, body mass index; RT, radiotherapy; 
SMS, somatostatin (analogs), long-acting. *, one patient is co-treated with Pegvisomant.
Table 2. Baseline, follow-up and change scores on self-
reported pain and functional l imitations, grip strength of  
the hands, and radiographic OA features in 58 patients with 
long-term controlled acromegaly followed for 2.6 years























































Data are shown as mean (SD). *, mean change (SD) over 2.6 years. **, 95% CI of the change.
AUSCAN, Australian/Canadian Osteoarthritis Hand Index; WOMAC, Western Ontario McMaster 
Universities Osteoarthritis Index; kg, kilograms; OP, osteophytes; JSN, joint space narrowing.
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Table 3. Risk factors for cl inical progression of  acromegalic 
arthropathy, as def ined by an increase in pain or functional 
impairment over time, in 58 patients with controlled disease, 
for hand and lower l imb OA, respectively
Hand Lower limb
Risk factors Clinical OA 
progression





















































Risk factors were analyzed with binary logistic regression analysis with progression of clinical OA as 
dependent variable, independently assessed for the hand and lower limb. Baseline IGF-1 SDS were 
IGF-1 SD scores at the time of the study visit in 2007. Disease cure is defined as normal glucose-
suppressed GH levels and IGF-1 levels for age after surgery and/or irradiation. 
CI, confidence interval; BMI, body mass index; NA, not applicable. *, p<0.05. 
#, adjustments were made for the use of pain medication. 
Determinants of clinical progression in hand and 
lower limb OA after 2.6 years 
HANDS: Both clinical progression of hand pain and functional limitations, 
defined by the predefined cut-off values of MCII for hand OA, were 
related to severe functional impairment (OR=1.29 (1.08-1.53), p=0.005 
and OR=1.18 (1.04-1.33), p=0.009 for baseline pain and function, resp.) 
and pain at baseline (OR=1.33 (1.09-1.60), p=0.004 and OR=1.32 
(1.11-1.58), p=0.002) for baseline pain and function, resp.), as reflected 
by AUSCAN function and pain scores, respectively, also when adjusted for 
the use of pain medication. Age, female sex, BMI, determinants reflecting 
acromegaly disease activity (i.e. baseline IGF-1 SDS, active disease 
duration, type of treatment for acromegaly) and structural abnormalities 
at baseline (i.e. osteophytes/JSN) were not associated with clinical 
deterioration (Table 3). 
LOWER LIMB: Demographic characteristics, acromegaly-specific 
parameters and structural abnormalities were not related to clinical 
progression of lower limb OA, defined as WOMAC pain or function 
scores above the predefined thresholds of the MPCI (Table 3). A higher 
BMI, however, was positively associated to functional progression 
(OR=1.20 (1.02-1.41), p=0.031), meaning that BMI was 1.2-fold higher 
in patients with functional deterioration over time. Clinical progression 
was not associated with the severity of self-reported pain or functional 
limitations at baseline (as reflected by WOMAC scores). 
Relationship between clinical change and 
radiographic progression in acromegalic arthropathy
As previously published, total scores of osteophytes and JSN deteriorated 
over time (Table 2), reflected by mean changes of total scores of 2.0±1.9 
and 1.7±1.7, respectively (3;6). Radiographic progression of osteophytes 
and JSN at any joint site was present in 42 (72%) and 43 (74%) patients, 
respectively. 
HANDS: The mean change in self-reported pain and functional limitations 
in the respective AUSCAN subscales was not different between patients 
with and without radiographic progression of hand OA, with mean 
differences (95%CI) in pain and functional limitations of -0.14 (-2.36, 
2.08) and -0.32 (-3.52, 2.87), respectively, between patients with and 
without osteophyte progression; mean differences between patients with 
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and without JSN progression were -0.02 (-1.72, 1.68) and -0.26 (-2.89, 
2.36) for pain and function, resp. Adjustments for age, sex, BMI, baseline 
AUSCAN total score, baseline osteophyte and JSN scores in the hand did 
not change these results. This indicates no relationship between clinical 
change and radiographic progression.
LOWER LIMB: In addition, there was no association between clinical 
change and radiographic progression in the lower limb, neither when 
adjusted for age, sex, BMI, baseline WOMAC total score, baseline 
osteophytes and JSN in the lower limb. Mean differences in pain and 
functional limitations (4.12 (-4.62, 12.86) and 0.91 (-9.39, 11.21), 
respectively) did not differ between patients with and without osteophyte 
progression, nor between patients with and without JSN progression 
(-2.68 (-11.43, 6.06) and -6.31 (-17.23, 4.60) for pain and function, 
resp.).  
DISCUSSION
The present study evaluates the clinical course of acromegalic arthropathy in well-
controlled patients and the relationship with radiographic changes. Although there 
was large interindividual variation, on average we found significant deterioration 
of hand and lower limb function, but not of pain, over time, as reflected by higher 
AUSCAN and WOMAC function scores and decreased grip strength after 2.6 
years of prospective follow-up. There was no clear association between the clinical 
and radiographic changes of acromegalic arthropathy over time.  
The prevalence of acromegalic arthropathy is high in patients with both 
active and well-controlled acromegaly, and is significantly increased when 
compared to general population (4). Acromegalic arthropathy affects 
both weight and non-weight-bearing joints, which is associated with 
decreased QoL (22). The pathophysiology of acromegalic arthropathy 
is not fully understood; there are some similarities with primary OA. 
It is hypothesized that there are two phases in the pathogenesis of 
acromegalic arthropathy. First, elevated GH and IGF-1 levels induce 
cartilage hypertrophy and laxity of the peri-articular ligaments, leading 
to thickening of the cartilage lining and congestion of the joint space 
resulting in a limited range of motion. Furthermore, IGF-1 is involved 
in the initiation and regulation of osteophyte development (23). This 
early stage is thought to be at least partially reversible by adequate 
treatment (24). However, when this GH/IGF-1 excess persists, the 
pathophysiological process becomes irreversible and self-perpetuating, 
eventually leading to joint failure. Recently, acromegalic arthropathy 
was reported to progress radiographically despite long-term biochemical 
remission (6). However, clinical disease course in treated patients have not 
been assessed before. 
Several issues are of interest with respect to clinical arthropathy in 
acromegalic patients. First, scores on the WOMAC and AUSCAN 
questionnaires, especially on pain and function subscales, were relatively 
low when compared to primary OA patients. This might be explained 
by the typical radiographic phenotype of acromegalic arthropathy, with 
predominantly osteophytosis in combination with preserved or even 
widened articular cartilage (3). This is in accordance with previous 
observations reporting less joint prostheses when compared to primary OA 
patients, suggesting that cartilage hypertrophy may protect against pain 
caused by osteophytes and, therefore, protect acromegalic patients against 
a decrease in functional capability. In addition, patients in our acromegaly 
cohort were not selected on the presence of arthropathy, but we included 
all consecutive patients that gave informed consent. This may probably 
explain the lower clinical OA scores in our patients. Second, there was 
no relation between clinical deterioration and radiographic progression 
of arthropathy. This discordance between clinical and radiographic OA 
course is also present in primary OA (3;25). We demonstrated that 
the clinical course of arthropathy was very heterogeneous: some of the 
acromegalic patients remained stable and in a substantial proportion 
of patients even improvement of symptoms was seen. Thus, clinical 
deterioration is not inevitable for each patient. In contrast, radiographic 
abnormalities worsen over time. It is important to bear in mind and 
inform patients that the evolution of symptoms and radiographic 
abnormalities are not related.
 This study might suffer from several limitations. First, the number 
of patients is relatively small, probably resulting in a power problem to 
identify risk factors for clinical progression over time. Therefore, larger 
patient cohorts have to be followed prospectively in order to draw firm 
conclusions. Second, it has to be kept in mind that the WOMAC and 
AUSCAN questionnaires are used primarily in primary OA research, and 
are not developed or validated for acromegalic arthropathy. However, 
since there are currently no acromegaly-specific scoring methods for 
arthropathy, we are limited to use these primary OA methods. Further 
study has to point out whether modification of present methods is needed 
in order to fit the typical phenotype of acromegalic arthropathy. Third, 
several patients received analgesic and NSAID therapy, and 31% of 
patients used SMS analogs which might have analgesic properties.  
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These factors might have lessened their joint complaints. However, 
the clinical course, as far as we know, is not influenced by any type of 
medication; and therefore we do not believe that the used medication 
will interfere with our results. On the other hand, this indicates that 
the optimal management of acromegalic arthropathy requires further 
study. In this respect, further investigation has to assess whether 
specific intervention therapies, for example with physiotherapy, could 
be beneficial. Fourth, since a considerable proportion of patients have 
multiple pituitary hormone deficiencies, it is difficult to examine to what 
extent the changes in joint problems can be attributed to (previous) 
GH excess. It could also be the consequence of suboptimal or excessive 
replacement therapy of other hormones, although, at present, no such 
associations with arthropathy are reported. Finally, ideally, we would 
prefer to include a control group of uncontrolled acromegaly patients 
that gives us insight into the course of arthropathy during active disease. 
Unfortunately, such a control group is not available in our center. A 
prospective study with a comparable study design among patients with 
primary generalized OA is the GARP Study (Genetics, ARthrosis and 
Progression) (26). The results of our study suggest that especially joint 
function deteriorates faster in acromegaly than in GARP patients, as 
reflected by higher mean changes in AUSCAN and WOMAC function 
scores over 2 years (27;28). However, based on these limited data, no firm 
conclusions can be drawn. 
 In conclusion, hand and lower limb function, not joint pain, 
deteriorated over time in a considerable proportion of patients with 
well-controlled acromegaly, although there was large variation between 
individuals. Clinical and radiographic course were not related, and, 
therefore, we believe that in clinical practice a combination of clinical and 
radiographic assessment is necessary to evaluate the course of acromegalic 
arthropathy. Additional studies in larger patient cohorts have to identify 
potential modifiable risk factors associated with clinical deterioration. 
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ABSTRACT
BACKGROUND: Arthropathy is a prevalent and invalidating complication 
of acromegaly with a characteristic radiographic phenotype. We aimed 
to further characterize cartilage and bone abnormalities associated with 
acromegalic arthropathy using Magnetic Resonance (MR) imaging. 
METHODS: Twenty-six patients (23% women, mean age 56.8±13.4 
years), with active (N=10) and controlled acromegaly (N=16) underwent 
a 3.0T MRI of the right knee. Osteophytes, cartilage defects, bone 
marrow laesions, and subchondral cysts were assessed by KOSS (Knee 
Osteoarthritis Scoring System). Cartilage thickness and cartilage T2 
relaxation times, in which higher values reflect increased water content, 
were measured. Fifty-nine controls (80% women, mean age 61.9±6.8 
years) with primary knee OA were included for comparison. 
RESULTS: In active acromegaly, structural OA defects were already highly 
prevalent. Active acromegaly patients had thicker cartilage and higher 
cartilage T2 relaxation times than controlled patients. When compared 
to primary OA subjects, acromegaly patients seem to have less cysts, but 
comparable prevalence of osteophytosis, cartilage defects and bone marrow 
laesions. Acromegalic patients had thicker joint cartilage with higher 
cartilage T2 relaxation times than primary OA subjects.
CONCLUSIONS: In active acromegaly, prevalence of structural OA 
abnormalities is high, in combination with thick joint cartilage. In 
addition, T2 relaxation times of cartilage are high in active patients, 
indicating unhealthy cartilage with increased water content, which is 
(partially) reversible by adequate treatment. Distribution of structural 
abnormalities on MR imaging differs from that observed in subjects with 
primary OA, with in particular differences in joint cartilage.
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INTRODUCTION
Acromegaly is a chronic rare endocrine disease, caused by a Growth 
Hormone (GH)-producing pituitary adenoma, resulting in elevated GH 
and Insulin-like Growth Factor-1 (IGF-1) concentrations. Acromegaly 
patients have an increased risk to develop secondary osteoarthritis (OA), 
having a considerable impact on physical functioning and psychological 
well-being (1;2). The pathophysiology of acromegalic joint disease is 
not fully elucidated, although there is growing evidence for a role of the 
GH/IGF-1 system both in the initiation and progression of acromegalic 
arthropathy (3-5). 
On conventional radiographs of patients with active acromegaly, 
joint disease is characterized by widening of joint spaces and severe 
osteophytosis (6). In a well-characterized cohort of patients with long-term 
disease control following currently available treatment, i.e. transsphenoidal 
pituitary surgery or GH-lowering medication, we recently observed a 4 
to 12-fold increased prevalence of arthropathy, already being present at 
young ages (1). Remarkably, the distribution of structural OA features 
differs from that in patients with primary OA. Acromegalic arthropathy is 
predominantly characterized by osteophytosis, frequently in combination 
with preserved or even widened joint spaces, suggesting that cartilage 
hypertrophy is maintained despite long-term biochemical disease control 
(7). However, no imaging studies of this unique phenotype of secondary 
OA with pathological cartilage hypertrophy have been performed, except 
for a single group that used ultrasonography (8;9). We have recently 
reported that several parameters indicating an increased GH/IGF-1 signal 
were associated with radiographic OA (ROA) and ROA progression in 
acromegalic patients, i.e. high IGF-1 levels at the time of diagnosis and 
the presence of the common exon 3 deletion (d3-GHR) GH receptor 
polymorphism (3-5). 
To further study the unique phenotype of acromegalic arthropathy, 
Magnetic Resonance (MR) imaging may give additional information 
to radiographs. MRI directly visualizes cartilage, enabling assessment of 
cartilage defects, thickness and quality, osteophytes but also other structural 
abnormalities of subchondral bone such as cysts and bone marrow edema. 
Cartilage quality can be measured by cartilage T2 relaxation times, being 
related to water content and collagen anisotropy, providing information on 
cartilage biochemical composition (15). A higher T2 value has previously been 
reported in cartilage of OA patients compared to healthy controls and it was 
reported that high T2 values correlate with the severity of the disease (16;17). 
In the present study, we investigated knees of 26 acromegaly patients 
by 3.0 Tesla (3.0T) MRI to study structural OA abnormalities. Both 
acromegaly patients with active and controlled disease were studied, to 
study the potential relationship between structural OA features and disease 
activity. We included subjects with primary OA as controls to differentiate 
which structural abnormalities on MRI were acromegaly-specific. 
MATERIALS AND METHODS
Study design and patient selection
STUDY DESIGN: In a cross-sectional study design, we performed 3.0T 
MRI scans of the knee in acromegaly patients, who were divided into 
two subgroups: (1) active patients and (2) patients in remission, by either 
transsphenoidal surgery and/or radiotherapy or SMS analog treatment. We 
included control subjects with primary knee OA from the geMstoan study 
(vide infra, (18)) to evaluate differences in structural joint abnormalities 
and cartilage thickness of the knee. In addition, we included literature 
controls with primary OA (19) to compare cartilage biochemical 
composition by measuring cartilage T2 relaxation times at different 
locations in the knee.
PATIENTS: All consecutive patients with acromegaly, who were referred 
to the Leiden University Medical Center, were collected in a database. 
Complementary to a cross-sectional and follow-up study evaluating 
clinical and radiographic arthropathy in long-term biochemically 
controlled patients, a subset of controlled acromegaly patients was invited 
to undergo an additional MRI assessment (1;4). In addition to controlled 
patients, active acromegaly patients were included in the present MRI 
study, resulting in a total of 26 eligible patients. Patients were divided into 
two subgroups: (1) active acromegaly, and (2) acromegaly in remission, 
comprising both patients cured after transsphenoidal surgery and, if 
required, additional radiotherapy, and patients controlled by SMS analogs. 
Two patients underwent two knee MRIs at different time points (i.e. one 
MRI before surgery and one MRI >6 months after successful surgery), 
resulting in 28 available MRIs for analysis.
Detailed yearly follow-up was performed from the onset of acromegaly 
treatment. The first treatment option in the majority of patients was 
transsphenoidal surgery performed by a single specialized neurosurgeon. 
If necessary, adjuvant treatment consisted of radiotherapy (prior to 1985) 
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or SMS analogs (from 1985 onwards). From 1998, some patients received 
depot formulations of long-acting SMS analogs as primary treatment. 
Since 2003, Pegvisomant was available for treatment-resistant acromegaly. 
Disease activity was assessed yearly by oral glucose tolerance tests 
(oGTT) (except in medically treated patients), fasting serum GH 
and IGF-1 levels. Remission of acromegaly was defined as a normal 
glucose-suppressed serum GH <1.25 (RIA assay until 1992) or 0.38µg/l 
(immunofluorometric assay (IFMA) from 1992 onwards), serum GH 
levels of <1.9µg/l (all years), and normal IGF-1 levels for age (from 
1986 onwards) (20-22). Patients not meeting these criteria were offered 
additional treatment. 
Hypopituitarism was supplemented with levothyroxine, 
hydrocortisone, testosterone/estrogens according to the following 
definitions (22). Estrogen deficiency in women was present in case of 
luteinizing hormone (LH)/follicle-stimulating hormone (FSH) deficiency 
in premenopausal women with prolonged amenorrea >1 year without 
adequate replacement therapy or by a low serum oestradiol concentration 
of <70nmol/liter and all postmenopausal women. In men, LH/FSH 
deficiency was defined as testosterone level below the reference range 
(8.0nmol/l). Thyroid-stimulating hormone (TSH) deficiency was 
defined as a free thyroxine level below the reference range (<10pmol/l). 
Adrenocorticotrophic hormone (ACTH) deficiency was defined as an 
insufficient increase of cortisol (peak <0.55µmol/l) after corticotrophin 
releasing hormone (CRH) test or insulin tolerance test (ITT). GH 
deficiency was not routinely assessed. 
The Medical Ethics Committee approved the study protocol, and all 
subjects gave written consent. 
CONTROLS: Three control groups were included for comparison with 
acromegaly patients.
A: For comparison of the structural OA abnormalities assessed by the 
Knee Osteoarthritis Scoring System (KOSS), acromegaly patients were 
compared to controls from the geMstoanstudy (GEneration of Models, 
Mechanisms & Markers for Stratification of OsteoArthritis patients). 
The geMstoan study (N=62) is a longitudinal study among primary OA 
patients with established symptomatic and radiographic knee OA, aiming 
on identification of new biomarkers for OA progression (18). Of 62 
geMstoan subjects, two MRIs were missing (vide infra), and one subject 
was diagnosed with rheumatoid arthritis, resulting in 59 eligible controls. 
The geMstoan study is approved by the Medical Ethics Committee, and all 
patients provided written informed consent.
B: Cartilage thickness measurements were compared with a random 
selection of 10 controls from the geMstoan study. 
C: For comparison of cartilage T2 relaxation times, we used a literature 
reference from Stahl et al. describing 17 controls (9 females/8 males) with 
mild primary OA, since reference values of cartilage T2 relaxation times 
were not available in our center (19). In this literature reference, OA was 
defined as radiographic OA (Kellgren-Lawrence (KL) 1 or 2) and clinical 
OA according to the clinical ACR criteria (mean age of 54.0±10.0 years; 
mean BMI 23.6±7.1 kg/m2).Cartilage T2 relaxation times were measured 
at the same knee locations as in the acromegalic patients (vide infra).
STUDY PROTOCOL: Acromegaly patients were seen on the outpatient 
clinic for a single study visit. All patients completed standardized 
questionnaires on demographic data, medical history and OA signs 
and symptoms, and the validated WOMAC questionnaire on pain, 
stiffness and functional disability of the lower limb (23). Conventional 
knee radiographs were obtained according to a standard protocol (vide 
infra), and all patients underwent an MRI scan of the right knee. 
Physical examination of the knee was performed by a single physician 
(K.M.J.A.C.), trained in structured joint assessment. 
GeMstoan controls underwent an MRI of the knee with symptomatic 
OA, and conventional knee radiographs were obtained. Self-reported pain 
was assessed by the visual analogue scale (VAS, 0-100) within two weeks of 
MRI acquisition and the WOMAC questionnaire was completed. 
Study parameters
PARAMETERS OF ACROMEGALIC DISEASE: Duration of active disease 
was estimated using the start of symptoms and signs to the date of 
normalization of serum IGF-1 concentration after treatment. Duration of 
remission was calculated from the date of biochemical remission until the 
start of the present study. Cure was defined by normal glucose-suppressed 
GH levels and IGF-1 levels for age after surgery and/or irradiation. 
Biochemical control was defined by normal serum IGF-1 levels for age 
during SMS analog treatment. Both cured and biochemically controlled 
patients were referred to as ‘in remission’.
ASSAYS: Serum GH was measured with a sensitive IFMA (Wallac, Turku, 
Finland), specific for the 22 kDA GH protein (detection limit: 0.01µg/l, 
interassay coefficient of variation (CV): 1.6-8.4% of 0.01-15.38µg/l) from 
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1992 onwards. For the conversion of µg/l to mU/l, multiply by 2.6. Before 
1992, GH was measured by RIA (Biolab, Serona, Coissins, Switzerland), 
detection limit: 0.5mU/l, with an interassay CV <5%; for the conversion 
of µg/l to mU/l, multiply by 2.
Serum IGF-1 concentrations (nmol/l) were measured using an 
immunometric technique on an Immulite 2500 system (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). The intra-assay variations 
at mean plasma levels of 8 and 75nmol/l were 5.0 and 7.5%, respectively. 
IGF-1 levels were expressed as SDS, using lambda-mu-sigma smoothed 
reference curves based on 906 controls (23;24). 
RADIOGRAPHIC PROTOCOL: Both in acromegaly patients and 
geMstoan controls, conventional knee radiographs (posterior-anterior 
(PA), in weight-bearing/semi-flexed and lateral) were obtained, employing 
the same standardized protocol with a fixed film-focus distance and fixed 
flexion-position (25). Radiographic examinations were performed by a 
single experienced radiographer. Radiographs were available in 24 of 28 
acromegaly patients, and in all geMstoan controls.  
Radiographic knee OA was assessed according to the KL scale by an 
experienced musculoskeletal radiologist (H.M.K.) (26), and was defined 
as KL≥2. The reproducibility, depicted by the intra-class correlation 
coefficient (ICC), was 0.99 and was based on a randomly selected sample 
of 36 radiographs (17 right and 17 left knees). 
MRI PROTOCOL / ACQUISITION: Patients: MRI scans were obtained using 
an eight-channel knee coil and a 3.0 Tesla (3.0T) superconducting magnet 
(Gyroscan Achieva; Philips Medical Systems, Best, the Netherlands), and were 
performed by a single experienced radiology technician. The scan protocol 
consisted of a series of standard knee sequences: PDW (proton-density 
weighted) frequency selective fat suppressed transverse (TR/TE 1900/18ms, 
TSE factor 6, FOV 150x150x115, matrix 288x228, slice thickness 3mm), 
PDW DRIVE sagittal and coronal (TR/TE 2225/25ms, TSE factor 12, FOV 
150x150x86, matrix 432x336, slice thickness 3mm), and a 3D gradient echo 
fat-suppressed sagittal scan (details below). In addition, a sagittal T2-mapping 
scan (vide infra) was performed.
Controls: GeMstoan controls underwent an MRI using the same 3.0T 
MRI scanner and eight-channel knee coil as the acromegalic patients. 
MRIs were available of 60 controls. Both axial and sagittal CE, T1-
weighted, turbo spin echo (TSE), and spectral presaturation with inversion 
recovery (SPIR) sequences were acquired. The control MRI exam did not 
include a T2-mapping scan.
Study parameters MRI 
Evaluation of  structural OA changes on MRI: Knee 
Osteoarthritis Scoring System (KOSS)
MRIs of both patients and geMstoan controls were scored according 
to the KOSS, which is a validated scoring system for quantifying OA 
changes in the knee, developed by Kornaat et al. (27). For the present 
study, cartilaginous defects (diffuse and focal), osteophytes, subchondral 
cysts and bone marrow edema were graded on a scale from 0 (absent) to 
3 (severe). Lesions were localized to any of five regions: medial femoral 
compartment, medial tibiofemoral compartment, lateral femoral 
compartment, lateral tibiofemoral compartment, and patellofemoral 
compartment. An osteoarthritic defect was present when a score ≥1 was 
given; a severe osteoarthritic defect was defined as KOSS ≥2. MRI scans 
of patients were scored by two experienced readers (A.W.V., E.Y.), blinded 
for any patient characteristics. Reproducibility was good, as reflected by 
ICCs of 0.67, 0.92, 1.00 and 1.00 for osteophytes, (diffuse and focal) 
cartilage defects, cysts and bone marrow laesions, respectively. MRI scans 
of controls were scored by another experienced reader (B.d.L.), according 
to the same protocol. ICCs for controls were 0.97, 0.94, 0.98 and 0.93 for 
osteophytes, (diffuse and focal) cartilage defects, cysts and bone marrow 
laesions, respectively.  
Carti lage thickness measurements
In patients and geMstoan controls, cartilage thickness was measured by the 
same experienced reader (P.d.B.)  in a 3D fat-suppressed spoiled gradient 
echo sequence with ProSet fat suppression (pulse type 1331), acquisition 
matrix 304x304, FOV 150, pixel size 0.5x0.5mm2. The sequence was 
slightly different between the acromegaly patients and geMstoan controls. 
Acromegaly patients: TR/TE 20/5.2ms, 60 slices, slice thickness 3.5mm, 
and acquisition time 6min 2s. Controls: TR/TE 16/9.2ms, 125 slices, 
slice thickness 1.5mm, and acquisition time 5min 9s. In the center of each 
ROI, the thickness of a non-degenerated cartilage section was measured 
perpendicular to the subchondral bone. All measurements were performed 
using Osirix (Version 5.6) (28). Reproducibility was good, as reflected by 
an ICC of 0.802, and was based on a random selection of 5 knee MRIs.
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T2-MAPPING: T2-mapping in acromegaly patients was performed using 
a sagittal 2D turbo spin-echo sequence with TR 3307ms, 7 echoes with 
TE1/ΔTE/TE7 13/13/91ms, acquisition matrix 480x300, in-plane 
resolution of 0.31x0.5mm2, slice thickness 3mm, FOV 150mm, and 
acquisition time 7 min 7 s. T2-maps were fitted using the on-scanner 
vendor-provided software based on a maximum likelihood approach.
ROIs were drawn on sagittal slices approximately through the center 
of the medial and lateral condyles in three locations: the weight-bearing 
and non-weight-bearing femoral cartilage, and the cartilage of the tibia 
plateau (Figure 1). Obvious defects in the cartilage were avoided. In 23 
patients, T2 maps of sufficient quality (motion- and artifact-free) were 
available, and were hence included in the present analysis. Reproducibility 
of cartilage T2 relaxation times was moderate, as reflected by an ICC of 
0.530, based on random selection of 5 knee MRIs throughout the scoring 
process, blinded for any patient characteristics.
Figure 1. Schematic representation of the ROIs drawn in the medial and lateral condyles of the 
knee 
The arrows indicate the approximate locations of the knee where the cartilage thickness was 
measured.
Figure 2. MRI scan of the medial compartment of the right knee of an active acromegalic 
patient showing preserved joint cartilage and small osteophytes.
Statistical analysis
SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA), was used 
for data analysis. Data are presented as mean±SD, unless otherwise stated. 
Prevalence of structural abnormalities was compared between active and 
controlled acromegaly patients, using a logistic regression model, adjusting 
for age, sex and BMI. The relationship between different acromegaly-
specific parameters and structural abnormalities was also assessed in a 
logistic regression model. Cartilage thickness and cartilage T2 relaxation 
times were compared between active and controlled acromegaly patients 
by a linear regression model, adjusted for age, sex and BMI. 
For the comparison of structural OA changes between acromegaly 
patients and controls with primary OA, we used a logistic regression 
model with adjustments for age and sex. Cartilage thickness was compared 
between patients and geMstoan controls in a linear regression model, 
adjusting for age, sex and BMI. For comparison of cartilage T2 relaxation 
times between acromegaly patients and 17 controls with mild OA from 
the literature reference of Stahl et al. (19), a pooled variance T test was 
performed. 
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RESULTS
Characteristics of patients and controls
Twenty-six acromegaly patients were included, comprising 10 patients 
with active acromegaly, of whom 9 patients were treatment-naïve, 
(mean age 50.6±13.8 years, 40% female) and 16 patients in biochemical 
remission  (mean age 60.6±11.9 years, 12.5% female), achieved by 
transsphenoidal surgery, radiotherapy and/or SMS analogs. Mean 
remission duration in the latter group was 13.2±10.6 years. Two patients, 
both in remission, had a history of knee arthroscopy surgery in the 
scanned knee. 
Patients were compared with 59 controls diagnosed with primary OA 
(mean age 61.9±6.8 years, 80% female). Clinical characteristics of patients 
and controls were shown in Table 1. Mean age was significantly higher 
in controls (p<0.001), and the control group comprises more females 
(p<0.001). Mean BMI was comparable between patients and controls. 
Definite radiographic knee OA of the scanned knee, defined as KL ≥2, was 
present in 7 patients (29%) and 45 (76%) controls. 
Table 1. Clinical characteristics of  acromegaly patients with 
active disease, acromegaly patients in remission, and controls 
with primary OA






Age (yr) 50.6 (13.8) 60.6 (11.9) 61.9 (6.8)
Female sex (N (%)) 4 (40%) 2 (13%) 47 (80%)
BMI (kg/m2) 28.1 (2.3) 30.0 (4.8) 29.8 (5.4)
Active disease duration (yr) 7.8 (5.6) 8.3(6.5) NA

























































Previous knee surgery (N (%)) * 0 (0%) 2 (13%) 10 (17%)




























Data are reported as mean ± SD, unless stated otherwise. Control subjects were diagnosed with 
primary knee OA, and were derived from the geMstoan Study (18).
N, number of patients; SMS, somatostatin analogs; OA, osteoarthritis; BMI, body mass index; D2 
agonists, dopamine 2 agonists; ACTH, adrenocorticotrophic hormone; TSH, thyroid-stimulating 
hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; GH, growth hormone; ADH, 
anti-diuretic hormone; KL, Kellgren-Lawrence score for presence of radiographic OA; NA, not 
applicable.
*, Previous knee surgery of the scanned knee. 
**, KL score of the scanned knee (ACRO, right knee; Controls, knee with symptomatic OA).
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Acromegaly patients: active versus controlled 
acromegaly
STRUCTURAL ABNORMALITIES IN THE KNEE ACCORDING TO KOSS: 
Structural abnormalities were already present in a high proportion of 
patients with active acromegaly, with comparable high prevalence of 
cartilage defects, subchondral cysts and bone marrow laesions in controlled 
patients, but osteophyte prevalence seemed to be lower after achievement 
of disease remission (Table 2A). 
Next, we incorporated age of diagnosis, active disease duration, and pre-
treatment IGF-1 SDS in a logistic regression model in addition to age, sex 
and BMI to study the relationship of acromegaly-specific parameters with 
OA changes in the total acromegaly group. None of the parameters reflecting 
disease activity was significantly related to structural abnormalities on MRI. 
CARTILAGE MORPHOMETRY: Mean cartilage thickness was significantly 
higher in patients with active acromegaly than in patients with controlled 
disease at several locations in the knee, adjusted for age, sex and BMI 
(Table 2B). Adjusted total cartilage thickness (i.e. sum of all measured 
sites) was 7% higher in active than in controlled patients (18.8±3.2mm 
and 17.5±2.7mm in active and controlled patients, respectively, p=0.008). 
In the total acromegaly group, total cartilage thickness correlated to the 
current IGF-1 SDS value (r=0.481, p=0.017), but not to pre-treatment 
IGF-1 SDS values. Cartilage thickness was not associated to the presence 
of structural abnormalities according to KOSS (data not shown).
BIOCHEMICAL CARTILAGE COMPOSITION: cartilage T2 relaxation 
times: Patients with active acromegaly had higher cartilage T2 relaxation 
times than controlled acromegalics at the non-weight-bearing medial 
femoral cartilage and at the lateral tibial plateau (Table 2C), adjusted for 
age, sex and BMI, but not at other knee locations. Cartilage T2 relaxation 
times were not related to pre-treatment IGF-1 SDS, current IGF-1 SDS or 
active disease duration (data not shown).
Table 2A. Prevalence of  joint defects on a 3.0T MRI of  the 
knee using KOSS, in acromegaly patients with active disease 
















































OA defects were scored according to the KOSS score, and were defined as KOSS ≥1. 
KOSS, Knee Osteoarthritis Scoring System; PF, patellofemoral; TF, tibiofemoral; BM, bone marrow.
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Table 2B. Comparison of  carti lage thickness in the knee 
between patients with active acromegaly vs patients in 
remission of  acromegaly




Adjusted B (95%CI) P value *
Femur
Medial femoral condyle (wb) 2.48 ± 0.34 2.09 ± 0.70 -0.426 (-0.956; 0.105) 0.109
Medial femoral condyle (nwb) 2.93 ± 0.45 2.63 ± 0.45 -0.657 (-1.134; -0.179) 0.010
Lateral femoral condyle (wb) 2.80 ± 0.91 2.87 ± 0.57 -0.247 (-1.093; 0.598) 0.545
Lateral femoral condyle (nwb) 3.19 ± 0.72 3.03 ± 0.74 -0.793 (-1.541; -0.044) 0.039
Tibia
Medial plateau  3.13 ± 0.86 2.72 ± 0.87 -0.515 (-1.523; 0.492) 0.296
Lateral plateau 4.29 ± 0.94 3.82 ± 0.80 -0.932 (-1.761; -0.150) 0.030
Total cartilage thickness 18.82 ± 3.17 17.16 ± 2.30 -3.569 (-6.085; -1.054) 0.008
Data are presented as mean ± SD. Cartilage thickness measurements were analyzed using a 
linear regression model with adjustments for age, sex and BMI. Total cartilage thickness was 
defined as the sum of all measured sites. Cartilage thickness measurements were available from 
23 patients. 
Mm, millimeters; wb, weight-bearing; nwb, non-weight-bearing; B (95%CI), beta with corresponding 
95% confidence interval.  
*, Adjusted for age, sex and BMI. 
Table 2C. Comparison of  carti lage T2 relaxation times 
between acromegaly patients with active disease vs patients 
in biochemical remission






Medial femoral condyle (wb) 39.6 ± 4.3 44.4 ± 8.3 NS
Medial femoral condyle (nwb) 48.4 ± 5.6 45.5 ± 5.7 0.044
Lateral femoral condyle (wb) 33.3 ± 4.1 32.9 ± 4.7 NS
Lateral femoral condyle (nwb) 42.9 ± 2.9 41.9 ± 4.2 NS
Tibia
Medial plateau 42.7 ± 7.4 39.6 ± 7.1 NS
Lateral plateau 31.3 ± 5.5 30.7 ± 6.8 0.029
Data are presented as mean ± SD. Cartilage T2 relaxation times were compared between 
patients with active and controlled acromegaly using a linear regression model with adjustments 
for age, sex and BMI.
Ms, milliseconds; wb, weight-bearing; nwb, non-weight-bearing.  
*, Adjusted for age, sex and BMI.
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Table 3A. Prevalence of  joint defects on a 3.0T MRI of  the 
















































OA defects were scored according to the KOSS score, and were defined as KOSS ≥1. Control 
subjects were diagnosed with primary knee OA, and were derived from the geMstoan Study (18).
KOSS, Knee Osteoarthritis Scoring System; PF, patellofemoral; TF, tibiofemoral; BM, bone marrow.
Table 3B. Comparison of  carti lage thickness in the knee 
between acromegaly patients and subjects with primary OA






Medial femoral condyle (wb) 2.24 ± 0.61 2.21 ± 0.25 NS
Medial femoral condyle (nwb) 2.75 ± 0.46 2.34 ± 0.14 0.109
Lateral femoral condyle (wb) 2.84 ± 0.70 2.49 ± 0.59 NS
Lateral femoral condyle (nwb) 3.09 ± 0.72 2.45 ± 0.46 0.182
Tibia
Medial plateau 2.88 ± 0.87 2.18 ± 0.41 NS
Lateral plateau 4.00 ± 0.875 2.52 ± 1.09 0.049
Total cartilage thickness 17.81 ± 2.73 14.19 ± 1.79 0.098
Data are presented as mean ± SD. Control subjects were diagnosed with primary knee OA, and 
were derived from the geMstoan Study (18). Mean age of controls was 64.3±7.1yr and 90% was 
female. Cartilage thickness measurements were between patients and controls compared using a 
linear regression model with adjustments for age, sex and BMI. 
Mm, millimeters; wb, weight-bearing; nwb, non-weight-bearing.  
*, Adjusted for age, sex and BMI
Figure 3. Severe structural OA changes detected on MRI, defined as KOSS ≥2, in acromegaly 
patients versus controls with primary OA
Data were presented as prevalence (%) of severe structural joint defects, according to the KOSS 
score. Severe OA changes were defined as KOSS ≥2.  
KOSS, Knee Osteoarthritis Scoring System; BML, bone marrow laesions.
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Comparison with subjects with primary OA
STRUCTURAL OA CHANGES ACCORDING TO KOSS: As depicted in Table 
3A, acromegaly patients seem to have less cysts than subjects with primary 
OA, but comparable prevalence of osteophytosis, cartilage defects and bone 
marrow laesions. Severe cartilage defects, cysts and bone marrow laesions, 
defined as KOSS ≥2, were less frequently seen in acromegaly patients than 
controls with primary OA, whereas the prevalence of severe osteophytosis was 
comparable (Figure 3). KOSS 3 was present less frequently in patients than in 
controls (4.2 vs 8.1 times per knee, p<0.001). Cartilage thickness: Cartilage 
thickness was higher in acromegaly patients than in primary OA subjects, 
although not statistically significant after adjusting for age, sex and BMI, 
except for the lateral tibia plateau (59% increase) (Table 3B, Figure 4). All 
acromegaly patients, except for one, had total cartilage thickness values above 
the mean value of controls.
BIOCHEMICAL COMPOSITION: cartilage T2 relaxation times:  Cartilage 
T2 relaxation times were compared between acromegaly patients 
and controls with mild OA from literature to assess the biochemical 
composition of cartilage. Patients had higher cartilage T2 relaxation times 
than controls at both the femoral and tibial level, at all measured sites (all 
p<0.01; Table 3C), indicating changes in cartilage quality. 
Case series: pre- and postoperative knee MRIs in two 
acromegaly patients
The first acromegaly patient was a 56-year old male with an estimated active 
disease duration of 8 years (pre-treatment GH levels and pre-treatment 
IGF-1 SDS were, respectively, 45.0ug/l and 7.70 SDS). The second patient 
was a 68-year old male with an estimated active disease duration of 15year 
(pre-treatment GH levels and pre-treatment IGF-1 SDS were, respectively, 
17.8ug/l and 7.91 SDS). Both patients underwent two MRIs of the knee: 
the first scan during the active, treatment-naïve, phase of acromegaly and the 
second scan 6 months after achievement of biochemical remission.
One patient, having no cartilage abnormalities on MRI in the active 
acromegaly phase, developed cartilage defects (grade 2 and 3) after 
achieving remission. Other structural OA abnormalities did not change. 
After establishment of biochemical remission, cartilage thickness regressed 
in both patients when compared to the pre-operative phase (decreases 
from, respectively, 26.6 to 17.4 and 23.5 to 16.3). Cartilage T2 relaxation 
times did not change.
Table 3C. Comparison of  carti lage T2 relaxation times 
between acromegaly patients and l iterature controls with 
primary OA






Medial femoral condyle (wb) 42.1 ± 7.0 33.7 ± 3.8 <0.01
Medial femoral condyle (nwb) 46.9 ± 6.0 33.8 ± 3.0 <0.01
Lateral femoral condyle (wb) 42.4 ± 3.8 31.2 ± 3.0 <0.01
Lateral femoral condyle (nwb) 40.9 ± 6.9 33.3 ± 2.7 <0.01
Tibia
Medial plateau 33.3 ± 4.3 27.5 ± 2.8 <0.01
Lateral plateau 31.0 ± 6.0 27.9 ± 3.1 <0.01
Data are presented as mean ± SD. Control subjects have mild radiographic OA (KL 1 or 2) and 
clinical OA according to the clinical ACR criteria, and were derived a literature reference from Stahl 
et al. (19).
Ms, milliseconds; wb, weight-bearing; nwb, non-weight-bearing. 
Figure 4. Cartilage thickness in the knee visualized on MRI in acromegaly patients vs controls 
with primary OA
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DISCUSSION
The present study is the first to evaluate acromegalic arthropathy by 
the use of MRI both in acromegaly patients with active and controlled 
disease. We found that structural OA abnormalities on MRI were already 
highly prevalent during the active acromegaly, especially of osteophytosis, 
when compared to controlled patients. In addition, in active patients 
articular knee cartilage was thicker and cartilage T2 relaxation times 
were higher than in controlled patients, reflecting differences in cartilage 
quality between these patients. When compared to primary OA subjects, 
acromegalic arthropathy seem to be predominantly characterized by 
alterations in joint cartilage, being thicker cartilage and changes in 
cartilage biochemical composition. In addition, acromegaly patients 
showed less cysts, whereas prevalence of cartilage defects, osteophytosis 
and bone marrow laesions was comparable. Severe OA defects were less 
prevalent in acromegaly patients. 
Arthropathy is one of the most invalidating complications in 
acromegaly, despite biochemical disease control (1;21), significantly 
impairing QoL. The exact pathogenesis of acromegalic arthropathy is 
currently unknown, but there are some similarities with primary OA. 
There is evidence that GH/IGF-1 activity is associated with both the 
onset and progression of acromegalic arthropathy (3-5). Interestingly, 
acromegaly patients have a characteristic radiographic phenotype with 
severe osteophytosis with preservation of joint cartilage (7;29). Until now, 
these characteristics were only observed in radiography studies and in a 
few studies using ultrasonography. 
The present study shows that structural OA defects are already highly 
prevalent during the active acromegaly phase. In addition, we found 
that in patients with active acromegaly articular cartilage is not only 
thicker than in the controlled disease phase, but is also from a different 
biochemical composition, as reflected by higher cartilage T2 relaxation 
times. Cartilage T2 relaxation times are influenced by several factors, 
such as the orientation of collagen fibers to the static magnetic field, 
water content, alterations in water proton mobility and the integrity of 
collagenous structures in the extracellular cartilage matrix (30-32). In 
previous studies, primary OA patients were shown to have higher T2 
relaxation times than healthy controls (16;17), with a clear correlation 
between these values and OA severity, indicating increased water content 
in these patients. The findings of the present study could introduce the 
hypothesis that in thickened joint cartilage in active acromegaly patients 
consists of two different components: a structural component of cartilage 
hypertrophy, being (partially) irreversible despite long-term biochemical 
remission (7;29), and a component of edema (reflected by cartilage T2 
relaxation times), that decreases after successful treatment. This may 
explain why joint cartilage of controlled acromegalics is still thickened 
compared to healthy controls due to persisting cartilage hypertrophy, but 
is thinner than in the active phase due to a decrease in water content by 
successful treatment. This hypothesis is underlined by a corresponding 
decrease in cartilage T2 relaxation times after achievement of biochemical 
control.
When compared to subjects with primary OA, acromegaly patients 
seemed to have thicker knee cartilage. These results are in keeping with 
radiographic studies reporting widened joint spaces (7;29), indicating 
persistent (protective) effects of previous GH excess on joint cartilage. 
A new finding is the presence of higher cartilage T2 relaxation times 
in acromegaly patients at all measured sites, suggesting that average 
biochemical composition of joint cartilage is altered in these patients. The 
observation of even higher cartilage T2 relaxation times in acromegaly 
patients might reflect increased cartilage damage in acromegalics, with 
more cartilage hydration and collagen breakdown. Observations of these 
altered cartilage composition should be confirmed in future studies. 
There were also differences in the distribution of structural 
abnormalities on MRI between acromegaly patients and subjects with 
primary OA. Acromegaly patients seemed to have a lower prevalence of 
cysts, whereas prevalence of cartilage defects, osteophytosis and bone 
marrow edema was comparable. In acromegalics, prevalence of severe OA 
defects was lower than in subjects with primary OA, which may explain 
why, despite significant joint complaints, joint replacement surgery is less 
frequently performed in acromegaly patients.
This study may suffer from several limitations. First, due to the 
relatively small number of patients, we only did explorative analyses 
in this pilot study. Larger studies are needed to draw firm conclusions. 
Second, the acromegaly group included in the study is very heterogeneous, 
including both active and controlled patients. However, we decided 
to include treated patients next to treatment-naïve patients, in order 
to assess the effects of adequate acromegaly treatment on joint level. 
Third, in the absence of T2 relaxation time control data in our center, 
we were limited to the inclusion of a literature reference with primary 
OA subjects for comparison. In this respect, differences between MRI 
scanners, scan protocols and scoring methods may confound these results. 
Finally, the cartilage thickness and T2 relaxation measurements are a 
first exploration of the MRI data. In future work, we aim to analyze the 
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data in more depth, including thickness measurements over the entire 
cartilage surface and T2-value assessment in the different cartilage layers. 
For future scans, these analyses may benefit from the higher resolution, 
both in the spatial and in the contrast domain, which can be achieved 
using the 7.0T MRI scanner of the C.J. Gorter Center in our hospital. In 
addition, the moderate ICC of the T2-mapping might be improved by the 
implementation of a (semi-)automatic analysis algorithm.
In conclusion, this first MRI study on acromegalic arthropathy 
demonstrates that in the active acromegaly phase structural OA defects 
are already highly prevalent. Active acromegaly have thicker joint cartilage 
with larger water content than patients with controlled disease, as reflected 
by increased cartilage T2 relaxation times. When compared to primary OA 
subjects, acromegalic arthropathy especially differs with respect to joint 
cartilage, which is thicker and from different biochemical composition. 
The findings of the present study underline that acromegalic arthropathy 
is a clinical entity with a unique phenotype. Future studies have to point 
out whether acromegaly-specific interventions can be beneficial in the 
management of acromegalic arthropathy. 
REFERENCE LIST
1. Wassenaar MJ, Biermasz NR, van DN 
et al. High prevalence of arthropathy, 
according to the definitions of radiological 
and clinical osteoarthritis, in patients 
with long-term cure of acromegaly: a 
case-control study. Eur J Endocrinol 2009; 
160(3):357-365.
2. Wassenaar MJ, Biermasz NR, Kloppenburg 
M et al. Clinical osteoarthritis predicts 
physical and psychological QoL in 
acromegaly patients. GrowthHorm IGF 
Res 2010; 20(3):226-233.
3. Biermasz NR, Wassenaar MJ, van der 
Klaauw AA et al. Pretreatment insulin-like 
growth factor-I concentrations predict 
radiographic osteoarthritis in acromegalic 
patients with long-term cured disease. J 
ClinEndocrinolMetab 2009; 94(7):2374-
2379.
4. Claessen KM, Ramautar SR, Pereira AM et 
al. Progression of acromegalic arthropathy 
despite long-term biochemical control: 
a prospective, radiological study. Eur J 
Endocrinol 2012; 167(2):235-244.
5. Wassenaar MJ, Biermasz NR, Pereira 
AM et al. The exon-3 deleted growth 
hormone receptor polymorphism 
predisposes to long-term complications of 
acromegaly. J ClinEndocrinolMetab 2009; 
94(12):4671-4678.
6. Barkan AL. Acromegalic arthropathy. 
Pituitary 2001; 4(4):263-264.
7. Wassenaar MJ, Biermasz NR, Bijsterbosch 
J et al. Arthropathy in long-term 
cured acromegaly is characterised 
by osteophytes without joint space 
narrowing: a comparison with generalised 
osteoarthritis. Ann Rheum Dis 2011; 
70(2):320-325.
8. Colao A, Marzullo P, Vallone G et 
al. Reversibility of joint thickening in 
acromegalic patients: an ultrasonography 
study. J ClinEndocrinolMetab 1998; 
83(6):2121-2125.
9. Colao A, Cannavo S, Marzullo P et 
al. Twelve months of treatment with 
octreotide-LAR reduces joint thickness 
in acromegaly. Eur J Endocrinol 2003; 
148(1):31-38.
10. Claessen KM, Kloppenburg M, Kroon HM, 
Romijn JA, Pereira AM, Biermasz NR. Two 
phenotypes of arthropathy in long-term 
controlled acromegaly? A comparison 
between patients with and without joint 
space narrowing (JSN). Growth Horm IGF 
Res 2013; 23(5):159-164.
11. Biermasz NR, Pereira AM, Frolich M, 
Romijn JA, Veldhuis JD, Roelfsema F. 
Octreotide represses secretory-burst 
mass and nonpulsatile secretion but 
does not restore event frequency or 
orderly GH secretion in acromegaly. 
Am J PhysiolEndocrinolMetab 2004; 
286(1):E25-E30.
12. Mackie EJ, Trechsel U, Bruns C. 
Somatostatin receptors are restricted to 
a subpopulation of osteoblast-like cells 
during endochondral bone formation. 
Development 1990; 110(4):1233-1239.
13. Weiss RE, Reddi AH, Nimni ME. 
Somatostatin can locally inhibit 
proliferation and differentiation of 
cartilage and bone precursor cells. Calcif 
Tissue Int 1981; 33(4):425-430.
14. Zapf J, Gosteli-Peter M, Weckbecker 
G, Hunziker EB, Reinecke M. The 
somatostatin analog octreotide inhibits 
GH-stimulated, but not IGF-I-stimulated, 
bone growth in hypophysectomized rats. 
Endocrinology 2002; 143(8):2944-2952.
15. Stahl R, Luke A, Li X et al. T1rho, T2 
and focal knee cartilage abnormalities in 
physically active and sedentary healthy 
subjects versus early OA patients--a 
3.0-Tesla MRI study. EurRadiol 2009; 
19(1):132-143.
16. Blumenkrantz G, Lindsey CT, Dunn 
TC et al. A pilot, two-year longitudinal 
study of the interrelationship between 
trabecular bone and articular cartilage in 
the osteoarthritic knee. Osteoarthritis 
Cartilage 2004; 12(12):997-1005.
17. Dunn TC, Lu Y, Jin H, Ries MD, Majumdar 
S. T2 relaxation time of cartilage at MR 
imaging: comparison with severity of 
knee osteoarthritis. Radiology 2004; 
232(2):592-598.
18. de Lange-Brokaar BJE, Ioan-Facsinay A, 
Yusuf E et al. Degree of synovitis on 
MRI is correlated with histological and 
macroscopic features of synovial tissue 
inflammation in knee osteoarthritis. 
Submitted . 2013. 
19. Stahl R, Blumenkrantz G, Carballido-
Gamio J et al. MRI-derived T2 relaxation 
times and cartilage morphometry of the 
tibio-femoral joint in subjects with and 
without osteoarthritis during a 1-year 
follow-up. Osteoarthritis Cartilage 2007; 
15(11):1225-1234.
Pathophysiology of the GH/IGF-1 axis: Long-term consequences on joints and bone110 IV. Acromegalic arthropathy in various stages of the disease: a Magnetic Resonance Imaging (MRI) study 111
20. Biermasz NR, van DH, Roelfsema F. Ten-
year follow-up results of transsphenoidal 
microsurgery in acromegaly. J 
ClinEndocrinolMetab 2000; 85(12):4596-
4602.
21. Biermasz NR, Pereira AM, Smit JW, 
Romijn JA, Roelfsema F. Morbidity after 
long-term remission for acromegaly: 
persisting joint-related complaints 
cause reduced quality of life. J 
ClinEndocrinolMetab 2005; 90(5):2731-
2739.
22. Roelfsema F, van DH, Frolich M. Long-
term results of transsphenoidal pituitary 
microsurgery in 60 acromegalic patients. 
ClinEndocrinol (Oxf) 1985; 23(5):555-
565.
23. Cole TJ. The LMS method for constructing 
normalized growth standards. Eur J 
ClinNutr 1990; 44(1):45-60.
24. Rikken B, van DJ, Ringeling A, Van den 
Brande JL, Massa G, Wit JM. Plasma 
levels of insulin-like growth factor (IGF)-I, 
IGF-II and IGF-binding protein-3 in the 
evaluation of childhood growth hormone 
deficiency. Horm Res 1998; 50(3):166-
176.
25. Peterfy C, Li J, Zaim S et al. Comparison 
of fixed-flexion positioning with 
fluoroscopic semi-flexed positioning for 
quantifying radiographic joint-space width 
in the knee: test-retest reproducibility. 
Skeletal Radiol 2003; 32(3):128-132.
26. Kellgren JH, Lawrence JS. Radiological 
assessment of osteo-arthrosis. Ann 
Rheum Dis 1957; 16(4):494-502.
27. Kornaat PR, Ceulemans RY, Kroon HM et 
al. MRI assessment of knee osteoarthritis: 
Knee Osteoarthritis Scoring System 
(KOSS)--inter-observer and intra-observer 
reproducibility of a compartment-based 
scoring system. Skeletal Radiol 2005; 
34(2):95-102.
28. Rosset A, Spadola L, Ratib O. OsiriX: an 
open-source software for navigating in 
multidimensional DICOM images. J Digit 
Imaging 2004; 17(3):205-216.
29. Biermasz NR, van ‘t KR, Wassenaar MJ 
et al. Automated image analysis of hand 
radiographs reveals widened joint spaces 
in patients with long-term control of 
acromegaly: relation to disease activity 
and symptoms. Eur J Endocrinol 2012; 
166(3):407-413.
30. Lusse S, Claassen H, Gehrke T et al. 
Evaluation of water content by spatially 
resolved transverse relaxation times of 
human articular cartilage. MagnReson 
Imaging 2000; 18(4):423-430.
31. Mosher TJ, Dardzinski BJ, Smith MB. 
Human articular cartilage: influence of 
aging and early symptomatic degeneration 
on the spatial variation of T2--preliminary 
findings at 3 T. Radiology 2000; 
214(1):259-266.
32. Nissi MJ, Rieppo J, Toyras J et al. T 
(2) relaxation time mapping reveals 
age- and species-related diversity of 
collagen network architecture in articular 
cartilage. Osteoarthritis Cartilage 2006; 
14(12):1265-1271.
Pathophysiology of the GH/IGF-1 axis: Long-term consequences on joints and bone112 V. Two phenotypes of arthropathy in long-term controlled acromegaly? 
A comparison between patients with and without joint space narrowing (JSN)
113
V.
Two phenotypes of 
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ABSTRACT
BACKGROUND: Arthropathy is an invalidating complication of 
acromegaly, also in long-term controlled patients, and is radiographically 
characterized by osteophytes and preserved joint spaces. However, joint 
space narrowing (JSN) is observed in the minority of patients. It is 
unknown whether JSN is the end-stage of acromegalic arthropathy or 
whether this feature develops independently of acromegaly. 
OBJECTIVE: To gain insight into the pathophysiology of acromegalic 
arthropathy, and, more specifically, in the process of JSN, risk factors for 
radiographic JSN were studied in a cross-sectional study.   
METHODS: We studied hips and knees of 89 well-controlled acromegaly 
patients (mean age 58.3 years, 51% female). Joints were divided into two 
groups based on the presence of JSN, defined as an Osteoarthritis Research 
Society (OARSI) score ≥1. Potential risk factors for JSN were assessed, 
and its relationship to joint complaints. Individual knees and hips were 
analyzed in a Generalized Estimating Equations model, adjusted for age, 
sex, BMI and intra-patient effect. 
RESULTS: In controlled acromegaly, JSN was found in, respectively, 
10.3% and 15.4% of the hips and knees. Increasing age and female 
sex were associated with more JSN; acromegaly-specific risk factors for 
JSN were joint-site specific. In the hip, JSN was related to more active 
disease: higher pre-treatment GH/IGF-1, longer and more severe GH 
exposure and immediate postoperative cure was less frequently achieved. 
In the knee, especially previous knee surgery, not acromegaly-specific 
characteristics, was associated with JSN. The presence of JSN was 
associated with more joint complaints. 
CONCLUSIONS: JSN is an infrequent finding in patients with 
acromegalic arthropathy, but is associated with more symptoms. This 
study indicates that, at least in the hip, early and ongoing GH/IGF-1 
activity play a role in JSN development. 
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INTRODUCTION   
Acromegaly is a chronic endocrine disease with high prevalence of 
arthropathy in active and cured disease, resulting in considerable 
functional disability (1). It is suggested that increased exposure to Insulin-
like Growth Factor-1 (IGF-1), the main mediator of Growth Hormone 
(GH) action, is the driving mechanism in secondary osteoarthritis (OA) 
in acromegaly (2). In a hypothetical model, acromegalic arthropathy has 
a bi-phasic pattern with initially reversible endocrine changes, followed 
by mechanical changes. First, elevated GH and/or IGF-1 levels promote 
the growth of articular cartilage and peri-articular ligaments, leading to 
cartilage hypertrophy with a limited range of movements. This early stage 
is thought to be, at least partially, reversible with adequate biochemical 
disease control. Subsequently, when GH excess persists, changes become 
irreversible. At this late stage, acromegalic joints acquire the characteristics 
of degenerative joint disease (3). However, little clinical studies are 
available to support this hypothesis. 
Previously, we have demonstrated that the prevalence of arthropathy 
is high, also in patients with long-term biochemical disease control (4). 
These patients have a 4- to 12-fold increased risk to develop OA, even 
at very young ages, in comparison to the general population (5). GH/
IGF-1 activity at diagnosis is related to the prevalence of radiographic 
OA (ROA) (6). Interestingly, despite long-term cure, the distribution of 
radiological abnormalities remained different from regular degenerative 
joint disease, i.e. primary OA. The radiographic phenotype in acromegaly 
is predominantly characterized by severe osteophytosis, frequently 
in combination with preserved normal or even widened joint spaces. 
Therefore, it is suggested that GH hypersecretion is especially involved 
in bone formation, but may protect against cartilage loss (7). This 
observation conflicts with the previous hypothesis that there is a final 
common pathway with primary OA, at least in the majority of patients. 
Nonetheless, a minority of acromegaly patients shows radiographic 
joint space narrowing (JSN), mimicking primary OA, instead of the 
characteristic joint space widening of acromegaly. This suggests that in 
acromegaly, there are two types of arthropathy: first, osteophytosis in 
combination with preserved/widened joint spaces, and second, in a small 
group, JSN with or without osteophytes. At present, the process of JSN 
is not fully understood, and it is unknown whether radiographic JSN 
is the end-stage of acromegalic arthropathy when the GH/IGF-1 excess 
has exceeded a critical threshold or whether it is a radiographic feature 
which develops independently of acromegaly, caused by, for example, high 
biomechanical forces or previous joint surgery. 
In order to gain insight in the pathophysiology of acromegalic 
arthropathy and, more specifically, in the process of JSN, we compared 
patients with and without radiographic JSN in the knee and hip with 
respect to patient and treatment characteristics and physical stress. Both 




All consecutive patients with acromegaly, who were referred for treatment 
from 1977 onwards to the Leiden University Medical Center, were 
collected in a database. For the present study, 126 consecutive patients 
with long-term controlled acromegaly (defined as ≥2 years) were invited 
for participation. Thirty-seven patients preferred not to participate for 
various reasons such as illness, travel distance, lack of time or psychological 
reasons. Consequently, 89 patients were included in the present analysis. 
The 37 non-included patients did not differ from the participating patients 
with respect to age, sex, BMI, active disease duration, pre-treatment GH/
IGF-1 levels, type of treatment, follow-up duration and self-reported joint 
complaints (6).
Detailed yearly follow-up was performed from the onset of acromegaly 
treatment. The first treatment option in the majority of patients was 
transsphenoidal surgery (TPS) performed by a single specialized 
neurosurgeon. If necessary, adjuvant treatment consisted of radiotherapy 
(RT) (prior to 1985) or SMS analogs (from 1985 onwards). From 1998, 
some patients received depot formulations of long-acting SMS analogs as 
primary treatment. Since 2003, Pegvisomant was available for treatment-
resistant acromegaly. 
Disease activity was assessed yearly by oral glucose tolerance tests 
(except in medically treated patients), fasting serum GH and IGF-1 
levels. Remission of acromegaly was defined as a normal glucose-
suppressed serum GH <1.25 (RIA assay until 1992) or 0.38µg/l 
(immunofluorometric assay (IFMA) from 1992 onwards), serum GH 
levels of <1.9µg/l (all years), and normal IGF-1 levels for age (from 
1986 onwards) (4;8;9). Patients not meeting these criteria were offered 
additional treatment. 
Hypopituitarism was supplemented with thyroxine, hydrocortisone, 
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testosterone/estrogens according to the following definitions (10). 
Estrogen deficiency in women was present in case of LH/FSH deficiency 
in premenopausal women with prolonged amenorrea >1 year without 
adequate replacement therapy or by a low serum oestradiol concentration 
of <70 nmol/l and all postmenopausal women. In men, LH/FSH 
deficiency was defined as testosterone level below the reference range 
(8.0 nmol/l). Thyroid stimulating hormone (TSH) deficiency was 
defined as a free thyroxine level below the reference range (<10 pmol/l). 
Adrenocorticotrophic hormone (ACTH) deficiency was defined as an 
insufficient increase of cortisol (peak <0.55 µmol/l) after corticotrophin 
releasing hormone test or insulin tolerance test. GH deficiency was not 
routinely assessed. 
Patients were seen at the outpatient clinic for a single visit. The study 
protocol was approved by the Medical Ethics Committee, and all subjects 
gave written consent. 
Study parameters
QUESTIONNAIRES: A standardized questionnaire was completed 
concerning demographic data, medical history, OA symptoms and signs 
and information on type of occupation and type of sport. Other relevant 
details of treatment and patient characteristics were derived from patient 
records. 
PHYSICAL EXAMINATION: Physical examination was performed by a 
single physician (M.W.) trained in structured joint assessment. Internal 
rotation and flexion of the hip and extension of the knees was assessed, in 
combination with both pain and crepitation. 
RADIOGRAPHIC PROTOCOL: Radiographs were obtained from 
all patients between September and December 2007. Conventional 
radiographs of the knee (posterior-anterior (PA), weight-bearing, fixed-
flexion (11;12) and hips (PA, supine) were obtained from all patients, 
according to a standardized protocol with a fixed film-focus distance 
and fixed joint position. All radiographs were performed by a single 
experienced radiology technician. 
ASSESSMENT OF RADIOGRAPHIC OA: For a semi-quantitative 
assessment of the radiographic cartilage damage, JSN was graded in the 
knee (both medial and lateral femorotibial compartments) and hip on a 
scale from 0 to 3, using the Osteoarthritis Research Society (OARSI) atlas 
(13). Radiographs were scored by consensus opinion of two experienced 
readers (M.W. & K.M.J.A.C.), blinded for patient characteristics. In cases 
of disagreement, the lower, more conservative score was adopted. The 
reproducibility for JSN in the hip and knee, reflected by the intra-class 
correlation coefficient (ICC), was good (0.89 and 0.82, respectively, for 
the hip and knee). The reproducibility was based on the repeat reading of 
15 randomly selected radiographs. JSN was defined as an OARSI score of 
≥1 at a particular joint site. Based on the presence of JSN, patients were 
divided into two groups (i.e. OARSI ≥1 vs OARSI 0), independently for 
the knee and hip joint. Joint prostheses could not be scored with OARSI, 
and therefore, these joints (i.e. 3 knees, 2 hips) were excluded from the 
analyses. 
Radiographic knee and hip OA were also scored according to the 
Kellgren-Lawrence (KL) scale, including other OA features, by a single 
experienced musculoskeletal radiologist (H.M.K.) (14). ICCs were 0.89 
and 1.00 for the knee and hip, respectively. Radiographic OA was defined 
as KL ≥2 or presence of a knee or hip prosthesis. 
DEFINITION OF CLINICAL OA: We used the clinical American College 
of Rheumatology (ACR) criteria for the assessment of clinical hip and 
knee OA. Criteria for clinical hip OA were pain in combination with 
internal rotation of ≥15° and morning stiffness for ≤60 min (15). Clinical 
criteria for knee OA were pain, crepitation on physical examination and 
morning stiffness ≤30 min in combination with bony enlargements (16). 
PARAMETERS OF ACROMEGALIC DISEASE: Active disease duration 
was calculated from the estimated date of onset, using start of signs and 
symptoms, and facial changes on photographs to the date of normalization 
of serum IGF-1 levels after surgery or additional therapy. Remission 
duration was calculated from the date of normalization of serum IGF-1 
concentrations until start of the present study, supported by the findings 
during the oral glucose tolerance test (oGTT). Both surgically and/
or irradiation cured patients and patients with controlled disease by 
treatment with SMS analogs were collectively referred to as ‘in remission’.
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ASSAYS: Blood samples were taken in the post-absorptive state to assess 
the actual GH and IGF1 concentrations. Serum GH was measured with 
a sensitive IFMA (Wallac, Turku, Finland), specific for the 22 kDA GH 
protein, calibrated against World Health Organisation International 
Reference Preparation (WHO IRP) 80/505 (detection limit: 0.01ug/l, 
interassay coefficient of variation (CV): 1.6-8.4% of 0.01-15.38ug/l) from 
1992 onwards. For the conversion of ug/l to mU/l, the values have to 
be multiplied by 2.6. Prior to 1992, GH was measured by RIA (Biolab, 
Serona, Coissins, Switzerland), calibrated against WHO IRP 66/21 
(detection limit: 0.5mU/l, with an interassay CV less than 5%; for the 
conversion of ug/l to mU/l, multiply by 2).
Serum IGF-1 concentration (nmol/l) was measured using an 
immunometric technique on an Immulite 2500 system (Diagnostic 
Products Corporation, Los Angeles, CA, USA). The intra-assay variations 
at mean plasma levels of 8 and 75nmol/l were 5.0 and 7.5%. IGF-1 levels 
were expressed as SDS, using lambda-mu-sigma smoothed reference curves 
based on the measurement in 906 healthy individuals (17;18). 
Statistical analysis
SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA), was 
used for data analysis. Data are presented as a mean±SD, unless specified 
otherwise. P<0.05 was considered to reflect statistical significance. Because 
hip and knee OA may be associated with different risk factors, these joints 
were analyzed independently (19), and, therefore, results are presented 
separately. For both hip and knee, joints were divided into two groups 
based on the radiographic presence of JSN in order to assess risk factors 
for JSN. Left and right hips, and left and right knees, respectively, were 
analyzed independently in a Generalized Estimating Equations (GEE) 
analysis, taking into account intra-patient effect. A binary logistic model 
was performed with adjustments for age, sex and BMI. 
RESULTS     
PATIENT CHARACTERISTICS: We studies 89 acromegaly patients (mean 
age 58.3 ± 11.5 years, 51% female), who were all in remission for a mean 
of 14.1 ± 6.2 years (Table 1). Fifty patients were cured by surgery alone, 
11 patients were cured by surgery and postoperative radiotherapy, and 
28 patients were medically controlled by long-acting SMS analogs, either 
as primary or secondary treatment. Three patients were co-treated with 
Pegvisomant. Mean estimated duration of active disease was 8.9 ± 7.4 
years. Mean actual IGF-1 SDS was 0.6 ± 1.5.
Hip joint: We studied hips of 87 acromegaly patients (n=174), of 
which 56 hips (32.2%) had radiographic OA (i.e. KL ≥2). With respect 
to cartilage damage, 18 hips (10.3%) had JSN and 156 hips (89.7%) had 
preserved joint spaces. JSN in the hip was associated with age (p<0.001). 
There were no significant relationships between JSN and sex, BMI or 
menopausal status. 
DURATION AND SEVERITY OF GH OVERPRODUCTION: Patients with 
JSN in the hip did not differ in age of diagnosis, active disease duration or 
remission duration from patients without JSN. As shown in Table 1, pre-
treatment GH levels were higher in patients with JSN (153.6±170.2 ug/l 
vs 83.3±108.1 ug/l, p=0.025). In addition, patients with JSN had higher 
pre-treatment IGF-1 SDS than patients with normal joint spaces (9.7±5.6 
vs 7.0±4.5, p=0.038). As a measure for GH exposure, we studied the 
interaction term of pre-treatment GH levels and active disease duration. 
Patients with JSN had higher GH exposures compared to patients without 
JSN, indicating that JSN was related to longer GH excess and higher GH 
levels (p=0.04). 
TREATMENT OF ACROMEGALY (TABLE 2): Patients with and without 
JSN in the hip differed significantly with respect to the type of acromegaly 
treatment. Patients with JSN received SMS analogs more frequently than 
patients without JSN (50% vs 22.2%, OR=8.16 (1.1-61.8), p=0.042), 
and immediate postoperative cure was less frequently achieved (OR=0.18 
(0.03-0.98), p=0.047). There was a trend of higher SMS exposure, 
calculated by the interaction term between duration of SMS treatment 
and SMS dose, in patients with JSN than patients without JSN in the hip, 
although not-significant after adjustments for age, sex and BMI (p=0.091). 
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Table 1. Clinical characteristics of  89 patients with 
acromegaly
Clinical characteristics Patients (N = 89)
Age (years) 58.3 (11.5)
Sex, female (n (%)) 45 (51)
BMI (kg/m2) 28.5 (4.7)
Treatment (n (%))*
  Surgery only
  Surgery + RT   
  SMS analogues 
        Primary
        Following surgery
        Following RT







Disease duration (years) 8.9 (7.4)
Duration of remission (years) 14.1 (6.2)







  Corticotrope failure
  Thyreotrope failure




Values are means (SD) unless stated otherwise. 
GH, growth hormone; IGF-1, insulin-like growth factor 1; BMI, body mass index; RT, radiotherapy; 
SMS, somatostatin (analogs).  
*    Three patients (3%) were co-treated with Pegvisomant. 
**  Including natural menopause (N = 40 (45%)) and hypogonadotropic hypogonadism
Table 2. Acromegaly-specif ic risk factors for JSN in the hip, 
studying 87 well-controlled acromegaly patients  








Age at diagnosis (yr) 40.2 ± 12.6 44.2 ± 9.1 1.0 (0.9-1.0) 0.259 #
Active disease duration (yr) 8.6 ± 7.6 10.1 ± 4.6 1.0 (0.9-1.1) 0.949
Duration of remission (yr) 13.7 ± 5.9 16.6 ± 7.5 1.1 (0.9-1.2) 0.318
Pre-treatment GH (µg/L) 83.3 ± 108.1 153.6 ± 170.2 1.01 (1.01-
1.01)
0.025
Pre-treatment IGF-1 SDS 7.0 ± 4.5 9.7 ± 5.6 1.1 (1.01-1.3) 0.038
Treatment
  Surgery and/or Radiotherapy (%)





8.2 (1.1-61.8) 0.042 *
Immediate postoperative cure (%) 57.3 21.1 0.2 (0.03-0.98) 0.047
n represents total number of hip joints included. Data are shown as mean, unless mentioned 
otherwise. Immediate cure was defined as immediate postoperative cure, without requiring 
additional radiotherapy and/or postoperative medical treatment for persisting disease activity. 
Data were analyzed by Generalized Estimating Equations (GEE) analysis taking into account intra-
patient effect, with additional adjustments for age, sex and BMI (except for #). 
CI, confidence interval; BMI, body mass index; SMS, somatostatin analogs.  
*    SMS analogs vs other therapies for acromegaly disease. 
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LOCAL BIOMECHANICAL FACTORS: Three patients had previous hip 
fractures or hip surgery for another reason. There was no association 
between physical intensive jobs or sports and JSN. 
RELATIONSHIP BETWEEN JSN IN THE HIP AND JOINT COMPLAINTS: 
Seventy-three % of the patients with JSN of the hip met the ACR criteria 
for clinical hip OA, indicating a much higher prevalence of clinical OA than 
in patients with preserved joint spaces, of which only 17.6% met the clinical 
ACR criteria (OR=14.0 (2.5-79.3), p<0.001). Pain/stiffness at physical 
examination did not differ between patients with and without JSN.
Knee joint: We studied knees of 88 patients (n=175), of which 48 
knees (27.4%) had radiographic OA (i.e. KL ≥2). With regard to cartilage 
damage, twenty-seven knees had JSN (15.4%) and 148 knees (84.6%) had 
preserved joint spaces. JSN in the knee was associated with age (65.2±8.0 
years vs 57.1±11.6 years, p<0.001) and female sex (70.0% vs 56.3%, 
p=0.018). There were no differences in BMI or menopausal status, but 
waist circumference was higher in patients with JSN (p=0.032). 
DURATION AND SEVERITY OF GH OVERPRODUCTION: JSN in the 
knee was not related to age at diagnosis, active disease duration, duration 
of remission, pre-treatment GH levels or pre-treatment IGF-1 SDS (Table 
3). However, GH exposure (product of pre-treatment GH levels and active 
disease duration) was higher in patients with JSN (p=0.029). 
TREATMENT OF ACROMEGALY: Acromegaly treatment was not different 
between patients with and without JSN in the knee. However, immediate 
postoperative cure was less frequently obtained in patients with JSN 
(p=0.019), but this did not remain significant after adjustments for age, 
sex and BMI. 
LOCAL BIOMECHANICAL RISK FACTORS: JSN in the knee was 
associated with a history of knee surgery (p=0.019): especially, the 
prevalence of meniscectomy was high in patients with JSN (14.8% vs 
6.1%, p=0.006) (Table 2). With respect to physical work load, type of 
occupation or type of sport were not related to JSN in the knee. 
After consideration of age, sex, BMI, pre-treatment IGF-1 levels, 
surgical cure vs medical control and meniscectomy in a multivariate GEE-
model, only age and meniscectomy were significantly associated with JSN 
in the knee (ORs were 1.1 (1.0-1.1) and 16.9 (3.1-92.1), p=0.012 and 
p=0.001, respectively), but no acromegaly-specific characteristics. 
RELATIONSHIP BETWEEN JSN IN THE KNEE AND JOINT 
COMPLAINTS: Patients with JSN reported more knee pain than patients 
without JSN (56.5% vs 33.6%) (p=0.035). Clinical knee OA, as assessed 
by the ACR criteria, was more prevalent in patients with JSN than in 
patients with preserved joint spaces (63.3% vs 18.1%; OR=8.2 (2.9-23.1), 
p<0.001). There were no significant differences found in pain and/or 
stiffness at physical examination. 
Table 3. Acromegalic-specif ic and general risk factors for JSN 
in the knee in 88 well-controlled acromegaly patients  
No JSN (OARSI 0) 
n = 148






Age at diagnosis (yr) 40.2 43.2 1.0 (0.9-1.0) 0.133 #
Active disease duration (yr) 8.0 ± 4.7 13.1 ± 4.6 1.1 (1.0-1.2) 0.111
Duration of remission (yr) 14.0 ± 6.4 14.6 ± 5.1 1.0 (0.9-1.1) 0.845
Pre-treatment GH (µg/L) 96.5 ± 119.4 93.2 ± 151.1 1.0 (1.0-1.01) 0.559
Pre-treatment IGF-1 SDS 7.2 ± 96.5 8.8 ± 93.2 1.1 (1.0-1.2) 0.146
Treatment
  Surgery and/or Radiotherapy (%)





1.4 (0.4-5.0) 0.576 *
Immediate postoperative cure (%) 56.4 32.1 0.6 (0.2-1.6) 0.295
Knee Surgery (%) 15.2 40.7 3.5 (1.2-9.8) 0.019
History of meniscectomy (%) 6.1 14.8 7.8 (1.8-34.3) 0.006
n represents total number of knee joints included. Data are shown as mean, unless mentioned 
otherwise. Immediate cure was defined as immediate postoperative cure, without requiring 
additional radiotherapy and/or postoperative medical treatment for persisting disease activity. 
Data were analyzed by Generalized Estimating Equations (GEE) analysis taking into account intra-
patient effect, with additional adjustments for age, sex and BMI (except for #). 
CI, confidence interval; BMI, body mass index; SMS, somatostatin analogs.  
* SMS analogs vs other therapies for acromegaly disease.
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DISCUSSION
This is the first study focusing on the process of JSN in acromegaly 
patients. JSN appears to be an infrequent finding in patients after long-
term follow-up of acromegaly, with a prevalence ranging between only 
10 and 15 % in our cohort. This low prevalence is in contrast to previous 
notions on the pathophysiology of this secondary form of OA. We found a 
clear association with well-known risk factors of OA, such as age, whereas 
other disease-specific risk factors for JSN were joint-site specific. At the 
hip site, disease characteristics reflecting more active disease were related 
to JSN: higher GH/IGF-1 levels at diagnosis, longer and more severe GH 
exposure, and immediate postoperative cure was less frequently achieved. 
This suggests that the GH/IGF-1 axis not only plays a role in the early 
stage of acromegalic arthropathy, but also in the late stage, as reflected by 
JSN. At the knee site, we did not find acromegaly-specific characteristics 
to be associated with JSN. Previous knee surgery was a risk factor for JSN 
in the knee, suggesting that JSN at the knee site is unrelated to GH excess. 
In acromegaly, the late effects of arthropathy are striking, even after 
long-term control of GH overproduction. The assumption is that persistent 
exposure to pathologically elevated GH and/or IGF-1 levels results in 
progressive changes in joint geometry. The phenotype of acromegalic 
arthropathy is characterized by osteophytosis, but most patients have preserved 
or even widened joint spaces (7). However, in a small subgroup of adequately 
treated patients radiographic JSN is present, suggesting that in acromegaly 
probably two types of arthropathy exist. In the present study, JSN was related 
to both well-known risk factors and acromegaly-specific risk factors. The 
high prevalence of JSN in older and female patients is in line with previous 
observations in primary OA (20). In the knee, JSN was strongly associated to 
previous knee surgery, especially meniscectomy. It is well-known from primary 
OA that joint dysplasias, fractures of articular surfaces, and tears of menisci 
and ligaments, which all increase joint instability, frequently precede the 
development of OA (20). This suggests that the JSN phenotype in the knee is 
probably unrelated to the previous GH excess.  
Remarkably, higher pre-treatment GH and IGF-1 levels were associated 
with JSN in the hip. These findings suggest that JSN in acromegalic joints 
can be predicted by a more severe biochemical presentation at diagnosis. 
An interesting observation is the difference in acromegaly treatment 
between patients with and without JSN of the hip. JSN was highly 
prevalent in patients controlled by SMS analogs, in contrast to a relatively 
low prevalence in patients cured postoperatively. This was not observed in 
the knee, which is most probably explained by the fact that the hip is the 
joint site that is most frequently systemically involved. The high prevalence 
of JSN in SMS-treated patients could be explained by the higher disease 
activity in patients with SMS analogs, since, during SMS treatment, subtle 
abnormalities in the GH secretion pattern persist (21). In accordance, 
previous studies report worse outcome in SMS-treated patients with 
respect to QoL and diastolic heart function (22;23). Alternatively, SMS 
analogs possibly could have a direct, IGF-1 independent, effect on joint 
structure. There is evidence for direct inhibitive local effects of SMS on 
cartilage (24;25), and, in addition, SMS receptors were demonstrated in 
bone cells (26). The finding that JSN occurs more frequently in patients 
with higher SMS-exposure (interaction term of SMS duration and dose) 
supports this hypothesis. Further studies have to establish the physiological 
significance of long-term SMS therapy on joint architecture. Another 
explanation is a generally less favorable previous course of acromegaly in 
SMS-treated patients, in which other acromegalic-specific factors within 
the group of SMS-treated patients could probably result in more severe 
cartilage damage (i.e. bias by indication). However, most previous studies 
failed to demonstrate a relationship between duration of active disease and 
arthropathy (4;27;28). 
JSN appeared to be related to a higher presence of joint complaints 
(both knee and hip), when applying clinical ACR criteria. Furthermore, 
JSN was related to more self-reported pain in the knee. Previously, 
acromegalic patients were reported to have better joint functions and, 
therefore, have less joint-replacement surgery than patients with primary 
OA, despite a higher prevalence of osteophytes. It was hypothesized that 
the preserved joint spaces in acromegaly may protect against pain caused 
by osteophytes, and, therefore, prevent acromegalic patients from a 
decrease in functional capability (7). 
Some limitations of this study have to be addressed. First, the used 
scoring methods, such as the OARSI score and clinical ACR criteria 
are subject to debate, since, at present, there are no acromegaly-specific 
classification systems for arthropathy available. Therefore, we were 
limited to the use of primary OA scales for the definition of arthropathy, 
although these methods are developed and validated for the use in primary 
OA. With respect to radiographic OA, these primary OA scales can 
not evaluate a main feature of acromegalic arthropathy, i.e. joint space 
widening. Therefore, we were unable to differentiate between preserved 
or widened joint spaces, reflecting cartilage hypertrophy. Second, the 
present study is a cross-sectional study, and therefore, the causality of the 
association between GH/IGF-1 activity and JSN is difficult to assess. 
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In conclusion, JSN is an infrequent finding in patients with acromegalic 
arthropathy. Patients with JSN have more joint complaints. Well-
known risk factors, such as age and female sex, are associated with JSN. 
In addition, especially at the hip site, acromegalic-specific risk factors 
reflecting more active disease are related to JSN. Remarkable is the high 
prevalence of JSN in patients who were controlled by SMS analogs when 
compared to patients immediately cured postoperatively. The findings 
of the present study suggest that, at least in the hip, there is a role for 
excessive GH/IGF-1 activity, not only in the early stage of acromegalic 
arthropathy, but also in the late phase of the disease, as reflected by JSN. 
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ABSTRACT
BACKGROUND: In active acromegaly, pathologically elevated GH and 
IGF-1 levels are associated with increased bone turnover and a high bone 
mass, the latter being sustained after normalization of GH values. In a 
cross-sectional study design, we have previously reported a high prevalence 
of vertebral fractures (VFs) of about 60% in patients with controlled 
acromegaly, despite normal mean bone mineral density (BMD) values. 
Whether these fractures occur during the active acromegaly phase or after 
remission is achieved is not known. 
OBJECTIVE: Our objective was to study the natural progression of VFs 
and contributing risk factors in patients with controlled acromegaly over a 
2.5-year follow-up period. 
METHODS: Forty-nine patients (mean age 61.3±11.1 years, 37% female) 
with controlled acromegaly for ≥2 years following surgery, irradiation 
and/or medical therapy and not using bisphosphonates were included in 
the study. Conventional spine radiographs including vertebrae Th4-L4 
were assessed for VFs according to the Genant method. VF progression 
was defined as development of new/incident fractures and/or a minimum 
1-point increase in the Genant scoring of pre-existing VFs. BMD was 
assessed by dual-energy X-ray absorptiometry (Hologic 4500). 
RESULTS : Prevalence of baseline VFs was 63%, being highest in men, 
and fractures were unrelated to baseline BMD. VF progression was 
documented in 20% of patients, especially in men and in case of ≥2 VFs at 
baseline. VF progression was not related to BMD values or BMD changes 
over time. 
CONCLUSION: Findings from this longitudinal study show that VFs 
progress in the long term in 20% of patients with biochemically controlled 
acromegaly in the absence of osteoporosis or osteopenia. These data 
suggest that an abnormal bone quality persists in these patients after 
remission, possibly related to pre-treatment long-term exposure to high 
circulating levels of GH. 




Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) are 
important regulators of bone growth modeling and remodeling during 
an individual’s life span (1). IGF-1 mediates most of the effects of GH 
on skeletal metabolism via the IGF-1 receptor (2). GH and IGF-1 act 
as anabolic hormones on bone by stimulating proliferation, and to some 
extent, differentiation of osteoblasts. Osteoclastic bone resorption is also 
stimulated, resulting in an overall increase in bone remodeling (3;4). 
In active acromegaly, pathologically high GH and IGF-1 levels increase 
bone turnover in favor of bone formation (2;5;6), resulting in an overall 
increase in bone mineral density (BMD). It has been suggested that high bone 
mass is sustained after long-term disease control (7-11). However, some studies 
have also reported a low BMD in patients with acromegaly, especially in the 
presence of concomitant hypogonadism (9;12). We have recently reported a 
remarkably high prevalence of vertebral fractures (VFs) (59%) in long-term 
cured acromegalic patients. The highest VF prevalence was observed in men, 
particularly in those with hypogonadism, and prevalence was significantly 
increased compared with that of the general population (13). Three other 
studies reported a comparably high VF prevalence in controlled acromegaly 
patients, independently of gonadal status (5;6;14), suggesting that VFs should 
be included in the panoply of complications of acromegaly. Since BMD has 
found to be normal in the majority of patients, the high VF risk is likely to 
be due to alterations in bone quality rather than a decrease in bone quantity. 
Another important factor in the acquisition of bone mass is the level of sex 
steroids, being illustrated by the development of osteopenia and an increased 
fracture risk in hypogonadal men and women and by the preservation of bone 
mass by restoration of normal endogenous sex steroid levels or by exogenous 
supplementation (15;16). 
Because all studies reported to date have been cross-sectional studies, an 
important question remaining to be addressed is whether patients solely 
fracture during the active phase of acromegaly or whether they continue 
to sustain fractures after achievement of cure (17). Another question to be 
addressed is how to best identify acromegaly patients at risk for (vertebral) 
fractures, because BMD is a bad predictor of fracture risk in this form of 
secondary osteoporosis. In view of the increased morbidity and mortality 
associated with VFs, these questions are of clinical relevance in the long-term 
management of acromegaly. In a prospective study design, we evaluated the 
course of VFs and potential determinants for VF progression in the long-term 
follow-up of biochemically controlled acromegalic patients.
PATIENTS AND METHODS
PATIENTS: All patients with acromegaly in long-term remission (≥2 years) 
after surgery (69%) or medical treatment (31%) and regularly followed 
up at the Department of Endocrinology and Metabolic Diseases of the 
Leiden University Medical Center were invited to take part in a cross-
sectional study in 2007. Eighty-nine patients positively responded and 
were included in the study (18). All 89 patients were invited for a further 
evaluation of skeletal status after a mean interval of 31±1.7 months (range 
28-35 months), of whom 58 (65%) positively responded. Reasons for 
nonparticipation in the follow-up evaluation were non-musculoskeletal-
related health problems (N=16), travel distance (N=6), lack of time (N=4), 
psychological reasons (N=3), or moving abroad (N=2). Demographic 
and disease characteristics did not differ between participants and 
nonparticipants in the follow-up study (data not shown), except for more 
women among non-participants (p=0.025). We excluded the 9 patients 
receiving bisphosphonate treatment at any time point during follow-up, so 
that 49 patients were included in the final analysis.
Clinical follow-up data were available yearly in all patients since 
initiation of treatment for acromegaly. From 1977 onward, first-line 
treatment was in the form of transsphenoidal surgery performed by a 
single experienced neurosurgeon. When required, adjuvant treatment was 
given in the form of radiotherapy (before 1985) or somatostatin (SMS) 
analogs (from 1985 onward). Since 1998, a small number of patients 
received treatment solely in the form of a depot formulation of long-acting 
SMS analogs. This treatment approach resulted in early postoperative 
control in 66% and late control in >90% of patients (19). From 2003 
onward, Pegvisomant was used for treatment-resistant acromegaly. 
Disease activity was assessed yearly by an oral glucose tolerance test 
(except in medically treated patients) and fasting serum GH and IGF-1 
levels. Other pituitary functions were also evaluated yearly. Remission was 
defined as a normal glucose-suppressed serum GH <1.25µg/L (RIA assay 
until 1992) or 0.38µg/L (immunofluorometric assay (IFMA) from 1992 
onwards), serum GH levels <1.9µg/L, and normal IGF-1 levels for age 
(from 1986 onwards). Treatment decisions were based on these remission 
criteria. 
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STUDY DESIGN: Fasting blood samples were obtained to assess GH 
and IGF-1 concentrations at baseline and at 2.5 years of follow-up. 
Conventional spine radiographs were obtained using a standardized 
protocol (vide infra) and BMD was assessed using dual energy X-ray 
absorptiometry (DXA) (Hologic QDR 4500) at the same time points. 
All patients had to complete a standardized questionnaire providing 
demographic data, data on medical history, and data on clinical risk 
factors for VFs, such as early menopause, previous fractures, glucocorticoid 
use and diagnosis of rheumatoid arthritis. 
The Medical Ethics Committee approved the study protocol, and 
informed consent was obtained in all patients. 
ACROMEGALY DISEASE PARAMETERS: Duration of active acromegaly 
was calculated from the estimated date of onset of the disease, defined as 
the date of onset of signs and symptoms or the date of changes in facial 
features using serial photographs, to the date of normalization of serum 
IGF-1 after surgery, irradiation and/or medical treatment. Duration of 
remission of acromegaly was calculated from the date of biochemical 
remission to the date of baseline evaluation at inclusion in the study. 
Cure was defined as normal glucose-suppressed age-related GH levels and 
IGF-1 levels after surgery and/or irradiation. Biochemical control was 
defined as normal serum IGF-1 levels for age during medical treatment. 
Both cured and biochemically controlled patients were referred to as being 
‘in remission’.
ASSESSMENT OF PITUITARY AND GONADAL FUNCTION: 
Hypopituitarism was diagnosed on the basis of clinically significant 
hormone deficiencies in at least one axis, which required supplementation 
with L-T4, hydrocortisone, testosterone or estrogens (in pre-menopausal 
women) according to the following definitions (20;21): TSH deficiency 
was defined as a free T4 level below the normal laboratory reference 
range (absolute value <10pmol/l). ACTH deficiency was defined as an 
insufficient increase in cortisol levels (absolute value <0.55µmol/l) after 
stimulation by CRH or insulin tolerance test. GH deficiency (GHD) was 
not routinely assessed. 
With respect to gonadal function, patients with adequately treated 
hypogonadism (i.e. gonadal hormone replacement therapy started <1 
year after the onset of hypogonadism) were considered eugonadal. Men 
with a total testosterone concentration of <8.0nmol/l for longer than 1 
year during follow-up or documented prior to diagnosis, were considered 
hypogonadal. Female patients with normal spontaneous menstrual cycle, 
those using estrogen replacement therapy or the pill, or patients with a 
history of only short-term amenorrhea who were treated with estrogen 
within 1 year of diagnosis were considered eugonadal. Females with 
prolonged untreated amenorrhea in the presence of a serum estradiol 
concentration of <70nmol/l or natural menopause were considered 
hypogonadal.
BIOCHEMICAL ASSAYS: Serum GH was measured with a sensitive IFMA 
(Wallac, Turku, Finland), specific for the 22 kDA GH protein, calibrated 
against World Health Organisation International Reference Preparation 
(WHO IRP) 80/505 (detection limit: 0.01µg/l, interassay coefficient of 
variation (CV): 1.6-8.4% of 0.01-15.38µg/l) from 1992 onwards. For 
the conversion of µg/l to mU/l, values were multiplied by 2.6. Before 
1992, GH was measured by RIA (Biolab, Serona, Coissins, Switzerland), 
calibrated against WHO IRP 66/21 (detection limit: 0.5mU/l, with an 
interassay CV less than 5%; for the conversion of µg/l to mU/l, multiply 
by 2.6).
Until 2005, serum IGF-1 concentrations were determined by a RIA 
(Incstar; Stillwater, MN, USA) with a detection limit of 1.5nmol/l and 
an inter-assay CV below 11%. IGF-1 is expressed as standard deviation 
score (SDS) for age- and sex-related normal levels determined in the 
same laboratory (32). From 2005 onwards, serum IGF-1 concentrations 
(nmol/l) were measured using an immunometric technique on an 
Immulite 2500 system (Diagnostic Products Corporation, Los Angeles, 
CA, USA). The intra-assay variations at mean plasma levels of 8 and 
75nmol/l were 5.0 and 7.5%, respectively. IGF-1 levels were expressed 
as SDS, using lambda-mu-sigma smoothed reference curves based on 
measurements in 906 healthy individuals (22;23). 
Markers of bone-turnover, beta-crosslaps (bone resorption) and 
procollagen type 1 amino-terminal propeptide (P1NP) (bone formation), 
were measured by an electrochemolumiscent immunoassay with a 
Modular Analytics E-170 system (Roche Diagnostics, Almere, The 
Netherlands). Serum calcium (adjusted for albumin binding) was 
measured by a semiautomated technique. 25-hydroxyvitamin D was 
measured by RIA (Incstar/DiaSorin, Stillwater, MN, USA). Serum 
concentrations of intact PTH (reference range 1.5-8 pmol/l) were 
measured using Immulite 2500 (Siemens Diagnostics, Breda, The 
Netherlands).
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BMD MEASUREMENTS: BMD was measured at the lumbar spine (L1-L4) 
and total hip using DXA (Hologic QDR 4500, Hologic Inc., Waltham, 
MA, USA) equipped with reference values based on the National Health 
and Nutrition Examination Survey (NHANES III). World Health 
Organization (WHO) criteria were used to define osteopenia (T-score 
between -1.0 and -2.5) and osteoporosis (T-score ≤-2.5). Baseline BMD 
data have already been published for the original cohort (13). Follow-up 
BMD data were available in a subset of 15 patients (31%) in the context 
of standard patient care.
RADIOGRAPHIC PROTOCOL AND VF ASSESSMENT: Conventional 
lateral radiographs of the thoracic and lumbar spine were performed by 
an experienced radiology technician following a standardized protocol, 
with the film centralized on Th7 and L3, respectively, at baseline and 
after 2.5 years of follow-up. Radiographs obtained in individual patients 
at both time points were assessed unpaired for presence of VFs in Th4 
to L4 according to the validated Genant’s semiquantitative method 
(24). Grade 1 (mild fracture) was defined as approximately 20% to 25% 
reduction in anterior, middle and/or posterior height; Grade 2 (moderate 
fracture) was defined as approximately 25% to 40% reduction in anterior, 
middle and/or posterior height; Grade 3 (severe fracture) was defined 
as approximately >40% reduction in anterior, middle and/or posterior 
height. Radiographs were blinded for any patient characteristics and 
were individually assessed by two independent observers (H.M.K. and 
K.M.J.A.C.), one of whom is an experienced musculoskeletal radiologist 
(H.M.K.). In case of discrepancy in assessment, a consensus opinion was 
obtained. The intra-observer and interobserver variability were good, as 
depicted by intra-correlation coefficients (ICCs) of, respectively, 0.950 and 
0.901. Individual vertebrae with confounding pathology were excluded (5 
vertebrae). 
Progression of VFs was defined as the development of new/incident 
VFs (in patients with no VFs or in patients with previous VFs in other 
vertebrae) and/or the documented minimum 1-point increase in the 
Genant scoring in pre-existing VFs during the period of follow-up. 
Statistical analysis
SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA), was 
used for data analysis. Data are presented as mean (SD), unless otherwise 
stated. P<0.05 was considered to be significant. Patient characteristics 
were grouped according to sex. BMD changes over time were analyzed by 
a Paired Samples T test. Mean baseline BMD, mean current BMD and 
mean BMD changes were studied compared patients with and without VF 
progression, using a binary logistic regression analysis, adjusted for age, sex 
and body mass index (BMI). An X2 test was used to assess VF progression 
rate according to the number of prevalent VFs at baseline.
Potential risk factors for VF progression were identified by binary 
logistic regression analysis, adjusted for age, sex, BMI, parameters of 
disease activity, and the presence of hypopituitarism. 





Forty-nine patients with well-controlled acromegaly (mean age 61.3±11.1 
years, 37% female) were included in the study (Table 1). Patients had been 
in remission for a mean of 17.0±7.1 years and mean actual IGF-1 SDS 
was 0.63±1.39. In 36 patients (73%), remission was achieved by surgery 
with additional radiotherapy, when required. The remaining 13 patients 
(27%) received long-acting SMS analogs, either as sole treatment or as 
postoperative treatment after transsphenoidal surgery (mean duration of 
treatment 105 (range 21-91) months). One patient received additional 
treatment with Pegvisomant. Thirty male patients were considered 
eugonadal (24 with preserved gonadal function, 6 with adequate androgen 
replacement), and only one was hypogonadal. Mean testosterone level at 
follow-up was 13.4±4.8 nmol/L. Two females were considered eugonadal 
(pre-menopausal with normal gonadal function), and 16 were post-
menopausal. One patient had diabetes mellitus type 1 and two patients 
had diabetes mellitus type 2.
All patients were Vitamin D replete at baseline and were still so at 
the end of study evaluation, except for 2 patients (25-hydroxyvitamin 
D concentrations <25nmol/L). Ten and 8 patients received respectively 
calcium and Vitamin D supplements during follow-up. 
Bone markers
Mean baseline P1NP and β-crosslaps concentrations were, respectively, 
39.4±20.9ng/mL and 0.39±0.20ng/mL. All values were within the normal 
laboratory reference range, except for slightly elevated P1NP levels in 
4 postmenopausal women at baseline and 2 postmenopausal women at 
follow-up. 
Values are means (SD) unless stated otherwise. Patient characteristics were grouped according to 
sex and were analyzed by Independent Samples T test or X2 test, when appropriate. Disease cure 
is defined as normal glucose-suppressed GH levels and IGF-1 levels for age after surgery and/or 
irradiation. 
Yr, years; GH, Growth Hormone; IGF-1, Insulin-like Growth Factor-1; BMI, body mass index; SMS, 
somatostatin (analogs); GHD, Growth Hormone Deficiency; PTH, parathyroid hormone; RA, 
rheumatoid arthritis.  
*, one patient is co-treated with Pegvisomant.
Table 1. Clinical characteristics of  49 patients with 






Age (yr) 60.1 (11.1) 63.5 (10.9) 0.30
BMI (kg/m2) 29.6 (4.5) 28.0 (4.9) 0.28
Treatment (n (%))
  Surgery only
  Surgery + RT   
  SMS analogues 
        Primary
        Following surgery *
        Following RT 




















  Corticotrope failure
  GHD
  Thyreotrope failure
















Hypogonadal/natural menopause (n (%)) 1 (3%) 16 (89%) <0.01
Disease duration (yr) 8.0 (5.3) 9.4 (11.2) 0.60























Calcium (mmol/l) 2.34 (0.10) 2.36 (0.09) 0.61
PTH (pmol/l) 6.0 (3.0) 5.3 (2.1) 0.43









β-crosslaps (ng/mL) 0.24 (0.11) 0.36 (0.16) 0.01
P1NP (ng/mL) 27.2 (8.8) 37.1 (19.2) 0.08
Current smoking (n (%)) 7 (23%) 3 (17%) 0.69
Glucocorticoid use (n (%)) 8 (26%) 6 (35%) 0.49
RA (n (%)) 0 (0%) 0 (0%) 1.00
Diabetes mellitus (n (%)) 2 (6%) 1 (6%) 0.35




BASELINE BMD MEASUREMENTS: At baseline, mean BMD at the lumbar 
spine was 1.05±0.15 g/cm2, mean T-score was -0.12±1.32, and mean 
Z-score was 0.99±1.53. Mean BMD at the total hip was 0.96±0.16 g/cm2, 
mean T-score was 
-0.53±2.29, and mean Z-score was 1.06±2.51. Three patients (6%) had 
osteoporosis at baseline, and 13 patients had osteopenia (27%) at one or 
more measured sites. 
LONGITUDINAL BMD MEASUREMENTS AFTER 31 MONTHS OF 
FOLLOW-UP IN PATIENTS WITH SUSTAINED REMISS ION OF 
ACROMEGALY (N=15): Follow-up DXA (2010) was available in 15 
patients (5 M, 10 F), who were in sustained remission for 18.1 (range 
11-28) years after treatment. Ten patients (67%) had hypopituitarism with 
adequate hormone substitution; all females were postmenopausal. Nine 
and 7 patients received calcium and Vitamin D supplements, respectively. 
In this subset, mean BMD did not change at the lumbar spine 
(1.00±0.20 g/cm2 at baseline and 1.00±0.19 g/cm2 at follow-up) or at the 
total hip (0.89±0.19 g/cm2 at baseline and 0.88±0.17 g/cm2 at follow-up) 
(Figure 1). Changes in BMD did not differ between men and women. 
Evaluation of  vertebral fractures at baseline and at follow-up
BASELINE EVALUATION OF VERTEBRAL FRACTURES (PREVALENT 
FRACTURES): As previously reported, VF prevalence was high at baseline 
(63%) (13). Mean number of VFs per patient was 2.3±1.4 (range 1-6). 
VF prevalence was higher in men than in women (74% vs 44%, p=0.039). 
Most fractures were documented in the thoracic vertebrae Th12 (N=13), 
Th9 (N=10) and Th8 (N=9). The VF grade varied from mild (Grade 1: 
93%) to moderate (Grade 2: 7%); no severe fractures (Grade 3) were 
observed. Figure 2a depicts the VF number at different vertebral levels, 
showing a typical bimodal pattern with peaks at Th9 and Th11-L1 in 
males. In females, fractures of vertebrae Th7 and Th8 were the most 
frequently observed. Figure 2b shows the VF severity distribution at 
different vertebral levels. 
Eight patients (14%) sustained a non-vertebral fracture after 
establishment of biochemical control (prevalence in women vs men: 15% 
vs 13%), giving an incidence rate of 7.8 / 1000 person-years for non-
vertebral fractures sustained after achieving remission. Most common 
fracture site was the hip (N=2).  
Figure 1. BMD and T-scores in 15 patients with long-term controlled acromegaly, stratified for 
sex, at baseline and after 31 months of follow-up (N=15) 
Data are presented as mean ± SD. Mean BMD and T-scores were presented for 15 acromegaly 
patients with available follow-up DXA. T-scores reflect the number of standard deviations (SD) 
above or below the mean for a healthy 30-year old adult of the same sex and ethnicity as the 
patient. No changes in mean BMD were observed at either the lumbar spine or total hip after a 
2.5-year follow-up period.
BMD, bone mineral density; SD, standard deviation. 
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VERTEBRAL FRACTURE PROGRESSION AND/OR INCIDENT 
FRACTURES OVER 31 MONTHS OF FOLLOW-UP: VF progression 
was observed in 10 patients (20%) (29% in men and 5.6% in women), 
especially at vertebra Th7 (wedge fractures). Eight patients (16%), of 
whom 3 (6%) had no previous VFs, developed new fractures; one patient 
showed progression of already existing VFs, and one patient had new 
fractures in addition to demonstrating progression of preexisting VFs. 
After excluding the only hypogonadal man, VF progression was seen 
in 30% of eugonadal men. Excluding the two premenopausal women 
resulted in VF progression in 6.3% of postmenopausal women. 
ANALYSIS OF POTENTIAL RISK FACTORS FOR PROGRESSION OF 
VERTEBRAL FRACTURES: Patients with ≥2 VFs at baseline had a 9.0-
fold increase in risk of VF progression than patients with only one or no 
VFs at baseline (p=0.005) (Figure 3). Risk of progression tended to be 
higher in males than in females (OR=7.0 (0.8-60.4), p=0.067). Age, BMI, 
menopausal state, duration of active disease, or pre-treatment/current 
IGF-1 SDS were not related to VF progression. VF progression rate did 
not differ between different types of treatment for acromegaly and no 
effect of Vitamin D status was found.
As assessed in the subset of 15 patients with available follow-up DXA, 
baseline BMD, current BMD or BMD changes at either the lumbar 
spine or total hip did not differ between patients with and without VF 
progression, adjusted for age, sex and BMI.
Figure 2A. Distribution of prevalent VFs at different vertebral levels at baseline, for male and 
female patients with long-term controlled acromegaly
Figure 2B. Severity distribution of VFs at baseline, for male and female patients with long-term 
controlled acromegaly
Figure 3. VF progression over 31 months of follow-up according to number of baseline VFs in 49 
long-term controlled acromegaly patients
Risk for VF progression in relation to number of baseline VFs is presented. Patients with at least 2 
VFs at baseline had a 9.0-fold increased risk of VF progression compared to patients with no or 
one VF at baseline (p=0.005). 
VF, vertebral fracture.
























































































































































Data from this longitudinal study of VFs in patients with acromegaly 
demonstrate that VFs progress in 20% of patients with long-term 
biochemically controlled acromegaly during a mean follow-up period of 
31 months. These findings suggest that VFs do not solely develop during 
the active phase of acromegaly, but continue to represent a problem after 
biochemical control or cure. We have previously shown that normal BMD 
is maintained during long-term follow-up of up to 17 years after cure. 
This, however, does not appear to protect against VF progression. Men 
and patients demonstrating two or more prevalent VFs appear to be more 
at risk for VF progression. 
GH and IGF-1 are important anabolic hormones. Most of the 
effects of GH is mediated by systemic and/or local IGF-1, enhancing 
the differentiated function of osteoblasts and bone formation, although 
GH may also act directly on bone cells (1). On the other hand, IGF-
1also induces receptor activator of nuclear factor kB ligand (RANK-L) 
synthesis and, as a consequence, osteoclastogenesis. In contrast to IGF-1, 
GH stimulates the production of osteoprotegerin, which competes with 
the RANK-L receptor, thereby impairing osteoclastogenesis (2). IGF-1 
increases the number of remodeling sites, thereby increasing bone activity 
and diminishing bone strength. 
In acromegaly, in which patients are exposed to pathologically high 
GH and IGF-1 levels for long periods, appropriate treatment by surgery, 
radiotherapy, medical therapy, or a combination of these treatment 
modalities considerably improves many of the comorbidities associated 
with this disorder (25). It is clear, however, that despite long-term 
biochemical control, a number of skeletal manifestations of acromegaly 
persist, possibly as a consequence of the severe albeit transient GH excess 
the skeleton has been originally exposed to. These skeletal complications 
are associated with increased morbidity and decreased quality of life 
(26;27). In this respect, a VF is one of the most invalidating (irreversible) 
complications of acromegaly, occurring in approximately 60% of treated 
patients (5;6;13;14). Highest VF prevalence has been reported in men, 
especially in the presence of hypogonadism (13). 
Because most previous studies on VFs in acromegaly were of a 
cross-sectional design, it is difficult to retrospectively discriminate 
which VFs occurred during the active acromegaly state and which 
VFs were sustained after disease remission (17). To date, it is still 
not known whether GH/IGF-1 control reduces this fracture risk. 
The 20% VF progression rate in adequately controlled acromegaly 
patients demonstrated in the present study suggests that risk factors 
for VFs still prevail after achievement of biochemical control. In 
keeping with earlier studies, progression was greatest in men and 
in patients with two or more prevalent VFs at baseline (28;29). 
Our data were consistent with a recent study of Mazziotti et al. 
longitudinally investigating VF progression in a cohort of both 
active and controlled acromegalics (30). In that particular study, 
in which control was achieved by medical therapy in the majority 
, a VF progression rate of 25% over 3 years was observed in their 
subset of patients with controlled acromegaly. 
The high VF prevalence observed in acromegalic patients was 
interestingly associated with a normal BMD (13), suggesting 
that BMD is a poor predictor of fracture risk in acromegaly, as is 
also the case in other forms of secondary osteoporosis (3;4;31). 
These data also suggest that bone quality may be altered in these 
patients, potentially irreversibly (32). A note of caution, however, 
is that BMD at the lumbar spine may be overestimated due to the 
high prevalence of degenerative changes in acromegaly, induced 
by prolonged exposure to GH excess (18). Imaging modalities to 
assess bone quality such as microindentation may allow a better 
evaluation of fracture risk than DXA in these patients (32;33).
Several comorbidities of acromegaly have been independently 
associated with fracture risk itself. For example, diabetes mellitus, 
both type 1 and type 2, is associated with an increased fracture risk, 
which was reported to be due to increased bone resorption resulting 
in bone loss and low bone turnover (34). (35). However, in the 
present study of controlled acromegaly, the number of patients with 
diabetes was very small. Also hypogonadism is an important factor. 
However, in the present study, we were not able to analyze the 
VF progression rate in hypogonadal men nor to explore whether 
hypogonadism is a risk factor for progression, being limited by the 
fact that only one man was hypogonadal. However, as described 
in our previous study, hypogonadal men had the highest VF 
prevalence of 86% when compared to eugonadal women (19%) 
and hypogonadal women (49%) (13). These former data strongly 
suggest that in acromegalic patients in long-term biochemical 
remission, hypogonadism is also associated with an increased VF 
risk.
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Studies investigating VF progression in general population over 2 to 
3 years are scarce; most studies had longer follow-up. Several studies, 
especially randomized controlled trials of bisphosphonates studying 
fracture risk in postmenopausal women, reported a VF progression 
rate of 5-7% over 4 to 5 years of follow-up in the control arm without 
bisphosphonate use (36-38). Although study designs are not fully 
comparable, the VF progression rate in acromegaly patients in remission 
is suggested to be much higher than in the general population. This 
study has a number of strengths and limitations. Of the study’s strengths 
are the relatively large number of acromegaly patients studies with 
well-documented follow-up, data including follow-up radiographs, VF 
scoring by two independent experienced observers with low intra- and 
interobserver variability, and the adequate supplementation of pituitary 
hormone deficiencies, which may have otherwise potentially increased 
fracture risk. We also excluded patients using bisphosphonate treatment 
to avoid confounding effects of this antiresorptive medication on fracture 
risk, although by doing so, we also excluded the patients with the worst 
risk for further fractures. The main limitation of this study may be the 
inclusion of Grade 1 fractures in our analysis. Although the predictive 
value of Genant grade 1 fractures for future fractures remains debatable, 
the prognostic impact of these fractures for future fractures in acromegaly 
patients is not known. Patients with these mild-grade fractures were 
therefore included in the final analysis of data from this study. 
In conclusion, we demonstrated that VFs progress in 20% of patients 
with long-term biochemically controlled acromegaly in the absence of 
osteoporosis or osteopenia. These data suggest persisting poor bone quality 
possibly related to long-term exposure to high circulating GH levels, 
although this also remains to be established. Based on our findings and the 
morbidity and mortality attached to VFs, we recommend the inclusion 
of VF assessment in the follow-up evaluation of acromegaly patients, also 
after establishment of biochemical remission, to allow timely therapeutic 
intervention to prevent further fractures. Future studies are needed to 
address the pathophysiological basis of the changes in bone quality leading 
to the high VF risk in long-term controlled acromegaly.
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factor-1 and radiographic 
disease in patients with 
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ABSTRACT
OBJECTIVE: To evaluate the association between radiographic 
osteoarthritis (OA) and either serum insulin-like growth factor-1 (IGF-1) 
levels or IGF-1 gene polymorphisms in patients with primary OA.
METHODS: We conducted a systematic review of reported associations 
between circulating IGF-1 and/or IGF-1 gene polymorphisms and 
radiographic OA. Studies were eligible when: 1) investigating serum IGF-1 
and/or IGF-1 gene polymorphisms in relation to prevalent or incident 
radiographic OA; 2) written in English; 3) full-text article or abstract; 4) 
patients had primary OA in knee, hip, hand or spine; 5) longitudinal, 
case-control or cross-sectional design. Quality assessment was done using 
a standardized criteria set. Best-evidence synthesis was performed based 
on guidelines on systematic review from the Cochrane Collaboration 
Back Review Group, using five evidence levels: strong, moderate, limited, 
conflicting and no evidence. 
RESULTS: We included 11 studies with more than 3000 primary OA cases. 
Data on the relationship between serum IGF-1 and radiographic OA were 
inconsistent. Adjustment for body mass index (BMI) was often omitted. 
Of four high-quality studies, three studies reported no association, one 
study found significantly higher IGF-1 levels in OA patients compared to 
controls. Patients with IGF-1 gene promoter polymorphisms and a genetic 
variation at the IGF-1R locus had an increased OA prevalence compared 
to controls.
CONCLUSIONS: Observational data showed no association between 
serum IGF-1 and occurrence of radiographic OA (moderate level of 
evidence), and a positive relationship between IGF-1 gene polymorphisms 
and radiographic OA (moderate level of evidence); however the 
confounding effect of BMI was insufficiently addressed. Future well-
designed prospective studies should further elaborate the role of the 
complex GH/IGF-1 system in primary OA. 




Osteoarthritis (OA) is a common disease, characterized by progressive 
degradation of articular cartilage and bone remodeling, resulting in pain 
and disability. Despite the increase in molecular knowledge accrued 
during the last years, the exact pathogenesis of the destructive process 
remains unknown. OA is considered to be a multifactorial disease in 
which age, body mass index (BMI), hormonal and local biomechanical 
factors together with genetic predisposition play a role (1-5). In OA, 
the stable equilibrium between synthesis and breakdown of cartilage 
components is disrupted and the rate of loss of proteoglycans and other 
matrix components eventually exceeds their formation rate (6). Factors 
responsible for preservation or loss of the articular cartilage matrix are of 
considerable interest to clinicians and scientists. Among chondrotrophic 
growth factors, insulin-like growth factor-1 (IGF-1) and its response on 
mature adult cartilage has been studied extensively.
IGF-1 is an important growth promoting peptide with structural and 
functional homology to pro-insulin. IGF-1 is mainly produced by the 
liver and mediates the effects of growth hormone (GH) at tissue level. In 
addition, IGF-1 is a key factor for longitudinal skeletal growth (7). Serum 
IGF-1 concentrations in adulthood decrease progressively with age and 
are influenced by many other factors, such as BMI (8,9). Three lines of 
research suggest IGF-1 involvement in OA pathogenesis. 
Firstly, IGF-1 has been shown to enhance chondrocyte proliferation 
and proteoglycan and collagen synthesis by chondrocytes in normal 
cartilage, both in vivo and in vitro (10-20), also during cytokine exposure, 
which drives most predominating catabolic processes in cartilage. 
Furthermore, IGF-1 inhibits cytokine-stimulated degradation of 
proteoglycans directly in normal cartilage in vitro (21,22). These anabolic 
and protecting properties make IGF-1 an obvious candidate for a major 
role in cartilage repair. 
Secondly, serum IGF-1 is elevated in acromegaly, a rare endocrine disease 
caused by GH overproduction from a pituitary adenoma. The GH excess 
results in high serum GH and IGF-1 levels and is associated with an increased 
risk of secondary OA (23,24). Prevalence and severity of arthropathy worsen 
with the duration of uncontrolled acromegaly. Furthermore, pre-treatment 
IGF-1 levels predict radiographic OA in a dose-dependent manner (25). 
Finally, earlier studies showed that genes regulating formation, 
degradation and repair of articular cartilage and subchondral bone 
remodelling may be involved in OA pathogenesis (26-29). Probably, 
genetic variations of GH/IGF-1 genes with functional properties may 
affect the pathogenesis of primary OA. 
Several epidemiological studies have explored the role of serum IGF-1 in 
primary OA, showing various results (30-33). We aimed to systematically 
review observational studies on the relationship between radiographic OA 
and either serum IGF-1 and IGF-1 gene polymorphisms in patients with 
primary OA, taking in account the variable quality of studies. 
MATERIALS AND METHODS
IDENTIFICATION AND SELECTION OF THE LITERATURE: To identify 
studies investigating the relationship between IGF-1 and radiographic 
primary OA, we searched the following databases, up to May 2011: 
Medline, EMBASE, Web of Science, the Cochrane Library, ScienceDirect, 
CINAHL, LWW Journals, Wiley, Academic Search Premier and WHO 
International Clinical Trials Registration Platform. The following 
combined key words were used: (“Insulin-Like Growth Factor I” OR 
“IGF-1” OR “Insulin-Like Somatomedin Peptide I” OR “Somatomedin 
C” OR “IGF-I-SmC” OR “Receptor, IGF Type 1” OR “IGF-1 Receptor” 
OR “IGF 1 Receptor” OR “IGF-I Receptor” OR “IGF I Receptor” OR 
“IGF-1 Receptors” OR “IGF Type 1 Receptor” OR “Insulin-Like-Growth 
Factor I Receptor”) AND (“Osteoarthritis” OR “Osteoarthritides” OR 
“Osteoarthrosis” OR “Osteoarthroses” OR “Degenerative Arthritides” OR 
“Degenerative Arthritis”). References of relevant articles were checked for 
additional articles.
A study was eligible for inclusion with the following criteria: 
(1) the association between serum IGF-1 levels and/or IGF-1 gene 
polymorphisms and prevalent or incident radiographic OA was 
investigated; (2) written in English; (3) full-text article or abstract; (4) 
patients had primary OA in knee, hip, hand or spine; (5) longitudinal, 
case-control or cross-sectional design. Incident OA was defined as the 
development of OA in joints that were previously unaffected during the 
specified time period in a longitudinal study. Prevalent OA was defined as 
the presence of OA at the moment of the study visit in a cross-sectional or 
case-control study.
A study was excluded if the studied population had a specific 
underlying pathology, such as trauma (fractures), infection, rheumatoid 
arthritis, or ankylosing spondylitis. Only human studies were evaluated. 
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DATA EXTRACTION AND ANALYSIS: Data extraction and eligibility 
were assessed by two independent investigators (K.M.J.A.C. and 
S.R.R.). Inconsistencies in data extraction were resolved by consensus. 
We used data comparing serum IGF-1 and/or presence of IGF-1 gene 
polymorphisms between patients with radiographic OA and controls 
without radiographic OA. 
The following data were extracted: (1) study population (patient 
characteristics, population size, gender, age, BMI); (2) exposure (serum 
IGF-1 or IGF-1 gene polymorphisms), (3) outcome (methods of 
assessment of radiographic OA, reproducibility, blinding); (4) potential 
confounders (age, sex, BMI, height, race).
METHODOLOGICAL QUALITY ASSESSMENT : The quality of each 
included paper was assessed by two independent reviewers (K.M.J.A.C. 
and S.R.R.) using a standardized set of criteria (Table 1), which have been 
used previously in reviews on musculoskeletal disorders (34) and were 
modified to cover the topic of our review. 
When the criterion was met in the article, ‘1’ was given, otherwise 
‘0’. A ‘0’was also given when no information was given about the specific 
criterion mentioned in the article. Several items are not applicable to 
certain types of study design and therefore do not contribute to the total 
score of that particular study. The maximum score (100%) for each study 
was based only on the items applicable to that particular study design 
(cohort and case-control 14, cross-sectional 11). Total scores per study 
were calculated as the percentage of maximum obtainable scores. For 
example, a quality score of 57% (8 / 14 x 100%) was assigned to a case-
control study with 8 positive items. A study was considered high-quality 
(HQ) if the methodological quality score was ≥64%, chosen as the median 
of all quality scores. 
Level of evidence synthesis: Because the observational studies were 
heterogeneous with regard to study population, methodological quality 
and determinants and measures of radiological OA assessment, we 
followed standard practice and refrained from statistically pooling the 
data and performed a ‘best evidence’ synthesis. A prospective cohort study 
was judged as the preferred design, followed by a case-control study, and 
then by a cross-sectional study. Subsequently, the studies were ranked 
according to their methodological quality score. The following ranking 
of the levels of evidence was formulated based on the guidelines on 
systematic review of the Cochrane Collaboration Back Review Group, a 
method to summarize evidence in observation studies with heterogeneous 
methodological study characteristics (Table 2) (35,36). 








Clear description of selection of study subjects. 
Sufficient description of characteristics of study groups.
Cases and controls were drawn from the same source 
population.
Participation rate ≥ 80% for cases/cohort.











Serum IGF-1/IGF-1 gene polymorphism was assessed 
with standardized or valid instruments.
IGF-1 measurement/IGF-1 gene polymorphism 









Radiographic OA measures were valid.
Presence of radiographic OA was assessed reproducibly.










Mean levels of IGF-1 (e.g. serum and/or synovial) were given.
Frequencies of radiographic OA were given.
Appropriate analysis techniques were used.





OA=osteoarthritis. IGF-1=insulin-like growth factor 1. 
* Applicable to CH=cohort study. CC=case-control study. CS=cross sectional study. GA=genetic 
association study.
Table 2. Levels of  evidence used in best-evidence synthesis. 
Strong                   
Moderate               
Limited       
Conflicting            
No evidence           
Generally consistent findings were presented in multiple high-quality 
cohort studies.
One high-quality cohort study and two or more high quality case-
control studies, or when at least three high-quality case-control studies 
show generally consistent results.
Generally consistent findings were found in a single cohort study, or in 
one or two case- control studies or in multiple cross-sectional studies.
Less than 75% of the studies reported consistent findings.
No study could be found.
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Sensitivity analyses by defining other cut-offs (mean score of all studies 
instead of median) of HQ studies were performed. Furthermore, a 
sensitivity analysis was performed based on all positive studies, regardless 
of methodological quality. A study was regarded as positive if it showed a 
significant association between serum IGF-1 and radiographic OA. 
RESULTS
IDENTIFICATION AND SELECTION OF THE LITERATURE: From initial 
668 potentially relevant studies identified, 634 were excluded on the basis 
of title and abstract. 34 papers were retrieved for detailed assessment: 7 
were excluded because no primary OA patients were included, 10 because 
OA was not assessed radiographically, and 3 were not original articles. One 
abstract appeared to be a duplicate of a full text article and was excluded. 
Another 2 studies were excluded because they studied OA progression and 
severity, respectively, and not prevalent or incident OA. Consequently, a 
total of 11 studies were included (Figure 1). 
Figure 1. Flow diagram of study selection and exclusion stages. 







668 potentially relevant publications 
identified  from electronic search 
34 publications retrieved for more      
detailed assessment 
11 studies eligible for inclusion 
634 studies excluded based on title and 
abstract 
23 articles did not fulfill the inclusion 
criteria because of the following   
reasons: 
 
  7 articles: no primary OA 
10 articles: no radiographic OA 
  3 articles: review article 
   1 article: duplicate of full text article 
 2 articles: OA severity or progression  
STUDY DESCRIPTION: A detailed study description is given in Tables 
3a&3b. These studies provided data on the relationship between serum 
IGF-1 and radiographic OA of knee (n=5) (30,33,37,38,40), hand (n=1) 
(32), OA in general (n=3) (31,39), and IGF-1 gene polymorphisms 
(n=3) (26-28). The studies were published from 1992 onwards. One 
had a nested case-control design; the other 10 were case-control/cross-
sectional studies. All studies used a radio-immuno assay (RIA) for IGF-1 
measurement in serum. Assays were generally done blinded to case status.    
Most studies investigated a middle-aged population and three 
exclusively included women (31,32,40). The majority of studies adjusted 
for age and sex, two studies were matched (30,39). Three studies adjusted 
for at least three variables (26,28,38).
Six studies assessed radiographic OA according to the 
Kellgren&Lawrence (KL) score, and two studies used personal scoring 
systems for individual radiographic OA features (individual score by Scott 
et al. (33), individual score by the principles of KL (30)). Two studies 
used both KL and a scoring method for individual OA characteristics. 
Two studies also assessed clinical OA; one by the American College of 
Rheumatology criteria (ACR) criteria for knee OA (37), the other used 
a question about knee pain from the Health and Nutrition Examination 
Survey (30).
METHODOLOGICAL QUALITY ASSESSMENT: The quality of studies was 
assessed according to the criteria stated in Table 1 and methodological 
quality scores are shown in Table 4. The scores ranged from 14 to 82% of 
the maximum obtainable score for each study design, with a median score 
of 64%. Only four of the eight studies on serum IGF-1 and radiographic 
OA (one cohort study, three case-control/cross-sectional studies) and all 
three studies on IGF-1 gene polymorphisms were HQ studies.
Overall, selection of study subjects was not clearly described. In 
addition, none of studies described participation rates for cases and 
controls in detail. Reproducibility of radiological OA scoring was 
described in only three studies with kappa or intracorrelation coefficient. 
Three studies adjusted for age, sex and BMI; the other studies did not 
correct for BMI-related IGF-1 changes.  
ASSOCIATION BETWEEN SERUM IGF-1 AND RADIOGRAPHIC OA IN 
PRIMARY OA PATIENTS: The largest study (Lloyd et al., N=761) showed a 
positive association between high serum IGF-1 and radiographic knee OA 
(31). In this HQ case-control study, a clear dose-response relationship was 
shown with the strongest association in patients with bilateral and more 
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severe knee OA (p<0.0001). High IGF-1 levels were also associated with 
hand OA, especially in the distal interphalangeal (DIP) joint (p=0.006). 
Results were adjusted for age, weight and height. Fraenkel et al. reported 
a trend towards significance for higher serum IGF-1 in men with bilateral 
knee OA, in a HQ longitudinal study with a nested case-control design. 
Adjustments for age, sex, BMI, height and race were made (30). 
In contrast, Denko et al. reported lower serum IGF-1 concentration in 
patients with general radiographic OA (39). In this low-quality (LQ) case-
control study (N=111; Tables 3a&3b), patients and controls were matched 
on age, sex, race, height and weight.
Five studies (two HQ (33,38), three LQ (32,37,40)), all case-control 
studies, reported no association between serum IGF-1 and radiographic 
OA. Three studies (37,38,40) found no relation between serum IGF-1 and 
knee OA. In two cross-sectional studies (32,33), Hochberg et al. reported 
significantly lower IGF-1 levels in patients with radiographic hand 
and knee OA from the Baltimore Longitudinal Study of Aging cohort. 
However, after adjustments for age-related IGF-1 decline, results were no 
longer significant. None of these studies corrected for BMI.
By taking the mean of all methodological quality scores as cut-off 
point, a study was considered high-quality with a score ≥59%. Using this 
alternative cut-off point didn’t change the results. The sensitivity analysis 
based on all positive studies without quality assessment, showed similar 
results with moderate evidence for no association between serum IGF-1 
and radiographic OA, and a positive association between IGF-1 gene 
polymorphisms and radiographic OA.
GENETIC ASSOCIATION BETWEEN IGF-1 GENE POLYMORPHISMS 
AND RADIOGRAPHIC OA: Three studies, all HQ studies, provided 
data on the outcomes of genetic association studies, in which Single 
Nucleotide Polymorphisms (SNPs) in the IGF-1 and IGF-1 receptor genes 
were investigated in relation to radiographic OA. All studies were cross-
sectional; one study contained only women from a Japanese population 
(27). 
Meulenbelt et al. investigated polymorphisms in the promoter region 
of the IGF-1 gene in relation to radiographic OA. Nine different alleles 
were identified, of which allele 3 and 4 (A3, A4) were associated with 
a higher prevalence of radiographic OA at any joint site, mostly in the 
hip. Especially A3, which is less prevalent than A4, is from a population 
genetic point the most likely allele associated with radiographic OA. 
Subjects heterozygous for A3 had a 1.9 times increased risk of radiographic 
OA compared to wildtypes (adjustments for age, sex, BMI and BMD). 
A 3.6 times increased risk of radiographic OA was found in patients 
homozygous for A3, however non-significant (26). 
Zhai et al. studied the 192bp allele of the IGF-1 promotor 
polymorphism in relation to radiographic OA in the knee, hip, hand and 
spine. Cases had at least one of the four joint sites affected. Previously, 
absence of 192bp (wildtype) allele was found to be associated with 
lower serum IGF-1 levels and lower height (41), indicating functional 
properties. In the overall study population, the polymorphism increased 
radiographic OA risk, although not statistically significant. In a subgroup 
aged ≤65years radiographic OA risk was significantly higher in SNP 
carriers (p=0.03 for trend), with highest prevalence in homozygotes 
(OR=1.9), suggesting an allele-dose effect. These findings were 
independent of age, sex, BMI and BMD (28). 
Urano et al. studied a SNP at intron1 in the IGF-1 receptor gene 
(IVS1+ 14488C>G, rs11247361) in relation to radiographic features of 
spinal disc degeneration in healthy postmenopausal Japanese women, 
assessed semi-quantitatively by the Genant method. In this population-
based study, the genetic variation was correlated with spinal disc narrowing 
(OR=2.0, p=0.0033), especially in homozygotes, suggesting a possible 
contribution of IGF-1R to human cartilage metabolism. Occurrence 
of endplate sclerosis and osteophytosis was comparable between SNP 
genotypes (27). 
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N Study design Population Sex Age (years, 
mean±SD)
Assessment ROA
Hand        Knee        Spine     Total
Adjustments 
Age      Sex       BMI      Height     Race












53.6 ± 18.2 KL - - - Yes NA No No No NS (P≥0.50) 57%
McAlindon, 
1993 (30)
156 Case-control Bristol Community Survey
78 knee OA 
78 healthy controls 
♀ 60%
♂ 40%
    
71.8 ± 7.6 - TFJ& PFJ
OP &JSN 
&SCL
- - Yes Yes No No No NS (P 0.48) 64%
Denko, 
1994 (39)




♀ 66 ± 12
♂ 68 ± 11
- - - JSN& 
OP
Yes Yes No Yes Yes Low  IGF-1 P<0.001 43%
Hochberg, 
1994 (33)






    
♀ 54 ± 18
♂ 56 ± 17
- KL - - Yes NA No No No NS 64%
Fernihough, 
1996 (37)




µ69 - ACR 
criteria
- - No No No No No NS 29%
Lloyd, 1996
(31)
761 Case-control Chingford study,





54.2 ± 6 KL KL KL - Yes NA No Yes No High IGF-1 & 













µ69.9 - KL - - Yes Yes Yes Yes Yes NS 
♀ OR 0.9  (0.6-1.7)  




162 Case-control 74 polyarticular OA  








Yes NA No No No NS 14%
OA=osteoarthritis. IGF1=insulin-like growth factor1. ROA=radiological osteoarthritis. ACR 
criteria=American College of Rheumatology criteria. KL=Kellgren&Lawrence. OP=osteophytosis. 
JSN=joint space narrowing. SCL=sclerosis. DIP=distal interphalangeal. PIP=proximal 
interphalangeal. CMC=carpometacarpal. NA=not applicable, NS=not significant. µ=mean. 
TFJ=tibiofemoral joints. PFJ=patellofemoral joint. N=number of studied patients. – =not assessed.
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Population Sex Age (years, 
mean±SD) 
BMI  (kg/m2, 
mean ±SD)
Genetic test Assessment ROA
Hand  Knee  Spine   Hip
Adjustments 
Age    Sex    BMI   













55-65 ROA+  26.6±3.7
ROA-   25.1±3.1
IGF-1 gene promoter 
polymorphisms Allele 
1-9 (A1-A9)
KL KL KL KL Yes Yes Yes A3 at IGF-1 locus 
associated with ROA at 












55-70 ROA+  26.5±3.7
ROA-   25.0±3.3
IGF-1 gene promoter 
polymorphism: 
absence of 192bp 
allele
KL KL KL KL Yes Yes Yes Positive association, 
only in a 
subgroup≤65yr 
(p=0.03), allele-dose 














66.5 ± 8.4 CC       22.3±2.8
GC       21.8±3.0
GG       22.6±3.2
C>G SNP 
(rs11247361) IGF-
1R gene at intron1
NA NA OP, 
SCL, 
DN
NA Yes NA No Positive association 
(p=0.0033), mostly 
with disc narrowing. 
(OR 2.0, 1.3-3.3)
64%
Table 4. Methodological quality scores of  the studies, 
according to study type. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Individual 
   score






Fraenkel, 1998 0 1 1 0 0 1 1 1 1 1 1 0 1 1 10 14 71%
Case-control
Lloyd, 1996 1 1 1 0 0 1 1 1 1 1 1 1 1 0 11 14 79%
McAlindon, 1993 0 1 1 0 0 1 1 0 1 1 1 1 1 0 9 14 64%
Hochberg, 1994 0 1 1 0 0 1 1 1 0 1 1 1 1 0 9 14 64%
Hochberg, 1993 0 1 1 0 0 0 1 1 0 1 1 1 1 0 8 14 57%
Denko, 1994 1 1 0 0 0 1 1 0 0 0 1 0 1 0 6 14 43%
Fernihough, 1996 0 0 0 0 0 1 1 0 0 0 1 0 1 0 4 14 29%
Jubb, 1998 0 0 0 0 0 1 1 0 0 0 0 0 0 0 2 14 14%
Cross-sectional 
Meulenbelt, 1998 1 1 NA 0 NA 1 1 1 0 1 NA 1 1 1 9 11 82%
Zhai, 2004 1 1 NA 0 NA 1 1 1 0 1 NA 1 1 1 9 11 82%
Urano, 2008 0 1 NA 0 NA 1 1 1 0 1 NA 1 1 0 7 11 64%
Table 4: Each item was scored 1 if it met the methodological criteria listed in Table 1, if not or 
otherwise not described, a score of 0 was assigned. Positive scores were summed to give an overall 
internal validity score. NA=not applicable.
OA=osteoarthritis. SNP=single nucleotide polymorphism. IGF-1=insulin-like growth factor 
ERGO=Erasmus Rotterdam Gezondheid Ouderen. ROA=radiological osteoarthritis. 
PSM=postmenopausal. µ=mean. KL=Kellgren&Lawrence. PMS=postmenopausal. 
OP=osteophytosis. SCL, sclerosis. DN, disc narrowing. NS=not significant. NA=not applicable. 
N=number of studied patients. CC=wildtypes. GC=heterozygotes. GG=homozygotes. 




A relationship between IGF-1 and radiographic primary OA is suggested 
from in vitro and anecdotal evidence, but is infrequently studied in 
observational studies. This is the first systematic review that summarizes 
current data on the relation between radiographic OA and either 
serum IGF-1 levels or IGF-1 gene polymorphisms, taking into account 
important factors influencing IGF-1 concentration, such as age, sex and 
BMI. Using strictly defined criteria, a total of only eight studies were 
included that studied serum IGF-1 in relation to radiographic OA. Based 
on these studies, we can conclude that there is moderate evidence for no 
association between serum IGF-1 and radiographic OA, although there 
is moderate evidence for a positive relationship between IGF-1 gene 
polymorphisms and radiographic OA. 
Only the HQ study of Lloyd et al. showed high serum IGF-1 to 
be related with radiographic knee and hand OA, especially in bilateral 
and more severe knee OA (31). Fraenkel et al. reported a trend for 
higher serum IGF-1 levels in men with bilateral knee OA, although 
non-significant. In contrast, Denko et al. found low IGF-1 levels to be 
associated with general radiographic OA (39); however, this study was 
ranked as low methodological quality. The remaining six studies (three 
HQ, three LQ) showed no significant relationship. 
We were able to include three HQ studies (26-28) on genetic 
polymorphisms in the GH/IGF-1 pathway in relation to radiographic 
OA. All three showed associations between IGF-1 gene polymorphisms 
and OA, in accordance with the hypothesis that genetic variations in the 
GH/IGF-1 system may be involved in OA pathogenesis. The SNP in the 
IGF-1 gene promotor region studied in Zhai et al., was earlier found to be 
associated with lower IGF-1 levels and lower body height, suggesting that 
chronic low IGF-1 levels play a role in the pathophysiology of primary 
OA (41). However, the exact role of the IGF-1 polymorphism in the 
GH/IGF-1 pathway has not yet been elucidated. The other SNPs (26,27) 
were not studied in relation to circulating IGF-1 levels. Furthermore, 
we have to take into account interactions between polymorphisms. 
Zhai et al. studied the interaction with a collagen type II A1 (COL2A1) 
polymorphism, which is associated with an extreme OA phenotype (29). 
Highest OA prevalence was found in individuals with both IGF-1 and 
COL2A1 risk phenotype, suggesting that the IGF-1 effect occurs in 
interaction with the COL2A1 gene (28). 
Our review may suffer from several limitations. Firstly, the review is based 
mainly on cross-sectional data and therefore the strength of evidence is 
limited by the quality of the available studies. Unfortunately, only one 
longitudinal study (nested case-control study) (38), investigated OA 
incidence in relation to serum IGF-1. There was an additional longitudinal 
study (44) on IGF-1 and radiographic OA, though this study focuses on 
OA progression and was therefore excluded.  In this 12-year follow-up 
study, Schouten et al. found high serum IGF-1 levels to be a risk factor for 
knee OA progression, especially of osteophytosis, independently of age, 
sex and BMI. Because the progression data could underline findings on 
prevalent and incident OA, more research is needed on the relationship 
between serum IGF-1 and primary OA progression. Secondly, we cannot 
rule out publication bias, especially in the genetic field, which can be 
explained by a selection of positive studies for publication. Thirdly, 
small study sizes may influence the findings, especially since the IGF-1 
concentration is affected by many factors that also influence OA risk. 
Finally, there is a possibility of misclassification of OA by inclusion of 
conventional radiographs only, which may contribute to not finding a 
consistent association between IGF-1 and radiographic OA. Magnetic 
resonance imaging (MRI) may give additional information to plain films, 
however at this moment no MRI studies have investigated the relationship 
between IGF-1 and OA.
Several sources of between-study heterogeneity can be identified. First 
of all, the study design can lead to heterogeneity. Secondly, assessing the 
role of IGF-1 in OA by serum samples is very complex, because individual 
IGF-1 levels are liable to temporal variations. Furthermore, IGF-1 levels 
are inversely correlated to age, estrogen levels and BMI (9,42,43), so 
adjustments for these factors are essential for interpretation of IGF-1 
levels. Most studies corrected for age and sex, however, only three adjusted 
for BMI. In addition, RIAs for measuring serum IGF-1 are subject to 
analytical difficulty. This means that large sample sizes are required for 
demonstrating an IGF-1 effect on radiographic OA at population level; 
unfortunately, only the study of Lloyd et al. (31) reported a large sample 
size (N=761). Another remaining problem is OA case definition. For 
epidemiological studies, there is general consensus that radiological 
features are the preferred method. However, the included studies used 
different scoring methods (KL, Ahlback, ACR criteria) at different joint 
sites.
Because of heterogeneity of several study aspects, no meta-analysis 
could be performed. We provided an alternative by performing a best-
evidence synthesis and methodological quality assessment, although no 
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generally accepted criteria set exists for methodological quality assessment 
in observational studies and for performing a best-evidence synthesis. 
Lievense et al. presented a reproducible criteria list for methodological 
quality assessment, which we modified to cover our review topic (36). 
The use of quality scores could be a technical limitation of our review at 
the same time, because using different criteria sets could result possibly in 
different interpretation of our results. According to our criteria set (Tables 
3a&3b), four of the eight studies on serum IGF-1 and all three genetic 
association studies were considered as HQ studies. 
Knowledge of the association between serum IGF-1 levels and 
radiographic OA is very important, because this could increase our 
understanding of the pathogenesis of OA, which subsequently could lead 
to development of new treatment options. 
An important question that needs further research is whether 
circulating total IGF-1 levels truly reflect tissue concentrations. 
Preliminary data indicate that measuring free unbound IGF-1 levels 
and IGF-1 bioactivity better reflect GH/IGF-1 status than serum total 
IGF-1 (45-47). Free IGF-1 is the major biologically active form of IGF-1; 
however, because of methodological difficulties in measurement, total 
serum IGF-1 is often used to assess GH/IGF-1 axis activity (45). This 
could possibly explain not finding a consistent effect of total IGF-1 on 
radiographic OA. 
In conclusion, in vitro studies, genetic association studies and the 
high secondary risk in pathological IGF-1 states suggest all an effect of 
the GH/IGF-1 system in OA development. Although the largest cross-
sectional study (31) and the longitudinal study on OA progression (44) 
found a positive association with high serum IGF-1, inconsistent results 
were shown in studies on serum IGF-1 and radiographic OA. This 
systematic review concludes that there is moderate evidence that IGF-1 
is no risk factor for primary radiographic OA. Since we cannot exclude 
that methodology, publication bias and small sample size of the available 
studies have influenced the results, we suggest that future well-designed 
large prospective studies are needed to strengthen the evidence for the role 
of IGF-1 in primary OA. 
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ABSTRACT
BACKGROUND: Several studies point towards a role of the growth 
hormone (GH)/insulin-like growth factor-1 (IGF-1) axis in the 
pathophysiology of primary osteoarthritis (OA). Few epidemiological 
studies investigated the relationship between serum IGF-1 levels and 
radiographic OA, reporting inconsistent results. 
OBJECTIVE: To investigate the relationship between serum IGF-1 and 
the presence and progression of radiographic OA in patients with a severe 
familial form of OA.
METHODS: We studied 340 subjects from the GARP (Genetics, 
osteoARthritis and Progression) Study with symptomatic OA at multiple 
joint sites on a familial base. Serum IGF-1 concentrations were measured 
and expressed as standard deviation scores (SDS), adjusted for age and 
sex. Radiographs of hands, knees and hips were obtained. Joint space 
narrowing (JSN) and osteophytes were scored semi-quantitatively using 
the Osteoarthritis Research Society (OARSI) atlas. Radiographic OA 
progression was defined as change ≥1 in osteophyte and/or JSN score. 
Generalized Estimated Equations (GEE) analysis was performed to 
adjust for intra-patient and intra-family relationships, with additional 
adjustments for age, sex, and BMI.
RESULTS: Mean (±SD) IGF-1 SDS was +0.79±1.39, which was 
significantly increased when compared to reference control values 
(p<0.01). Baseline IGF-1 SDS was not associated with the presence 
of radiographic OA, at none of the investigated joints. In addition, 
no association was found between IGF-1 SDS and radiographic OA 
progression or worsening of individual radiographic features after 2 years 
of follow-up.
CONCLUSIONS: Mean IGF-1 SDS was increased in patients with familial 
and symptomatic OA at multiple sites when compared to reference values. 
In this cohort, consisting exclusively of systemically affected patients, no 
relationship was found between IGF-1 SDS and either the presence or 
progression of radiographic OA. Further study has to clarify the complex 
role of the GH/IGF-1 axis in OA pathophysiology.  
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INTRODUCTION
Primary osteoarthritis (OA) is a debilitating disease, characterized by 
progressive degradation of articular cartilage and bone remodeling. 
Etiology is known to be multifactorial, in which age, body mass index 
(BMI), genetic, hormonal and local biomechanical factors play a role 
(1-3). With respect to the hormonal system, the interesting role of growth 
factors in this process is not elucidated. Insulin-like Growth Factor-1 
(IGF-1) is the main factor involved in longitudinal skeletal growth (4). 
Growth Hormone (GH) secreted by the pituitary stimulates IGF-1 
secretion mainly at the liver, but also by other tissues. IGF-1 mediates the 
effects of GH at the tissue level. Serum IGF-1 concentrations are age-
dependent, being highest during puberty and adolescence, and declining 
thereafter with aging. In addition, they are influenced by many other 
factors, such as estrogens and BMI (5;6). 
Several lines of research suggest a role of the GH/IGF-1 axis in 
the pathogenesis of primary OA. First, IGF-1 enhances chondrocyte 
proliferation and proteoglycan and collagen synthesis (7;8). Second, 
genetic functional variations of GH/IGF-1 genes, such as the exon 3 
deletion of the GHR (d3-GHR), are associated with primary OA (9-
12). The d3-GHR polymorphism is associated with an increased signal 
transduction, resulting in an enhanced GH responsiveness of the GHR 
and, thereby, increasing GH/IGF-1 activity. Third, in pathologically high 
GH/IGF-1 conditions, which is the case in acromegaly, a rare endocrine 
disease caused by a GH-producing pituitary adenoma, there is a strongly 
increased risk to develop secondary OA (13). In acromegaly, GH/IGF-1 
activity (at diagnosis) has been associated with radiographic severity and 
progression of arthropathy (14-16), further supporting the hypothesis 
of GH/IGF-1 axis involvement in OA pathophysiology. Fourth, recent 
GWAS data show genetic evidence for significant association between 
height, being largely dependent on IGF-1 concentrations during the 
process of longitudinal skeletal growth, and OA, being suggestive of a 
common genetic etiology (17). 
Recently, in a systematic review summarizing the evidence for 
association between serum IGF-1 and primary OA, results among studies 
were inconsistent (18). However, sample sizes were small and sex and 
BMI, both important factors for the interpretation of IGF-1 levels, were 
not taken into account in most studies. Moreover, only two studies had a 
longitudinal design enabling to study OA progression (19;20).
Based on the evidence in literature, we hypothesize that an increased GH/
IGF-1 activity, as reflected by increased serum IGF-1 levels, increases the 
risk of primary OA. We, therefore, investigated the relationship between 
serum IGF-1 and the presence and progression of radiographic OA in a 
well-characterized OA population with a severe OA phenotype.
MATERIALS AND METHODS
PATIENTS: The GARP (Genetics, osteoARthritis and Progression) Study 
is a prospective cohort study, aimed at identifying determinants of OA 
susceptibility and progression. The GARP Study consists of 192 sib pairs 
(N=384) between 40 and 70 years of age of Dutch ancestry, all having 
symptomatic OA at multiple sites in the hands or in ≥2 of the following 
joint sites: hand, spine (cervical or lumbar), knee, or hip. Patients with other 
(secondary) forms of OA were excluded. Details of recruitment and patient 
selection have been reported elsewhere (21). Sib pairs with at least one subject 
with symptomatic knee or hip OA (but not in a radiographic end-stage OA) 
were eligible for the 2-year follow-up visit, resulting in the inclusion of 105 
eligible sib pairs (N=210)(22). The GARP Study was approved by the Medical 
Ethics Committee of the Leiden University Medical Center.
IGF-1 MEASUREMENT: Baseline blood samples were drawn and 
stored. Serum IGF-1 concentrations (nmol/l) were measured using 
an immunometric technique on an Immulite 1000 (Siemens Medical 
Solutions Diagnostics, Los Angeles, CA, USA), since February 2006. 
The lower limit of detection was 25ng/ml and the inter-assay variation 
was 6.4%–3.8% in the range of 60–400ng/ml. In order to adjust IGF-1 
levels for age and sex, which is common practice in the evaluation of 
endocrine diseases, IGF-1 levels were expressed as standard deviation 
scores (SDS), using lambda-mu-sigma smoothed (LMS) reference curves 
based on the widely accepted method of Rikken and Cole (23;24), with a 
normal IGF-1 SDS reference range between -2 and +2 SDS. Serum IGF-1 
measurement was successfully performed in 340 patients.
RADIOGRAPHIC ASSESSMENT: Conventional radiographs of the hands, 
knees, hips, and spine were obtained according to a standardized protocol, as 
previously described in detail (21). Radiographic OA was scored according 
to the Kellgren-Lawrence (KL) scale by a single experienced musculoskeletal 
radiologist (H.K.), as described in detail elsewhere. ICCs were good (21;25). 
Radiographic OA was defined according to the ROA score, which is described 
in detail elsewhere (26). Radiographic knee and hip OA were defined as KL≥2 
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in, respectively, at least one knee or hip. Radiographic OA in the hand was 
defined as KL≥2 in at least 3 of the following joints: distal interphalangeal 
joint (DIP) 2–5, proximal interphalangeal joint (PIP) 2–5, interphalangeal 
joints 1, and carpometacarpal (CMC) joint 1. Spinal disc degeneration was 
defined as KL≥2 at at least 3 levels.
Individual OA features, being joint space narrowing (JSN) and osteophytes 
were assessed semi-quantitatively (Grade 0-3), using the Osteoarthritis 
Research Society (OARSI) atlas, in consensus opinion of two experienced 
readers (26). OARSI≥1 reflects presence of JSN or osteophytes. The 
reproducibility for JSN and osteophyte grading was based on the repeat 
reading of 20 radiographs (randomly selected throughout the study period) 
and was depicted by the intra-class correlation coefficient (ICC). ICCs for, 
respectively, JSN and osteophytes were 0.92 and 0.98 in the hands, 0.88 and 
0.87 in the knees and 1.00 and 1.00 in the hips. 
To assess radiographic OA progression, baseline and 2-year radiographs 
of the knee, hip, hands, and spine were scored in consensus paired without 
knowledge of chronological order, blinded for patient characteristics, 
for osteophytes and JSN by two experienced readers, using the OARSI 
atlas. Progression was defined as the change in JSN or osteophyte scores 
above the smallest detectable change (SDC), reflecting the change above 
measurement error (27;28). Since the SDCs for osteophytes and JSN were 
respectively 0.22 and 0.71 in the knee, 0.00 and 0.00 in the hip, and 0.35 
and 0.62 in the hand, a change ≥1 in osteophyte/JSN score was defined 
as progression at all sites. Also joints (without end-stage (Grade 3) OA 
at baseline) replaced by a knee or hip prosthesis during follow-up, were 
considered to have radiographic progression.
STATISTICAL ANALYSIS: SPSS version 20.0 (SPSS inc., Chicago, IL, USA) 
was used for data analysis. Mean IGF-1 levels were compared between males 
and females using an Independent Samples T test. To compare mean IGF-1 
SDS between GARP patients and 906 healthy literature controls from Rikken 
et al.(24), we performed a pooled variance T test, since sample sizes differ 
substantially between both groups. Mean baseline IGF-1 SDS was studied 
in relation to presence of radiographic OA at different sites, using a One-way 
ANOVA test. To assess the risk of radiographic OA at a given IGF-1 SDS, 
a Generalized Estimated Equations (GEE) analysis was carried out, thereby 
adjusting for intra-patient and intra-familial effects in GARP. A binary logistic 
model was used, stratified for sex, with presence of radiographic OA as 
dependent variable and age, BMI, and IGF-1 SDS divided into tertiles (based 
on the distribution in the patients) as covariates. 
In a subset of patients with available follow-up radiographs, baseline 
IGF-1 SDS (tertiles) was studied in relation to progression of osteophytes 
and JSN over 2 years. We performed a GEE-analysis with a binary logistic 
model to take into account intra-patient and intra-family relationships, 
with additional adjustments for age, sex, BMI, and radiographic score at 
baseline. 
RESULTS
PATIENT DESCRIPTION: Complete set of radiographs and successful 
serum IGF-1 measurements were available of 340 patients with 
symptomatic OA at multiple joint sites (82% female, of which 
9.6% premenopausal). Baseline characteristics are shown in Table 1. 
Radiographic knee, hip, hand, and spine OA were, respectively, present in 
37%, 26%, 74%, and 89% of the females, and in 38%, 28%, 70%, and 
83% of the males. Eight patients from separate families had a unilateral 
knee replacement; one patient had bilateral knee replacements. In the 
hip, 22 patients had a unilateral prosthesis and fifteen patients had 
bilateral prostheses. Mean serum IGF-1 level was 18.2±6.3 nmol/l, being 
significantly higher in males than in females (p=0.013). As expected, 
IGF-1 levels were negatively correlated with age (Pearson correlation 
coefficient r=-0.119, p=0.030) and BMI (r=-0.162, p=0.003).
RELATIONSHIP BETWEEN SERUM IGF-1 SDS AND RADIOGRAPHIC 
OA: Mean IGF-1 SDS among GARP patients was +0.79±1.39 
(95%CI +0.64;+0.93), with 67 patients (20%) above +2 SDS. When 
compared to 906 literature controls, mean IGF-1 SDS was significantly 
increased in GARP patients (p<0.01). Mean IGF-1 SDS did not differ 
between specific joint sites with radiographic OA. In addition, no dose-
response relationship between baseline IGF-1 SDS and the presence of 
radiographic OA was observed, at none of the investigated joint sites, 
although in females a trend towards associations between higher baseline 
IGF-1 SDS and both knee and discus OA was observed (Table 2). No 
significant differences were seen between males and females or between 
patients <65 years and ≥65 years. 
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RELATIONSHIP BETWEEN SERUM IGF-1 SDS AND PROGRESSION OF 
RADIOGRAPHIC OA OVER 2 YEARS OF FOLLOW-UP: IGF-1 SDS and 
complete baseline and 2-yr follow-up radiographs were available in 174 
patients (80% female). Radiographic progression of respectively knee, 
hip, and hand OA was seen in 37 (21.3%), 17 (9.8%) and 60 (34.5%) 
patients, being comparable between males and females. Baseline IGF-1 
SDS was not related to radiographic progression of hip, knee or hand OA 
(Table 3), or worsening of individual radiographic features (i.e. osteophyte 
growth or joint space loss) (data not shown).     





Age, years 59.6 ± 7.5 60.1 ± 6.8














IGF-1 (nmol/l) 17.8±6.3 20.1±6.3
IGF-1 SDS 0.69±1.40 1.23±1.26
 
Data are shown as mean±SD, unless mentioned otherwise, and were stratified for sex. 
Radiographic OA was defined as ROA≥1, based on KL≥2(26). Spine OA is defined as radiographic 
disc degeneration of the spine.  
*, 27 of the 280 studied females (9.6%) were premenopausal.
GARP, Genetics, osteoARthritis and Progression Study; N, number of patients; OA, osteoarthritis; 
BMI, body mass index; IGF-1, Insulin-like Growth Factor-1; SDS, standard deviation score; KL, 
Kellgren-Lawrence score. 
Table 2. Risk of  having radiographic OA according to terti les 
of  IGF-1 SDS for, respectively, 60 male and 280 female 
patients with famil ial OA at multiple joint sites
Males
Radiographic OA risk: adjusted OR (95%CI)*
IGF-1 SDS (tertiles) Knee (N=23) Hip (N=17) Hand (N=42) Discus (N=50)
1 1.0 1.0 1.0 1.0
2 0.7 (0.2-2.4) 0.8 (0.2-3.8) 0.3 (0.1-1.6) 0.2 (0.0-2.7)
3 0.6 (0.2-2.3) 0.9 (0.2-3.8) 0.3 (0.1-1.5) 0.2 (0.0-2.5)
Females
Radiographic OA risk: adjusted OR (95%CI)*
IGF-1 SDS (tertiles) Knee (N=103) Hip (N=72) Hand (N=206) Discus (N=248)
1 1.0 1.0 1.0 1.0
2 1.6 (0.9-3.0) 0.4 (0.2-0.9) 0.8 (0.4-1.6) 1.4 (0.5-3.8)
3 1.7 (0.9-3.2) 0.8 (0.4-1.6) 0.7 (0.3-1.4) 2.8 (1.0-8.3)
* IGF-1 SDS at the time of the baseline study visit was divided into tertiles (based on the 
distribution among patients). A Generalized Estimating Equations (GEE) analysis was performed to 
adjust for intra-patient and intra-familial effects, stratified for sex. A binary logistic model was used 
with radiographic OA as outcome parameter and IGF-1 SDS tertiles, age, and BMI as covariates. 
The lowest IGF-1 SDS tertile was used as reference level. 
N, number of patients with radiographic OA according to Kellgren-Lawrence ≥2; OR, odds ratio; CI, 
confidence interval; OA, osteoarthritis; IGF-1, Insulin-like Growth-Factor 1; BMI, body mass index; 
Disc, disc degeneration.  
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Table 3. IGF-1 SDS at baseline were not related to 
radiographic progression of  knee, hip or hand OA over 2 
years of  follow-up in patients with famil ial OA at multiple 
joint sites (N = 174)
                           Number of patients (N=174)      
Knee OA**
IGF-1 SDS (tertiles) With progression (N=37) Without progression (N=137) Adjusted OR (95%CI)*
1 11 44 1.0
2 14 47 1.3 (0.5-3.3)
3 12 46 1.1 (0.4-2.7)
Hip OA**
IGF-1 SDS (tertiles) With progression (N=17) Without progression (N=157) Adjusted OR (95%CI)*
1 5 50 1.0
2 10 51 0.7 (0.2-2.4)
3 2 56 0.4 (0.1-1.6)
Hand OA**
IGF-1 SDS (tertiles) With progression (N=60) Without progression (N=114) Adjusted OR (95%CI)*
1 20 35 1.0
2 21 40 0.6 (0.2-1.3)
3 19 39 0.7 (0.3-1.7)
 
* IGF-1 SDS at the time of the baseline visit was divided into tertiles (based on the distribution 
among patients). A Generalized Estimating Equations (GEE) analysis was performed to adjust 
for intra-patient and intra-familial effects. A binary logistic model was used with radiographic OA 
progression as dependent variable and IGF-1 SDS tertiles, age, sex, BMI, and radiographic score at 
baseline as covariates. The lowest IGF-1SDS tertile was used as reference level.  
** Radiographic OA progression was defined as an increase of ≥1 in OARSI score for JSN and/or 
osteophytes.  
N, number of patients; OR, odds ratio; CI, confidence interval;  IGF-1, insulin-like growth-factor 1; 
SDS, standard deviation score; BMI, body mass index. 
DISCUSSION
In the present longitudinal study, we investigated the association 
between serum IGF-1 and, respectively, the presence and progression of 
radiographic OA in patients with familial OA at multiple joint sites from 
the GARP Study. Mean IGF-1 SDS in OA patients was significantly 
higher than in reference values from controls, indicating that, overall, 
serum IGF-1 concentrations are high. When looking at specific joint 
sites, however, we did not observe a relationship between IGF-1 SDS and 
the presence of radiographic OA. In addition, baseline IGF-1 SDS was 
not related to radiographic OA progression over 2 years or worsening of 
individual OA features.
IGF-1 is an important growth promoting polypeptide belonging to the 
same family of growth factors as insulin (4). IGF-1 is mainly produced by the 
liver and mediates the effects of GH in many organs, primarily by the IGF-1 
receptor type 1. Serum IGF-1 concentrations reflect the GH concentrations 
over 24 hours and IGF-1 bioavailability is regulated by IGF-1 binding 
proteins. Serum IGF-1 concentrations in adulthood decrease progressively 
with age and are influenced by many other factors, such as estrogen and BMI 
(5;6). In clinical practice, serum IGF-1 levels are converted into IGF-1 SDS in 
order to standardize IGF-1 levels for age and sex. 
Several functional genetic variants involved in the process of 
endochondral ossification, being the main process in longitudinal growth, 
are identified to be associated with primary OA (9;10;12). GH and IGF-1 
play important roles in this process (29). Recently, we found evidence for 
an association between the common d3-GHR polymorphism, associated 
with an enhanced GH responsiveness, and primary OA in females, 
indicating that increased activity of the GH/IGF-1 axis might play a role 
in OA pathophysiology (9). In vitro studies also indicate that IGF-1 has 
stimulatory effects in chondrocyte proliferation and proteoglycan and 
collagen synthesis (7;8;29), supporting involvement of the GH/IGF-1 
axis in OA development. Moreover, in acromegaly disease, GH/IGF-1 
activity has been associated with radiographic severity and progression 
of arthropathy (14-16). With respect to the association between serum 
IGF-1 levels and primary OA, only few epidemiological studies have 
been previously performed. A recent systematic review summarizing 
literature on this association showed moderate evidence for no relationship 
between serum IGF-1 and radiographic OA (18). However, this review 
included mainly cross-sectional data and study sizes were relatively small. 
In addition, most studies did not adjust for age, sex, and BMI, which 
all independently influence IGF-1 concentrations. In this respect, it 
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should also be noted that comparisons between studies are difficult, since 
differences exist in IGF-1 assays, OA scoring methods, reading order 
of baseline and follow-up radiographs, mean age of participants and 
statistical analyses used.
In the present study, we found that mean IGF-1 SDS was significantly 
increased in GARP patients when compared to control/reference values, 
suggesting that high serum IGF-1 levels are associated with the presence 
of a severe familial form of OA. Although mean IGF-1 SDS was high in 
the GARP Study, no clear dose-response relationship was found between 
IGF-1 SDS and either the presence or progression of OA. This might 
probably be explained by the fact that per inclusion all GARP patients had 
severe radiographic and clinical OA at multiple joint sites on a familial 
base. Furthermore, serum IGF-1 levels of most GARP subjects were 
within the normal reference range, probably resulting in too less variation 
in IGF-1 levels to detect a dose-response relationship with radiographic 
occurrence or progression of OA. In addition, an important question 
which requires further investigation is whether circulating total IGF-1 
levels truly reflect peripheral IGF-1 activity. There is increasing evidence 
that measuring free unbound IGF-1 levels and IGF-1 bioactivity better 
reflect the GH/IGF-1 status than total IGF-1 (30;31). However, because 
of methodological difficulties in measurement, total serum IGF-1 is often 
used to assess GH/IGF-1 activity (30). Presence of negative endocrine 
feedback systems further complicates the interpretation of IGF-1 levels. 
Strengths of the present study are, first, the relatively large number 
of patients with a severe, familial form of primary OA. This specific OA 
phenotype increases the a priori chance to detect an association between 
IGF-1 levels and OA. Second, we had the availability of a cohort that 
was longitudinally followed and we were, therefore, able to study IGF-1 
in relation to OA progression. Since a population with OA at multiple 
joint sites, such as the GARP Study, is associated with rapid progression, 
our study population is suitable to investigate OA progression within a 
relatively short period. In this respect, we chose the 2-year time point to 
study progression, since we expect more differentiation in (and faster) 
OA progression, increasing the sensitivity to detect risk factors. Third, we 
adjusted for age, sex, and BMI in our analyses, since all these factors are 
important confounders when studying IGF-1 in relation to primary OA.
This study has a number of limitations. First, since all GARP subjects 
have a severe OA phenotype of familial OA at multiple joint sites, joint-
specific analyses are difficult to perform. In addition, since the GARP 
Study is a very homogeneous cohort with less variation in OA phenotype 
(i.e. all patients have severe familial symptomatic OA at multiple joint 
sites), the detection of a clear relationship with OA at different joint sites 
is very difficult. In this respect, also the generalizability of our results in 
other population settings has to be investigated (32). Second, it should be 
noted that the GARP Study consists mainly of females, a phenomenon 
that is well-known from OA literature (33). To adjust for the female 
overrepresentation in our cohort, analyses were stratified for sex. Third, 
IGF-1 measurement by serum samples is very complex, because individual 
IGF-1 levels are liable to temporal variations and are inversely correlated 
to age, estrogen levels, and BMI. Fourth, we compared mean IGF-1 
SDS of the GARP cohort with literature-based reference values. Ideally, 
it would be preferred to use a control population of subjects without 
signs of OA for comparison. Furthermore, radio-immuno assays (RIA) 
for measuring serum IGF-1 are subject to analytical difficulty. Finally, in 
general, it should be noted that due to a complex pathophysiology, the 
extent to which hormones are involved in common diseases is difficult 
to assess. Therefore, to investigate the individual roles of GH and IGF-1 
in joint disease, acromegaly is a unique human model of which findings 
might possibly be extrapolated to primary OA (14;34;35).
In conclusion, mean IGF-1 SDS was increased in patients with 
familial OA at multiple joint sites when compared to control values from 
literature, suggesting that high serum IGF-1 is associated with OA. This is 
similar to several lines of previous evidence suggesting a role for increased 
GH/IGF-1 activity in the pathophysiology of OA. However, no clear 
relationship between IGF-1 SDS and either the presence or progression 
of radiographic OA at different joint sites was found. Taking into 
account imperfections in IGF-1 measurement and the homogeneous OA 
phenotype in the GARP Study thereby prohibiting the detection of a clear 
dose-response association, further research has to clarify the complex role 
of the GH/IGF-1 axis in OA pathophysiology.    
Pathophysiology of the GH/IGF-1 axis: Long-term consequences on joints and bone184 VIII. High serum Insulin-like Growth Factor-1 (IGF-1) levels are associated with the presence of primary 
osteoarthritis, but not with radiographic progression: the GARP Study
185
REFERENCE LIST
1. Felson DT, Lawrence RC, Dieppe PA et 
al. Osteoarthritis: new insights. Part 1: the 
disease and its risk factors. Ann Intern 
Med 2000; 133(8):635-646.
2. Peyron JG. Osteoarthritis. The 
epidemiologic viewpoint. Clin Orthop 
Relat Res 1986;(213):13-19.
3. Spector TD, Cicuttini F, Baker J, Loughlin 
J, Hart D. Genetic influences on 
osteoarthritis in women: a twin study. BMJ 
1996; 312(7036):940-943.
4. Le RD, Bondy C, Yakar S, Liu JL, Butler 
A. The somatomedin hypothesis: 2001. 
Endocr Rev 2001; 22(1):53-74.
5. Copeland KC, Colletti RB, Devlin JT, 
McAuliffe TL. The relationship between 
insulin-like growth factor-I, adiposity, and 
aging. Metabolism 1990; 39(6):584-587.
6. Juul A. Serum levels of insulin-like growth 
factor I and its binding proteins in health 
and disease. Growth Horm IGF Res 2003; 
13(4):113-170.
7. Guenther HL, Guenther HE, Froesch ER, 
Fleisch H. Effect of insulin-like growth 
factor on collagen and glycosaminoglycan 
synthesis by rabbit articular chondrocytes 
in culture. Experientia 1982; 38(8):979-
981.
8. McQuillan DJ, Handley CJ, Campbell 
MA, Bolis S, Milway VE, Herington AC. 
Stimulation of proteoglycan biosynthesis 
by serum and insulin-like growth factor-I 
in cultured bovine articular cartilage. 
Biochem J 1986; 240(2):423-430.
9. Claessen KM, Kloppenburg M, Kroon HM 
et al. Relationship between the functional 
exon 3 deleted growth hormone 
receptor polymorphism and symptomatic 
osteoarthritis in women. Ann Rheum Dis 
2013.
10. Meulenbelt I, Bijkerk C, Miedema HS 
et al. A genetic association study of the 
IGF-1 gene and radiological osteoarthritis 
in a population-based cohort study (the 
Rotterdam Study). Ann Rheum Dis 1998; 
57(6):371-374.
11. Urano T, Narusawa K, Shiraki M et 
al. Association of a single nucleotide 
polymorphism in the insulin-like growth 
factor-1 receptor gene with spinal disc 
degeneration in postmenopausal Japanese 
women. Spine (Phila Pa 1976 ) 2008; 
33(11):1256-1261.
12. Zhai G, Rivadeneira F, Houwing-
Duistermaat JJ et al. Insulin-like growth 
factor I gene promoter polymorphism, 
collagen type II alpha1 (COL2A1) gene, 
and the prevalence of radiographic 
osteoarthritis: the Rotterdam Study. Ann 
Rheum Dis 2004; 63(5):544-548.
13. Barkan AL. Acromegalic arthropathy. 
Pituitary 2001; 4(4):263-264.
14. Biermasz NR, Wassenaar MJ, van der 
Klaauw AA et al. Pretreatment insulin-like 
growth factor-I concentrations predict 
radiographic osteoarthritis in acromegalic 
patients with long-term cured disease. J 
Clin Endocrinol Metab 2009; 94(7):2374-
2379.
15. Biermasz NR, van ‘t Klooster R, 
Wassenaar MJ et al. Automated image 
analysis of hand radiographs reveals 
widened joint spaces in patients with 
long-term control of acromegaly: relation 
to disease activity and symptoms. Eur J 
Endocrinol 2012; 166(3):407-413.
16. Claessen KM, Ramautar SR, Pereira AM et 
al. Progression of acromegalic arthropathy 
despite long-term biochemical control: 
a prospective, radiological study. Eur J 
Endocrinol 2012; 167(2):235-244.
17. Elliott KS, Chapman K, Day-Williams A 
et al. Evaluation of the genetic overlap 
between osteoarthritis with body mass 
index and height using genome-wide 
association scan data. Ann Rheum Dis 
2013; 72(6):935-941.
18. Claessen KM, Ramautar SR, Pereira AM, 
Smit JW, Biermasz NR, Kloppenburg M. 
Relationship between insulin-like growth 
factor-1 and radiographic disease in 
patients with primary osteoarthritis: a 
systematic review. Osteoarthritis Cartilage 
2012; 20(2):79-86.
19. Fraenkel L, Zhang Y, Trippel SB et al. 
Longitudinal analysis of the relationship 
between serum insulin-like growth factor-I 
and radiographic knee osteoarthritis. 
Osteoarthritis Cartilage 1998; 6(5):362-
367.
20. Schouten JS, Van den Ouweland FA, 
Valkenburg HA, Lamberts SW. Insulin-like 
growth factor-1: a prognostic factor of 
knee osteoarthritis. Br J Rheumatol 1993; 
32(4):274-280.
21. Riyazi N, Meulenbelt I, Kroon HM et al. 
Evidence for familial aggregation of hand, 
hip, and spine but not knee osteoarthritis 
in siblings with multiple joint involvement: 
the GARP study. Ann Rheum Dis 2005; 
64(3):438-443.
22. Botha-Scheepers SA, Watt I, Slagboom 
E et al. Influence of familial factors on 
radiologic disease progression over two 
years in siblings with osteoarthritis at 
multiple sites: a prospective longitudinal 
cohort study. Arthritis Rheum 2007; 
57(4):626-632.
23. Cole TJ. The LMS method for constructing 
normalized growth standards. Eur J Clin 
Nutr 1990; 44(1):45-60.
24. Rikken B, van Doorn J, Ringeling A, Van 
den Brande JL, Massa G, Wit JM. Plasma 
levels of insulin-like growth factor (IGF)-I, 
IGF-II and IGF-binding protein-3 in the 
evaluation of childhood growth hormone 
deficiency. Horm Res 1998; 50(3):166-
176.
25. Kellgren JH, Lawrence JS. Radiological 
assessment of osteo-arthrosis. Ann 
Rheum Dis 1957; 16(4):494-502.
26. Meulenbelt I, Kloppenburg M, Kroon 
HM et al. Urinary CTX-II levels are 
associated with radiographic subtypes of 
osteoarthritis in hip, knee, hand, and facet 
joints in subject with familial osteoarthritis 
at multiple sites: the GARP study. Ann 
Rheum Dis 2006; 65(3):360-365.
27. Botha-Scheepers S, Watt I, Breedveld FC, 
Kloppenburg M. Reading radiographs in 
pairs or in chronological order influences 
radiological progression in osteoarthritis. 
Rheumatology (Oxford) 2005; 
44(11):1452-1455.
28. Bruynesteyn K, Boers M, Kostense P, van 
der Linden S, van der Heide D. Deciding 
on progression of joint damage in paired 
films of individual patients: smallest 
detectable difference or change. Ann 
Rheum Dis 2005; 64(2):179-182.
29. Okazaki K, Jingushi S, Ikenoue T et al. 
Expression of insulin-like growth factor I 
messenger ribonucleic acid in developing 
osteophytes in murine experimental 
osteoarthritis and in rats inoculated 
with growth hormone-secreting tumor. 
Endocrinology 1999; 140(10):4821-4830.
30. Janssen JA, van der Lely AJ, Lamberts SW. 
Circulating free insulin-like growth-factor-I 
(IGF-I) levels should also be measured to 
estimate the IGF-I bioactivity. J Endocrinol 
Invest 2003; 26(6):588-594.
31. Varewijck AJ, Lamberts SW, Uitterlinden 
P, Hofland LJ, Janssen JA. IGF-I bioactivity 
better reflects growth hormone deficiency 
than total IGF-I. J Clin Endocrinol Metab 
2011; 96(7):2248-2254.
32. Ledingham J, Regan M, Jones A, Doherty 
M. Factors affecting radiographic 
progression of knee osteoarthritis. Ann 
Rheum Dis 1995; 54(1):53-58. 
33. Dieppe P, Cushnaghan J, Tucker M, 
Browning S, Shepstone L. The Bristol 
‘OA500 study’: progression and impact of 
the disease after 8 years. Osteoarthritis 
Cartilage 2000; 8(2):63-68.
34. Wassenaar MJ, Biermasz NR, van Duinen 
N et al. High prevalence of arthropathy, 
according to the definitions of radiological 
and clinical osteoarthritis, in patients 
with long-term cure of acromegaly: a 
case-control study. Eur J Endocrinol 2009; 
160(3):357-365.
35. Wassenaar MJ, Biermasz NR, Pereira 
AM et al. The exon-3 deleted growth 
hormone receptor polymorphism 
predisposes to long-term complications of 
acromegaly. J Clin Endocrinol Metab 2009; 
94(12):4671-4678.
Pathophysiology of the GH/IGF-1 axis: Long-term consequences on joints and bone186 IX. Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and 




the functional exon 3 
deleted growth hormone 
receptor polymorphism 
and symptomatic 
osteoarthritis in women 
 
Kim M.J.A. Claessen, Margreet Kloppenburg, Herman M. Kroon, 
Jessica Bijsterbosch, Alberto M. Pereira, Johannes A. Romijn, Tahar 
van der Straaten, Rob G.H.H. Nelissen, Albert Hofman, André G. 
Uitterlinden, Bouke J. Duijnisveld, Nico Lakenberg, Marian Beekman, 
Joyce B. van Meurs, P. Eline Slagboom, Nienke R. Biermasz, Ingrid 
Meulenbelt 
Annals of Rheumatic Diseases 2014; 73(2): 433-436
ABSTRACT
BACKGROUND: Several studies suggest a role of the growth hormone 
(GH)/insulin-like growth factor-1 (IGF-1) axis in the pathophysiology 
of primary osteoarthritis (OA). A common polymorphism of the 
GH receptor (exon 3 deletion, d3-GHR) is associated with increased 
GH/IGF-1activity. 
OBJECTIVE: To study associations between the d3-GHR polymorphism 
and symptomatic OA.
METHODS: In the GARP (Genetics, osteoARthritis and Progression) 
Study, we compared the d3-GHR polymorphism between OA patients 
and controls. GARP patients were genotyped for 7 single nucleotide 
polymorphisms encompassing the d3-GHR gene, using rs4590183 as 
proxy for d3-GHR (pairwise r2=1). Binary logistic regression models with 
robust standard errors were performed, stratified by sex. For replication, 
rs4590183 was tested in three additional cohorts. Fixed- and random-
effects combined analyses were performed.
RESULTS: In female GARP patients with severe familial OA, d3-GHR was 
associated with OA (adjusted odds ratio (OR) 1.36 (95%CI 1.01-1.83), 
p=0.043), independently of age and BMI. Combined analysis of all studies 
showed suggestive evidence for association between d3-GHR and OA 
(OR=1.17 (95%CI 1.04-1.30), p=0.008). Evidence was strongest in hip 
OA cases, without any evidence for heterogeneity.
CONCLUSIONS: In women, the d3-GHR polymorphism was associated 
with symptomatic OA, especially at the hip site. 
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INTRODUCTION 
Osteoarthritis (OA) is a debilitating disease characterized by progressive 
degradation of articular cartilage and bone remodelling (1). Although the 
exact pathogenesis remains to be elucidated, genetic studies have identified 
several variants associated with primary OA, such as the 7q22 containing 
multiple potential genes, Growth Differentiation Factor 5 (GDF5) gene, 
frizzled related protein (FRZB) gene, Deiodinase IOdothyronine type II 
(DIO2) gene and Mothers Against Decapentaplegic homolog 3 (SMAD3) 
gene (2). Together, these genes provide evidence that endochondral 
ossification may be involved in OA onset (3). 
Endochondral ossification is driven by growth plate chondrocytes, 
resulting in longitudinal skeletal growth through a combination of 
proliferation, extracellular matrix (ECM) secretion and hypertrophy. 
Subsequently, terminally differentiated chondrocytes die and are replaced 
with bone tissue (4). At all stages, chondrocyte behaviour is tightly 
regulated by a complex network of interactions between circulating 
hormones, locally produced growth factors and ECM components. 
These chondrocytes likely play a role in bone shape and/or the quality 
of articular cartilage. One of the strongest stimulators of chondrocyte 
proliferation is Growth Hormone (GH), predominantly via insulin-like 
growth factor-1 (IGF-1) secretion (5). This qualifies variations within GH/
IGF-1 genes as obvious candidates for association studies. 
The dimeric GH receptor (GHR) mediates the effect of GH on 
target tissues and exists of different molecular structures, depending on 
assortments of coding polymorphisms in the GHR gene. Three GHR 
variants, differing in the presence or absence of exon 3 (GHRfl-fl, 
GHRfl-d3, GHRd3-d3), are commonly seen. Exon 3 loss (d3-GHR) 
results in a truncated receptor with increased GH responsiveness by 
enhanced signal transduction (6;7). 
We hypothesize that the d3-GHR polymorphism increases OA risk 
by increasing (local) GH/IGF-1 activity. Therefore, we compared the 
effects of the d3-GHR polymorphism between cases with symptomatic 
generalized OA and controls. We tested for confirmation in three 
additional cohorts. A combined analysis was performed in women (2175 
OA cases and 2623 controls).
PATIENTS AND METHODS
SUBJECTS: The discovery study was the GARP (Genetics ARthrosis 
and Progression) Study (8). For replication, the PAPRIKA (PAtients 
Prospectively Recruited In Knee and hip Arthroplasty)/RAAK (Research 
Articular osteoArthritis Cartilage), ACRO (acromegaly) and Rotterdam 
Studies were used (9-11). All patients and controls were from Dutch 
descent. Details of original study design and phenotype definition were 
described in Supplementary File 1. 
GENOTYPING: Genomic DNA was isolated from peripheral blood according 
to standard procedures. In GARP, the d3-GHR polymorphism was detected 
as described previously (12), based on specific amplification of the wild type 
(935 base pairs (bp)) and mutant (532bp) alleles. To allow high-throughput 
genotyping, we assessed linkage disequilibrium (LD) between d3-GHR and 
Single Nucleotide Polymorphisms (SNPs) covering the gene as determined in 
a GWAS, by means of Illumina 660W. GWAS details are published elsewhere 
(13). Previously, only one SNP (rs6873545) was described to capture the 
d3-GHR polymorphism (14). We genotyped 373 GARP subjects and 752 
controls for 7 other SNPs (rs4590183, rs13354167, rs7721081, rs7701605, 
rs4242116, rs6878512, rs10941583), all being in high LD with the d3-GHR 
polymorphism (Supplementary File 2). All SNPs were in Hardy-Weinberg 
equilibrium. In cases and controls, rs4590183 was selected as proxy for d3-
GHR genotype (r2=1). Throughout this report, the d3 allele of rs4590183 was 
designated as risk allele.
Replication cohorts: Samples of the Rotterdam Study were genotyped 
with the Illumina HumanHap 550v3 Genotyping BeadChip. GWAS 
details are published elsewhere (15). Other cohorts were genotyped 
by mass spectrometry using the homogeneous MassARRAY system of 
Sequenom (San Diego, California, USA) using standard conditions. 
STUDY DESIGN/STATISTICAL ANALYSIS: First, association with d3-
GHR with OA was performed in the GARP Study (men and women) 
since this study consists of genetically enriched patients with symptomatic 
OA at multiple joint sites. Subsequently, we tested for confirmation in 
women of three other cohorts, the PAPRIKA/RAAK (joint replacement), 
acromegaly (signs of clinical and radiographic OA), and Rotterdam (severe 
radiographic OA) studies. 
Logistic regression analyses were performed with STATA Statistical 
Software version 10.1 (Statacorp, College Station, TX). A dominant 
genotypic model was applied. To adjust for family relationships within 
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the GARP Study, robust standard errors were estimated from the variance 
between sibling pairs (16). Combined analyses were performed in women, 
using R version 2.15.0(17). If the heterogeneity metric I2 exceeded 25%, 
a random-effects model was also used, otherwise only a fixed-effects 
model was applied. Given that only one polymorphism was studied with 
well established functional effects, p<0.05 was considered as reflecting 
significance.
RESULTS
Table 1 describes the phenotypic characteristics of the GARP Study 
(discovery sample). As shown in Table 2, we found evidence for association 
between the d3-GHR polymorphism and OA, only in women of the 
GARP Study (OR=1.36, 95%CI 1.01-1.83, p=0.043). Adjustment for 
age and body mass index (BMI) did not significantly affect the genotypic 
association. 
Since women drove the association with d3-GHR, our replication 
was aimed at women with symptomatic OA of the PAPRIKA/RAAK 
and ACRO Studies, and severe radiographic OA in the Rotterdam 
Study (Table 1). For the combined analysis, 2175 cases and 2623 
controls were available, and the respective genotype frequencies are 
shown in Supplementary File 3. Although the association with d3-GHR 
was significant only in the PAPRIKA/RAAK Study, the combined 
analysis of four studies with OA at any joint location provides evidence 
for association with d3-GHR, with an OR of 1.17 (95%CI 1.04-
1.32,p=0.008), without any evidence for heterogeneity (p=0.470, I2=0%) 
(Table 2). In a sensitivity analysis excluding the discovery GARP Study, the 
association persisted (OR=1.14, 95%CI 1.01-1.30, p=0.042). 
When we stratified for joint site in the combined analysis (Table 2), we 
observed consistent effect sizes of approximately 1.2–1.3 among the joint 
strata, being significant in hip OA cases (p=0.002), without evidence for 
heterogeneity (Figure 2B). Allelic data were presented in Supplementary 
File 4. 




Data are shown as mean (SD), unless mentioned otherwise. For the replication studies, only female 
data are shown.
GARP, Genetics osteoARthritis and Progression Study (primary OA); PAPRIKA/RAAK, PAtients 
Prospectively Recruited In Knee and hip Arthroplasty/Research Articular osteoArthritis Cartilage 
(primary OA); ACRO, acromegaly patients; Rotterdam, cases of the Rotterdam Study; BMI, body 
mass index; ROA, radiographic osteoarthritis; KL, Kellgren-Lawrence; THP, total hip prosthesis; TKP, 
total knee prosthesis; NA, not applicable. NR, not reported. 
*, In the GARP Study, 8 patients had a unilateral knee prosthesis, 1 patient had bilateral 
knee prostheses, 22 patients had a unilateral hip prosthesis and 15 patients had bilateral hip 
prostheses, due to end-stage OA. All cases with prostheses were from separate families. 
**, Hand OA was defined as KL≥2 in 2 of the following 3 groups: distal interphalangeal (DIP), 
proximal interphalangeal (PIP), carpometacarpal (CMC) or trapezium scaphoid (TS) joints. 
***, 98% of patients had Kellgren Lawrence ≥2 pre-operatively































Age, years 59.8 (7.6) 61.3 (7.6) 57.0 (6.9) 61.3 (7.2) 61.9 (6.5) 57.7 (1.4) 60.8 (12.2) 57.7 (1.4) 70.0 (8.1) 66.3 (7.8)
BMI, kg/m2 27.0 (4.9) 27.1 (3.4) 25.4 (3.9) 25.8 (3.2) NR NR 28.4 (4.9) NR 27.1 (4.1) 26.2 (3.9)
ROA, by joint site*
    Knee (n (%))
    Hip (n (%))
    Hand (n (%))
116 (38%)





























ROA definition KL≥2** KL≥2** NA NA THP/TKP*** NA KL≥2** NA KL≥3** NA
Pathophysiology of the GH/IGF-1 axis: Long-term consequences on joints and bone192 IX. Relationship between the functional exon 3 deleted growth hormone receptor polymorphism and 
symptomatic osteoarthritis in women
193
Table 2. Study-specif ic and combined analyses investigating 
the association between the d3-GHR polymorphism and 
symptomatic OA in females for OA at any joint site, and 
combined analyses after joint stratif ication
Studies OA at any joint site* Heterogeneity*** joint site Combined analyses* Heterogeneity***
OR (95%CI)** p-value I2 p-value OR (95%CI)** p-value I2 p-value
GARP* 1.36 (1.01-1.83) 0.043 NA NA Hip OA 1.34 (1.11-1.62) 0.002 0% 0.709
PAPRIKA / RAAK* 1.32 (1.00-1.73) 0.048 NA NA Knee OA 1.20 (0.84-1.72) 0.308 66.7% 0.029
ACRO* 1.17 (0.73-1.90) 0.514 NA NA Hand OA 1.29 (0.99-1.67) 0.055 51.7% 0.126
RDAM* 1.09 (0.94-1.27) 0.244 NA NA
Combined analysis 1.17 (1.04-1.32) 0.008 0% 0.470
 
*, Data were presented for female OA cases only.  
**, OR (95%CI) and p-values were calculated for the dominant genotypic model, and were 
presented with the minor allele (exon 3 deletion, d3) as the dominant risk allele. rs4590183 was 
used as proxy for the d3-GHR polymorphism in all cases and controls. The OR represents the risk 
of having the d3-GHR polymorphism in female OA cases vs controls, as shown for the total cohort 
and stratified for joint site. Logistic regression analysis is performed, applying a binary logistic 
model. 
***, Heterogeneity across the OA studies quantified by the I2 statistic, whereas its statistical 
significance was determined by the X2 distributed Cochran Q statistic (20).
OA, osteoarthritis; NA, not applicable; GARP, Genetics ARthrosis and Progression Study; PAPRIKA/
RAAK, PAtients Prospectively Recruited In Knee and hip Arthroplasty/Research Articular 
osteoArthritis Cartilage (primary OA); ACRO, acromegaly patients. 
Figure 1. Forest plots for the association between the d3-GHR polymorphism and symptomatic 
OA in females. Results are presented for the combined analyses of the GARP, PAPRIKA/RAAK, 
ACRO and Rotterdam Studies, showing the association with OA at any joint site (A), and hip OA 
(B). 
GHR, growth hormone receptor; ROA, radiographic osteoarthritis; GARP, Genetics osteoARthritis 
and Progression Study; PAPRIKA, PAPRIKA, PAtients Prospectively Recruited In Knee and hip 
Arthroplasty; RAAK, Research Articular osteoArthritis Cartilage; ACRO, acromegaly patients, 
ROTTERDAM, cases from the Rotterdam Study. 
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DISCUSSION
In a combined analysis of 2175 female OA cases and 2623 controls, 
we found evidence for association between the functional d3-GHR 
polymorphism and symptomatic OA (pooled OR=1.17,95%CI 1.04-1.32, 
p=0.008), without evidence of heterogeneity and independently of age 
and BMI. Stratifying by joint site indicated that the association was most 
predominant in female cases with hip OA.
Human GH is a strong modulator of important physiological processes 
such as fuel homeostasis, cell differentiation and metabolic control. The 
GH/IGF-1 axis is essential for longitudinal skeletal growth. During 
growth, long bones increase in height through endochondral ossification, 
replacing a cartilage model by bone tissue. The main player in this process 
is the chondrocyte. GH is a main stimulator of chondrocyte proliferation 
in the growth plate, and, to a lesser extent, of ECM secretion and the 
hypertrophic switch of post-proliferative chondrocytes (5). Chondrocytes 
in OA cartilage share a fair amount of their expressed genes with those 
expressed in the terminal layer of the growth plate (3). Therefore, genes 
involved in skeletal morphogenesis early in life determining joint shape, 
might play a late-acting deleterious role towards OA. IGF-1 is associated 
with increased cartilage formation and laxity of peri-articular ligaments, 
and plays a role in osteophyte development (18). All these changes 
together contribute to an altered joint geometry, eventually resulting in an 
arthritic joint. The d3-GHR polymorphism is hypothesized to accelerate 
the OA process in susceptible patients by increasing GH responsiveness 
and, thereby, (local) IGF-1 levels. 
Typically, the OR observed in the GARP discovery study was higher 
when compared to the replication studies but also generally higher 
than large scale GWA studies, such as of Zeggini et al.(19). This could 
be explained by the fact that for the GARP Study we have applied a 
family-based sampling scheme towards the extreme spectrum of the 
OA phenotype, consisting of sibling pairs with both symptomatic and 
radiographic OA at multiple sites. In general, such a study is tailored to 
find genetic variants in the low frequency range with moderate to large 
effect sizes. Here, the GARP phenotype may have been most efficient in 
detecting predisposition of the d3-GHR polymorphism, although the 
allele frequency is not rare. Moreover, in a sensitivity analysis excluding 
GARP, the association between the d3-GHR polymorphism and OA 
persisted, whereas the consistency of the effect sizes among the different 
cohorts and joint strata, adds to the credibility of d3-GHR. 
Several potential limitations need to be addressed. Firstly, although the 
direction and effect sizes were similar in our replication cohorts, only the 
association in the PAPRIKA/RAAK cohort was significant. This is likely 
to be explained by the low number of cases of ACRO and Rotterdam 
Study, providing insufficient power. Secondly, inclusion of acromegaly 
patients might introduce a bias, since disease processes in acromegalic 
arthropathy may differ from those in primary OA. However, since the 
d3-GHR polymorphism is not predisposing to acromegaly itself, the 
inclusion of acromegalics with OA is not likely to influence our results. 
Merely, we expect that a general detrimental effect of GH excess on joint 
tissue homeostasis predisposes to OA. Finally, the unknown OA status in 
controls might have led to an underestimation of the reported effect. 
In conclusion, we found an association between the d3-GHR 
polymorphism and symptomatic OA in women, especially in cases with 
hip OA. Being aware of the tendency of association studies to produce 
false-positive results, additional replication is necessary. Furthermore, 
studying the d3-GHR polymorphism in relation to GH profiles and IGF-
1 levels could further elucidate the role of the GH/IGF-1 axis in OA. 
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SUPPLEMENTARY FILE 1.
 Study populations & Phenotype def inition
The discovery study is the GARP (Genetics, osteoARthritis and 
Progression) Study, which is a prospective cohort study aimed at 
identifying determinants of OA susceptibility and progression. This 
study consists of 191 sibling pairs (N=382) affected by symptomatic and 
radiographic OA at multiple joint sites. Radiographic OA of the knee, 
hip and hands was assessed on conventional radiographs, according to 
the Kellgren-Lawrence (KL) scale (1;2). Radiographic knee and hip OA 
were defined by the ROA score (ROA ≥1) (3), in which the specific ROA 
score (0-2) represents no, unilateral or bilateral involvement based on KL 
≥2. For hand ROA we used the following definition to be comparable 
to the definitions used in the Rotterdam Study (vide infra): KL≥2 in at 
least 2 of the following 3 groups: distal interphalangeal (DIP), proximal 
interphalangeal (PIP), carpometacarpal (CMC) or trapezium scaphoid 
(TS) joints (4). Details of patient recruitment and phenotypic description 
are reported in Riyazi et al. (2). We used data from the baseline visit, 
excluding one patient for unsuccessful DNA analysis and eight for missing 
radiographs, resulting in the inclusion of 373 patients. The GARP Study 
was compared with 753 independent individuals (i.e. partners) from the 
Leiden Longevity Study (5). One patient was excluded for missing data on 
sex, resulting in 752 controls. 
In the confirmation and replication studies, only female cases and 
controls were studied. The PAPRIKA (PAtients Prospectively Recruited In 
Knee and hip Arthroplasty) and RAAK (Research Articular osteoArthritis 
Cartilage) cohorts consist of patients with total knee prosthesis (TKP) or 
total hip prosthesis (THP) for end-stage OA (98% had a pre-operative KL 
score of  ≥2), and were, therefore, likely to have significant symptomatic 
disease. Female patients aged ≤70 years were selected with a TKP or 
THP for primary OA (N=332). Controls comprise a random selection of 
unrelated female subjects (N=563) from the Rotterdam Study (6), that 
were not selected on the basis of phenotype. 
The acromegaly cohort consists of long-term well-controlled patients 
(7), of which 41 female patients were successfully genotyped and therefore 
included. All patients had signs of arthropathy at any joint. In the 
acromegalics, radiographic OA was defined by the ROA score, based on 
KL ≥2. The controls comprise a random selection of another sample of 
unrelated subjects (N=361) from the Rotterdam Study (6), that were not 
selected on the basis of phenotype. 
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The Rotterdam Study, which comprises 7983 Caucasian participants, is 
a prospective, population-based cohort study of determinants and the 
prognosis of chronic diseases in the elderly (6). Radiographs of the knee, 
hip and hands were made; however, symptomatic data were not available. 
In order to select comparable female cases for the GARP and PAPRIKA/
RAAK Studies, and in the absence of symptomatic data, 1497 Rotterdam 
cases were selected according to the following definitions: knee and hip 
OA as KL ≥3, and hand OA as KL ≥2 in at least 2 of the following 3 
groups (DIP, PIP, CMC/TS joints). Subjects did not show overlap to 
the Rotterdam control subjects mentioned above. Rotterdam cases were 
compared to 1264 other female controls from the Rotterdam Study.  
All patients and controls were from Dutch descent. Study protocols 
were approved by the local Medical Ethics Committee and written 
informed consent was obtained from all participants.
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SUPPLEMENTARY FILE 2
 Linkage disequilibrium patterns between the 7 
SNPs selected from HAPMAP and the d3-GHR 
polymorphism.
SNP, single nucleotide polymorphism; GHR, growth hormone receptor.
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SUPPLEMENTARY FILE 3. 
Genotype frequencies of the d3-GHR polymorphism 
(using rs4590183) in the different case and control 
populations, for, respectively, the total cohort and 
female subjects only
 
a Females only. 
Data are shown as number (frequency). N, number of patients. GARP, Genetics osteoARthritis and 
Progression Study; PAPRIKA/RAAK, PAtients Prospectively Recruited In Knee and hip Arthroplasty/






















GHRfl-fl 202 (0.542) 442 (0.588) 268 (0.534) 579 (0.579) 50 (0.588) 374 (0.588) 1264 (0.575) 1585 (0.599)
GHRfl-d3 154 (0.413) 260 (0.346) 206 (0.410) 354 (0.354) 29 (0.341) 255 (0.382) 817 (0.372) 936 (0.354)




















GHRfl-fl 163 (0.534) 265 (0.609) 172 (0.518) 330 (0.586) 22 (0.537) 208 (0.576) 853 (0.570) 757 (0.599)
GHRfl-d3 127 (0.416) 141 (0.324) 138 (0.416) 201 (0.357) 17 (0.415) 132 (0.366) 565 (0.377) 453 (0.358)
GHRd3-d3 15 (0.049) 29 (0.067) 22 (0.066) 32 (0.057) 2 (0.049) 21 (0.058) 79 (0.053) 54 (0.043)
SUPPLEMENTARY FILE 4A. 
Study-specif ic and combined analyses by allele 
frequency data of rs4590183 for female cases with 
symptomatic OA 
GARP* PAPRIKA / RAAK* ACRO* RDAM*
Joint site OR (95%CI)** p-value OR (95%CI)** p-value OR (95%CI)** p-value OR (95%CI)** p-value
Overall 1.17 (0.92-1.49) 0.205 1.28 (1.03-1.60) 0.025 1.08 (0.64-1.83) 0.763 1.07 (0.95-1.22) 0.280
Hip OA 1.29 (0.87-1.90) 0.203 1.31 (1.02-1.68) 0.038 1.30 (0.53-3.18) 0.569 1.17 (0.94-1.46) 0.160
Knee OA 1.40 (1.01-1.93) 0.042 1.24 (0.91-1.70) 0.172 1.05 (0.48-2.28) 0.930 0.87 (0.70-1.09) 0.230
Hand OA 1.30 (1.00-1.71) 0.052 NA NA 1.23 (0.70-2.18) 0.473 1.09 (0.96-1.24) 0.190
Combined analyses* Heterogeneity
Joint site OR (95%CI)** p-value I2*** p-value
Overall 1.13 (1.02-1.24) 0.016 0% 0.544
Hip OA 1.24 (1.06-1.44) 0.006 0% 0.924
Knee OA 1.11 (0.86-1.45) 0.414 56.2% 0.077
Hand OA 1.13 (1.01-1.27) 0.033 0% 0.472
*, Data were presented for female OA cases only.  
**, OR (95%CI) and p-values were calculated using the allelic model, and were presented with the 
minor allele (exon 3 deletion, d3) as risk allele.  
***, Heterogeneity across the OA studies quantified by the I2 statistic, whereas its statistical 
significance was determined by the X2 distributed Cochran Q statistic.
OA, osteoarthritis; NA, not applicable; GARP, Genetics ARthrosis and Progression Study; PAPRIKA/
RAAK, PAtients Prospectively Recruited In Knee and hip Arthroplasty/Research Articular 
osteoArthritis Cartilage (primary OA); ACRO, acromegaly patients; RDAM, Rotterdam Study cases. 
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SUPPLEMENTARY FILE 4B. 
Frequencies of the minor allele (exon 3 deletion, d3) 
across the different study cohorts with patients with 
symptomatic OA and corresponding controls
Joint site    GARP* PAPRIKA / 
RAAK*
ACRO* RDAM* #
Overall 0.257 0.283 0.256 0.245
Hip OA 0.276 0.287 0.292 0.262
Knee OA 0.293 0.277 0.250 0.210
Hand OA 0.278 NA 0.281 0.248
Controls 0.229** 0.235*** 0.241*** 0.226***
 
*, Minor allele frequencies (MAF), with the exon 3 deletion (d3) allele as minor allele, are 
presented for the different studies, stratified by joint site with symptomatic OA.  
**, Controls of the Leiden Longevity Study. 
***, Controls of the Rotterdam Study. 
#, The Rotterdam Study did not comprise cases with symptomatic OA. We chose a severe 
radiographic phenotype (see Method section) in order to be comparable to the other cohorts with 
symptomatic OA.
OA, osteoarthritis; NA, not applicable; GARP, Genetics ARthrosis and Progression Study; PAPRIKA/
RAAK, PAtients Prospectively Recruited In Knee and hip Arthroplasty/Research Articular 
osteoArthritis Cartilage (primary OA); ACRO, acromegaly patients; RDAM, Rotterdam cases.
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ABSTRACT
BACKGROUND: The beneficial effects of recombinant human growth 
hormone (rhGH) therapy in growth hormone deficient (GHD) adults are 
well-established in the short term. However, data documenting the effects 
during prolonged follow-up are relatively scarce. 
OBJECTIVE: To evaluate the reported effects of rhGH replacement (≥5 
years) in GHD adults on biochemical and anthropometric parameters, 
quality of life (QoL), bone metabolism, muscle strength, serious adverse 
events (SAEs) and mortality. 
METHODS: We conducted a systematic literature search. Quality 
assessment of retrieved papers was performed using a quality assessment 
based on the modified STROBE statement.
RESULTS: We included 23 prospective studies with a rhGH treatment 
duration ranging from 5 to 15 years. Overall, beneficial effects were 
reported on QoL, body composition, lipid profile, carotid intima media 
thickness and bone mineral density. In contrast, the prevalence of the 
metabolic syndrome, glucose levels, BMI and muscle strength were not, or 
negatively influenced. Most of the studies were uncontrolled, lacked the 
presence of a control group (of non-treated GHD patients), and reported 
no data on lipid-lowering and anti-diabetic medication. Overall mortality 
was not increased.
CONCLUSION: rhGH treatment in adult GHD patients is well-tolerated 
and positively affects QoL in the long term. However, the metabolic and 
cardiovascular effects during long-term treatment are variable. The low 
numbers of long-term studies and studied patients and lack of control 
data hamper definite statements on the efficacy of prolonged treatment. 
Therefore, continuous monitoring of the effects of rhGH replacement 
to enable an adequate risk-benefit analysis that may justify prolonged, 
potentially life-long, treatment is advisable. 
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INTRODUCTION
Growth hormone deficiency (GHD) in adults has been associated 
with an adverse metabolic profile and increased cardiovascular 
mortality by inducing abdominal obesity, hypercholesterolaemia and 
hypertriglyceridaemia (1;2). Consistent beneficial effects of treatment with 
recombinant human growth hormone (rhGH) were reported on body 
composition and lipid profile, resulting in reduction of fat mass combined 
with an increase in lean body mass (LBM) and a reduction in total 
cholesterol (TC) levels (3). In addition, favorable effects were reported on 
bone turnover, bone mineral density (BMD), muscle strength, cognitive 
function and quality of life (QoL) (3-5). Most of these effects have been 
documented in short-term studies, sometimes placebo-controlled, with a 
follow-up duration ranging from 6 to 18 months. 
The beneficial effects of rhGH therapy have been reported to be 
sustained for at least 5 years of treatment; however data with a longer 
follow-up duration are scarce. With respect to cardiovascular disease, 
a direct improvement of several cardiovascular risk factors was noted 
within the first treatment year, which was reported to be sustained during 
prolonged rhGH treatment (6;7). In a small study, sustained improvement 
of lipid spectrum and diastolic blood pressure (DBP) was reported over 
7 and 10 years, suggesting ongoing beneficial effects even beyond 5 
years (6;7). However, it is presently unknown whether rhGH therapy 
has favorable effects on the incidence of cardiovascular events, including 
cardiovascular death. With respect to bone, rhGH replacement therapy 
increases bone remodeling, indicated by an increase of biochemical 
markers of both bone formation and resorption. This results in an initial 
decline in BMD, followed by a significant increase in BMD, reaching a 
plateau phase after 5 to 7 years of treatment (8-10). 
In general, rhGH replacement therapy in adults is regarded as safe. 
Recently, Van Bunderen et al. reported no differences in overall or malignancy-
related mortality rate between GHD-treated patients and the background 
population (11). However, an increased risk in cardiovascular death was 
observed in rhGH-treated women. This increased cardiovascular mortality, 
however, is not easily explained. These recent findings accentuate the necessity 
to critically evaluate long-term efficacy and safety data.
We performed a systematic review of all available papers on long-term 
rhGH replacement in adult GHD patients. We aimed to evaluate the 
effects of long-term rhGH replacement in GHD adults on cardiovascular 
parameters, bone metabolism, muscle strength, QoL, mortality and 
adverse events.  
MATERIALS AND METHODS
SEARCH STRATEGY AND ELIGIBILITY CRITERIA: To identify studies that 
investigated the long-term effects of rhGH replacement in GHD adults, we 
searched the following databases, up to September 2012 (Date of initial search 
9th March, 2012): Medline, EMBASE, Web of Science, and the Cochrane 
Library, in collaboration with a trained clinical librarian (J.S.). We composed 
a search strategy focusing on long-term rhGH treatment, GHD adults, bone 
metabolism, QoL, metabolic effects, muscle strength, mortality, and adverse 
events. Chronic stable replacement was arbitrarily defined as replacement for 
≥5 years, since such a period will reflect a stable metabolic situation without 
confounding by ongoing metabolic changes induced by the start and titration 
of rhGH replacement (3;12). We used all relevant keyword variations, 
including free text words. Duplicated articles were excluded. The complete 
search strategy is provided in Appendix 1. References of relevant articles were 
checked for additional articles. Only original articles were included. 
Studies were eligible when all of the following criteria were met: (1) 
they investigated effects on biochemical, metabolic/anthropometric 
parameters, bone metabolism, QoL, muscle strength, mortality, or adverse 
events, (2) in adult patients with either childhood-onset (CO) or adult-
onset (AO) GHD and (3) with at least 5 years of rhGH treatment and (4) 
were written in English. Only human studies were evaluated. 
DATA EXTRACTION AND ANALYSIS: Data extraction and eligibility 
were assessed by two independent investigators (K.M.J.A.C. and 
N.M.A.-D.). Inconsistencies were resolved by consensus. The following 
data were extracted: (1) study population (patient characteristics, 
population size, GHD assessment, control population); (2) exposure 
to rhGH (duration of rhGH treatment, rhGH dose), (3) outcome 
(biochemical and anthropometric parameters, QoL, bone metabolism, 
muscle strength, mortality, serious adverse events (SAEs)) (4) potential 
confounders (age, sex, CO/AO). 
METHODOLOGICAL QUALITY ASSESSMENT:  The quality of each included 
paper was assessed in consensus by two independent reviewers (K.M.J.A.C. 
and N.M.A.-D.), using a standardized set of criteria based on the STROBE 
statement (Appendix 2), which was modified to cover the topic of our review 
(12). A maximum score of 10 points could be obtained. According to the total 
quality score, articles were considered as having poor (0-2), intermediate (3-5), 
good (6-8), or excellent methodological quality (9-10).
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RESULTS
IDENTIFICATION AND SELECTION OF THE LITERATURE: From the 
initial 841 potentially relevant studies identified, 803 were excluded on the 
basis of title and abstract. Thirty-eight papers were retrieved for detailed 
assessment: 9 were excluded because of rhGH treatment duration <5 
years, 2 studies described pediatric patients only, 1 study did not report 
original data and 3 studies did not address the long-term effects of rhGH 
suppletion. Consequently, 23 studies were eligible for inclusion, several 
describing part of the same patient cohort (Göteborg) (4;6;9;10;13-16) 
(KIMS database, (5;17)) (Figure 1 & Table 1). Therefore, we also mention 
the specific study centre. 
QUALITY ASSESSMENT: According to the predefined quality criteria, 
no studies were classified as being poor quality. Two studies scored 
intermediate (18;19), 15 studies were good quality (4-6;9;11;15;18;21-28) 
and 6 studies had an excellent methodological quality (7;10;13;15;16;20) 
(Table 1). Mean quality score was 7.3 (range 5.0-9.0), indicating that 
overall methodological quality was good. However, especially the items on 
potential bias, handling with missing data, reasons for non-participation 
at each study stage and the use of/handling with co-medication were not 
clearly described. 
METHODOLOGY: All selected studies (n=23) were prospective follow-up 
studies, and eleven of these had a controlled design. Healthy controls were 
included in six studies (5;13;19-22), of which two studies used National 
Registries. Four other studies included GHD patients with intermittent 
rhGH treatment or untreated GHD patients as controls (11;22;24;25). 
Gibney et al. compared rhGH-treated patients with both untreated 
GHD patients and healthy controls (23). Four reports involved multi-
center studies (5;11;17;24). No randomized controlled trials (RCT) were 
available.
ENDOCRINE EVALUATION: Different established stimulation tests 
were used for the diagnosis of severe GHD. The insulin tolerance test 
(ITT) was used as standard test in 16 studies and the combined GHRH-
arginine test, glucagon stimulation test or stimulation with clonidine 
alone, in the case of contraindications for ITT. Eight studies did not 
specify which stimulation tests were used (5;11;14;17;22;24-26). Thirteen 
studies applied the generally used cut-off value for severe GHD of a peak 
GH<3µg/L (4;6;7;9;10;13;15;16;19;20;23;27;28), in seven studies no 
exact cut-off value was reported (5;11;14;17;22;24;26), and three studies 
used, respectively, <1.7µg/l (21), <5µg/l (18) and <10mU/l (25) as cut-off. 
In all studies, except for one (25), information on additional pituitary 
deficiencies was given. Most patients had multiple anterior deficiencies, 
especially gonadotrope deficiency, but thyreotrope and corticotrope 
deficiency was also frequently encountered. 
Duration of rhGH treatment: Mean treatment duration with rhGH 
ranged from 5 years to 15 years: 8 studies reported 5-year effects, 2 studies 
had a 6-year follow-up (11;18), 3 studies investigated 7-year effects 
(7;21;28), 1 study investigated the 9-year effects (25), 8 studies reported 
10-year effects (6;10;13-15;23;24;26), 1 study described 15 years of 
rhGH suppletion (4). In one study, treatment duration varied among the 
different countries from 4-8 years (5). 






841 potentially relevant publications 
identified from electronic search 
38 publications retrieved for more 
detailed assessment 
23 eligible for inclusion 
803 studies excluded on the basis of 
title and abstract 
15 articles did not fulfill the 
inclusion criteria because of the 
following reasons: 
 
9 articles: follow-up <5yr 
2 articles: children with GHD 
3 articles: other primary question 
1 article: no original article 
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Table 1. Included studies on the ef fects of  long-term rhGH 
suppletion

























Healthy controls, age, sex 
& BMI matched (N=12)
0.025IU/kg/d 10 Gibney (1999(22) x x x x x 7.5
Chrisoulidou (2000(20)) 12 (6/6)
10/2
52 ± 10 GHD, 0.5-1.5yr rhGH 
(N=11)
Untreated GHD (N=10)
NR 7 Chrisoulidou (2000(20)) x x x 6.5











- 0.3 (median) 5 Götherström  (2001(9))**
Göteborg







Healthy controls, age 






x x x 8.0




Group A = continuously
Group B = no
Group C = intermittently
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Chrisoulidou (2000(21)) 12 (6/6)
10/2











48.0 (R 20-62) initial 1.10
end 0.61






50.0 (R 22-74) initial 0.88
end 0.46
5 = weight & BMI
Giavoli (2004(28)) 20 (11/9)
20/0







65.0 (R 61-74) initial 0.73
end 0.36
5 = weight & BMI




46.7 ± 14.3 initial 0.2
end 0.5
7 = WC & WHR
↑ BMI




45.2 ± 9.1 initial 0.2
end 0.5






44.1 (R 22-74) initial 0.98
end 0.47
7 = weight, ↑ BMI
Cenci (2008(20)) 14 (10/4) 
14/0
R 33-62 initial 0.87
end 0.64






50 R (22-74) initial 0.88 
end 0.47





♀ 36.7 ± 8.4
♂ 35.1 ± 8.1
(R 20-49)
♀ initial 0.27
    end 0.46 
♂ initial 0.31
    end 0.40






49.4 (R 22-74) initial 0.63
end 0.41





















Gibney (1999(22)) 10 (7/3)
NR
38 (R 21-48) 0.025IU/kg/d 10 = BF
↑ LBM
↑ thigh muscle area
Chrisoulidou (2000(21)) 12 (6/6)
10/2
52 ± 10 NR 7 ↓ BF
↑ LBM














48.0 (R 20-62) initial 1.10
end 0.61










Giavoli (2004(28)) 20 (11/9)
20/0





















Cenci (2008(20)) 14 (10/4) 
14/0
R 33-62 initial  0.87 
end 0.64









Roemmler (2010(24))* 22 (14/8)
16/6
51.5 (R 33-75) 0.3 (median) 10 (2-42) = BF 
= LBM
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Gibney (1999(22)) 10 (7/3)
NR
38 (R 21-48) 0.025IU/kg/d 10 = BF
↑ LBM
↑ thigh muscle area
Chrisoulidou (2000(21)) 12 (6/6)
10/2
52 ± 10 NR 7 ↓ BF
↑ LBM














48.0 (R 20-62) initial 1.10
end 0.61










Giavoli (2004(28)) 20 (11/9)
20/0





















Cenci (2008(20)) 14 (10/4) 
14/0
R 33-62 initial  0.87 
end 0.64









Roemmler (2010(24))* 22 (14/8)
16/6
























Gibney (1999(22)) 10 (7/3)
NR
38 (R 21-48) 0.025IU/kg/d 10 =
Chrisoulidou (2000(21)) 12 (6/6)
10/2












48.0 (R 20-62) initial 1.10
end 0.61
7 =




46.7 ± 14.3 initial 0.2
end 0.5
7 ↓











44.1 (R 22-74) initial 0.98
end 0.47
10 ↓
Cenci (2008(20)) 14 (10/4)           
14/0
R 33-62 initial 0.87 
end 0.64
5 =
Roemmler (2010(24))* 22 (14/8)
16/6







♀ 36.7 ± 8.4
♂ 35.1 ± 8.1
(R 20-49)
♀ initial 0.27
    end 0.46 
♂ initial 0.31
    end 0.40
10 = 
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Gibney (1999(22)) 10 (7/3)
NR
38 (R 21-48) 0.025 IU/kg/d 10 = glucose, = insulin 
Chrisoulidou (2000(21)) 12 (6/6)
10/2
52 ± 10 initial 0.98
end 0.48













48.0 (R 20-62) initial 3-8 µg/
kg/d
end 0.3
7 = glucose & insulin 
sensitivity
Giavoli (2004(28)) 20 (11/9)
20/0
44 ± 14 initial 0.98
end 0.47
5 ↑ glucose & insulin 
= HOMA-IR & 
QUICKI




44.1 (R 22-74) initial 0.2
end 0.5
7 = glucose











46.7 ± 14.3 initial 0.2
end 0.5
10 ↑ glucose, ↓ HbA1c
Cenci (2008(20)) 14 (10/4)
14/0
R 33-62 initial 0.87 
end 0.6
5 = glucose & insulin & 
HOMA-IR
Roemmler (2010(24))* 22 (14/8)
16/6
51.5 (R 33-75) initial 1.10
end 0.61
10 (2-42) = all glucose parameters 
(including glucose, 








♀ 36.7 ± 8.4
♂ 35.1 ± 8.1
(R 20-49)
♀ initial 0.27



























Gibney (1999(22)) 10 (7/3)
NR
38 (R 21-48) 0.025
IU/kg/d
10 = SBP & DBP
= LVM & ESM & EDM
↓ carotid IMT
Chrisoulidou (2000(21)) 12 (6/6)
10/2
52 ± 10 NR 5 = SBP & DBP 
= IVRT, = LVM
= HR, ↓ resting DBP, 
= SBP
= exercise time




46.7 ± 14.3 initial 0.2
end 0.5
7 = SBP & DBP




45.2 ± 9.1 initial 0.2
end 0.5
5 = SBP & DBP
↑ MS prevalence
Cenci (2008(20)) 14 (10/4)
14/0
R 33-62 initial 0.87 
end 0.64




Gibney (1999(22)) 10 (7/3)
NR
38 (R 21-48) 0.025IU/
kg/d





50.0 (R 22-74) initial 0.88
end 0.46 
5 ↑ knee flexor & extensor 
strength





65.0 (R 61-74) initial 0.73
end 0.36
5 ↑ knee flexor & extensor 
strength





50 R (22-74) initial 0.88 
end 0.47
10 ↑ knee flexor & extensor 
strength





65.2 ± 3.4 initial 0.72
end 0.37
10 ↑ knee flexor strength
= hand grip strength
= muscle endurance
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Clanget (2001(19)) 12 (8/4)
9/3
42.5 (R 24-61) µ 2.4IU 
(0.80mg)
6 ↑ BMC & BMD (lumbar 






49.3 (R 22-74) initial 0.98
end 0.48
5 ↑ BMC & BMD






44.1 (R 22-74) initial 0.98
end 0.47
10 ↑ BMC & BMD (total 
body, lumbar spine, prox 
femur)
↑ osteocalcin & Ca2+ 
Roemmler (2010(24))* 22 (14/8)
16/6





49.4 (R 22-74) initial 0.63
end 0.41
15 ↑ BMC & BMD (total 
body, lumbar spine, 
plateau)
↑ BMC, = BMD (prox 
femur, peak at 7yr, 
thereafter ↓) 




Gibney (1999(22)) 10 (7/3)
NR
38 (R 21-48) 0.025IU/kg/d 10 ↑ overall psychological 
well-being, energy, 
emotional reaction
Gilchrist (2002(23)) 61 (27/34)
43/1
37.9 ± 11.8 0.25IU/kg/wk 9 NHP: ↑ energy levels, 
= sleep & emotional 
reaction & social 
isolation & physical 
mobility & pain










































QoL-AGHDA: ↑ in 1st 
yr, after that regression 






♀ 36.7 ± 8.4
♂ 35.1 ± 8.1
(R 20-49)
♀ initial 0.27
    end 0.46 
♂ initial 0.31
    end 0.40
10 QoL-AGHDA: ↑ in 














5 = overall mortality & 
malignancy rate
↓ MI rate, ↑ CVA rate
Van Bunderen (2011(11)) 2229 
(1160/1069)
1718/511
42.6 ± 16.3 µ 0.48 5.7 
(median)
= mortality compared to 
background pop (after 
exclusion high-risk)
= malignancy mortality






CO 26.9 ± 9.9
AO 48.8 ± 13.0
NR 4.9 ↑ overall mortality in ♀ 
(moderate)
= malignancy & CVD 
mortality
↑ CVA & infection 
mortality
↑ progression primary 
tumour & endocrine 
complications
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*  3 patients treated <5yr 
**  Overlapping patient cohorts Götherström 2010, Götherström 2005, Götherström 2001,  
Götherström 2007, Götherström 2007, Götherström 2009, Elbornsson 2012, Svensson 2003, 
Svensson 2004  
***  Overlapping patient cohorts Van der Klaauw 2006 & Van der Klaauw 2007  
****  Control group at baseline differed from controls at 10 year 
***** Overlapping patient cohorts KIMS database Koltowska-Häggström 2006, Gaillard 2012, 
Spielhagen 2011
rhGH, recombinant human growth hormone; GHD, growth hormone deficiency; AO, adult-onset 
GHD; CO, childhood-onset GHD; R, range; BF, body fat; LBM, lean body mass; ITT, insulin-
tolerance test; GHRH, growth hormone releasing hormone; BMD, bone mineral density; BMC, 
bone mineral content; TG, triglycerides; HDL, high-density lipoprotein cholesterol; LDL, low-density 
lipoprotein cholesterol; BP, blood pressure; MS, metabolic syndrome; WC, waist circumference; 
HC, hip circumference; WHR, waist-hip ratio; HOMA-IR, homeostasis model assessment of 
insulin resistance; QUICKI, quantitative insulin check index, Carotid IMT, intima media thickness of 
carotid arteries; QoL, quality of life; NHP, Nottingham Health Profile; PGWB, psychological general 
well-being schedule; QoL-AGHDA, quality of life-assessment of GH deficiency in adults; LVM, left 
ventricular mass; ESM, end systolic diameter; EDM, end diastolic diameter; Ca2+, calcium; NEFA, 
nonesterified fatty acids; Lp (a), lipoprotein (a); APU, apparent phalangeal ultrasound transmission 
velocity; CVD, cardiovascular disease; IVRT, isovolumic relaxation time; LVM, left ventricular mass; 
VF; vertebral fracture; UK, United Kingdom; NL, Netherlands; MI, myocardial infarction; CVA, 
cerebrovascular attack; SAE, serious adverse event; NR, not reported.
DOSE OF RHGH TREATMENT & IGF-1 LEVELS: Fourteen studies 
(nine from Göteborg) calculated the GH starting dose based on body 
weight (4;6;9;10;13-16;19;21-23;25;27). Of the remaining nine studies, 
three studies used dose titration of rhGH on an individual basis in 
the beginning of treatment, with the aim to reach IGF-1 levels within 
the normal age- and sex-related range, and adjusted the rhGH dose 
accordingly (7;20;26). Six studies did not report their rhGH dosage 
regimen (5;11;17;18;24;28). GH start dose ranged from 0.2mg/day (7;20) 
to 1.1mg/day (21). Twelve studies reported mean GH dose after dose 
titration (at 1 year) (6;9;10;13-17;19;21;24;27), ranging from 0.3mg/day 
(19) to 0.85mg/day (21) (median dose 0.54 mg/day).
 Sixteen studies reported mean IGF-1 levels (4;7;9;10;13-
16;18;19;21-24;26;28), and 13 studies described IGF-1 SDS to 
evaluate treatment response (4;6;9;10;13-17;20-22;24) (Appendix 3). 
Based on available IGF-1 values, we can conclude that all patients were 
physiologically substituted at least after 5 to 7 years treatment with rhGH, 
independently of the applied starting dosage regimen.
Outcome of long-term rhGH replacement (Table 2)
ANTHROPOMETRIC PARAMETERS: Thirteen studies (N=1185) assessed 
the effects on body weight, body mass index (BMI) and/or waist-hip ratio 
(WHR) (4;6;7;9;10;13;14;20;21;24;26-28). rhGH suppletion did not 
affect WHR or waist circumference (7;20;21;26-28), except for one study 
reporting an increased waist circumference (24). Seven studies reporting 
BMI found a significant increase during rhGH suppletion ≥5years, 
while the other six studies reported no change (4;6;7;9;13;14;16;19-
21;24;27;28). Two of the eight studies reporting body weight found an 
increase in weight during rhGH suppletion; the other studies reported no 
change (4;10;13;14;16;21;27;28). 
In conclusion, results on long-term effects on BMI appear to be 
inconclusive with seven studies reporting an increase, and six reporting no 
change. In addition, there is little evidence for an increase in body weight. 
BODY COMPOSITION: Eleven studies (N=538) 
(6;9;13;14;16;19;21;23;26-28) assessed the effects of rhGH suppletion 
on body composition using dual-energy X-ray absorptiometry (DEXA) 
scan (6;9;13;14;16;26;28), bioelectrical impedance analysis (BIA) (19;21) 
or a helicoidal CT scan (27). Gibney et al. measured body composition 
with radioisotope potassium (23). The majority of studies (n=9) reported 
consistent effects with an increase in LBM and a decrease in total body fat 
(BF) (6;9;13;14;16;19;21;23;28). One study could not detect any effect of 
rhGH on body composition (26). Cenci et al. reported only a decrease in 
visceral fat (27).  
In conclusion, rhGH suppletion had favourable effects on body 
composition, with an increase in LBM and a decrease in total BF. Several 
methods are available to evaluate body composition, which may account 
for differences between studies. These differences might have influenced 
the results significantly. In literature, DEXA is reported to be the best 
currently available technique for measuring body composition (29); 
however, in this respect, it has to be noted that DEXA cannot distinguish 
between body cell mass (BCM) and water. Therefore, the LBM data may 
not be accurate, since rhGH replacement is associated with an increase 
in the intracellular water component (30-33). However, also when using 
other modalities to evaluate body composition, positive long-term effects 
of rhGH replacement were found.
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LIPID METABOLISM: Ten studies (N=827) assessed the effects of rhGH 
suppletion on fasting plasma lipid profiles (6;7;9;20;21;23;24;26-28). 
Three studies did not find any effect of rhGH therapy on plasma lipids 
(24;26;27). The seven remaining studies reported generally similar results, 
i.e. reduction of total cholesterol (TC) and low-density lipoprotein (LDL) 
cholesterol, an increase in high-density lipoprotein (HDL) cholesterol and 
no effect on triglycerides (6;7;9;20;21;23;28). In 6 patients, new-onset 
hyperlipidaemia was reported (Göteborg). However, only four studies 
reported the number of patients on lipid-lowering medication, especially 
statins, (6;7;20;26) but without excluding these patients from analysis.  
In summary, there are ongoing beneficial effects of rhGH suppletion on 
plasma lipids. However, a strong limitation is the lack of data concerning 
lipid-lowering treatment, which has a considerable influence on the 
outcome parameter. Due to the lack of information on lipid-lowering 
drugs and the overlap in patient groups, meta-analysis was not an option. 
GLUCOSE METABOLISM: Eleven studies (N=847) assessed the effects of 
rhGH suppletion on glucose and insulin levels (6;7;9;19-21;23;24;26-28). 
Seven studies showed no effect on glucose (7;20;23;24;26-28), three an 
increase (6;9;19) and one study found a transient increase of glucose levels 
only during the first year of rhGH therapy (21). Insulin levels increased 
only in one study (19). HbA1c was evaluated in three studies, two of 
which observed a decrease (6;9); the other found no change (26). Three 
studies investigated insulin resistance by the homeostasis model assessment 
(HOMA) (19;26;27), reporting no significant effects of rhGH suppletion. 
Insulin sensitivity was not affected in two studies (21;26), while another 
study reported a transient decrease, using the quantitative insulin 
check index (QUICKI), showing a trend to return towards basal values 
afterwards (19). In at least ten patients, new-onset diabetes mellitus type 2 
(DM2) was diagnosed (4 Göteborg, 6 KIMS (24)). Five studies reported 
the number of patients starting anti-diabetic medication during follow-up 
(6;9;21;26;27). Only one study excluded diabetic patients from analysis 
(9), while the other studies did not report the handling with anti-diabetic 
medication in their statistical analysis. 
In conclusion, there is moderate evidence for an increase in mean 
glucose levels after chronic rhGH treatment; however, insulin sensitivity 
appeared not to be affected in the long term. Due to the lack of 
information on anti-diabetic medication and the overlap in patient 
cohorts, we were not able to perform a meta-analysis on this parameter.
CARDIOVASCULAR PARAMETERS: Four studies (N=135) investigated 
the effects of rhGH suppletion on blood pressure (7;9;20;23;28). No 
effect was found on systolic blood pressure (SBP); one study reported a 
decrease in resting DBP (28). Only two studies described the number of 
patients on antihypertensive medication (7;20), without excluding them 
from analysis. Prevalence of the metabolic syndrome (MS) was assessed in 
one study, reporting a strong increase when compared to healthy controls, 
despite 5 years of rhGH treatment (38.0% vs 15.7%) (20).
Two studies (N=22) evaluated the long-term effects on cardiac function 
(23;28) using echocardiography; Chrisoulidou et al. also performed 
an exercise test (28). Left ventricular mass (LVM) was not affected. In 
addition, no effect on end diastolic or systolic diameter (23) nor on 
isovolumetric relaxation time (IVRT) or LVM was demonstrated (23;28). 
Two studies (N=24) evaluated carotid intima media thickness (IMT), 
reporting a decrease in IMT up to 18% after long-term rhGH therapy 
(23;27). 
In conclusion, no effect on SBP of LVM was reported. In addition, 
conclusions on the prevalence of MS cannot be made, since this parameter 
was only evaluated in one study. Long-term rhGH suppletion had positive 
effects on IMT.
MUSCLE STRENGTH: Five studies (N=278, all AO-GHD) investigated 
the effects of rhGH suppletion on muscle strength (13-16;23). In general, 
5 years of rhGH improved knee flexor and extensor strength and hand-
grip strength. However, these effects were not sustained after 10 years. One 
study also investigated muscle endurance; no significant effects of rhGH 
suppletion were demonstrated (15). In addition, rhGH suppletion did 
not affect muscle strength in the elbow, shoulder or hip (23). Compared 
with population-based controls, rhGH was found to be protective to the 
normal age-related decline in muscle performance and neuromuscular 
function (13;14). 
In general, rhGH suppletion improved muscle strength during the 
first 5 years of treatment; however, these effects were not sustained after 
prolonged follow-up. Since almost all studies described one patient group, 
we were not able to perform a meta-analysis on this parameter.
BONE PARAMETERS: Four studies (N=343) evaluated the long-term 
effects of rhGH on bone (4;9;10;18). After an initial decline, all studies 
reported an increase in both BMD and BMC within the first 5 years 
of treatment. After 5 years, all studies reported a plateau phase, which 
lasted for the entire study period (i.e. sustained effects) (4;9;10;18). Only 
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one study investigated (symptomatic) fracture prevalence, reporting 
1 hip fracture and 1 symptomatic vertebral fracture (4). None of the 
studies described the use of calcium or Vitamin D suppletion, or the 
use of bisphosphonates, selective estrogen receptor modulator (SERM), 
teriparatide or strontium ranelate. Again, most patients were from the 
same study centre, prohibiting the performance of a meta-analysis.  
QOL: Two large cohort studies (both KIMS database, N=1686 and 
N=440, respectively) and two smaller studies (N=71) addressed the 
effects on QoL and neuropsychological well-being, by QoL-Assessment 
of GHD in Adults (QoL-AGHDA), Nottingham Health Profile (NHP), 
and Psychological General Well-Being (PGWB) questionnaires (5;23-25). 
Within the first year of treatment, a direct beneficial response on well-
being was noticed, as assessed by QoL-AGHDA, with marginal changes 
after the dose-titrating phase (5;24). Improvement was related to the 
degree of QoL impairment at baseline (5). Scores on NHP and PGWB 
improved in the long-term, especially with respect to energy level and 
emotional reaction (23;25). 
In conclusion, QoL seemed to improve during long-term rhGH 
replacement, but positive effects on QoL were especially seen within the 
first year of treatment. Since studies are scarce and none of them had a 
placebo-controlled randomized controlled design, which is of paramount 
importance for the interpretation of QoL, no firm conclusions can be 
drawn on the effects of long-term rhGH replacement on QoL.
EFFECTS OF RHGH ON MORTALITY: Three cohort studies (N=16501) 
reported data on mortality after long-term rhGH suppletion (11;17;22), of 
which one study reports KIMS data (N=13983). In Gaillard et al., overall 
mortality rate was moderately increased, especially in females, young attained 
age, patients with aggressive tumours and lower IGF-1 SDS during therapy 
(17). The other studies did not report differences in overall mortality or 
malignancy-related death. In two studies (17;22), the rate of cerebrovascular 
accidents (CVAs) was increased, but the incidence of myocardial infarction 
was decreased (risk ratio (RR) 0.27, 95%CI 0.03-0.99) when compared 
with the background population (22). In addition, rates of death due to 
infections (standardized mortality ratio (SMR) 4.97, 95%CI 3.98-6.14), 
primary tumour progression (SMR=6.96, 95%CI 4.45-10.3) and endocrine 
complications (SMR=2.79, 95%CI 1.30-5.23) were increased (17). Van 
Bunderen et al. (N=2229; median rhGH treatment of 5.7 yr) reported an 
increase in cardiovascular-related deaths in GHD-treated women (SMR 2.36) 
(11). This was not supported by the other long-term studies (17;22). 
In summary, there is evidence for a moderate increased mortality rate 
despite long-term rhGH replacement, especially in females. Differences 
in pituitary disease, hormone replacement- and radiation therapies may 
account for differences between studies. However, since long-term studies 
on mortality are scarce, at this moment, no firm conclusions on the safety 
of long-term rhGH replacement can be drawn.
SERIOUS ADVERSE EVENTS (SAES): Twelve studies reported SAEs 
during long-term rhGH treatment (n=9 from Göteborg) (4;6;7;9;13-
16;21;24;28). Since several studies described the same patient cohort, the 
total number of SAEs could not be extracted.
Malignancies: A total of 6 malignancy cases were reported in the GHD 
cohort of Göteborg: colonic carcinoma (N=1), prostate carcinoma (N=1), 
chronic lymphatic leukaemia (N=1), renal carcinoma (N=1), bladder 
carcinoma (N=1), and pulmonary carcinoma (N=1). In addition, 12 cases 
of de novo malignancies, not further specified, were reported (7;24). 
Cardiovascular events: Three cases of myocardial infarction (Göteborg, 
Van der Klaauw et al. (7)) were reported, of which two with fatal outcome. 
Five patients suffered from a CVA (Göteborg, Van der Klaauw et al. (7)), 
resulting in death in four cases, and one patient died from a subarachnoid 
hemorrhage (Göteborg). In addition, angina pectoris was reported (N=3) 
(Göteborg), and 1 patient died from a pulmonary embolism (Göteborg). 
In at least ten patients, new-onset DM2 was diagnosed (4 Göteborg, 6 
KIMS (24)). In, respectively, 6 and 4 patients new-onset hyperlipidaemia 
and hypertension were reported (Göteborg, (28)).
Other SAEs: Two studies reported primary tumour growth (N=11), 
either recurrence of the pituitary or central nervous system tumour (7;24).
In conclusion, half of the studies reported SAEs during rhGH therapy. 
Due to the lack of a control group including non-treated GHD patients, 
no firm conclusions can be drawn.
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DISCUSSION
The short-term effects of rhGH treatment are well-established, showing 
favourable effects of rhGH therapy within the first 3 years on body 
composition, lipid profile, bone turnover, BMD, muscle strength, 
cognitive function, and QoL. This is the first systematic review focusing 
on the long-term effects of rhGH treatment (beyond ≥5 years of 
treatment). Overall, long-term rhGH therapy beneficially affected QoL 
and BMD. In addition, sustained beneficial effects were reported on lipid 
spectrum and on carotid IMT after 10 years of treatment. Consistent 
effects on body composition were reported with an increased LBM and 
a decreased total BF. Muscle strength increased after 5 years of rhGH 
suppletion, but these effects were not sustained during longer follow-up. 
Negative effects were reported on mean glucose levels; however, insulin 
sensitivity appeared not to be affected by long-term rhGH treatment. 
The effects of rhGH replacement on bone turnover, and thus on 
BMD, are dynamic over time. Initially, BMD decreases due to increased 
bone resorption and formation, followed by an increase within the first 
years of treatment, finally resulting in a plateau phase. The five studies 
addressing this topic showed a significant increase within the first 5 years 
of treatment. Thereafter, BMD was conserved but did not further increase 
(4;9;10). Only one study described the number of symptomatic fractures 
(4), however, without radiographic assessment of the vertebral column. As 
a consequence, the reported fracture rate is most probably underestimated, 
since 21% of the fractures in patients with osteopenia or osteoporosis are 
asymptomatic (34). Fracture incidence was also studied by Holmer et al. 
(35), but a considerable proportion of patients were treated <5 years. In 
CO-GHD women, not in AO-GHD women or CO-GHD men, fracture 
risk was doubled,  and in men with AO-GHD fracture incidence was 
even decreased (35). Further research has to establish the efficacy of rhGH 
treatment with respect to fracture risk.
Presently, in clinical practice, QoL is the most frequently addressed 
outcome parameter, but in the long-term, QoL was studied only in 
four studies (5;23-25). The two largest studies (KIMS database) showed 
improvement within the first year of treatment, with thereafter steady 
progress towards the country-specific mean (i.e. normalization) (5;24). 
The other two studies found ongoing beneficial effects on energy level and 
emotional reaction (23;25). Unfortunately, none of these studies had a 
placebo-controlled randomized controlled design. Thus, based on current 
literature, long-term effects on QoL are inconclusive, and therefore, in daily 
clinical practice, QoL should be individually evaluated in each patient. 
With respect to plasma lipids, seven out of ten studies investigating the 
long-term effects of rhGH replacement on the lipid profile report ongoing 
beneficial effects, with a reduction of TC and LDL-C levels, an increase 
in HDL-C and no effect on triglycerides. However, in this respect, a 
strong limitation is the lack of data concerning lipid-lowering treatment, 
prohibiting to draw firm conclusions on this outcome parameter. When 
comparing these long-term results to short-term studies on plasma lipids, 
it has be noted that there were also several (randomized controlled) short-
term studies reporting no change or minimal effects on lipid levels, and 
that even these effects were limited to men (36;37). Overall, however, 
as shown in a meta-analysis of Maison et al. investigating 37 placebo-
controlled randomized controlled studies (follow-up up to 18 months), 
rhGH replacement was shown to improve LDL-C and TC levels in the 
short term (3). 
Concerning the safety of rhGH suppletion, in children, long-term 
safety data have shown conflicting data, raising the question whether 
long-term use of rhGH is safe. Several large studies did not find an 
increased mortality in paediatric GHD patients after rhGH replacement, 
especially not due to new-onset malignancies or recurrence of central 
nervous system tumors. Cause of death was assessed as unrelated to rhGH 
replacement in the majority of patients (38-42). In contrast, a recent 
study of Carel et al. showed an increased incidence in bone tumor-related 
mortality and mortality due to cardiovascular diseases in a large cohort 
of French children, especially in those with highest GH doses (>50µg/
kg/day) (43). Cancer mortality was also increased in a large paediatric 
UK cohort, especially in high-risk patients (44). Moreover, Bell et al. 
reported an increase in the occurrence of second tumors in children 
with a prior history of malignancy, especially in case of prior exposure to 
radiotherapy (38). These discrepant results could be possibly explained 
by the different dosage regime, with higher GH doses in the French 
study. A recent meta-analysis underlines this hypothesis, establishing that 
both low and high IGF-1 levels are associated with increased mortality 
(hazard ratio (HR) 1.18, 95%CI 1.04-1.34) (45). Adult studies did 
not show an increased mortality or malignancy rate (11;22), except for 
one study showing moderate increase in overall mortality in females 
(17). However, the studies do not represent unselected patients, as 
initiation of rhGH replacement is not likely in patients with an a priori 
increased cancer risk, thus creating a clear selection bias. With respect to 
cardiovascular outcomes, an increase in cardiovascular deaths and number 
of CVAs was reported in women, whereas the myocardial infarction rate 
decreased (11;17;22). The increased incidence in cardiovascular deaths in 
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women might partly be attributed to the more atypical presentation of 
cardiovascular diseases in women (46). Other factors such as inadequately 
substituted hypogonadism causing preterm menopause or hypocortisolism 
may also have influenced this risk. In this respect, it has to be noted that 
available data suggest that both mortality risk and the causes for mortality 
are related in both patients receiving and those not receiving rhGH 
replacement. However, it is of paramount importance to accentuate that 
all observed increased mortality rates reported to date have been associated 
only with the presence of hypopituitarism per se, but that it is still 
uncertain if, and to what extent, this can be attributed to GHD. 
We assessed the methodological quality of all studies using a modified 
STROBE list (12), classifying 21 of the 23 included studies as having 
a good or excellent methodological quality. Several quality criteria were 
not clearly described; specifically, information on potential bias, handling 
with missing data and reasons for dropout was lacking in most studies. In 
addition, the use of co-medication, especially lipid-lowering and anti-
diabetic drugs, was not clearly reported. It is of importance to emphasize 
this limitation, because the effects of rhGH therapy on lipid profile, 
glucose levels and other cardiovascular parameters could not be interpreted 
without this information. In addition, no RCTs were identified with a 
follow-up duration >5 years and only a limited number of centres have 
reported their data, with half of the long-term studies describing (part of ) 
the same patient cohort (Göteborg). Other studies were relatively small 
and might have been, therefore, underpowered to allow firm conclusions. 
Due to these limitations, we were not able to perform a meta-analysis.
Another limitation is the report of outcomes only for patients that had 
completed 5 or 10-years of follow-up, instead of describing the original cohort. 
This may introduce a significant selection bias, since patients discontinued 
rhGH therapy for specific reasons, and, therefore, are likely to differ from 
patients with complete follow-up. Furthermore, a major limitation of most 
studies is the lack of a control group and thereby the lack of control for ageing. 
This limitation is important to notice when interpreting the long-term effects 
of rhGH replacement on for example body weight, BMI, blood pressure, lipid 
profile, body composition and BMD (47-49). Consequently, it is very difficult 
to discriminate between effects as a consequence of natural ageing processes 
and effects by rhGH replacement per se. Firm conclusions on the effects of 
rhGH per se can therefore not be drawn from present results. Another feature 
that needs to be addressed is the change in patient characteristics and approach 
to rhGH suppletion over time, which may represent an important confounder 
for any analysis (50). This emphasizes the need of ongoing monitoring during 
rhGH treatment.
In summary, available literature on long-term rhGH replacement in adult 
GHD patients shows inconsistent results with respect to its expected 
beneficial effects, in the presence of several drawbacks to enable a definite 
interpretation. First, long-term studies were generally uncontrolled 
and lacked a control group (of non-treated GHD patients) enabling 
adjustment for subjective changes or changes due to ageing. Second, 
only a limited number of centres have reported their data, resulting in 
a low number of evaluable patients with a follow-up duration of ≥5 
years of rhGH replacement with half of the long-term studies describing 
(part of ) the same patient cohort. Especially the course of QoL during 
ongoing therapy is unestablished. With respect to the metabolic profile, 
rhGH therapy has shown prolonged, beneficial effects on the long-
term for body composition, lipid profile, carotid IMT and BMD, but 
overall cardiovascular risk, as assessed by the prevalence of the metabolic 
syndrome, glucose levels, BMI appeared not to be influenced or were even 
negatively affected. Therefore, the benefit of long-term rhGH treatment 
should be a matter of ongoing research to enable adequate risk-benefit 
analyses and, in clinical daily practice, the benefits of rhGH should be 
considered carefully in each patient.
Pathophysiology of the GH/IGF-1 axis: Long-term consequences on joints and bone232 X. Therapy of Endocrine Disease Long-term effects of recombinant human Growth Hormone (rhGH) 
replacement in adults with Growth Hormone Deficiency (GHD): a systematic review
233
REFERENCE LIST
1. Rosen T, Bengtsson BA. Premature 
mortality due to cardiovascular disease 
in hypopituitarism. Lancet 1990; 
336(8710):285-288.
2. Tomlinson JW, Holden N, Hills RK et al. 
Association between premature mortality 
and hypopituitarism. West Midlands 
Prospective Hypopituitary Study Group. 
Lancet 2001; 357(9254):425-431.
3. Maison P, Griffin S, Nicoue-Beglah M, 
Haddad N, Balkau B, Chanson P. Impact 
of growth hormone (GH) treatment 
on cardiovascular risk factors in GH-
deficient adults: a Metaanalysis of Blinded, 
Randomized, Placebo-Controlled Trials. J 
Clin Endocrinol Metab 2004; 89(5):2192-
2199.
4. Elbornsson M, Gotherstrom G, Bosaeus I, 
Bengtsson BA, Johannsson G, Svensson J. 
Fifteen years of GH replacement increases 
bone mineral density in hypopituitary 
patients with adult-onset GH deficiency. 
Eur J Endocrinol 2012; 166(5):787-795.
5. Koltowska-Haggstrom M, Mattsson AF, 
Monson JP et al. Does long-term GH 
replacement therapy in hypopituitary 
adults with GH deficiency normalise 
quality of life? Eur J Endocrinol 2006; 
155(1):109-119.
6. Gotherstrom G, Bengtsson BA, Bosaeus 
I, Johannsson G, Svensson J. A 10-year, 
prospective study of the metabolic effects 
of growth hormone replacement in adults. 
J Clin Endocrinol Metab 2007; 92(4):1442-
1445.
7. van der Klaauw AA, Romijn JA, Biermasz 
NR et al. Sustained effects of recombinant 
GH replacement after 7 years of 
treatment in adults with GH deficiency. 
Eur J Endocrinol 2006; 155(5):701-708.
8. Biermasz NR, Hamdy NA, Pereira AM, 
Romijn JA, Roelfsema F. Long-term 
skeletal effects of recombinant human 
growth hormone (rhGH) alone and 
rhGH combined with alendronate in 
GH-deficient adults: a seven-year follow-
up study. Clin Endocrinol (Oxf) 2004; 
60(5):568-575.
9. Gotherstrom G, Svensson J, Koranyi J 
et al. A prospective study of 5 years 
of GH replacement therapy in GH-
deficient adults: sustained effects on body 
composition, bone mass, and metabolic 
indices. J Clin Endocrinol Metab 2001; 
86(10):4657-4665.
10. Gotherstrom G, Bengtsson BA, Bosaeus 
I, Johannsson G, Svensson J. Ten-year 
GH replacement increases bone mineral 
density in hypopituitary patients with adult 
onset GH deficiency. Eur J Endocrinol 
2007; 156(1):55-64.
11. van Bunderen CC, van N, I, Arwert LI et 
al. Does growth hormone replacement 
therapy reduce mortality in adults with 
growth hormone deficiency? Data from 
the Dutch National Registry of Growth 
Hormone Treatment in adults. J Clin 
Endocrinol Metab 2011; 96(10):3151-
3159.
12. von Elm E, Altman DG, Egger M, Pocock 
SJ, Gotzsche PC, Vandenbroucke JP. 
The Strengthening the Reporting of 
Observational Studies in Epidemiology 
(STROBE) statement: guidelines for 
reporting observational studies. J Clin 
Epidemiol 2008; 61(4):344-349.
13. Gotherstrom G, Bengtsson BA, 
Sunnerhagen KS, Johannsson G, Svensson 
J. The effects of five-year growth hormone 
replacement therapy on muscle strength 
in elderly hypopituitary patients. Clin 
Endocrinol (Oxf) 2005; 62(1):105-113.
14. Gotherstrom G, Elbornsson M, Stibrant-
Sunnerhagen K, Bengtsson BA, Johannsson 
G, Svensson J. Ten years of growth 
hormone (GH) replacement normalizes 
muscle strength in GH-deficient adults. J 
Clin Endocrinol Metab 2009; 94(3):809-
816.
15. Gotherstrom G, Elbornsson M, Stibrant-
Sunnerhagen K, Bengtsson BA, Johannsson 
G, Svensson J. Muscle strength in elderly 
adults with GH deficiency after 10 years 
of GH replacement. Eur J Endocrinol 
2010; 163(2):207-215.
16. Svensson J, Sunnerhagen KS, Johannsson 
G. Five years of growth hormone 
replacement therapy in adults: age- and 
gender-related changes in isometric 
and isokinetic muscle strength. J Clin 
Endocrinol Metab 2003; 88(5):2061-2069.
17. Gaillard RC, Mattsson AF, Akerblad AC et 
al. Overall and cause-specific mortality in 
GH-deficient adults on GH replacement. 
Eur J Endocrinol 2012; 166(6):1069-1077.
18. Clanget C, Seck T, Hinke V, Wuster C, 
Ziegler R, Pfeilschifter J. Effects of 6 years 
of growth hormone (GH) treatment on 
bone mineral density in GH-deficient 
adults. Clin Endocrinol (Oxf) 2001; 
55(1):93-99.
19. Giavoli C, Porretti S, Ronchi CL et al. 
Long-term monitoring of insulin sensitivity 
in growth hormone-deficient adults on 
substitutive recombinant human growth 
hormone therapy. Metabolism 2004; 
53(6):740-743.
20. van der Klaauw AA, Biermasz NR, Feskens 
EJ et al. The prevalence of the metabolic 
syndrome is increased in patients with 
GH deficiency, irrespective of long-term 
substitution with recombinant human GH. 
Eur J Endocrinol 2007; 156(4):455-462.
21. Svensson J, Fowelin J, Landin K, Bengtsson 
BA, Johansson JO. Effects of seven years 
of GH-replacement therapy on insulin 
sensitivity in GH-deficient adults. J Clin 
Endocrinol Metab 2002; 87(5):2121-2127.
22. Svensson J, Bengtsson BA, Rosen T, Oden 
A, Johannsson G. Malignant disease and 
cardiovascular morbidity in hypopituitary 
adults with or without growth hormone 
replacement therapy. J Clin Endocrinol 
Metab 2004; 89(7):3306-3312.
23. Gibney J, Wallace JD, Spinks T et al. The 
effects of 10 years of recombinant human 
growth hormone (GH) in adult GH-
deficient patients. J Clin Endocrinol Metab 
1999; 84(8):2596-2602.
24. Spielhagen C, Schwahn C, Moller K et 
al. The benefit of long-term growth 
hormone (GH) replacement therapy in 
hypopituitary adults with GH deficiency: 
results of the German KIMS database. 
Growth Horm IGF Res 2011; 21(1):1-10.
25. Gilchrist FJ, Murray RD, Shalet SM. The 
effect of long-term untreated growth 
hormone deficiency (GHD) and 9 years 
of GH replacement on the quality of 
life (QoL) of GH-deficient adults. Clin 
Endocrinol (Oxf) 2002; 57(3):363-370.
26. Roemmler J, Kuenkler M, Schneider HJ, 
Dieterle C, Schopohl J. Comparison of 
glucose and lipid metabolism and bone 
mineralization in patients with growth 
hormone deficiency with and without 
long-term growth hormone replacement. 
Metabolism 2010; 59(3):350-358.
27. Cenci MC, Conceicao FL, Soares DV et 
al. Impact of 5 years of growth hormone 
replacement therapy on cardiovascular 
risk factors in growth hormone-deficient 
adults. Metabolism 2008; 57(1):121-129.
28. Chrisoulidou A, Beshyah SA, Rutherford 
O et al. Effects of 7 years of growth 
hormone replacement therapy in 
hypopituitary adults. J Clin Endocrinol 
Metab 2000; 85(10):3762-3769.
29. Henche SA, Torres RR, Pellico LG. An 
evaluation of patterns of change in total 
and regional body fat mass in healthy 
Spanish subjects using dual-energy X-ray 
absorptiometry (DXA). Eur J Clin Nutr 
2008; 62(12):1440-1448.
30. Salomon F, Cuneo RC, Hesp R, Sonksen 
PH. The effects of treatment with 
recombinant human growth hormone 
on body composition and metabolism in 
adults with growth hormone deficiency. N 
Engl J Med 1989; 321(26):1797-1803.
31. Moller J, Jorgensen JO, Moller N, Hansen 
KW, Pedersen EB, Christiansen JS. 
Expansion of extracellular volume and 
suppression of atrial natriuretic peptide 
after growth hormone administration 
in normal man. J Clin Endocrinol Metab 
1991; 72(4):768-772.
32. Moller J, Moller N, Frandsen E, Wolthers 
T, Jorgensen JO, Christiansen JS. Blockade 
of the renin-angiotensin-aldosterone 
system prevents growth hormone-induced 
fluid retention in humans. Am J Physiol 
1997; 272(5 Pt 1):E803-E808.
33. Janssen YJ, Deurenberg P, Roelfsema 
F. Using dilution techniques and 
multifrequency bioelectrical impedance 
to assess both total body water and 
extracellular water at baseline and during 
recombinant human growth hormone 
(GH) treatment in GH-deficient adults. J 
Clin Endocrinol Metab 1997; 82(10):3349-
3355.
34. Netelenbos JC, Lems WF, Geusens PP 
et al. Spine radiographs to improve the 
identification of women at high risk 
for fractures. Osteoporos Int 2009; 
20(8):1347-1352.
35. Holmer H, Svensson J, Rylander L et 
al. Fracture incidence in GH-deficient 
patients on complete hormone 
replacement including GH. J Bone Miner 
Res 2007; 22(12):1842-1850.
36. Sesmilo G, Biller BM, Llevadot J et al. 
Effects of growth hormone administration 
on inflammatory and other cardiovascular 
risk markers in men with growth hormone 
deficiency. A randomized, controlled 
clinical trial. Ann Intern Med 2000; 
133(2):111-122.
37. Hoffman AR, Biller BM, Cook D et al. 
Efficacy of a long-acting growth hormone 
(GH) preparation in patients with adult 
GH deficiency. J Clin Endocrinol Metab 
2005; 90(12):6431-6440.
38. Bell J, Parker KL, Swinford RD, Hoffman 
AR, Maneatis T, Lippe B. Long-term safety 
of recombinant human growth hormone 
in children. J Clin Endocrinol Metab 2010; 
95(1):167-177.
39. Ogilvy-Stuart AL, Gleeson H. Cancer 
risk following growth hormone use 
in childhood: implications for current 
practice. Drug Saf 2004; 27(6):369-382.
Pathophysiology of the GH/IGF-1 axis: Long-term consequences on joints and bone234 X. Therapy of Endocrine Disease Long-term effects of recombinant human Growth Hormone (rhGH) 
replacement in adults with Growth Hormone Deficiency (GHD): a systematic review
235
40. Savendahl L, Maes M, bertsson-Wikland 
K et al. Long-term mortality and causes 
of death in isolated GHD, ISS, and SGA 
patients treated with recombinant growth 
hormone during childhood in Belgium, 
The Netherlands, and Sweden: preliminary 
report of 3 countries participating in the 
EU SAGhE study. J Clin Endocrinol Metab 
2012; 97(2):E213-E217.
41. Sklar CA, Mertens AC, Mitby P et al. 
Risk of disease recurrence and second 
neoplasms in survivors of childhood 
cancer treated with growth hormone: 
a report from the Childhood Cancer 
Survivor Study. J Clin Endocrinol Metab 
2002; 87(7):3136-3141.
42. Taback SP, Dean HJ. Mortality in Canadian 
children with growth hormone (GH) 
deficiency receiving GH therapy 1967-
1992. The Canadian Growth Hormone 
Advisory Committee. J Clin Endocrinol 
Metab 1996; 81(5):1693-1696.
43. Carel JC, Ecosse E, Landier F et al. Long-
term mortality after recombinant growth 
hormone treatment for isolated growth 
hormone deficiency or childhood short 
stature: preliminary report of the French 
SAGhE study. J Clin Endocrinol Metab 
2012; 97(2):416-425.
44. Swerdlow AJ, Higgins CD, Adlard P, Preece 
MA. Risk of cancer in patients treated 
with human pituitary growth hormone in 
the UK, 1959-85: a cohort study. Lancet 
2002; 360(9329):273-277.
45. Burgers AM, Biermasz NR, Schoones JW 
et al. Meta-analysis and dose-response 
metaregression: circulating insulin-like 
growth factor I (IGF-I) and mortality. J Clin 
Endocrinol Metab 2011; 96(9):2912-2920.
46. Dey S, Flather MD, Devlin G et al. Sex-
related differences in the presentation, 
treatment and outcomes among patients 
with acute coronary syndromes: the 
Global Registry of Acute Coronary Events. 
Heart 2009; 95(1):20-26.
47. Ettinger WH, Wahl PW, Kuller LH et al. 
Lipoprotein lipids in older people. Results 
from the Cardiovascular Health Study. 
The CHS Collaborative Research Group. 
Circulation 1992; 86(3):858-869.
48. Nooyens AC, Visscher TL, Verschuren 
WM et al. Age, period and cohort effects 
on body weight and body mass index in 
adults: The Doetinchem Cohort Study. 
Public Health Nutr 2009; 12(6):862-870.
49. Franklin SS, Gustin W, Wong ND et 
al. Hemodynamic patterns of age-
related changes in blood pressure. The 
Framingham Heart Study. Circulation 
1997; 96(1):308-315.
50. Kreitschmann-Andermahr I, Siegel S, 
Francis F et al. Variation of the baseline 
characteristics and treatment parameters 
over time: an analysis of 15 years of 
growth hormone replacement in adults 
in the German KIMS database. Pituitary 
2012.
APPENDIX 1. 
Search strategy used for systematic literature search
The following combined key words were used: ((“recombinant growth hormone” OR 
“recombinant growth hormones” OR “recombinant human growth hormone” OR “recombinant 
human growth hormones” OR “r-hGH” OR ((“Growth Hormone”[mesh] OR “growth 
hormone” OR “growth hormones” OR Somatotropin OR Somatotropins OR Somatropin OR 
hGH OR Serostim OR Zomacton OR “Cryo-Tropin” OR “Cryo Tropin” OR CryoTropin OR 
“r-hGH-M” OR Humatrope OR Umatrope OR Maxomat OR Norditropin OR Norditropine OR 
Nutropin OR Omnitrope OR Saizen OR Genotropin OR Genotonorm) AND (“Recombinant 
Proteins”[mesh] OR recombinant[tw]))) AND (“long term effects” OR “long term effect” OR 
“longterm effects” OR “longterm effect” OR longterm OR “long term” OR ((“Twenty years” OR 
“Twenty year” OR “20 years” OR “20 year” OR “Nineteen years” OR “Nineteen year” OR “19 
years” OR “19 year” OR “Eighteen years” OR “Eighteen year” OR “18 years” OR “18 year” 
OR “Seventeen years” OR “Seventeen year” OR “17 years” OR “17 year” OR “Sixteen years” 
OR “Sixteen year” OR “16 years” OR “16 year” OR “Fifteen years” OR “Fifteen year” OR “15 
years” OR “15 year” OR “Fourteen years” OR “Fourteen year” OR “14 years” OR “14 year” 
OR “Thirteen years” OR “Thirteen year” OR “13 years” OR “13 year” OR “Twelve years” OR 
“Twelve year” OR “12 years” OR “12 year” OR “Eleven years” OR “Eleven year” OR “11 years” 
OR “11 year” OR “Ten years” OR “Ten year” OR “10 years” OR “10 year” OR “Nine years” 
OR “Nine year” OR “9 years” OR “9 year” OR “Eight years” OR “Eight year” OR “8 years” OR 
“8 year” OR “Seven years” OR “Seven year” OR “7 years” OR “7 year”) AND (effect[tiab] OR 
effects[tiab] OR outcome OR outcomes))) AND (adult OR adults)) OR ((“recombinant growth 
hormone” OR “recombinant growth hormones” OR “recombinant human growth hormone” OR 
“recombinant human growth hormones” OR “r-hGH” OR ((“Growth Hormone”[mesh] OR 
“growth hormone” OR “growth hormones” OR Somatotropin OR Somatotropins OR Somatropin 
OR hGH OR Serostim OR Zomacton OR “Cryo-Tropin” OR “Cryo Tropin” OR CryoTropin OR 
“r-hGH-M” OR Humatrope OR Umatrope OR Maxomat OR Norditropin OR Norditropine OR 
Nutropin OR Omnitrope OR Saizen OR Genotropin OR Genotonorm) AND (“Recombinant 
Proteins”[mesh] OR recombinant[tw]))) AND (“long term effects” OR “long term effect” OR 
“longterm effects” OR “longterm effect” OR longterm OR “long term” OR ((“Twenty years” OR 
“Twenty year” OR “20 years” OR “20 year” OR “Nineteen years” OR “Nineteen year” OR “19 
years” OR “19 year” OR “Eighteen years” OR “Eighteen year” OR “18 years” OR “18 year” 
OR “Seventeen years” OR “Seventeen year” OR “17 years” OR “17 year” OR “Sixteen years” 
OR “Sixteen year” OR “16 years” OR “16 year” OR “Fifteen years” OR “Fifteen year” OR “15 
years” OR “15 year” OR “Fourteen years” OR “Fourteen year” OR “14 years” OR “14 year” OR 
“Thirteen years” OR “Thirteen year” OR “13 years” OR “13 year” OR “Twelve years” OR “Twelve 
year” OR “12 years” OR “12 year” OR “Eleven years” OR “Eleven year” OR “11 years” OR “11 
year” OR “Ten years” OR “Ten year” OR “10 years” OR “10 year” OR “Nine years” OR “Nine 
year” OR “9 years” OR “9 year” OR “Eight years” OR “Eight year” OR “8 years” OR “8 year” OR 
“Seven years” OR “Seven year” OR “7 years” OR “7 year”) AND (effect[tiab] OR effects[tiab] OR 
outcome OR outcomes))) NOT (“child”[mesh] NOT “Adult”[mesh])) NOT (“Animals”[mesh] 
NOT “Humans”[mesh]).
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APPENDIX 2. 
List of criteria used for methodological quality 
assessment, modif ied STROBE statement
Item Criterion
1. Clear presentation of key elements of study design.
2. Description of setting, locations, relevant dates including periods of recruitment, 
exposure, follow-up, and data collection.
3. Description of eligibility criteria, and the sources and methods of selection of 
participants.
   i) Description of methods of follow-up (cohort study)
   ii) Rationale for the choice of cases and controls (case-control study)
4. Clear definition of all outcomes, exposures, predictors, potential confounders.
5. Description of any effects to address potential sources of bias.
6. Clear description of statistical methods and handling with missing data.
7. Report of reasons of non-participation at each stage of the study (for example, flow 
diagram).
8. Clear description of characteristics of study participants.
9. Clear description of follow-up time.
10. Presentation of unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (i.e. 95% confidence interval). 
APPENDIX 3. 
Mean serum IGF-1 levels and IGF-1 SDS at start of 
rhGH suppletion and during follow-up, specif ied per 
study
Study(ref ) Baseline 1yr 5yr 7yr 10yr 15yr
Götherström 2010(16)
IGF-1 ug/l
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Data are presented as mean (SD), unless specified otherwise.  
IGF-1, insulin-like growth; NR, not reported; R, range; M, males; F, females
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ABSTRACT
BACKGROUND: The metabolic effects of recombinant human GH 
(rhGH) therapy in adults are well-documented in the short term. 
The effects of long-term rhGH therapy beyond 5 years on metabolic 
parameters are presently unknown. 
OBJECTIVE: The aim of the study was to evaluate the long-term effects of 
rhGH treatment on biochemical and anthropometric parameters in a large 
cohort of GH-deficient adults.
METHODS: Ninety-eight adult GH-deficient patients treated with rhGH 
for at least 10 years were included (mean age 59.4 years, 50% female). 
Total cholesterol, high-density lipoprotein cholesterol, low-density 
lipoprotein cholesterol, triglycerides, anthropometric parameters, IGF-1, 
and glucose were evaluated at baseline, and after 5, 10 and 15 years of 
treatment. In addition, the prevalence of the metabolic syndrome (MS) 
and the incidence of cardiovascular events were assessed. 
RESULTS: Total cholesterol and low-density lipoprotein cholesterol 
concentrations were lower, and high-density lipoprotein cholesterol levels 
were significantly higher during long-term rhGH replacement when 
compared to baseline (all p<0.001). Both waist circumference (p<0.001) 
and BMI (p=0.018) were significantly higher after 10 years, as were fasting 
plasma glucose levels (p<0.001). No significant changes were observed 
in triglycerides, waist-to-hip ratio and blood pressure during follow-up. 
In the subset of patients with 15-yr rhGH treatment (N=43), generally 
similar metabolic effects were found. MS prevalence was increased after 10 
years of rhGH treatment (57.1% vs 32.7%, p<0.001), especially in males 
(69.4% vs 32.7%, p<0.001). 
CONCLUSION: Despite improvement of several cardiovascular risk 
factors, MS prevalence increased significantly during rhGH treatment. The 
effect of long-term rhGH treatment on overall cardiovascular risk profile 
needs to be established in a larger cohort. 
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INTRODUCTION
Recombinant human GH (rhGH) replacement therapy has been a 
regular treatment option for adult GH-deficient (GHD) patients since 
the nineties. Adult GHD is hypothesized to be a cardiovascular risk 
factor associated with increased mortality, by inducing abdominal obesity, 
hypercholesterolemia, and hypertriglyceridemia (1;2). In short-term 
studies, GH replacement reduces some, but not all of these cardiovascular 
risk factors (3). Consistent ‘short-term’ effects on body composition 
and lipid metabolism were documented, resulting in reduction of body 
fat combined with an increase of fat-free mass, and a reduction of total 
cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels 
(3). In addition, favorable effects on bone mineral density (BMD) and 
quality of life (QoL) have been reported (3-6). 
Sustained improvement of lipid spectrum and diastolic blood pressure 
(DBP) has been reported over 7-10 years (7-9). However, despite a 
significant improvement of some, but not all, individual cardiovascular 
risk factors, overall cardiovascular risk profile, as reflected by the prevalence 
of the metabolic syndrome (MS), was still increased when compared 
with the general population and was not affected by rhGH after 5 years 
of treatment (10). Moreover, a recent study reported an increased risk of 
cardiovascular death in GHD women treated with rhGH when compared 
with background population (11). 
A recent review addressing the effects of rhGH replacement in elderly 
patients (>60 years old) with GHD, revealed that rhGH replacement 
decreases LDL-C levels and improves QoL, but the effects on other 
parameters were not unequivocal (12). However, sufficient data 
concerning the use of long-term rhGH therapy in elderly are currently 
unavailable, as is the case in younger patients. In view of the overall scarce 
documentation of cardiovascular effects over 10 years (8;13;14), the 
efficacy of ongoing rhGH therapy in reducing cardiovascular risk in adult 
GHD still has to be established. 
Therefore, the aim of this study was to evaluate the long-term effects of 
rhGH treatment on biochemical and anthropometric parameters in a large 
cohort of GHD adults that were treated with rhGH for at least 10 years. 
PATIENTS AND METHODS
PATIENTS: Since 1994, consecutive patients diagnosed with GHD at 
the Endocrinology Department of the Leiden University Medical Center 
were collected in a database, including both adult-onset (AO) and 
childhood-onset (CO) GHD. Severe GHD had been defined prior to 
start of treatment by a GH peak response to the Insulin Tolerance Test 
(ITT) <3µg/l (glucose nadir<2.2mmol/l) or Growth Hormone Releasing 
Hormone/Arginine-test (GHRH/Arg) (with body mass index (BMI)-
adjusted GH cut-offs) in case of contraindications for ITT, according to 
guidelines (10;15). All patients with rhGH treatment during childhood 
were retested at time of transition to the adult outpatient clinic, after 
treatment cessation for more than 3 months. After dose titration, aiming 
at an IGF-1 level in the normal range, patients were evaluated at least 
yearly at the outpatient clinic according to a standard protocol.
For the present analysis, we selected patients who started with rhGH 
treatment in 2002 or before (N=184). Exclusion criteria were: 1) rhGH 
treatment duration less than 10 years; 2) cessation for at least 2 years; 
3) more than 3 missing visits. Part of this GHD cohort used for present 
analysis was previously described (9;10;16;17).
TREATMENT PROTOCOL: All patients were treated with s.c. injections of 
rhGH (Genotropin Pharmacia/Pfizer, Zomacton Ferring, or Norditropin 
NovoNordisk) injected in the evening. The initial dose of rhGH was 0.2mg/
day, which was individually adjusted each month in the first half year to 
achieve serum IGF-1 concentrations within the age-dependent laboratory 
reference range, aimed at an SD score (SDS) between 0 and +2. When stable 
plasma concentrations were reached, this individualized dose was continued 
and adjusted as necessary. ACTH deficiency was defined as an insufficient 
increase in cortisol levels (absolute value 0.55mmol/l) after a CRH stimulation 
test or ITT. When secondary amenorrhea was present for more than 1year, 
premenopausal women were classified as gonadotropin deficient. In men, 
gonadotropin deficiency was defined as a testosterone level below the reference 
range (8.0nmol/l). TSH deficiency was defined as total T4 or free T4 level 
below the reference range (<10pmol/l). Hypopituitarism was supplemented 
by hydrocortisone, l-T4, testosterone in men, and estrogen in combination 
with prostagens in premenopausal women only. Dosages were monitored 
and adjusted as required. Thyroid hormone replacement, lipid-lowering 
medication and antihypertensive medication were started according to the 
discretion of the attending physicians. 
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EFFICACY PARAMETERS: The following efficacy parameters were assessed 
at baseline and at the yearly visits at the outpatient clinic:
I. Biochemical parameters: levels of glucose, TC, high-density lipoprotein 
cholesterol (HDL-C), and triglycerides (TG) after an overnight fast. 
LDL-C concentrations were calculated using the Friedewald formula. 
II. Anthropometric parameters: body weight and height, waist circumference, 
hip circumference, systolic and diastolic blood pressures (SBP and DBP, 
respectively) were measured. BMI and waist-to-hip (WH) ratio were 
calculated. Body weight was measured to the nearest 0.1kg, and body 
height was measured barefoot to the nearest 0.001m. The BMI was 
calculated as weight in kilograms divided by the square of height in 
meters. 
III.  Additional information with respect to medication use, co-morbidity and 
possible side effects and adverse events was gathered from patient records.
For the present study, we analyzed the efficacy parameters at baseline and 
after 5, 10 and 15 years of rhGH therapy.
METABOLIC SYNDROME: The MS was defined according to the updated 
third report of the 2006 National Cholesterol Education Program’s Adult 
Treatment Panel (NCEP-ATP III) criteria, which required at least three of 
the following conditions (18;19): 
1. Fasting plasma glucose concentration of at least 100mg/dl or on anti-
diabetic drug treatment;
2. TG concentration of at least 150mg/dl or on drug treatment;
3. HDL-C concentration below 40mg/dl in men and below 50mg/dl in 
women, or on drug treatment;
4. Blood pressure of at least 130/85mmHg or on antihypertensive treatment
5. Waist circumference greater than 102cm in men and greater than 88cm in 
women.
ASSAYS: Serum GH was measured with a sensitive IFMA (Wallac, Turku, 
Finland), specific for the 22 kDA GH protein (detection limit: 0.01µg/
l,interassay coefficient of variation (CV): 1.6-8.4% of 0.01-15.4µg/l) from 
1992 onwards. For the conversion of µg/l to mU/l, multiply by 2.6. Before 
1992, GH was measured by RIA (Biolab, Serona, Coissins, Switzerland), 
detection limit: 0.5mU/l, with an interassay CV<5%; for the conversion 
of µg/l to mU/l, multiply by 2.
From 1986 to 2005, serum IGF-1 concentrations were determined 
by RIA (Incstar, Stillwater, MN) with a detection limit of 1.5nmol/l 
and an interassay CV less than 11%. IGF-1 is expressed as SD score for 
age- and sex-related normal levels determined in the same laboratory 
(20). Since 2005, serum IGF-1 concentrations (nmol/l) were measured 
using an immunometric technique on an Immulite 2500 system (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). The intra-assay variations at 
mean plasma levels of 8 and 75nmol/l were 5.0 and 7.5%. IGF-1 levels 
were expressed as SDS, using lambda-mu-sigma smoothed reference curves 
based on 906 controls (21;22). 
A Hitachi 747 autoanalyzer (Roche) was used to quantify serum 
concentrations of glucose, TC, and TG. HDL-C was measured with a 
homogenous enzymatic assay (Hitachi 911,Roche). In 2003, the Hitachi 
747 was replaced by a modular P800 with no change in the chemistry 
components.
STATISTICS: SPSS for Windows, Version 17.0 (SPSS, Inc., Chicago, IL, 
USA) was used for statistical analysis. Results are presented as mean±SD, 
unless stated otherwise. ANOVA repeated measurements with Bonferroni 
correction for multiple comparisons were used to compare biochemical 
and anthropometric parameters between baseline and after rhGH 
treatment. We incorporated age, sex, CO vs AO GHD, hydrocortisone 
use, radiotherapy and GH dose in a linear regression model to identify 
factors influencing the metabolic effects of long-term rhGH suppletion. 
The Friedman test for related fractions was used to assess the effect of 
rhGH treatment on the MS prevalence. Furthermore, we calculated 
the incidence rate of cardiovascular events (i.e. cardiovascular death, 
myocardial infarction, cerebrovascular attack, intermittent claudication, 
(progressive) angina pectoris or coronary bypass surgery, pulmonary 
embolism) during rhGH therapy. 
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RESULTS
A total of 184 adult patients with GHD started rhGH suppletion in 2002 
or before (Figure 1). Forty-two patients are on current rhGH treatment, 
but did not complete 10 years of treatment yet. Fourty-four patients 
discontinued rhGH treatment for various reasons (Figure 1). Reasons 
for preliminary discontinuation of rhGH treatment were: no subjective 
beneficial effect (N=10), death (N=9), tumor growth (N=7), malignancy 
(N=12), high age (N=1), new-onset diabetes mellitus type 2 (N=1), other 
(N=4). Consequently, we included 98 patients (50% female, mean age 
59.4yr) for the present analysis, of which 43 patients completed 15 years 
of rhGH therapy (44% female, mean age 61.3yr). Baseline characteristics 
are shown in Table 1. 
No differences were found between the patients with and without 
complete 10-yr ore more rhGH treatment, with respect to sex, BMI, 
age of start rhGH therapy, etiological diagnosis, surgery, radiotherapy, 
pituitary deficiencies, and use of lipid-lowering or antihypertensive 
medication. Only the number of patients with CO GHD was higher 
among non-completers (p=0.009) (data not shown). 
 




All adult GHD patients 
started with rhGH 
therapy in 2002 or 
before from LUMC 
N=184 
Exclusion N=86 
Patients which did not 
complete 10yr rhGH 
treatment 
Patients with complete 
10yr rhGH treatment 
N=98 
Patients with complete 
15yr rhGH treatment 
N=43 
Exclusion N=55 
Stop rhGH treatment 
<15yr N=13 
Continuous rhGH 
therapy, but <15yr N=42 
Reasons for discontinuation: 
No subjective beneficial 
effect N=4 
Malignancy N=6 
High PSA N=1 
CVA N=1 
Unknown N=1 
<10yr rhGH treatment N=42 
Reasons for discontinuation: 
No subjective beneficial 
effect N=10 
Death N=9 
Tumor growth N=7 
Malignancy N=12 
High age N=1 
New onset DM2 N=1 
Other N=4 
GH DOSE AND IGF-1 CONCENTRATION: Mean GH dose after 
dose titration (after 1yr) was 0.46±0.20mg/day (range 0.20-1.50mg), 
0.48±0.25mg/day (range 0.15-1.50mg) at 5yr. At 10 and 15 years mean 
GH doses were 0.44±0.26mg/day (range 0.10-1.50mg) and 0.39±0.21mg/
day (range 0.10-1.50mg), respectively (5-, 10- and 15-yr GH doses were 
not significantly different from the GH dose after dose titration). Serum 
IGF-1 levels remained significantly higher during rhGH replacement for 
the duration of the study up to 15 years compared with baseline (Table 2). 
During the entire study period, mean IGF-1 SDS was within the normal 
range, increased from -0.68±2.27 at baseline to 0.20±2.25 at 15 years of 
rhGH suppletion (Figure 2). In males, mean IGF-1 SDS was -0.24±2.26 
at baseline and increased to 0.21±2.31 at 15 years (p=0.007); in females, 
mean IGF-1 SDS increased from -1.13±2.17 at baseline to 0.19±2.25 after 
15 years of rhGH treatment (p<0.001). 
Figure 2. Mean IGF-1 SD scores during 15 years of rhGH therapy, for the total cohort of GHD 
patients (A, N=98) and separated for males (B) and females (C), respectively
Mean IGF-1 SD scores ± SD during rhGH treatment are presented for the total GHD cohort 
(N=98), and separately for male (N=49) and female patients (N=49). IGF-1 SD scores were 
evaluated at start of rhGH therapy, and after 2, 5, 7, 10, 12, and 15 years of rhGH suppletion. 
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Table 1. Baseline characteristics of  98 patients with GHD, 
which completed minimal 10 years of  rhGH replacement 
therapy
Patient characteristics GHD patients with complete 10yr 
follow-up (N=98)
Sex, female / male (n) 49 / 49
Age at start rhGH therapy, yr (range) 44.9 ± 13.6 (17 – 84)
AO / CO (n) 87 / 11 
BMI, kg/m2 (range) 28.2 ± 5.9 (16.9 – 45.4)
Etiological diagnosis of GHD (n)
   NFA
   Functioning adenoma
   Craniopharyngeoma
   Cerebral malignancy
   Congenital







Surgery, TS / TC (n) 53 / 24 
Radiotherapy (n) 37 
Pituitary deficiencies (n)
   TSH
   ACTH
   FSH/LH
   ADH






Lipid-lowering drugs (n) 10
Antihypertensive medication (n) 10
Data are presented as mean ± SD, unless specified otherwise. n, number of patients. 
GHD, growth hormone deficiency; rhGH, recombinant human growth hormone; AO, adult-onset 
GHD; CO, childhood-onset GHD; NFA, non-functioning adenoma; TSH, thyroid stimulating 
hormone; ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; LH, luteinizing 
hormone; ADH, anti-diuretic hormone
Table 2. Ef fects of  10 years of  rhGH replacement in 98 adults 
with GHD on biochemical and anthropometric parameters 
Baseline† 5 years of rhGH 
replacement††
10 years of rhGH 
replacement†††
IGF-1, nmol/l 14.8 ± 10.3 25.4 ± 13.3 * 22.2 ± 10.7 *
Fasting glucose, mmol/l 4.7 ± 0.8 5.0 ± 1.1 ** 5.1 ± 1.0 *
TC, mmol/l 6.2 ± 1.4 5.5 ± 1.0 * 5.2 ± 1.0 *, b
LDL-C, mmol/l 4.5 ± 1.4 3.7 ± 0.9 * 3.3 ± 0.8 *, a
HDL-C, mmol/l 1.3 ± 0.5 1.5 ± 0.5 * 1.6 ± 0.6 *
TG, mmol/l 1.8 ± 1.1 1.8 ± 1.0 1.8 ± 1.1
Waist circumference, cm 94.6 ± 13.7 97.0 ± 14.3 98.9 ± 14.2 *, a
WH ratio 0.95 ± 0.07 0.97 ± 0.12 0.96 ± 0.06
BMI, kg/m2 28.2 ± 5.9 28.8 ± 6.3 29.9 ± 6.9 ***, c
SBP, mmHg 129.9 ± 14.7 130.4 ± 17.8 130.9 ± 16.6
DBP, mmHg 83.5 ± 9.7 80.4 ± 9.8 ** 80.4 ± 9.1 ***
Data are presented as mean ± SD. IGF-1, insulin-like growth factor-1; TC, total cholesterol; LDL-C, 
low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; 
WH ratio, waist-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure. 
†, statins N=10 (10.2%), antihypertensive medication N=10 (10.2%); ††, statins N=32 (32.7%), 
antihypertensive medication N=32 (32.7%); †††, statins N=34 (34.7%), antihypertensive 
medication N=33 (33.7%)
*, p<0.001; **, p<0.01; ***, p<0.05 vs baseline  
a, p<0.001; b, p<0.01; c, p<0.05 10 vs 5 years of rhGH treatment 
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EFFECTS ON GLUCOSE, LIPID PROFILE , ANTHROPOMETRIC 
PARAMETERS AND BLOOD PRESSURE: Fasting plasma glucose levels 
significantly increased from 4.7±0.8mmol/l at baseline to 5.0±1.1mmol/l 
at 5 years (6% increase), thereafter remaining stable at 5.1±1.0mmol/l 
after 10 years rhGH treatment (Table 2) (p<0.001 vs baseline). TC 
and LDL-C concentrations decreased, and HDL-C levels increased 
significantly after 5 years when compared with baseline (all p<0.001), 
further improving after 10 years of rhGH treatment. Both waist 
circumference and BMI increased after 10 years of rhGH suppletion 
(p<0.001 and p=0.018, respectively). No significant changes were observed 
in TG, WH ratio and SBP; only DBP decreased slightly after 5 and 10 
years (p<0.01 and p=0.016, resp.). 
Among the subgroup of patients who completed 15 years of rhGH 
treatment (N=43), comparable significant effects of rhGH suppletion 
were found on fasting glucose levels, lipids and waist circumference 
(Table 3). The effects on TC, HDL-C, LDL-C and TG were not affected 
when patients using lipid-lowering medication at any time point during 
follow-up were excluded (N=41, 42%). TG, WH ratio, BMI and DBP 
did not change when compared to baseline; SBP was significantly higher 
(p=0.001). Within the 15-yr treated group, there were, in general, 
no differences between 10 and 15 years of rhGH therapy; except for 
SBP, being significantly higher after 15 years. Excluding patients on 
antihypertensive medication at any time point (N=41, 42%) revealed no 
changes in DBP; however, the observed increase in SBP between 10 and 
15 years of treatment was not significant any longer.
INFLUENCE OF SEX: The dose of rhGH was significantly higher in 
women in comparison to men at all time points, resulting in a higher 
GH dose/IGF-1 SDS ratio in female GHD patients. After 10 years 
of rhGH treatment, the GH dose was 0.53±0.30mg (range 0.20-
1.50mg) and 0.36±0.18mg (range 0.10-1.20mg) in females and males, 
respectively (p=0.001); at 15 years 0.47±0.23mg (range 0.20-1.20mg) and 
0.30±0.14mg (range 0.10-0.60mg), respectively (p=0.009). We found no 
differences in the metabolic response to rhGH treatment between both 
sexes.
OTHER POTENTIAL INFLUENCING FACTORS: Forty-nine patients 
(50%) were less than 60 years old, 49 patients (50%) were at least 60 years 
of age at baseline. The individualized rhGH dose used in older patients did 
not differ from the dose in younger patients. In addition, there were no 
significant differences in the rhGH response between younger and older 
patients with respect to IGF-1, glucose, lipid profile, WH-ratio, BMI 
or blood pressure. Furthermore, the number of pituitary insufficiencies 
did not affect the response to rhGH treatment. Mean hydrocortisone 
doses were 25.6±7.3mg/day, 23.1±5.8mg/day, 21.4±4.1mg/day, and 
21.1±4.3mg/day at baseline and after 5, 10 and 15 years of rhGH 
suppletion, respectively. However, patients with hydrocortisone substitution 
did not differ from hydrocortisone-independent patients, except for a greater 
decrease in LDL-C levels after 10 years (-1.35 vs -0.70mmol/l, p=0.021). 
Patients with CO-GHD did not differ from AO-GHD patients in their 
response to any of the metabolic parameters studied. In addition, there was 
no difference between patients with or without cranial irradiation, except for a 
higher waist circumference (p=0.024) among irradiated patients. 
When incorporating all factors in a linear regression model, neither age, 
sex, CO- vs AO-GHD, nor hydrocortisone use significantly influenced 
any of the metabolic parameters. Radiotherapy, however, influenced 
waist circumference and DBP negatively. In addition, higher GH dose 
was associated with higher BMI and waist circumference after 10 years of 
rhGH suppletion. 
PREVALENCE OF THE MS: The prevalence of the MS increased from 
32.7% at baseline to 46.9% after 5 years of rhGH therapy (p=0.040), 
further increasing to 57.1% after 10 years of rhGH treatment (p<0.001 vs 
baseline). As shown in Figure 3, this was mainly due to a gradual increase 
in abdominal obesity, hypertriglyceridemia, and hyperglycaemia. 
At baseline, the MS was equally prevalent in men and women (32.7% 
vs 32.7%). After 5 years of rhGH suppletion, 49.0% of the males and 
44.9% of the female GHD patients had MS (p=0.687). After 10 years 
of rhGH suppletion, 69.4% of men fulfilled the criteria of MS vs 44.9% 
of the women, p=0.015. This indicates that males especially drove the 
increase in MS prevalence over time, and that MS prevalence stabilized 
in females after 5 years. In a logistic regression model incorporating age, 
sex, hydrocortisone use, radiotherapy and GH dose, only higher GH 
dose negatively influenced the MS prevalence after 10 years of rhGH 
suppletion. 
CARDIOVASCULAR EVENTS: We assessed the number of major cardiovascular 
events in the patients who completed at least 10year of rhGH treatment (N=98). 
In total, 25 events were reported: myocardial infarction (N=2), progressive angina 
pectoris and/or coronary bypass surgery (N=7), cerebrovascular attack (N=2), 
intermittent claudication (N=1), pulmonary embolism (N=1). No cardiovascular 
death was reported. Consequently, the incidence rate of major cardiovascular 
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events in our GHD cohort was 25/16552 (mean duration of rhGH therapy 168.9 
months x 98 patients) = 1.5/1000py.  
In addition, new-onset diabetes mellitus (N=3), new-onset 
hypertension or start of antihypertensive medication (N=24), new-onset 
hypercholesterolaemia or start of lipid-lowering treatment (N=23) was 
reported during rhGH therapy.
Figure 3. Prevalence of (individual components of ) the MS in 98 GHD adults at baseline, and 
after 5 and 10 years of rhGH suppletion, respectively, separated for males and females
The bars denote the prevalence of the (individual components of ) the MS, at baseline and after 5 
and 10 years of rhGH treatment, respectively. 
TG, triglycerides; HDL, high-density lipoprotein cholesterol; BP, blood pressure; waist, waist 
circumference; MS, metabolic syndrome. *, p<0.05
Table 3. Ef fects of  15 years of  rhGH treatment in 43 adults 
with GHD on biochemical and anthropometric parameters 
Baseline† 15 years of rhGH 
replacement††
IGF-1, nmol/l 9.6 ± 5.5 19.6 ± 8.2 *, a
Fasting glucose, mmol/l 4.5 ± 0.7 5.0 ± 0.5 **
TC, mmol/l 6.6 ± 1.5 5.4 ± 1.1 *
LDL-C, mmol/l 4.9 ± 1.4 3.4 ± 0.9 *
HDL-C, mmol/l 1.4 ± 0.5 1.7 ± 0.6 *
TG, mmol/l 1.7 ± 1.0 1.5 ± 0.6
Waist circumference, cm 91.2 ± 10.5 99.5 ± 11.9 *
WH ratio 0.96 ± 0.06 0.95 ± 0.07
BMI, kg/m2 25.9 ± 3.6 29.2 ± 8.3 ***
SBP, mmHg 128.2 ± 14.0 134.6 ± 15.3 **, b
DBP, mmHg 83.5 ± 9.1 80.8 ± 9.1
Data are presented as mean ± SD. IGF-1, insulin-like growth factor-1; TC, total cholesterol; LDL-C, 
low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; TG, triglycerides; 
WH ratio, waist-hip ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure. 
†, statins N=4 (9.3%), antihypertensive medication N=5 (11.6%); ††, statins N=20 (46.5%), 
antihypertensive medication N=20 (46.5%)
*, p<0.001; **, p<0.01; ***, p<0.05 vs baseline  
a, p<0.001; b, p<0.01; c, p<0.05 15 vs 10 years of rhGH treatment
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DISCUSSION
The present study demonstrates ongoing beneficial effects of rhGH 
treatment on lipids in patients with GHD after 10 and 15 years in the 
presence of an increase in anthropometric parameters such as BMI, waist 
circumference and SBP. As a consequence, overall cardiovascular risk, as 
assessed by the prevalence of the MS increased significantly after 10 years 
of rhGH replacement. This increase in MS prevalence was higher than 
expected as a consequence of ageing alone in non-GHD adults (23).
The short-term effects of rhGH therapy on cardiovascular risk factors 
are well documented. A meta-analysis of placebo-controlled studies 
in GHD adults showed favorable effects of short-term (up to 1.5yr) 
rhGH replacement therapy on TC and HDL-C levels, DBP, as well 
as on lean body and fat mass, but unfavorable effects on glucose and 
insulin concentrations (3). Data on the long-term effects of adult rhGH 
replacement therapy are limited and are based on observational studies. 
The metabolic changes after at least 10 years of rhGH substitution have 
been reported in only three studies (8;13;14), including a total of 119 
patients, and their conclusions were inconclusive. The first study, Gibney 
et al. (13), reported favorable effects on HDL-C and LDL-C, but no 
changes in TC, TG, insulin, or blood pressure, whereas the second study, 
Götherström et al. (8), reported a decrease in TC and LDL-C, an increase 
in HDL-C levels, and an increase in BMI and glucose levels. The third 
study, Roemmler et al. (14), did not demonstrate any effect of treatment 
on lipids, glucose or anthropometric parameters.
In this study, we documented a decrease in TC and LDL-C levels, 
and an increase in HDL-C, in accordance with the findings reported by 
Gibney et al. and Götherström et al.(8;13). TG levels, however, did not 
change during rhGH therapy. The pattern of observed changes in lipid 
concentrations did not change after exclusion of patients using lipid-
lowering drugs. The observed mean decrease in TC and LDL-C levels 
after 15 years of rhGH therapy was 1.3 (20%) and 1.6mmol/l (32%), 
respectively. In the general population, every 10% decrease in cholesterol 
levels by statins reduces cardiovascular mortality risk in patients with 
hypercholesterolemia by 15% (24). Whether lowering of TC levels by 
rhGH replacement is associated with the same magnitude of reduction 
in cardiovascular mortality remains to be established. Furthermore, it 
is crucial not only to ascertain whether the beneficial effects of rhGH 
suppletion on lipid profile are comparable to the effects obtained with 
conventional lipid-lowering drugs, but also whether these effects can 
be superimposed. From a cost-effectiveness point of view, the latter is 
of paramount importance, but to date, only one study, including 61 
GHD patients on statin treatment, has demonstrated such an additional 
beneficial effect of rhGH treatment on lipid profile (25). In addition, 
Schneider et al. reported a cardiovascular risk reduction of approximately 
50% after 2 years of rhGH treatment, using Framingham and Procam 
risk scores (26). Because hypopituitarism per se is also associated with 
increased cardiovascular mortality (12,13), any additional effect of rhGH 
substitution next to conventional lipid-lowering drugs may be beneficial. 
Despite improvement of lipid spectrum, the MS prevalence increased 
after 10 years of rhGH replacement when compared with baseline, 
especially in males. Previously, we demonstrated an increased MS 
prevalence in untreated GHD adults, defined by the NCEP-ATP III 
criteria (27), in comparison to a Dutch historical reference population 
(data collected between 1993 and 1997) (38.0% vs 15.7%) (10). 
Subsequently, age-adjusted prevalence rates of 29% for the MS were 
reported by Attanasio et al. before start of rhGH treatment in 1420 
European adults with AO and CO-GHD (Hypopituitary Control and 
Complications Study, HypoCCS) (28), and of 41% before start of rhGH 
suppletion by Verhelst and colleagues among 2479 patients with severe 
AO-GHD, using the same updated NCEP-ATP III criteria (27). Two 
studies have shown a persistently high MS prevalence after 3 and 5 years 
of rhGH treatment, respectively (10;28). In our study, we found a further 
increase in MS prevalence to 57% after 10 years of rhGH substitution, 
mainly due to an increase in abdominal obesity, hypertriglyceridaemia and 
hyperglycaemia. 
A limitation of the present study, and a general drawback of long-term 
follow-up studies, is the lack of a non-treated control group. Since the 
beneficial effects of rhGH therapy are well-established in the short term, 
it is unethical to withhold patients with GHD receive rhGH in case of no 
contra-indications. This makes it difficult, if not impossible, to perform 
long-term randomized, controlled follow-up studies including GHD 
patients without rhGH treatment. However, several Dutch population-
based studies reported the MS prevalence in the general population. In a 
Dutch survey among 4000 subjects, conducted in 2009-2010, an overall 
MS prevalence of 34% and 24% was reported, in males and females, 
respectively. When stratified by age (per decade), MS prevalence for males 
and females, respectively, were 20% and 10% (30-39yr), 29% and 17% 
(40-49yr), 41% and 29% (50-59yr), and 48% and 44% (60-69yr) (23). 
Another study involving a cohort of Dutch adults aged 65 years or older 
(Longitudinal Aging Study Amsterdam, LASA) reported an MS prevalence 
of 37.1% (29). Based on these literature data, the MS prevalence of 57.1% 
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in our cohort of GHD patients (mean age 59yr) is strongly increased, 
despite 10 years of rhGH replacement. 
As demonstrated previously (8;30;31), we observed a significant 
increase in fasting glucose levels during rhGH replacement. This 
finding is in accordance with the well-known negative effects of GH on 
peripheral insulin sensitivity, thereby impairing peripheral glucose uptake. 
These increased fasting glucose levels may have significantly affected 
cardiovascular morbidity or mortality, because previous reports have 
indicated that even when glucose levels were below the diabetic threshold, 
there was a positive correlation with the occurrence of cardiovascular 
events (32;33).
Previous radiotherapy was shown to negatively influence abdominal 
obesity and blood pressure in GHD adults. This finding is consistent 
with earlier studies among long-term survivors of childhood cancer, 
reporting a higher MS prevalence after cranial irradiation (34;35). A 
possible explanation might be that, in addition to pituitary damage, 
cranial irradiation induces damage to the hypothalamic area. Therefore, 
cranial radiotherapy might be an independent risk factor for cardiovascular 
disease.
Due to the presence of multiple pituitary hormone deficiencies in 
almost all patients, it is difficult to examine to what extent the reported 
effects can be attributed to rhGH treatment, or whether they are the 
consequence of suboptimal or excessive replacement therapy of other 
hormones. Isolated GHD provides the ideal model to characterize 
GHD without interference from other pituitary deficiencies or their 
treatment. Abs et al. showed generally similar clinical presentation and 
rhGH treatment response in IGHD patients and patients with multiple 
deficiencies, especially in AO-GHD (36), supporting the concept that 
GH per se, at least in part, affects the metabolic phenotype of substituted 
patients with multiple pituitary hormone deficiencies. In accordance with 
these findings, in a recent meta-analysis, both low and high IGF-1 levels 
increased mortality in the general population (hazard ratio (HR) 1.18, 
95%CI 1.04-1.34) (37). 
Paradoxically, there are also human studies linking reduced IGF-1 
levels/signaling to a reduced cancer risk as well as improved longevity 
(38). In addition, functional mutations of the IGF-1R gene resulting in 
altered IGF-1 signaling are more common in centenarians than in younger 
controls. The activity of the GH/IGF-1 axis decreased with ageing, yet 
smaller individuals within a species usually live longer (39). Life span 
was also expanded in mice lacking GHR, resulting in lower IGF-1 
levels. Although these mutant mice lack other hormones, their extended 
longevity is thought to be primarily due to GHD, as restoration of GH 
levels reverted their longevity to that of non-mutants (40;41). Collectively, 
these data suggest that optimizing the GH/IGF-1 axis to promote healthy 
ageing in humans is more complex than originally appreciated and will 
require a greater understanding of its array of interactions and tissue 
specificity. 
Another feature that needs to be addressed is the presence of interactions 
between glucocorticoids and rhGH during substitution. In the past, 
hydrocortisone doses used in hypopituitarism resulted in supraphysiological 
cortisol levels, accounting for at least part of the adverse metabolic profile. 
Decreasing the glucocorticoid dose from 20-30mg/day to 15mg/day had 
beneficial effects (42). In our study, mean hydrocortisone dose was lowered 
during 15 years of follow-up from 25.6±7.3 to 21.1±4.3mg/day. When 
hydrocortisone use was incorporated in a regression model, no relation to MS 
presence/worsening was found. Possible explanations for the absence of an 
effect may be the lower hydrocortisone substitution scheme when compared 
to Danilowicz et al., in addition to less variation in the hydrocortisone 
doses used. Furthermore, it has been reported that GH accelerates cortisol 
metabolism by inhibiting 11β-hydroxysteroid dehydrogenase 1 resulting in 
decreased tissue exposure to cortisol (43;44), thereby reducing hydrocortisone 
bioavailability.
IGF-1 SD levels were closely monitored and were titrated on a 
physiological level, adjusted for age during the entire study period. This is 
one of the most important differences between our GHD cohort and other 
GHD cohorts, in which an initial high dose resulted high IGF-1 SDS (over 
+2SDS) and excessive changes in body composition, especially in men. Our 
data showed no obvious differences in IGF-1 levels or metabolic effects of 
rhGH suppletion between men and women, taken into account the need of 
a higher rhGH substitution dose in women to maintain stable plasma IGF-1 
concentrations. In addition, we did not find differences between younger and 
older GHD patients with respect to response to long-term rhGH treatment. 
However, we cannot exclude lack of power to detect any differences due to the 
relatively small number of patients within each age group. 
In conclusion, the present study showed ongoing beneficial effects of 
rhGH therapy in GHD adults on lipid profile, whereas other cardiovascular 
risk factors continued to deteriorate after long-term rhGH treatment. The 
increases in glucose levels and BMI were striking and negatively affected the 
prevalence of the MS in the long-term. Therefore, the net beneficial effects 
of long-term rhGH treatment on overall cardiovascular risk still need to be 
established in further studies that adequately address and balance all these 
factors involved, including cost-effectiveness and QoL. 
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ABSTRACT
BACKGROUND: Adult GH deficiency (GHD) is associated with increased 
cardiovascular mortality. Recombinant human GH (rhGH) replacement 
has beneficial short-term metabolic effects. Although these positive effects 
sustain during longer follow-up, the prevalence of the metabolic syndrome 
(MS) remains increased in comparison with population data not adjusted 
for the higher mean BMI in GHD adults. 
OBJECTIVE: To explore whether middle-aged patients with proposed 
physiological rhGH replacement have been normalized with respect to MS 
and its individual components in comparison with the general population, 
adjusted for age, sex and BMI. 
METHODS: One-hundred and sixty-one GHD patients (aged 40-70yr) 
were studied before the start and after 5 years of rhGH replacement, 
and were compared with 1671 subjects (aged 45-66yr) from the general 
population (NEO Study).
RESULTS: MS proportion in GHD patients was 41.0% before the start of 
rhGH suppletion, increasing to 53.4% after 5 years (p=0.007). Despite 
chronic rhGH replacement, GHD patients had a 1.3-times higher MS 
proportion than the general population, independently of age, sex and 
BMI (95%CI 1.1-1.5, p=0.008). The GHD population showed a different 
metabolic profile than the general population with similar BMI: an 
increased risk of hypertriglyceridaemia (adjusted prevalence ratio (PR) 2.0, 
95%CI 1.7-2.3) and low HDL-C (adjusted PR 1.8, 95%CI 1.5-2.2), but 
less hyperglycaemia (adjusted PR 0.5, 95%CI 0.4-0.7). 
CONCLUSIONS: Despite 5 years of rhGH replacement, GHD patients 
still have a different metabolic profile and more frequently MS than the 
general population. These differences were independent of BMI, and 
resemble the unfavorable metabolic profile of untreated GHD patients, 
pointing to question the long-term benefits of rhGH replacement.
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INTRODUCTION
Growth Hormone Deficiency (GHD) in adults is associated with an 
adverse metabolic profile, including abdominal obesity, dyslipidemia, 
and an increased mortality risk (1;2). Short-term follow-up studies have 
shown that recombinant human GH (rhGH) replacement reduced some, 
but not all of these cardiovascular risk factors (3). Consistent effects were 
reported on body composition and lipid metabolism, characterized by 
reduction of body fat and an increase of lean body mass, and a reduction 
of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) 
levels (3). Based on these positive short-term metabolic effects, as well as 
an improvement in quality of life (QoL), rhGH replacement has become 
widely accepted as chronic therapy in adult GHD. 
Despite improvement of individual components of the metabolic 
syndrome (MS), the overall prevalence of the MS was not normalized in 
GHD patients after several years of physiological rhGH replacement (4;5). 
At present, data on long-term efficacy and safety of rhGH replacement are 
limited and uncontrolled for the effect of aging (5-18). Recently, we have 
reported a further increase in body mass index (BMI) and MS prevalence 
despite 10 years of rhGH replacement (19). Thus, it can be questioned 
whether in the long term rhGH replacement is able to improve or even 
normalize the adverse metabolic profile present in hypopituitary patients. 
As an ideal unselected GHD control group without rhGH replacement 
is not available, we selected the Leiderdorp cohort of the Netherlands 
Epidemiology of Obesity (NEO) Study as representation of the general 
population for comparison. The NEO Study is a population-based cohort 
study of middle-aged Dutch adults from the same geographical area as the 
GHD patients. 
The primary aim of the present study was to compare the metabolic 
profile, as reflected by proportion of the MS and its individual 
components, between GHD patients after chronic rhGH replacement and 
the general population, adjusted for age and sex, to assess the ability of 
current rhGH replacement strategies to normalize MS features. Second, 
we critically compared metabolic parameters between treated GHD 
patients and the general population, while additionally adjusting for BMI. 
Finally, we compared the MS proportion in GHD patients before start 
and after chronic rhGH replacement. 
PATIENTS AND METHODS
STUDY DESIGN: In the present study, we compared the proportion of the 
MS and its individual components between middle-aged GHD patients 
and the general population. First, adult GHD patients were studied before 
the start of rhGH suppletion and after 5 years of rhGH replacement, 
to study the metabolic effects of chronic rhGH suppletion. Second, we 
compared chronically treated GHD patients (defined as 5 years) with the 
general population, using data from the Leiderdorp cohort of the NEO 
Study (vide infra) (20), adjusting for age and sex and subsequently with 
additional adjustments for BMI, to assess the ability of current rhGH 
replacement strategies to completely normalize MS features.
PATIENT SELECTION: This study includes all consecutive patients 
diagnosed with adult-onset (AO) and childhood-onset (CO) GHD at the 
Endocrinology Department of the LUMC from 1994 onwards. Data have 
been prospectively collected in a database. We investigated the effects of 
chronic stable rhGH replacement in middle-aged GHD patients. Chronic 
stable replacement was arbitrarily defined as replacement for ≥5 years, 
because in such a period metabolic changes induced by rhGH therapy 
start will have been stabilized (3;21). We selected all GHD patients aged 
40-70 years, who started rhGH replacement ≤2007, to enable a 5-year 
follow-up period. The age criterion used was chosen to match the GHD 
patients with middle-aged persons from the general population from the 
Leiderdorp cohort (vide infra) and to avoid nonpositivity. This resulted 
in a total inclusion of 161 eligible GHD patients (AO 155/6 CO). The 6 
patients with CO-GHD received rhGH replacement during childhood, 
and restarted with rhGH replacement as this therapy became widely 
accepted for adult GHD patients. 
TREATMENT PROTOCOL: GHD had been defined before start of rhGH 
replacement by a GH peak response to the Insulin Tolerance Test (ITT) 
<3µg/l (glucose nadir <2.2mmol/l) according to current guidelines or 
Growth Hormone Releasing Hormone/Arginine-test (GHRH/Arg) with 
BMI-adjusted GH cut-offs, in case of contraindications for ITT (5;22). 
All patients receiving rhGH replacement during childhood were retested 
at the time of transition to the adult outpatient clinic, after treatment 
cessation for >3 months. All patients were treated with rhGH (Genotropin 
Pharmacia/Pfizer, Skokie, IL; Zomacton Ferring, Troy Hills, NJ; or 
Norditropin NovoNordisk, Princeton, NJ), injected subcutaneously in 
the evening. In all patients, GH starting dose was 0.2mg/day, which was 
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individually adjusted each month in the first half year to achieve serum 
IGF-1 concentrations within the age-dependent laboratory reference 
range, aimed at SDS between 0 and +2. After reaching stable plasma 
concentrations, this individualized dose was continued and adjusted 
according to the IGF-1 SDS. 
Adrenocorticotropic hormone (ACTH) deficiency was defined as an 
insufficient increase in cortisol levels (absolute value 0.55mmol/l) after 
an ITT or corticotropin-releasing hormone stimulation test in case of 
contraindications for ITT. When secondary amenorrhea was present 
for >1 year, premenopausal women were classified as gonadotropin-
deficient. In men, gonadotropin deficiency was defined as a testosterone 
level <8.0nmol/l. Thyroid-stimulating hormone (TSH) deficiency was 
defined as total thyroxine (T4) or free T4 level <10pmol/l in addition to 
≥2 deficient pituitary axes. Hypopituitarism was adequately supplemented 
by hydrocortisone, L-thyroxine, testosterone in men, and/or estrogen in 
combination with progestagens (in premenopausal women only). Dosages 
of the hormonal replacement therapy were monitored and adjusted as 
required. 
Patients were treated with lipid-lowering medication and 
antihypertensive medication according to the discretion of their attending 
physicians. Efficacy and safety parameters were assessed yearly, next to a 
routine assessment of pituitary function. 
GENERAL POPULATION: The NEO Study is currently performed at 
the Leiden University Medical Center (LUMC) to investigate pathways 
that lead to obesity-related diseases. The NEO Study is a population-
based prospective cohort study of individuals aged 45-65 years, with an 
oversampling of individuals with overweight or obesity (BMI ≥27kg/
m2) (20). Within the NEO Study, as reference group, all inhabitants aged 
between 45-65 years from one municipality (Leiderdorp) were invited, 
irrespective of their BMI. Baseline measurements have been performed 
between 2008 and 2012. The study was approved by the Medical Ethics 
Committee of the LUMC and all participants gave informed consent. 
We used the Leiderdorp cohort (N=1671) for comparison with our 
chronically rhGH-treated GHD patients. GHD patients and subjects 
from the general population were from the same geographic area. 
STUDY PARAMETERS: The following efficacy parameters were studied:
1. Biochemical parameters: fasting glucose, total cholesterol (TC), high-
density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels. 
LDL-C concentrations were calculated by the Friedewald formula. Blood 
samples were taken after an overnight fast. 
2. Anthropometric parameters: body weight and height, waist circumference, 
hip circumference, systolic and diastolic blood pressures (SBP and DBP, 
respectively) were measured. BMI (in kg/m2) and waist-hip ratio were 
calculated.
3. Additional information on medication use and comorbidity was gathered 
from patient records.  
METABOLIC SYNDROME (MS): The MS was defined according to 
the updated third report of the 2006 National Cholesterol Education 
Program’s Adult Treatment Panel (NCEP-ATP III) criteria, which required 
the presence of ≥3 of the following conditions (23;24): 
1. Fasting plasma glucose concentration ≥100mg/dl or on anti-diabetic drug 
treatment;
2. TG concentration ≥150mg/dl or on lipid-lowering drug treatment (statins 
and/or fibrates);
3. HDL-C concentration<40mg/dl in men and<50mg/dl in women, or on 
lipid-lowering drug treatment (statins and/or fibrates);
4. BP ≥130/85mmHg or on anti-hypertensive treatment;
5. Waist circumference ≥102cm in men and ≥88cm in women.
ASSAYS: From 1986 to 2005, serum IGF-1 concentrations were 
determined by RIA (Incstar, Stillwater, MN) with a detection limit of 
1.5nmol/l and an interassay CV <11%. IGF-1 is expressed as SDS for 
age- and gender-related normal levels determined in the same laboratory 
(21). Since 2005, serum IGF-1 concentrations (nmol/l) were measured 
using an immunometric technique on an Immulite 2500 system (Siemens 
Healthcare Diagnostics, Deerfield, IL, USA). The intra-assay variations 
at mean plasma levels of 8 and 75nmol/l were 5.0 and 7.5%, respectively. 
IGF-1 levels were expressed as SDS, using lambda-mu-sigma smoothed 
reference curves based on 906 controls (25;26). 
In GHD patients, a Hitachi 747 autoanalyzer (Roche) was used to 
quantify serum concentrations of glucose, TC, and TG. HDL-C was 
measured with a homogenous enzymatic assay (Hitachi 911, Roche). In 
2003, a Roche Modular Analytics P800 replaced the Hitachi 747 with no 
change in the chemistry components. In the general population, glucose, 
TC, HDL-C and TG levels were measured by Roche Modular Analytics 
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P800. Samples in patients and controls were analyzed in the same 
laboratory. Samples of patients were obtained between 1994 and 2013; 
samples of controls between 2008 and 2012.
STATISTICAL ANALYSIS: SPSS for Windows, Version 20.0 
(SPSS,Inc.,Chicago,IL,USA) was used for statistical analysis. Results 
are presented as mean±SD, unless stated otherwise. For comparison of 
the MS proportion in GHD patients before start and after 5 years of 
rhGH suppletion, we performed the Friedman Test for related fractions. 
Although 19 patients did not complete 5 years of rhGH replacement for 
various reasons (vide infra), these patients were included using the last 
observation carried forward method (intention-to-treat approach), thereby 
including the last available measurements during rhGH replacement in the 
analyses. Independent T tests were used to compare crude metabolic data 
between 5-year rhGH-treated GHD patients and the general population. 
The relationships in MS (components) proportion between GHD 
patients after 5 years of rhGH replacement and the general population 
are reported as prevalence ratios (PRs), using the log-binominal regression 
model using STATA Statistical Software version 12.1(Statacorp,College 
Station,TX), allowing direct estimation of PRs (27;28), which is, because 
of the high incidence of the MS, more appropriate than logistic models 
that only allow estimation of odds ratios. Analyses were adjusted for age 
and sex, and subsequently with additional adjustments for BMI. P<0.05 is 
considered statistically significant.
RESULTS
CHARACTERISTICS OF PATIENTS AND CONTROLS: We studied 161 
adult GHD patients, aged 40-70 years at the time of GHD diagnosis (Table 
1). Pituitary deficiency was mainly caused by pituitary tumors or their 
treatment. Patients had been treated with surgery (transsphenoidal N=109/
transcranial N=24) and radiotherapy (N=76). Etiological diagnoses of GHD 
were non-functioning adenoma (N=67), functioning adenoma (N=52), 
craniopharyngeoma (N=12), cerebral malignancy (N=2), congenital (N=6) 
and other causes (N=22). Most patients had multiple pituitary hormone 
deficiencies (ACTH deficiency N=142, TSH deficiency N=132, FSH/LH 
deficiency N=120, ADH deficiency N=27), whereas only 6 patients had 
isolated GHD. Sex steroids were supplemented in 21% of female patients 
(N=15) and 87% of male patients (N=77). 
One-hundred and forty-two patients completed 5 years of rhGH 
replacement (Figure 1). Reasons for preliminary discontinuation in 19 
patients (11.8%) wer: death (N=5), malignancy (N=2), growth of primary 
tumor (N=2), increase in prostate-specific antigen (PSA) level (N=1), lack 
of subjective benefit (N=4), side-effects: carpal tunnel syndrome (N=2), 
weight increase (N=1), and follow-up in other centers (N=2).
At 5 years of rhGH replacement, GHD patients were compared with 
1671 subjects from the general population (Table 1). Proportion of men 
and mean BMI were higher in patients than in the general population 
(p=0.006 and p<0.001, respectively).  
Figure 1. Flow chart of selection and follow-up of our middle-aged GHD cohort
GH DOSE, IGF-1 SDS AND HYDROCORTISONE DOSE DURING 
RHGH REPLACEMENT: Mean GH doses after dose titration (1 year) and 
5 years of rhGH replacement were, respectively, 0.35±0.16mg/day and 
0.37±0.19mg/day (p=0.399). After 5 years of rhGH replacement, females 
received higher mean GH doses than males (0.40±0.23mg/day and 
0.34±0.17mg/day, respectively, p=0.05). 
During the entire period of rhGH suppletion, median of IGF-1 SDS was 
within the normal range. Median IGF-1 SDS increased significantly from the 
untreated state from -1.30 (interquartile range (IQR) -2.43, +0.16) to 0.47 
(IQR -0.50, +1.93) after 5 years of rhGH suppletion (p<0.001). In males, 
median IGF-1 SDS increased from -1.17 (IQR -2.17, +0.92) before treatment 
to 0.42 (IQR -0.43, +2.03) after 5 years (p<0.001); in females, median IGF-1 
SDS increased from -1.63 (IQR -3.04, +-0.47) before treatment to 0.51 (IQR 
-0.57, +1.71) after 5 years (p<0.001). 
Mean hydrocortisone doses were 17.43±12.40mg/day and 
18.18±10.81mg/day at the start and after 5 years of rhGH suppletion, 
respectively, indicating no significant change during follow-up. Mean fT4 
levels did not significantly change during 5 years of rhGH replacement 
(16.2±3.7pmol/l at the start and 16.8±3.7pmol/l after 5 years of rhGH).
All GHD patients (aged 
40-70 yr) started with 
rhGH replacement  
≤ 2007 from the LUMC 
N=161 
Patients receiving 5 yr 
rhGH replacement 
N=142 
Reasons for discontinuation: 
Death N=5 
No subjective beneficial 
effect N=4 
Side-effects N=3 
Follow-up other center N=2 
Malignancy N=2 
Growth primary tumor N=2 
High PSA N=1 
Discontinued N=19 
Preliminary stop of 
rhGH replacement, for 
various reasons 
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MS PROPORTION IN UNTREATED GHD PATIENTS: Before the 
initiation of rhGH replacement, 66 out of 161 patients fulfilled the 
NCEP-ATP III criteria, resulting in an MS proportion of 41.0% in 
untreated GHD (37.1% in males, 45.8% in females). Hyperglycaemia, 
hypertriglyceridaemia, low HDL-C levels, hypertension and abdominal 
obesity were present in, respectively, 13.0%, 59.0%, 47.8%, 68.3% and 
35.4% of the patients.   
EFFECTS OF 5 YEARS RHGH REPLACEMENT ON THE MS 
PROPORTION IN GHD ADULTS: The MS proportion increased 
significantly from 41.0% before to 53.4% after 5 years of rhGH 
replacement (p=0.007), especially due to an increased proportion of 
hyperglycaemia (p=0.02). In males, HDL-C levels decreased significantly 
(p<0.001). As indicated in Figure 2, the increase in MS proportion was 
most prominent in males (from 37.1% at the start of rhGH replacement 
to 53.9% after 5 years, p=0.005). Exclusion of CO-GHD patients (N=6) 
did not significantly change these results. BMI did not significantly change 
over time, from 27.5±4.5 kg/m2 before rhGH replacement to 28.0±4.5 
kg/m2 after 5 years (p=0.772). 
COMPARISON OF MS PROPORTION BETWEEN GHD PATIENTS ON 
CHRONIC RHGH REPLACEMENT AND THE GENERAL POPULATION, 
ADJUSTED FOR AGE AND SEX (TABLE 2): In the general population, we 
observed an MS proportion of 30.3%. The MS proportion in chronically 
treated GHD patients was increased when compared to controls, taking 
into account age and sex (53.4% vs. 30.3%) (adjusted PR (95%CI) 
= 1.4(1.1-1.6), p=0.001) (Table 2). For clinical interpretation, mean 
laboratory values were also presented (Table 3). 
COMPARISON OF MS PROPORTION BETWEEN GHD PATIENTS AFTER 
5 YEARS OF RHGH REPLACEMENT AND THE GENERAL POPULATION, 
ADDITIONALLY ADJUSTED FOR BMI: After additional correction for 
BMI, besides age and sex, GHD patients still had a 1.3-times increased 
MS proportion when compared with the general population, despite 
5 years of rhGH replacement (adjusted PR (95%CI) = 1.3(1.1-1.5), 
p=0.008) (Table 2). Both in male and female GHD patients, an significant 
increased MS proportion was seen when compared with the general 
population (Figure 2). When looking at the individual MS components, 
treated GHD patients differed from BMI-matched controls with respect 





Proportion of MS (components) in adult GHD patients, before the initiation of rhGH 
replacement and after 5 years, in comparison to the general population, separated for females 
(A) and males (B)
We studied the MS proportion and its individual components in: (1) 5-year treated GHD patients 
in comparison to situation before the start of rhGH replacement, using the Friedman test for 
related fractions; and (2) between GHD patients after 5 years of rhGH replacement compared to 
the general population, using a log-binominal regression model with adjustments for age and BMI. 
Analyses were stratified for sex. MS was defined according to the NCEP-ATP III criteria (23;24).
*, p<0.05
TG, triglycerides; HDL, high-density lipoprotein cholesterol; BP, blood pressure; waist, waist 
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Table 1. Characteristics of  161 middle-aged GHD patients 
before the start and after 5 yr of  rhGH replacement and 
1671 controls representing the general population 
Patient characteristics GHD patients 
Before start of rhGH 
(N = 161)
GHD patients




Sex, female (N (%)) 72 (44.7%) 72 (44.7%) 937(56.1%)*
Age, years 54.7 ± 8.5 (40 – 70) 59.7 ± 8.5 (45 – 75) 56.0 ± 6.0 (45 – 66)*
BMI, kg/m2 (range) 27.5 ± 4.5 (19.6 – 57.1) 28.0 ± 4.5 (18.5 – 53.8) 26.3 ± 4.5 (17.2 – 57.1)*
Lipid-lowering drugs (N (%)) 36 (22.3%) 78 (48.4%) 182 (10.9%)*
Antihypertensive medication (N (%)) 36 (22.3%) 77 (47.8%) 402 (24.1%)*
Anti-diabetic medication (N (%)) 8 (5.0%) 14 (8.7%) 52 (3.1%)*
 
Data are presented as mean ± SD, unless specified otherwise.  
#, The Leiderdorp cohort of the NEO Study was used as control group representing the general 
population (20). 
*, p<0.05 (Patients after 5 years of rhGH replacement vs general population).
N, number of patients; GHD, Growth Hormone Deficiency; rhGH, recombinant human Growth 
Hormone replacement; BMI, body mass index. 
Table 2. Comparison of  MS proportion, according to the 
NCEP-ATP III criteria, between middle-aged GHD patients 





PR (95%CI)1 PR (95%CI)2
Fasting glucose 37 / 161 (23.0%) 539 / 1663 (32.4%) 0.5 (0.4 – 0.7)* 0.5 (0.4 – 0.7)*
Triglycerides 106 / 161 (65.8%) 427 / 1666 (25.6%) 2.0 (1.7 – 2.4)* 2.0 (1.7 – 2.3)*
HDL-C 92 / 161 (57.1%) 418 / 1666 (25.1%) 2.0 (1.7 – 2.3)* 1.8 (1.5 – 2.2)*
Blood pressure 109 / 161 (67.7%) 1054 / 1668 (63.2%) 0.9 (0.8 – 1.0) 0.9 (0.8 – 1.1)
Waist 69 / 161 (42.9%) 597 / 1669 (35.8%) 1.1 (0.9 – 1.4) 1.0 (0.8 – 1.3)
Metabolic syndrome 86 / 161 (53.4%) 503 / 1660 (30.3%) 1.4 (1.1 – 1.6)* 1.3 (1.1 – 1.5)*
 
Values are expressed as number (percentage). Chronic rhGH replacement was defined as 5 years. 
MS was defined according to the NCEP-ATP III criteria (23;24). Log-binominal regression models 
were applied with robust standard errors, allowing direct estimations of PRs adjusted for age and 
sex, and, subsequently, with additional adjustments for BMI. 
N, number of patients; rhGH, recombinant human Growth Hormone replacement; GHD, Growth 
Hormone Deficiency; HDL-C, high-density lipoprotein cholesterol; waist, waist circumference; BMI, 
body mass index; PR, prevalence ratio; 95%CI, 95% confidence interval. 
 
RR1, adjusted for age and sex.  
RR2, adjusted for age, sex and BMI.  
*, p<0.01.
Table 3. Mean values of  the metabolic parameters of  
the MS as included in the NCEP-ATP III criteria, in adult 
GHD patients before the start and after 5 years of  rhGH 
replacement, and the general population 
GHD patients
Before start of rhGH 
(N = 161)
GHD patients





Fasting glucose (mmol/l) 4.8 ± 0.8** 5.2 ± 1.6* 5.5 ± 1.1
Triglycerides (mmol/l) 2.0 ± 1.2 1.9 ± 0.9* 1.2 ± 0.8
HDL-C (mmol/l) 1.4 ± 0.4** 1.5 ± 0.5# 1.6 ± 0.5
Systolic blood pressure (mmHg) 134.0 ± 17.8 135.7 ± 17.6* 130.4 ± 16.9
Diastolic blood pressure (mmHg) 83.9 ± 9.3 83.4 ± 9.5 83.4 ± 10.1
Waist circumference (cm) 97.2 ± 11.8 98.6 ± 11.2* 91.2 ± 12.8
 
Values are expressed as mean ± SD. 
N, number of patients; rhGH, recombinant human Growth Hormone replacement; GHD, Growth 
Hormone Deficiency; MS, metabolic syndrome; HDL-C, high-density lipoprotein cholesterol.
*, p<0.01; #, p<0.05 (GHD after 5 years rhGH replacement vs the general population). 
**, p<0.001 (GHD after 5 years of rhGH replacement vs GHD before the start of rhGH 
suppletion).
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DISCUSSION
This study demonstrates a high MS proportion of 41.0% in middle-aged 
GHD patients before the start of treatment, which further increases to 
53.4% after 5 years of rhGH replacement. Especially a higher proportion 
of hyperglycaemia contributed to this increase, whereas the lipid profile 
was not affected. Despite chronic rhGH replacement, GHD patients still 
have a 1.3-times increased MS proportion when compared to the general 
population, independently of age, sex and BMI. GHD patients still have 
a different metabolic profile, characterized by hypertriglyceridaemia and 
low HDL-C, whereas the proportion of hyperglycaemia is lower than that 
observed in the general population. 
In middle-aged GHD patients, the increased cardiovascular risk profile 
is a main justification of rhGH replacement. Important components of 
this risk are dyslipidemia, manifesting as raised levels of LDL-C and TGs, 
and reduced HDL-C levels (29). In addition, increased fat mass, reduced 
insulin sensitivity, and increases in inflammatory markers are often present 
(29;30). Mortality is substantially higher in GHD adults than in general 
population, particularly among women (1;2). RhGH replacement has 
beneficial metabolic effects in the short-term, including improvement 
in the lipid profile, body composition and cardiac function (3), which 
were reported to be sustained during longer follow-up (14;18), although 
glucose and insulin levels increase. However, despite improvement of 
several cardiovascular risk factors, MS prevalence remains increased 
(4;5;19). Obvious limitations of the few available long-term studies are 
the lack of an untreated GHD control population and difficulties with 
physiological rhGH replacement. 
This study is the first to investigate the metabolic profile of chronically 
treated GHD patients in a controlled manner, taking into account not 
only age and sex, but also BMI. In this respect, the Leiderdorp cohort 
represents the general population with comparable BMI distribution to 
that observed in other Dutch population-based studies (http://www.rivm.
nl/nldemaat.rivm.2012). We demonstrated that, independent of BMI, 
chronically treated GHD patients have a persistently different metabolic 
profile than the general population, with a lower prevalence of insulin 
resistance, but an adverse lipid profile. It is remarkable that although this 
GHD cohort is thought to be adequately substituted, as reflected by mean 
IGF-1 SDS within the physiological range as well as no hydrocortisone 
oversubstitution, the metabolic profile after chronic rhGH replacement 
resembles the profile of an untreated GHD patient, with predominantly 
lipid abnormalities. Additional analyses in which we compared the GHD 
patients before starting rhGH replacement with general population show 
similar results, suggesting that the metabolic profile is not significantly 
influenced by long-term rhGH replacement (data not shown).  
These findings give rise to several questions. First, there is an increasing 
awareness of intrinsic imperfections of endocrine replacement therapy in 
general (31), that may also well apply to GHD patients. It is questioned 
whether circulating total IGF-1 levels truly reflect peripheral IGF-1 
activity, as several earlier reports indicate that measuring free unbound 
IGF-1 levels and IGF-1 bioactivity better reflect the GH/IGF-1 status 
(32). Further study is needed to identify sensitive biomarkers to monitor 
rhGH replacement therapy. Second, it is previously shown that there 
is an optimum for GH dosing with respect to insulin resistance (33). 
In this respect, further lowering of the GH dose is probably needed to 
minimize insulin resistance. On the other hand, the MS proportion in 
GHD patients remained increased despite chronic rhGH replacement 
and resembles the metabolic profile of untreated GHD, suggesting that 
GHD may have irreversible effects on the cardiovascular system. In the 
context of increasing evidence for, on the one hand, a limited or even 
negative role of GH and IGF-1 in cancer, longevity and cardiovascular 
disease (34-36), and, on the other hand, the limited evidence for benefit 
of rhGH substitution in the elderly GHD population and long-term 
positive effects on QoL (37)27), long-term rhGH use in GHD adults 
should be critically re-evaluated. Third, we cannot exclude coexisting 
hypothalamic damage, especially in case of a history of large tumors with 
suprasellar extension (38). Obesity is a well-recognized complication in 
patients treated for tumors in the hypothalamic-pituitary region, which is 
attributed to compression of surrounding tissues (39). This hypothalamic 
damage could be an independent factor influencing the metabolic profile 
in GHD patients. Finally, most patients had multiple pituitary hormone 
deficiencies, making distinction between effects of rhGH replacement or 
effects of suboptimal or excessive replacement therapy of other hormones 
difficult.
Several validated definitions can be applied for the definition of the 
MS, precluding direct comparisons between studies (40). We used the 
NCEP-ATP III criteria (23;24) to be comparable to our previous studies 
on MS (5;19). In the NCEP-ATP III criteria, the use of antihypertensive, 
anti-diabetic and lipid-lowering medication is incorporated. In the original 
description of the NCEP-ATP III criteria, statins are not specifically 
mentioned. However, the lipid-lowering effects of statins are well 
established in the general population, and thereby significantly influencing 
the lipid criteria of the MS (41). 
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We found sex-specific differences in MS proportion and the metabolic 
response to rhGH replacement. In untreated GHD females, MS 
proportion was very high compared with the general population. This 
might be in line with a recent report of Van Bunderen et al., describing 
an increased risk of cardiovascular death in GHD females, despite rhGH 
substitution (42). The increased incidence in cardiovascular deaths in 
females might partly be attributed to the more atypical presentation of 
cardiovascular diseases (43) or inadequately substituted hypogonadism 
causing preterm menopause or hypocortisolism. The most predominant 
increase in the MS proportion during rhGH replacement in males further 
supports that the cardiovascular risk pattern in GHD patients is sex-
specific. 
When compared with other population-based control cohorts, such as 
the MORGEN cohort (1993-1997) or the Tromsø Study (1994-1995) 
(44), the MS proportion found in the Leiderdorp cohort was nearly 
doubled (30.3% in Leiderdorp cohort vs 15.7% in MORGEN cohort 
and 19.2% (males) and 17.8% (females) in the Tromsø Study) (5). As 
the same criteria for MS were applied, we expect that this increase in MS 
proportion most likely reflects the increase in BMI and an increased use of 
antihypertensive medication in the general population over 15 years and 
emphasizes the importance for a contemporary comparison group from 
the general population.
The strength of the present study is the availability of large recent 
population-based control data and the inclusion of analysis on the 
crude metabolic laboratory data in addition to the age-, sex-, and 
BMI-adjusted analysis using the NCEP-ATP III criteria of MS. Our 
relatively large middle-aged GHD cohort reflects the best-case scenario 
in which hormonal suppletion of all pituitary axes is optimalized and 
adequately monitored. A potential limitation could be the fact that we 
evaluated the MS proportion in the untreated GHD situation only in 
patients in whom rhGH replacement was actually initiated. This could 
introduce a selection bias, because GHD patients without receiving 
rhGH replacement are likely to differ from patients that actually received 
rhGH replacement. Second, it has to be noted that the patients in our 
GHD cohort are very heterogeneous with respect to the cause of GHD, 
failure of other pituitary hormone axes and history of cranial irradiation 
and/or surgery, which may have influenced the results. Third, we only 
reported the metabolic parameters included in the MS according to the 
NCEP-ATP III criteria, not for example LDL-C or body fat percentages, 
which are also GH-dependent parameters. Another feature that needs 
to be addressed is the presence of interactions between glucocorticoids 
and rhGH during substitution. In the past, hydrocortisone suppletion in 
hypopituitary patients frequently resulted in supraphysiological cortisol 
levels, which accounted for at least part of the adverse metabolic profile in 
these patients. However, as most patients received hydrocortisone doses 
of 20 mg/day or less during the entire follow-up period and cortisol levels 
were highly monitored, we expect that in our cohort hydrocortisone 
oversuppletion is not likely to have negatively influenced the results. 
In this respect, it has also be noted that minor thyroid dysfunction and 
insufficient thyroid replacement has a significant independent negative 
impact on cardiovascular risk factors in hypopituitary adults (45), further 
emphasizing the importance of adequate hormonal suppletion of all 
deficient pituitary axes. In addition, it would be ideally preferred to 
include a longitudinal follow-up control group for comparison; however, 
such a control group was not available in the Netherlands. Finally, it has 
to be noted that a priori GHD patients are more likely to receive anti-
diabetic and/or lipid-lowering medication than controls in case of lipid 
and/or glucose abnormalities, since these patients are regularly followed up 
at the Deptartment of Endocrinology, which is not the case for controls 
without a history of pituitary disease. 
In conclusion, despite 5 years of rhGH replacement, GHD patients 
still have a different metabolic profile and a higher MS proportion 
than the general population. These differences were independent of 
BMI, and resemble the metabolic profile of untreated GHD patients. 
This emphasizes the need for further study to establish whether 
rhGH replacement is actually beneficial in the long-term, adequately 
incorporating the cost-effectiveness, QoL, and the potential negative 
effects of GH/IGF-1 on cancer, longevity and cardiovascular risk.
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ABSTRACT
BACKGROUND: Growth Hormone Deficiency (GHD) in adulthood may 
be associated with a decreased bone mineral density (BMD), a decreased 
bone mineral content (BMC) and an increased fracture risk. Recombinant 
human GH (rhGH) replacement induces a progressive increase in BMD 
for up to 5-7 years of treatment. Data on longer follow-up are however 
scarce. 
METHODS: Two-hundred and thirty adult GHD patients (mean age 47.1 
years, 52.6% female), of whom 88% patients had adult-onset (AO) GHD, 
receiving rhGH replacement for ≥5 years were included in the study. 
Most patients had multiple pituitary hormone deficiencies. Bone turnover 
markers, BMC and BMD and T-scores at the lumbar spine and femoral 
neck were evaluated at baseline, and after 5, 10 and 15 years of rhGH 
replacement. In addition, clinical fracture incidence was assessed.
RESULTS: Mean lumbar spine BMD, lumbar spine BMC and T-scores 
gradually increased during the first 10 years of rhGH replacement and 
remained stable thereafter. Largest effects of rhGH supplementation were 
found in men. In the small subset of patients using bisphosphonates, use 
of bisphosphonates did not impact additional beneficial effects in the 
long-term. Low baseline BMD positively affected the change in BMD and 
BMC over time, but there was a negative effect of high GH dose at 1 year 
on the change in BMD and BMC over time. Clinical fracture incidence 
during long-term rhGH replacement was 20.1/1000 py.
CONCLUSIONS: Fifteen years of rhGH replacement in GHD adults 
resulted in a sustained increase in BMD values at the lumbar spine, 
particularly in men, and stabilization of BMD values at the femoral neck. 
Clinical fracture incidence was suggested not to be increased during long-
term rhGH replacement. 
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INTRODUCTION
Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) are 
important regulators of bone growth and metabolism during the life span 
(1). IGF-1 mediates most of the effects of GH on skeletal metabolism via 
the IGF-1 receptor (2), although GH also exerts direct effects on bone 
(3). GH and IGF-1 act as anabolic hormones on bone by stimulating 
proliferation, and to some extent, differentiation of osteoblasts. 
Furthermore, osteoclastic bone resorption is stimulated, resulting in an 
overall increase in bone remodeling (3;4). 
Untreated Growth Hormone Deficiency (GHD) is characterized by 
low bone turnover, decreased bone mineral density (BMD) and bone 
mineral content (BMC)(5-7). Treatment with recombinant human GH 
(rhGH) replacement has shown to increase bone turnover as reflected by 
an increase in bone formation and bone resorption markers. Consequently, 
there is an initial decline in (or unchanged) BMD, followed by a small 
increase of about 1-2% in the first 2 years of rhGH replacement due to a 
net positive balance in bone formation (3;8). 
Data on the skeletal effects of long-term rhGH replacement are, 
however, scarce. Previous studies reported that rhGH replacement induces 
a progressive increase in BMD and BMC up to 5-7 years of treatment, 
which is followed by a plateau phase (9-12). Götherström et al. reported 
an increase of total body and lumbar spine BMD and BMC even up to 
10 years of rhGH replacement, whereas femoral neck BMD and BMC 
reached a peak value after 5-7 years (13). Only one study reported the 
effects of 15 years of rhGH supplementation, showing a sustained increase 
in total body and lumbar BMD and BMC over 15 years, whereas femoral 
neck BMD and BMC returned towards baseline values after 7 years (14). 
The primary aim of our study was to assess the effects of 5, 10 and 15 
years of rhGH replacement on bone metabolism in the Leiden Cohort 
Study, a well-characterized cohort of adult GHD patients. Furthermore, 
we studied potential influencing factors on the bone response to rhGH 
replacement and studied clinical fracture incidence in these patients.
PATIENTS AND METHODS
PATIENTS: Consecutive adult patients with an established diagnosis of 
childhood-onset (CO) or adulthood-onset (AO) GHD followed up at 
the Department of Endocrinology and Metabolic Diseases of the Leiden 
University Medical Center (LUMC) were collected in a database from 
1994 onwards. In the present study, we selected all GHD patients who 
started rhGH replacement therapy in or before 2007, and, therefore, had 
the potential to receive rhGH replacement for ≥5 years. We arbitrarily 
defined chronic treatment as replacement for ≥5 years, since such a period 
will reflect a stable situation without confounding by ongoing changes 
induced by the start and titration of rhGH replacement (15;16). This 
strategy resulted in inclusion of a total of 230 eligible GHD patients, of 
which part of the included patients has been previously described (17).
GHD was diagnosed on the basis of a GH peak response to the Insulin 
Tolerance Test (ITT) <3µg/l (glucose nadir <2.2mmol/l) according 
to current guidelines or, in case of contraindications for ITT, to the 
combined Growth Hormone Releasing Hormone/Arginine-test (GHRH/
Arg) with BMI-adjusted GH cut-offs (18;19). All patients receiving rhGH 
replacement during childhood were re-tested at the time of transition 
to the adult outpatient clinic, after treatment cessation for >3 months. 
GHD was replaced according to a standardized Leiden protocol, in which 
patients received rhGH replacement (Genotropin, Pharmacia/Pfizer, 
Capelle a/d Ijssel, The Netherlands; Zomacton, Ferring, Hoofddorp, 
The Netherlands; Norditropin, NovoNordisk, Alphen a/d Rijn, The 
Netherlands), injected subcutaneously in the evening. GH starting dose 
was 0.2mg/day, which was individually adjusted each month in the first 
half year to achieve serum IGF-1 concentrations within the age-dependent 
laboratory reference range, aimed at SDS between 0 and +2. When 
stable plasma concentrations were reached, this individualized dose was 
continued during the entire study period and adjusted according to the 
IGF-1 standard deviation score (SDS). After dose titration, patients were 
evaluated at least yearly at the outpatient clinic, according to a standard 
protocol.
Adrenocorticotropic hormone (ACTH) deficiency was defined as an 
insufficient increase in cortisol levels (absolute value 0.55umol/l) after 
an ITT or a corticotropin-releasing hormone stimulation test in case 
that an ITT was contra-indicated. Standard hydrocortisone replacement 
was 20 mg divided in 3 doses, individually adjusted when necessary. 
Premenopausal women were classified as gonadotropin-deficient when 
secondary amenorrhea persisted for >1year. In men, gonadotropin 
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deficiency was defined as a testosterone level <8.0nmol/l. Thyroid-
stimulating hormone (TSH) deficiency was defined as total thyroxine (T4) 
or free T4 levels below the normal laboratory reference range (<10pmol/l). 
Hypopituitarism was supplemented by hydrocortisone, L-thyroxine, 
testosterone in men, and/or estrogen in combination with progestagens 
(in premenopausal women only) and adequacy of supplementation was 
regularly controlled and adjusted as required. 
Patients were treated with bone-modifying medication according to the 
discretion of their attending physicians. 
METHODS: Data were collected from the patients’ electronic hospital 
records on the following efficacy parameters, which were assessed on a 
yearly basis after establishment of diagnosis and start of treatment at the 
outpatient clinic:
1. Anthropometric parameters: body weight was measured to the nearest 
0.1kg, and body height was measured barefoot to the nearest 0.001m. 
BMI was calculated as weight in kilograms divided by the square of height 
in meters (kg/m2). 
2. Biochemical parameters: data were collected on serum concentrations of 
IGF-1, GH, TSH, fT4, LH, FSH, estradiol, testosterone and prolactin, 
which were collected after an overnight fast. Assays were presented in 
Supplementary File 1. 
3. Markers of bone metabolism: Data on serum creatinine, calcium, albumin, 
alkaline phosphatase, vitamin D, PTH, procollagen type 1 amino-terminal 
propeptide (P1NP, bone formation) and β-crosslaps concentrations (bone 
resorption) (the latter two markers available from 2006 onwards). Assays 
were presented in Supplementary File 1.
4. BMD and BMC: Data on BMD and BMC measurements were collected.
BMD was measured yearly at the lumbar spine (L1-L4) and femoral neck 
using dual energy X-ray absorptiometry (DXA) (Hologic QDR 1000 
(until 2008) and Hologic QDR 4500 (thereafter), Hologic Inc., Waltham, 
MA, USA) equipped with reference values based on the National Health 
and Nutrition Examination Survey (NHANES III) from the time of start 
of rhGH replacement onwards (20). Coefficient of variation of lumbar 
spine and femoral neck BMD measurements was 1%. An in-house 
comparison using 300 measurements provided a conversion formula for 
all Hologic 1000 measurements, which were converted for comparison for 
the laterally acquired Hologic 4500 BMD measurements. BMD T-scores 
were used to reflect the number of standard deviations (SD) above or 
below the mean for a healthy age- and sex-matched adult. World Health 
Organization (WHO) criteria were used to define osteopenia (T-score 
between -1.0 and -2.5) and osteoporosis (T-score ≤-2.5). BMC was 
measured at the lumbar spine using the same DXA apparatus.
5. Fracture data: Specific information on clinical fractures was retrieved 
from the medical charts. No routine spine radiographs were performed to 
assess the presence of vertebral fractures; however, radiographs were made 
in case of height loss >3cm or specific complaints at the discretion of the 
treating physician (21).Vertebral fractures were defined as clinical fractures 
(i.e. pain or decrease in height) and/or radiographic fractures in case of 
available radiographs, defined as the presence of Genant≥2(22). 
6. Data on medication use and co-morbidity was obtained from electronic 
files.
STATISTICAL ANALYSIS: SPSS for Windows, Version 20.0 (SPSS, Inc., 
Chicago, IL, USA) was used for statistical analysis. Although 19 patients 
did not complete 5 years of rhGH replacement for various reasons (vide 
infra), these patients were included using the last observation carried 
forward method according to the intention-to-treat approach used. Results 
are presented as mean±SD, unless stated otherwise. ANOVA repeated 
measurements with Bonferroni correction for multiple comparisons 
were used to compare anthropometric parameters, bone markers, BMD, 
T-scores and BMC between baseline and after rhGH treatment. Analyses 
were repeated after stratification for bisphosphonate use. For the subgroup 
of patients followed ≥10  years, we only analyzed the baseline data of 
this specific subgroup.We identified factors influencing the response 
to long-term rhGH supplementation on bone by incorporating age, 
sex, childhood-onset versus adult-onset GHD, hydrocortisone use, 
GH dose, hypogonadism, number of pituitary deficiencies (<2 vs ≥2), 
bisphosphonate use, baseline Vitamin D levels and baseline BMD values 
in a linear regression model. Finally, clinical fracture incidence rate was 
calculated during rhGH replacement. 
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RESULTS
DESCRIPTION OF PATIENTS: Baseline characteristics of the 230 
adult GHD patients (202 AO/28 CO) are shown in Table 1. Pituitary 
insufficiency was mainly caused by pituitary tumors or their treatment. 
Most patients had multiple pituitary hormone deficiencies. Two-
hundred and eleven patients completed 5 years of rhGH replacement 
(Supplementary File 2). Reasons for earlier discontinuation (19 patients, 
8.3% of total) are shown in Supplementary File 2. There were no 
differences between patients completing 5 years of rhGH replacement and 
non-completers with respect to age, sex, pituitary hormone deficiencies or 
co-morbidity. Ninety-eight and 43 patients, respectively, completed10 and 
15 years of rhGH replacement.
At baseline, 10 patients (4.3%) received bisphosphonates, and, 
respectively, 84 (36.5%) and 85 patients (37.0%) received calcium 
and Vitamin D supplements. After respectively 5, 10 and 15 years of 
rhGH replacement 28 (12.2%), 19 (19.4%) and 8 (18.6%) patients 
used bisphosphonates. Thirty-eight patients used bisphosphonates at 
any moment during the study, for a mean duration of 6.9±4.3 years. 
Indications for bisphosphonate use were osteoporosis (N=23), clinical 
fractures (N=10), osteoporosis and clinical fractures (N=8), and other 
(N=7). Mean age at start of bisphosphonate-therapy was 52.6±13.5 years.
GH dose, IGF-1 SDS and hydrocortisone dose during rhGH 
replacement: Mean GH doses after dose titration (i.e. after 1year) and 
5 years of rhGH replacement were, respectively, 0.39±0.20mg/day and 
0.43±0.27mg/day (p=0.016 compared to 1year dose). Mean doses after, 
respectively, 10 and 15 years of rhGH replacement were 0.44±0.26mg/day 
and 0.39±0.21 mg/day (both NS compared to 1 year dose). 
Mean IGF-1 SDS was within the normal range during the entire study 
period, and increased significantly from -1.09±2.46 at baseline to 0.66±2.01 
after 5 years and was 1.24±2.45 after 10 years (both p<0.01 compared to 
baseline). In men, mean IGF-1 SDS increased significantly from -0.60±2.21 
at baseline to 0.95±1.88 after 5 years (p=0<001) and to 1.64±2.57 after 10 
years (p=0.011). In women, mean IGF-1 SDS increased significantly from 
-1.73±2.63 at baseline to 0.35±2.11 after 5  years of rhGH replacement 
(p<0.001) and to 0.83±2.29 after 10 years (p=0.003) (Figure 1). 
Mean hydrocortisone doses were 24.1±7.3mg/day, 21.4±4.10mg/
day and 21.1±4.3mg/day at baseline, after 10 and after 15 years of 
rhGH replacement, respectively, indicating no significant change in 
hydrocortisone dose during rhGH replacement.
Table 1. Baseline characteristics of  230 adult GHD patients
Patient characteristics GHD patients
(N = 230)
Sex, female / male (N) 121 / 109
Age at start rhGH replacement, years (range) 47.1 ± 14.9 (15 – 81)
AO / CO (N) 202 / 28
BMI, kg/m2 (range) 27.3 ± 5.1 (16.9 – 57.1)
Etiological diagnosis of GHD (N)
   NFA
   Functioning adenoma
   Craniopharyngeoma
   Cerebral malignancy
   Congenital







Surgery, TS / TC (N) 136 / 38
Radiotherapy (N) 102
Pituitary deficiencies (N)
   TSH
   ACTH
   FSH / LH
   ADH







Calcium supplementation (N) 84
Vitamin D supplementation (N) 85
 
Data are presented as mean ± SD, unless specified otherwise. 
N, number of patients; GHD, Growth Hormone Deficiency; rhGH, recombinant human Growth 
Hormone replacement; AO, adult-onset GHD; CO, childhood-onset GHD; BMI, body mass index; 
NFA, non-functioning adenoma; TS, transsphenoidal; TC, transcranial; TSH, thyroid stimulating 
hormone; ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; LH, luteinizing 
hormone; ADH, anti-diuretic hormone; Vitamin D, vitamin D. 
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BIOCHEMICAL BONE MARKERS: Baseline calcium and Vitamin D 
levels were, respectively, 2.40±0.24mg/dl and 60.3±26.7nmol/l. After 
5 years, mean calcium and Vitamin D levels were 2.40±0.11mg/dl 
(NS compared to baseline) and 63.3±24.5nmol/l (p=0.02 compared to 
baseline), respectively, and 2.39±0.26mg/dl and 61.8±26.0nmol/l (both 
NS compared to baseline) after 10 years of rhGH replacement. 
At baseline, P1NP and β-crosslaps concentrations were only available 
in 12 and 30 patients and were therefore not reported. After 5 years or 
rhGH replacement, mean P1NP and β-crosslaps concentrations were 
45.3±26.6ng/mL and 0.42±0.24ng/mL, respectively, and 48.4±25.4ng/mL 
and 0.71±2.19ng/mL after 10 years. After 15 years of rhGH replacement, 
mean P1NP and β-crosslaps concentrations were 42.1±24.7ng/mL and 
0.37±0.20ng/mL. These data indicate normal bone turnover throughout 
the entire study period with stable rhGH replacement.
BMC and BMD: Mean height, weight and BMI at the different time 
points during rhGH replacement are shown in Table 2. Mean lumbar 
spine BMD gradually increased during the first 10 years of rhGH 
replacement, from 0.98±0.15g/cm2 at baseline to 1.03±0.16g/cm2 after 
10 years (p<0.001, 5% above the baseline value) and stabilized thereafter 
(Table 2). Mean lumbar spine T-scores increased during the first 10 years 
of rhGH replacement from -0.69±1.30 to -0.43±1.33 (p<0.001), and 
remained constant thereafter. Lumbar spine BMC increased throughout 
the first 10 years of rhGH replacement being 4% above the baseline level 
after 10 years (from 63.2±15.4kg to 65.8±18.0kg), and then reached a 
plateau. Similar results were obtained after stratification for the use of 
bisphosphonates, indicating that in the long-term there was no beneficial 
effect impacted from additional bisphosphonate use (Figure 2). 
Left femoral neck BMD did not change during rhGH replacement (Table 
2), neither in the small subgroup of patients using bisphosphonates (Figure 2).
 In Supplementary File 3, the mean BMC, BMD and T-score values 
at the different time points during rhGH supplementation were shown 
for the subgroup of GHD adults with 15 years of rhGH replacement 
(N=43).Within this subgroup, mean lumbar spine BMD and BMC scores 
increased during the first 10 years of rhGH supplementation and stabilized 
thereafter. With respect to left femoral neck, no changes during rhGH 
supplementation were found. 
Table 2. Ef fects of  15 years of  rhGH replacement in 230 
adults with GHD on BMC, BMD and T-scores measured using 






















63.6 ± 13.9 
 1.01 ± 0.14* 
 -0.54 ± 1.11 








-0.77 ± 1.18 
0.83 ± 0.15 

















Statistical analyses were done by performing a Repeated Measurements ANOVA. To take into 
account multiple testing, p<0.01 was considered statistically significant. 
N, number of patients on rhGH replacement at different time points; rhGH, recombinant human 
Growth Hormone; GHD, Growth Hormone Deficiency; BMC, bone mineral content; BMD, bone 
mineral density; DXA, dual energy X-ray absorptiometry; BMI, body mass index; SD, standard 
deviation. 
*, p<0.01 (versus baseline) 
**, p<0.001 (versus baseline)
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Figure 2. BMD changes during 15 years of rhGH replacement at the lumbar spine and the 
left femoral neck, stratified for the use of bisphosphonates in male (A) and female GHD adults 
(B) 
Data are presented as mean BMD values (g/cm2), stratified by the use of bisphosphonates. 
Vertical bars indicate SD values. 
rhGH, recombinant human Growth Hormone therapy; GHD, Growth Hormone Deficiency; BMD, 
bone mineral density; SD, standard deviation. 
*, p<0.01 (versus baseline)
Figure 3A  
Figure 3B 
 
Scatterplots of individual BMD values at the lumbar spine and left femoral neck in female (A) 
and male (B) GHD patients after 10 years of rhGH supplementation
Closed circles indicate individual scores, the interrupted line indicates mean BMD value for age and 
the solid lines indicate, respectively, +2 S.D. and -2 S.D. Dashed line indicates T-score -2.5 S.D.
BMD, bone mineral density; rhGH, recombinant human Growth Hormone supplementation; LWK, 
lumbar spine.
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OSTEOPENIA AND OSTEOPOROSIS: At baseline, 29.1% and 31.7% of 
the patients had osteopenia (T-score<-1.0SD) in the lumbar spine and 
femoral neck, respectively. After 10 years of rhGH replacement, 37.8% of 
the patients had osteopenia at the lumbar spine and 35.7% at the femoral 
neck. The patients with persisting osteopenia at the femoral neck and/
or lumbar spine at the study end, were older (68.5 years vs 59.2 years, 
p=0.014) and included more women (66.7% vs 46.7%, although NS). 
No differences were found with respect to 1 year GH dose or number 
of pituitary deficiencies between patients with and without persisting 
osteopenia and/or osteoporosis at the study end. 
At baseline, 11 GHD patients (4.8%) had osteoporosis at the lumbar 
spine (4 women/7 men), with a mean age of 54.1±15.2 years. Six of 
these patients used bisphosphonates and respectively 7 and 5 patients 
had calcium and Vitamin D supplementation. Seventeen patients (7.4%) 
had baseline osteoporosis at the femoral neck (7 women/10 men), of 
whom nine patients used bisphosphonates, 11 calcium and 9 Vitamin D 
supplementation. In this small subgroup of patients with osteoporosis, no 
change in femoral neck BMD was found during rhGH supplementation. 
However, lumbar spine BMD increased during the first 5 years of rhGH 
supplementation, without a further increase afterwards. After 10 years of 
rhGH supplementation, osteoporosis was found in, respectively, 7.1% and 
1.1% of patients at the femoral neck and the lumbar spine. BMD values 
of individual GHD patients after 10 years of rhGH supplementation were 
shown in Figure 3A+3B. 
Influence of sex: Mean GH dose was significantly higher in women 
compared to men for the first 10 years of rhGH replacement, resulting in 
a higher GH dose/IGF-1 SDS ratio in female GHD patients. After 5 years 
of rhGH treatment, mean GH dose in men and women was respectively 
0.37±0.26mg/day and 0.49±0.28mg/day (p=0.001) and at 10 years 
respectively 0.36±0.18mg/day and 0.53±0.30mg/day (p=0.001).
Men had a greater increase in lumbar spine BMD than women at all 
time points (all p<0.01 compared to baseline), but not in femoral neck 
BMD (Figure 4A+2B). These data were similar in patients with and 
without bisphosphonate use (Figure 2A-D). Similar sex differences, with 
highest response to rhGH replacement in men, were seen for lumbar spine 
BMC. Also in lumbar spine T-scores highest increase was seen in men after 
10 and 15 years of rhGH replacement, although this was not shown for 
femoral neck T-scores (data not shown).
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Figure 4. Sex differences in the effects of 15 years of rhGH replacement in 230 adult GHD 
patients on lumbar (L1-L4) spine BMD (A) and left femoral neck BMD (B)
Data are presented as mean BMD values (g/cm2), stratified by sex. Vertical bars indicate SEM 
values. Men had a greater increase in lumbar spine BMD than women at all time points when 
compared to baseline (all p<0.001).
rhGH, recombinant human Growth Hormone therapy; GHD, Growth Hormone Deficiency; BMD, 
bone mineral density; SEM, standard error of the mean.
*, p<0.001 (versus baseline)
OTHER POTENTIAL INFLUENCING FACTORS : Subsequently, we 
identified potential factors influencing the response to rhGH replacement 
on BMD and BMC. One hundred seventy-seven patients (77%) were 
<60 years and 53 patients (23%) were ≥60 years of age at baseline. 
The individualized rhGH dose used in older patients was significantly 
lower than in younger patients (0.41±0.21mg/day vs 0.32±0.13mg/day, 
p<0.001). After adjustment for the difference in rhGH dose, the rhGH 
response did not differ between younger and older patients with respect 
to IGF-1, BMD, BMC and T-scores at the lumbar spine or femoral 
neck. Univariate analyses including GH dose at 1year, low Vitamin D 
levels, hydrocortisone use, use of bisphosphonates, use of L-thyroxine, 
childhood- vs adulthood-onset, presence of ≥2 pituitary hormone 
deficiencies, or hypogonadism showed that these factors did not affect the 
effects of rhGH replacement on femoral neck BMD, lumbar spine BMD 
or BMC. A lower baseline lumbar BMD was found to be associated with 
a higher increase in lumbar BMD during 15 years of rhGH replacement, 
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in both sexes. Bone response to rhGH replacement did not differ between 
patients with a history of functioning vs non-functioning adenoma or 
between patients with childhood- vs adulthood-onset GHD. 
When incorporating all factors in a linear regression model, only higher 
GH dose at 1 year was associated with a decreased response to rhGH on 
BMC over 15 years. No other influencing factors were found.
FRACTURE DATA: Twenty-three patients (10%, 11 women/12 men) 
sustained fractures during rhGH supplementation, of which 12 at ≥2 
sites. Fifteen patients had vertebral fractures (10 patients had ≥2 fractures), 
9 patients non-vertebral fractures (hip N=6 (2 patients bilateral hip 
fracture), toe N=2, clavicula N=1). Consequently, the incidence rate of 
fractures during rhGH replacement was 46/2288.5 (mean duration of 
rhGH therapy 9.95 years x 230 patients) = 20.1/1000py in our GHD 
cohort (incidence rates for, respectively, non-vertebral and vertebral 
fractures in our cohort were 3.9/1000py and 16.2/1000py).
DISCUSSION
The present study describes the long-term effects of rhGH replacement 
on bone metabolism in a well-defined cohort of adult GHD patients. 
We found a sustained increase in BMD at the lumbar spine during the 
first 10 years of rhGH replacement, and stabilization thereafter, as was 
found for lumbar spine BMC and T-scores. At all time points, the largest 
effects of rhGH replacement on lumbar spine BMD and BMC were 
observed in men. In the small subset of patients using bisphosphonates, 
bisphosphonate use did not impact additional beneficial effects beyond 
an initial early effect. Lower baseline BMD and high GH dose at 1year 
significantly, respectively, positively and negatively influenced the bone 
response to long-term rhGH replacement. Clinical fracture incidence 
during long-term rhGH supplementation was 20.1/1000py.
Untreated GHD in adults is characterized by low bone turnover, decreased 
BMD and BMC (5-7), which increased or even normalized by short-term 
rhGH replacement (3;5;8). We have previously shown that 2 years of 
physiological dose of rhGH in GHD adults increased bone turnover in favor 
of bone formation, as reflected by a significant increase in BMD (23) that 
sustained after 7 years of treatment (24). In addition, during the first 4 years 
of rhGH supplementation, we observed a significant greater increase in BMD 
in GHD patients with osteoporosis with additional bisphosphonate treatment 
(24). These additional beneficial effects of bisphosphonates were preserved 
during another 3 years of rhGH replacement (25). 
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To date, only a single other study has reported the skeletal effects of rhGH 
replacement in GHD adults beyond 10 years (14). In agreement with this 
report, we observed a sustained increase of lumbar spine BMD and BMC 
during 15 years of rhGH replacement with a peak value after 5-7 years, 
being largest in male patients. In both studies, no changes in femoral neck 
BMD were found. However, since due to an ageing effect, it would be 
expected that femoral neck BMD decreases with increasing age over time 
(26). The observed stabilization of the femoral neck BMD in our study 
among GHD adults indicates that, in addition to an effect on lumbar 
spine BMD, rhGH supplementation also exerts an effect at the level 
of the femoral neck. The present study is the first to report that during 
long-term rhGH replacement, concomitant bisphosphonate use has no 
additional beneficial effect on BMD after an initial early effect (25;27), in 
the presence of stringently controlled Vitamin D and calcium status. In 
addition, this study also focused on clinical fracture incidence during long-
term rhGH replacement.  
When stratifying analyses for sex, lumbar spine BMD increases in 
both sexes during the first 5 years of rhGH replacement. Thereafter, we 
observed a further increase in BMD in men, whereas in women BMD 
decreased towards baseline values. Gender-specific differences in the bone 
response to rhGH supplementation were also demonstrated in several 
other studies, with largest effects in men (28;29). The lack of response 
in BMD in adult GHD women is suggested to due to the inhibition of 
the effect of GH on IGF-1 production by orally administered estrogens 
(30;31) or by inhibiting direct actions of GH on both osteoblasts and 
osteoclasts by estrogen (3). However, in this respect, it should be noted 
that GH doses are adjusted according to sex-adjusted IGF-1 levels. In 
general, given that IGF-1 levels are comparable between men and women, 
it is likely that other factors, such as differences in bone structure between 
both sexes play a role in sex-specific differences in bone response to rhGH  
supplementation.
Literature on fracture risk in rhGH-treated adult GHD patients is 
scarce and, to date, has been investigated in only three studies. Holmer 
et al. studied clinical fracture incidence in 832 rhGH-treated patients 
compared to 2581 matched healthy controls and reported a two-fold 
increase in fracture risk in CO-GHD women, although in AO-GHD men 
fracture risk was significantly lowered. No increased risk was found in AO-
GHD women and CO-GHD men (32). Elbornsson et al. reported clinical 
fractures in a Swedish GHD cohort, and observed only 1 hip fracture and 
1 symptomatic vertebral fracture (14). Mazziotti et al. reported a high 
prevalence of radiographic vertebral fractures of 53.8% in rhGH-treated 
GHD adults when compared to a prevalence of 78.6% in untreated GHD 
patients (33), suggesting that rhGH supplementation decreases fracture 
risk in GHD adults. In our cohort,10% of patients sustained a clinical 
fracture during long-term rhGH replacement, giving an incidence rate of 
20.1/1000py. When compared to the Rotterdam Study in a healthy Dutch 
population aged ≥55 years, reporting a vertebral fracture incidence rate of 
10.9/1000py and a non-vertebral fracture incidence rate of 25.0/1000py 
in women and 9.6/1000py in men (34;35) and in view of the younger age 
of our cohort, our data may suggest that fracture incidence is not increased 
in rhGH-treated GHD patients.
Our study has strengths as well as limitations. Its main strengths are the 
duration of follow-up and the size of our adult GHD cohort, who were 
regularly followed and stringently controlled over the  years according to 
internationally used guidelines. Care for attention was given to Vitamin D 
status as reflected by normal average levels of Vitamin D and normal bone 
turnover rates throughout the entire study period. Limitations of the present 
study, and a general drawback in long-term follow-up studies, are, first, the 
lack of a non-rhGH treated control group. Since the beneficial effects of 
rhGH therapy are well-established in the short-term, rhGH replacement 
became a widely available therapy for adult GHD in the Netherlands, in case 
of no contra-indications. Consequently, it is no longer possible or ethical 
to perform long-term randomized placebo-controlled studies in GHD 
patients. A second limitation is the potential underestimation of the fracture 
incidence in our patients as spinal X-rays were only performed in case of a 
clinical fracture. Another feature that needs to be addressed is that due to the 
presence of multiple pituitary hormone deficiencies in almost all patients, it 
is difficult to examine to what extent the reported effects can be attributed 
to rhGH treatment. In this respect, the presence of interactions between 
glucocorticoids and rhGH during substitution and the negative effects of 
cortisol excess, either endogenous or supraphysiological supplementation, on 
bone has to be noted (23;36). However, in our study, there were no signs of 
hydrocortisone oversupplementation and when incorporating hydrocortisone 
use in a regression model, we found no significant association with BMD 
response. Finally, bisphosphonates, calcium and Vitamin D supplementation 
were initiated at the discretion of the treating physician and not given 
using a standardized protocol with only a small subset of patients using 
bisphosphonates. However, in other studies investigating skeletal effects of 
long-term rhGH supplementation, information on bisphosphonate use is 
often not available. In this respect, the combined use of bisphosphonates and 
rhGH supplementation should be a topic for future research. 
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In conclusion, these findings from our cohort study of GHD patients 
demonstrate ongoing beneficial effects on bone metabolism of 10 years 
of rhGH replacement therapy, particularly in men, with stabilization 
thereafter. Beneficial effects are most marked on BMD at the lumbar 
spine. In addition, clinical fracture incidence seems low in our adult GHD 
patients. Sex-specific differences in bone response to rhGH replacement 
and the long-term beneficial effects of bisphosphonates on fracture risk 
warrant further studies in adult GHD patients, and therefore, protocolled 
prolonged follow-up of these patients is mandatory.
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Serum GH was measured with a sensitive IFMA (Wallac, Turku, 
Finland), specific for the 22 kDA GH protein (detection limit: 0.01µg/l, 
interassay coefficient of variation (CV): 1.6-8.4% of 0.01-15.38µg/l) 
from 1992 onwards. For the conversion of µg/l to mU/l, multiply by 
2.6. Before 1992, GH was measured by RIA (Biolab, Serona, Coissins, 
Switzerland), detection limit: 0.5mU/l, with an interassay CV <5%; 
for the conversion of µg/l to mU/l, multiply by 2. From 1986 to 2005, 
serum IGF-1 concentrations were determined by RIA (Incstar, Stillwater, 
MN) with a detection limit of 1.5nmol/l and an interassay CV less than 
11%. IGF-1 is expressed as SD score for age- and gender-related normal 
levels determined in the same laboratory (33). Since 2005, serum IGF-1 
concentrations (nmol/l) were measured using an immunometric technique 
on an Immulite 2500 system (Siemens Healthcare Diagnostics, Deerfield, 
IL, USA). The intra-assay variations at mean plasma levels of 8 and 
75nmol/l were 5.0 and 7.5%, respectively. IGF-1 levels were expressed as 
SDS, using lambda-mu-sigma smoothed reference curves based on 906 
controls(21;22). 
B-crosslaps and P1NP concentrations were measured by an 
electrochemolumiscent immunoassay with a Modular Analytics E-170 
system (Roche Diagnostics, Almere, The Netherlands). References values 
for β-crosslaps and P1NP concentrations were, respectively, <0.854ng/ml 
and <59ng/ml. Vitamin D25OH was measured by RIA (Incstar/DiaSorin, 
Stillwater, MN, USA) (reference range (50 – 250nmol/l).
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In this thesis, a number of observations have been described in acromegaly 
patients with cured or biochemically well-controlled disease during long-
term follow-up. These observations focus on the long-term consequences 
of the disease on joints and bone, which have been investigated in a 
prospective follow-up study (Part A). In addition, we investigated the role 
of the Growth Hormone (GH) / Insulin-like Growth Factor-1 (IGF-1) 
axis in patients with primary osteoarthritis (OA), looking at serum IGF-1 
levels within the normal range and the exon 3 deleted GH receptor 
(d3-GHR) polymorphism (Part B). Finally, we studied the long-term 
consequences of recombinant human GH (rhGH) treatment in GH 
Deficient (GHD) adults, focusing on the cardiovascular effects and the 
effects on bone metabolism in comparison to healthy controls (Part C).
Part A. Long-term effects of acromegaly on joints 
and bone
Acromegaly is a rare endocrine disease caused in most cases by a pituitary 
adenoma resulting in excessive GH secretion. As a consequence, patients 
suffer from elevated GH and IGF-1 levels. As clinical manifestations 
appear slowly and first symptoms are non-specific, it is a typical disease 
with a delay in diagnosis of 6 to 9 years. Following appropriate therapy, 
by surgery, radiotherapy, medical treatment or a combination of these 
treatment modalities, many systemic co morbid conditions of acromegaly 
improve considerably. Unfortunately, it has become apparent that despite 
biochemical control, many manifestations of acromegaly remain detectable 
during prolonged follow-up, significantly impairing QoL. Although 
acromegaly is a very heterogeneous disease with individual susceptibility 
for GH and IGF-1 levels, skeletal manifestations are one of the most 
prevalent and invalidating complications of acromegaly. 
Part A describes the long-term effects of acromegaly on joints and bone 
in a well-characterized cohort of controlled acromegaly patients, who were 
in remission for a mean duration of 17 years. We focused on the course of 
arthropathy and vertebral fractures over time in treated patients and risk 
factors for poor outcome, since, at present, the prognosis and determinants 
of both acromegalic arthropathy and vertebral fractures during prolonged 
follow-up are unknown. In order to address these questions, we designed a 
prospective 2.5-year follow-up study.
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Arthropathy is one of the most common complications of acromegaly, 
and is highly prevalent both in active and (long-term) controlled disease. 
Previously, elevated GH / IGF-1 activity was found to be associated with 
the onset of acromegalic arthropathy. Especially patients with high IGF-1 
levels at the time of diagnosis and with the common exon 3 deleted GH 
receptor (d3-GHR) polymorphism, that is associated with enhanced GH 
responsiveness (vide infra), were at increased risk to develop secondary 
arthropathy. Although acromegalic arthropathy shares features with 
primary OA, radiographic features significantly differ. Severe osteophytosis 
is seen, but joint spaces are widened rather than narrowed in patients with 
long-term controlled acromegaly. However, usually performed semi-
quantitative measures as used and validated in primary OA cohorts do not 
include joint space widening. Recently, a new quantitative semi-automated 
image analysis method of hand radiographs by Van ‘t Klooster et al. was 
shown to be sensitive enough to relate joint space width to markers of 
disease activity of acromegaly and is therefore able to fully characterize the 
effects of previous GH excess on joints, including joint space widening. 
RADIOGRAPHIC AND CLINICAL PROGRESSION OF ACROMEGALIC 
ARTHROPATHY: The disease course of acromegalic arthropathy in treated 
patients during prolonged follow-up is unknown. In addition, information 
on risk factors for poor OA outcome is currently lacking. Therefore, 
we studied in Chapter 2 and Chapter 3 the course of acromegalic 
arthropathy and determinants of poor outcome in a prospective study with 
2.5 years of follow-up. Chapter 2 focuses on the radiographic change over 
time, and Chapter 3 describes the course of clinical joint symptoms and 
signs during prolonged follow-up, and assesses the relationship between 
clinical and radiographic change of arthropathy. All 58 patients included 
were biochemically controlled, by either transsphenoidal surgery and/
or additional radiotherapy or (primary) medical treatment, for a mean of 
17.6 years, as evidenced by a mean actual IGF-1 SDS of 0.5. 
Chapter 2 demonstrates progressive osteophytosis and joint space 
narrowing in a considerable proportion of patients (>70%), despite 
biochemical disease control. Higher age and parameters reflecting higher 
GH / IGF-1 activity were associated with progressive joint disease. 
Remarkably, biochemical control by SMS analogs was associated with 
more radiographic OA progression than surgical cure, independently of 
age, sex, BMI and baseline IGF-1 SDS. These findings are in accordance 
with earlier studies documenting differential effects on QoL and diastolic 
heart function in patients controlled with SMS analogs vs patients with 
surgical cure of acromegaly. The hypothesis of insufficient GH control 
when applying current guidelines is further supported by a previous 
report in which GH secretion was found to be persistently abnormal 
during treatment with SMS analogs, and might imply the need of more 
aggressive therapy, probably by addition of Pegvisomant. Further studies 
have to confirm whether co-treatment with Pegvisomant can optimize 
disease control and is thereby able to improve joint symptoms. Alternative 
explanations for increased OA progression in SMS-treated patients may 
be a direct IGF-1 independent effect of SMS analogs on joint structure, or 
a generally less favourable previous course of acromegaly in SMS-treated 
patients. Since SMS analogs are preferred as adjunctive therapy after 
incomplete surgery and are considered as a valuable alternative for surgery 
as primary therapy, present findings may have implications for current 
treatment strategies. 
Chapter 3 focuses on the clinical course of acromegalic arthropathy 
during prolonged follow-up in remission. Clinical arthropathy was 
assessed by validated questionnaires on self-reported joint complaints 
of the hands and lower limb, by structured physical examination and 
joint performance tests. We found that on average, hand and lower 
limb function deteriorated during follow-up, although interindividual 
variations were large. Joint pain was stable over time. High levels of 
pain and functional impairments at baseline were risk factors for clinical 
progression with respect to hand pain and function. In the lower limb, 
high BMI was a risk factor for function loss. Changes in clinical symptoms 
were not related to radiographic progression during follow-up, which is a 
discrepancy that is well-known from primary OA. 
We can conclude from Chapter 2 and Chapter 3 that acromegalic 
arthropathy is a progressive joint disease that is not merely halted or 
reversed by biochemical disease control. Since clinical and radiographic 
progression of arthropathy are not related, we propagate that in clinical 
practice a combination of clinical and radiographic assessment is necessary 
to evaluate the course of acromegalic arthropathy. As previously shown, 
physical joint symptoms significantly impair QoL. In this respect, since 
the optimal management of acromegalic arthropathy is currently unknown 
and (any) medication does not influence the clinical course of arthropathy, 
further investigation has to assess whether specific intervention therapies, 
for example physiotherapy, are beneficial. 
VISUALIZATION OF ACROMEGALIC ARTHROPATHY BY MRI : In 
Chapter 4, we further characterize acromegalic joints by 3.0T MRI 
scans of the knee. We chose for this imaging modality since MRI 
may give additional information to plain films, especially on cartilage 
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damage and subchondral bone abnormalities, such as osteophytes, cysts 
and bone marrow edema. Comparisons were made between patients 
with active acromegaly and acromegaly patients in remission, either by 
medical treatment or surgery/radiotherapy. Primary OA patients from 
the geMstoan study, which is a longitudinal study among primary OA 
patients with established knee OA, were included as controls in order to 
differentiate which structural abnormalities on MRI were acromegaly-
specific. Furthermore, cartilage thickness and cartilage T2 relaxation 
times, providing information on the biochemical composition of 
cartilage, were compared between acromegaly patients and, respectively, 
geMstoan controls and literature controls. In the present study, which is 
the first study on acromegalic arthropathy using MRI, we showed that 
structural OA defects are already highly prevalent in the active acromegaly 
phase. In patients with active acromegaly articular cartilage is not only 
thicker than in the controlled disease phase, but is also from a different 
biochemical composition, as reflected by higher cartilage T2 relaxation 
times, suggesting increased water content and collagen breakdown in these 
patients. The findings of the present study could introduce the hypothesis 
that in active acromegaly the thickened joint cartilage consists of two 
different components: a structural component of cartilage hypertrophy, 
being (partially) irreversible despite long-term biochemical remission, and 
a component of edema, which is reflected by the cartilage T2 relaxation 
times, that decreases after successful treatment. This may explain why 
joint cartilage of controlled acromegalics is still thickened due to persisting 
cartilage hypertrophy, but decreases after achievement of biochemical 
remission compared to the active disease phase due to a decrease in water 
content, with a corresponding decrease in cartilage T2 relaxation times. 
When compared to subjects with primary OA, acromegaly patients had 
thicker knee cartilage and, at all measured sites, cartilage T2 relaxation 
times were higher in acromegaly patients, indicating that joint cartilage 
is not only thicker in acromegaly patients but has also an altered average 
biochemical composition. The relevance of these altered cartilage 
composition should be investigated in future studies. 
RADIOGRAPHIC PHENOTYPE OF ACROMEGALIC ARTHROPATHY: 
Joint space narrowing is an infrequent radiographic finding in patients 
with acromegalic arthropathy. It is unknown whether joint space 
narrowing reflects the end-stage of acromegalic arthropathy or whether 
this feature develops independently of acromegaly. In Chapter 5, risk 
factors for joint space narrowing and its relationship to clinical symptoms 
were studied. We found joint space narrowing in, respectively, 10.3% 
and 15.4% of the hips and knees of patients with controlled acromegaly. 
Well-known risk factors, such as age and female sex were associated with 
more joint space narrowing; acromegaly-specific risk factors for joint 
space loss were joint-site specific. In the hip, joint space narrowing was 
related to more active acromegaly disease, as reflected by higher pre-
treatment GH/IGF-1, longer and more severe GH exposure, and less cure 
by surgery/radiotherapy. In the knee, especially previous knee surgery, 
not acromegaly-specific characteristics, was associated with joint space 
narrowing. The presence of joint space narrowing was associated with 
more joint complaints. The present study shows that joint space narrowing 
in an infrequent finding in patients with acromegalic arthropathy, but 
is, although, associated with more clinical symptoms. At least in the hip, 
there is a role for excessive GH / IGF-1 activity, not only in the early stage 
of acromegalic arthropathy, but also in its late phase, as reflected by joint 
space narrowing. Present findings underline the irreversibility of the joint 
effects caused by previous GH excess, and characterize the progressiveness 
of acromegalic arthropathy. 
PROGRESSION OF VERTEBRAL FRACTURES IN CONTROLLED 
ACROMEGALY: Another long-term consequence of acromegaly is the 
occurrence of vertebral fractures in a high proportion of patients. Also 
in controlled disease, prevalence of vertebral fractures was shown to 
be impressively high (up to 60%). Most patients suffer from multiple 
vertebral fractures, especially of the anterior wedge type. In these patients, 
BMD is frequently normal and is therefore a bad predictor of future 
fracture risk in this form of secondary osteoporosis. Therefore, in these 
patients, the high vertebral fracture risk appears to be caused by a problem 
in bone quality rather than bone quantity. To date, it is unclear whether 
patients in long-term remission have a persistent, irreversible high risk of 
future fractures, or whether GH/IGF-1 control reduces the fracture risk 
to normal, despite presence of prevalent vertebral fractures. In view of 
the excess mortality and significant morbidity associated with vertebral 
fractures, insight in progression is of paramount clinical significance. 
In Chapter 6, the disease course of vertebral fractures and potential 
determinants for progression were studied in treated acromegaly patients. 
We found that patients not using bisphosphonates, baseline prevalence of 
vertebral fractures was very high (63%). Prevalence was highest in males 
and was unrelated to BMD. Patients frequently suffered from multiple 
vertebral fractures. We found progression of vertebral fractures in 20% 
of patients over a relatively short follow-up period of 2.5 years, with 
highest progression rate in males and in case of ≥2 vertebral fractures at 
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baseline. No other risk factors for progression were identified. Progression 
of vertebral fractures was not related to BMD values or the change in 
BMD over time, at either the lumbar spine or total hip. The present study 
indicates that in acromegaly, vertebral fractures do not solely develop 
during the active phase of disease. During prolonged follow-up, normal 
BMD was shown to be maintained, although apparently this does not 
protect against progression of vertebral fractures. These results suggest 
that the high vertebral fracture risk in acromegaly patients is due to 
abnormalities in bone quality. We hypothesize that in active acromegaly 
the following process occurs: due to cortical proliferation, the bone 
volume produced per time unit increases, whereas due to trabecular loss, 
the mechanical loading strength of the bone decreases, despite thickening 
of trabecles. We postulate that these changes result in decreased bone 
material strength properties, in the presence of normal BMD. This 
decreased bone quality might explain the high fracture risk in acromegalic 
vertebrae, since vertebrae mostly consist of trabecular bone. As shown in 
previous studies from our center, this trabecular widening sustains after 
disease cure, whereas the amount of cortical bone decreases. Therefore, 
vertebral fracture risk remains irreversibly high despite long-term disease 
remission. 
Since BMD is normal in most acromegaly patients and is therefore a 
bad predictor for fracture risk, it is a clinically relevant question how to 
identify patients at risk for (vertebral) fractures. We propose to include 
vertebral fracture assessment in the screening of acromegaly patients and 
during follow-up after establishment of biochemical control. Further 
research should address the question whether acromegalic patients require 
treatment for these (vertebral) fractures and whether they actually benefit 
from bisphosphonates.
Part B. The role of the GH / IGF-1 axis in primary 
osteoarthritis
Part B describes studies investigating the involvement of the GH / IGF-1 
axis in the development and progression of primary OA. OA is a common 
disease, characterized by progressive degradation of articular cartilage and 
bone remodeling, resulting in pain and disability. Despite the increase in 
molecular knowledge accrued during the last years, the exact pathogenesis 
of the destructive process remains unknown. OA is considered to 
be a multifactorial disease in which age, BMI, hormonal and local 
biomechanical factors together with genetic predisposition play a role. 
RELATIONSHIP BETWEEN SERUM IGF-1 CONCENTRATIONS AND 
PRIMARY OA : Several lines of research suggest a role of the GH / IGF-1 
axis in OA pathogenesis. First, IGF-1 has been shown to enhance 
chondrocyte proliferation and proteoglycan and collagen synthesis by 
chondrocytes in normal cartilage, both in vivo and in vitro, also during 
cytokine exposure. These anabolic and protecting properties make 
IGF-1 an obvious candidate for a major role in cartilage repair. Second, 
in acromegaly disease, we found further evidence for an association 
between the activity of the GH/IGF-1 axis and the risk of secondary 
OA. Prevalence and severity of arthropathy worsen with the duration 
of uncontrolled acromegaly, and pre-treatment IGF-1 levels predict 
radiographic OA in a dose-dependent manner. Finally, previous studies 
showed that genes regulating formation, degradation and repair of 
articular cartilage and subchondral bone remodelling may be involved in 
OA pathogenesis. In this respect, especially endochondral ossification is of 
importance (vide infra).
In this context, in Chapter 7, we summarized the evidence for a role 
of serum IGF-1 concentrations in primary OA by conducting a systematic 
review of literature. We also addressed the association between several 
IGF-1 gene polymorphisms and the onset of primary OA. In total, 11 
studies were eligible for inclusion. Methodological quality of all individual 
studies was assessed using a standardized set of criteria, which have been 
used previously in reviews on musculoskeletal disorders. In vitro studies, 
genetic association studies and the high secondary OA risk in pathological 
IGF-1 states all suggest an effect of the GH / IGF-1 system in OA 
development. However, although the largest cross-sectional study and 
the longitudinal study on OA progression found a positive association 
with high serum IGF-1, inconsistent results were shown in studies on 
serum IGF-1 and radiographic OA. We concluded from this systematic 
review that there is moderate evidence that IGF-1 is no risk factor for 
radiographic OA in patients with primary OA. Since we cannot exclude 
that methodology, publication bias and small sample size of the available 
studies have influenced the results; we suggest that future well-designed 
large prospective studies are needed to strengthen the evidence for the 
role of IGF-1 in primary OA. In this respect, especially age, sex and BMI 
has to be taken into account, since these factors are important for the 
interpretation of IGF-1 levels. 
Since our systematic review, which we described in Chapter 7, reported 
inconsistent results among epidemiological studies investigating the 
association between serum IGF-1 and radiographic OA, we studied serum 
IGF-1 concentrations in relation to primary OA onset and progression in 
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a large familial OA cohort, taking into account age, sex and BMI. These 
results are described in Chapter 8. We used a well-characterized cohort 
of patients with familial OA at multiple joint sites from the Genetics 
osteoARthritis and Progression (GARP) Study, in which serum IGF-1 
levels were within the normal range. We found that in the GARP cohort 
mean IGF-1 SDS was significantly increased when compared to reference 
values. We were, however, not able to demonstrate a relationship between 
serum IGF-1 levels and presence or progression of radiographic OA or 
worsening of individual OA features (i.e. osteophyte growth or joint 
space loss) at specific joint sites within the GARP study. Several remarks 
have to be made. First, it should be noted that all GARP subjects have 
a severe OA phenotype of familial OA at multiple joint sites, making 
joint-specific analysis difficult to perform. In addition, since the GARP 
Study is a very homogeneous cohort with less variation in OA phenotype, 
the detection of a clear dose-response relationship is difficult. Second, 
serum IGF-1 levels of almost all GARP subjects were within the normal 
reference range, resulting probably in too less variation in IGF-1 levels to 
detect an association with OA severity or progression. In addition, IGF-1 
measurement by serum samples is very complex, because individual IGF-1 
levels are liable to temporary variations and are inversely correlated to age, 
estrogen levels and BMI. Furthermore, radio-immuno assays (RIA) for 
measuring serum IGF-1 are subject to analytical difficulty. The findings 
of the present study are in accordance to several lines of previous evidence 
suggesting a role for increased GH/IGF-1 activity in the pathophysiology 
of OA. However, no clear dose-response relationship between IGF-1 
SDS and either the presence or progression of radiographic OA was 
found. Taking into account imperfections in IGF-1 measurement and 
the homogeneous severe OA phenotype in the GARP Study, further 
research has to clarify the complex role of the GH / IGF-1 axis in OA 
pathophysiology.  
ASSOCIATION BETWEEN D3-GHR POLYMORPHISM AND PRIMARY 
OA: Genetic influences play a considerable role in the pathogenesis of 
primary OA. Genetic studies have identified several variants associated 
with primary OA, which were all involved in the process of endochondral 
ossification, being the main process in longitudinal skeletal growth. 
Endochondral ossification is driven by growth plate chondrocytes, and 
result in longitudinal growth through a combination of proliferation, 
extracellular matrix (ECM) secretion and hypertrophy. Subsequently, 
terminally differentiated chondrocytes die and are replaced with bone 
tissue. At all stages, chondrocyte behaviour is tightly regulated by a 
complex network of interactions between circulating hormones, locally 
produced growth factors and ECM components. One of the strongest 
stimulators of chondrocyte proliferation is GH, predominantly via IGF-1 
secretion. This qualifies variations within GH / IGF-1 genes as obvious 
candidates for association studies. 
The effects of GH on target tissues are mediated by the dimeric GHR, 
which exists of different molecular structures, depending on assortments 
of coding polymorphisms in the GHR gene. In 2004, Dos Santos et al. 
described a common polymorphism of the GHR, called exon 3 deleted 
GHR (d3-GHR), which was found to increase the growth response in 
children with different causes of growth failure. This common d3-GHR 
polymorphism is present in ~30-35% of the normal population, and 
results in a truncated receptor with an increased GH responsiveness, being 
attributed to an enhanced signal transduction. Since 2004, in various 
clinical conditions, such growth failure in children and acromegaly, 
d3-GHR polymorphism was shown to have functional consequences. 
In this context, in acromegaly patients, the d3-GHR polymorphism was 
previously reported to be associated with the presence and the severity of 
radiographic arthropathy. The association with primary OA, however, has 
never been studied. 
To further explore the role of the GH / IGF-1 axis in primary OA, we 
studied in Chapter 9 the association between the d3-GHR polymorphism 
and (symptomatic) primary OA, using a candidate-gene study approach. 
We initially did explorative analyses in males and females with familial 
OA at multiple joint sites from the GARP Study vs population-based 
controls without (signs of ) OA. The GARP Study was chosen as discovery 
cohort, because this study consists of genetically enriched OA patients 
with information on multiple joint sites. Patients from the GARP 
Study were genotyped for 7 single nucleotide polymorphisms (SNPs) 
encompassing the d3-GHR gene (rs4590183, rs13354167, rs7721081, 
rs7701605, rs4242116, rs6878512, rs10941583). All SNPs were in high 
linkage disequilibrium with d3-GHR. We selected the SNP rs4590183 
as proxy for d3-GHR, and tested this SNP in three additional cohorts 
for replication purposes, being the PAPRIKA (PAtients Prospectively 
Recruited In Knee and hip Arthroplasty)/RAAK (Research Articular 
osteoArthritis Cartilage) study including subjects with a total hip and/
or knee prosthesis due to end-stage OA, Rotterdam study among subjects 
with severe symptomatic OA and ACRO study including acromegalic 
patients with symptomatic and/or radiographic OA. Finally, the GARP, 
PAPRIKA/RAAK, Rotterdam and ACRO studies were combined in 
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a genetic meta-analysis. In the GARP Study, we found an association 
between the d3-GHR polymorphism and OA in females (adjusted odds 
ratio (OR) 1.36 (95%CI 1.01-1.83), p=0.043), not in males. Since the 
association between d3-GHR and OA was only present in females, the 
meta-analysis was aimed on female OA cases, comprising a total of 2175 
OA cases and 2623 controls. The combined analysis showed evidence 
for association between the d3-GHR polymorphism and OA at any 
joint location in females (OR=1.17 (95%CI 1.04-1.32), p=0.013). This 
association remained significant after exclusion of the discovery study 
(OR=1.14, 95%CI 1.01-1.30, p=0.042). Stratifying by joint site revealed 
consistent effect sizes of approximately 1.2–1.3 among the joint strata, 
with most profound effects in cases with hip OA. It has to be noted that 
the effect sizes reported in our study are relatively large in contrast to 
recent large scale GWA studies, such as of Zeggini et al.. This is likely to be 
explained by the fact that we have applied a family-based sampling scheme 
towards the extreme spectrum of the OA phenotype for the GARP Study. 
Thereby, this study is tailored to find genetic variants in the low frequency 
range with moderate to large effect sizes. Being aware of the tendency of 
association studies to produce false-positive results, additional replication 
of our results is necessary.
The results of the present study are in line with those of Chapter 
8, indicating that overactivity of the GH / IGF-1 axis accelerates the 
OA process in susceptible patients, and is thereby associated with an 
increased OA risk. We conclude from Chapter 9 that the effects of the 
d3-GHR polymorphism are not limited to subtle variations in growth 
parameters in children with growth failure or acromegaly patients. 
Despite the fact that the effect of d3-GHR on the GH /IGF-1 axis itself 
is not yet completely elucidated, the functional effects of the d3-GHR 
affect many pathophysiological processes in which the GH / IGF-1 axis 
is involved to some extent. The findings of the studies described in Part 
B provide further evidence for involvement of the GH / IGF-1 axis in 
the pathophysiology of primary OA. For clinical practice, the increased 
activity of the GH / IGF-1 system as a risk factor for primary OA (onset) 
could be a potential therapeutic target.
Part C. Long-term outcome of recombinant human 
GH (rhGH) therapy in GH def icient (GHD) adults
Part C addresses the long-term effects of rhGH therapy in adult patients 
with GHD, studied in a large well-defined cohort of GHD patients that 
were diagnosed and followed yearly at the outpatient clinic of the LUMC. 
GHD in adults is associated with an adverse metabolic profile that 
includes abdominal obesity, dyslipidemia and an increased mortality risk. 
Short-term follow-up studies have shown that rhGH replacement reduced 
some, but not all of these cardiovascular risk factors. Consistent effects 
were reported on body composition and lipid metabolism, characterized 
by reduction of body fat and an increase of lean body mass, and a 
reduction of total cholesterol (TC) and low-density lipoprotein cholesterol 
(LDL-C) levels. In selected patients, also positive effects on QoL and 
general well-being were described. Based on these positive short-term 
effects, rhGH replacement has become widely accepted as chronic therapy 
in adult GHD. These effects were reported to be sustained for the first 5 
years of rhGH treatment; however, long-term efficacy and safety data are 
very limited and frequently uncontrolled for the effect of ageing.  
LONG-TERM OUTCOME OF RHGH SUPPLEMENTATION IN GHD 
ADULTS: In Chapter 10, we systematically reviewed the effects of chronic 
rhGH therapy, defined as at least 5 years, in GHD adults on biochemical 
and anthropometric parameters, QoL, bone metabolism, muscle strength, 
serious adverse events (SAEs) and mortality. In total, 23 studies met our 
inclusion criteria, and were therefore eligible for inclusion. Methodological 
quality of all studies was assessed using a standardized set of criteria based 
on the STROBE statement. We reported that available literature on long-
term rhGH replacement in adult GHD patients shows inconsistent results 
with respect to its expected beneficial effects, in the presence of several 
drawbacks to enable a definite interpretation. First, long-term studies 
were generally uncontrolled, lacking a control group (of non-treated 
GHD patients) enabling adjustment for subjective changes or changes 
due to ageing. Second, only a limited number of centers have reported 
their data, resulting in a low number of evaluable patients with half of the 
long-term studies describing (part of ) the same patient cohort. Especially 
the course of QoL during ongoing therapy is unestablished. With respect 
to the metabolic profile, rhGH therapy has shown prolonged, beneficial 
effects on body composition, lipid profile, carotid IMT and BMD, but 
overall cardiovascular risk, as assessed by the prevalence of the metabolic 
syndrome (MS), glucose levels, BMI appeared not to be influenced or were 
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even negatively affected. It has to be noted that accurate data on the use 
of lipid-lowering or anti-diabetic medication was lacking in most studies. 
Therefore, we concluded that the benefit of long-term rhGH treatment 
should be a matter of ongoing research to enable adequate risk-benefit 
analyses and, in clinical daily practice, the benefits of rhGH should be 
considered carefully in each patient. 
METABOLIC EFFECTS OF LONG-TERM RHGH SUPPLEMENTATION IN 
GHD ADULTS: Since 10-year follow-up studies on the effects of rhGH 
suppletion are scarce, patient numbers are small in most studies and 
information on the use and handling with lipid-lowering and anti-diabetic 
medication is frequently lacking, we studied the 10-years metabolic 
effects of rhGH replacement in our own GHD cohort. In Chapter 11 
we described the effects of 10 years rhGH replacement on biochemical 
and anthropometric parameters in 98 adult GHD patients, of which a 
subset of patients (N=49) had been received rhGH suppletion for 15 
years. In addition, we studied the prevalence of the metabolic syndrome 
(MS), and calculated the incidence of major cardiovascular events. All 
GHD patients were stringently controlled with proposed physiological 
rhGH replacement by closely monitoring IGF-1 SD levels, adjusted 
for age during the entire study period. We reported ongoing beneficial 
effects on the lipid profile after 10 years of rhGH replacement, with a 
significantly decrease in total cholesterol and LDL-C levels and an increase 
in HDL-C when compared to baseline. On the other hand, the increases 
in waist circumference, BMI and fasting glucose levels during rhGH 
replacement were striking. In the subset of patients with 15-year rhGH 
replacement, generally similar metabolic effects were found. However, 
despite improvement of several cardiovascular risk factors, MS prevalence 
increased significantly despite rhGH replacement, from 32.7% before 
the start of rhGH replacement to 57.1% after 10 years. This increase was 
most definite in male GHD patients. Incidence of major cardiovascular 
events was low (1.5/1000 patient-years). In conclusion, since, currently, 
improvement of cardiovascular risk, in addition to QoL, is the major 
target for rhGH treatment in adult GHD patients, larger and controlled 
studies have to establish the net beneficial effects of long-term rhGH 
suppletion on the cardiovascular risk in these patients. In addition, 
our metabolic findings merit critical re-evaluation of prolonged rhGH 
replacement, also from a cost-benefit point of view. In this respect, rhGH 
replacement should be compared with widely available drugs, i.e. statins, 
that have been proven to be effective in secondary cardiovascular risk 
prevention. 
A limitation of the study described in Chapter 11, and a general drawback 
of long-term follow-up studies, is the lack of a non-treated control group. 
Because the beneficial effects of rhGH therapy are well-established in 
the short term, it is regarded to be unethical to withhold patients with 
GHD from receiving rhGH in case of no contraindications. This makes it 
difficult, if not impossible, to perform long-term randomized controlled 
studies including GHD patients without rhGH treatment. Since an 
ideal unselected GHD control group without rhGH replacement is not 
available, an alternative strategy to explore long-term (metabolic) effects 
of rhGH in GHD patients is the comparison with healthy controls. 
Recently, in the LUMC, a large population-based study focused at the 
pathophysiology of obesity (Nederlandse Epidemiologie van Obesitas 
(NEO) Study) was conducted. Therefore, large scale contemporary 
control data of normal-weight and obese subjects, derived from the same 
geographic area as the GHD patients, are available. 
In order to assess the ability of current rhGH replacement strategies to 
normalize metabolic parameters, we describe in Chapter 12 the long-
term effects of rhGH replacement on the metabolic profile. We compared 
a large cohort of 161 middle-aged GHD patients on chronic rhGH 
replacement (i.e. 5 years) with healthy normal-weight middle-aged control 
subjects from the Leiderdorp cohort of the NEO Study. We reported 
that, despite chronic rhGH replacement, GHD patients had a 1.3-times 
higher MS risk than controls, independently of age, sex and BMI 
(53.4% vs 30.3%). In addition, GHD patients remain to have a different 
metabolic profile than controls with similar BMI, with an increased risk 
of hypertriglyceridaemia and low HDL-C, but less hyperglycaemia. This 
indicates that the metabolic phenotype of middle-aged GHD patients is 
complex and cannot simply be extrapolated to the adverse cardiovascular 
phenotype as is present in the general population. It is remarkable that 
although this GHD cohort is thought to be adequately hormonally 
substituted, the metabolic profile after chronic rhGH replacement 
resembles the profile of an untreated GHD patient, with predominantly 
lipid abnormalities. These findings question whether long-term rhGH 
replacement is as beneficial as previously propagated with respect to 
net cardiovascular risk reduction. We propagate that in the context of 
increasing evidence for, on the one hand, a (negative) role of GH and 
IGF-1 in cancer, longevity and cardiovascular disease, and, on the other 
hand, the limited evidence for benefit of rhGH substitution in the elderly 
GHD population, the long-term rhGH use in GHD adults should be 
critically re-evaluated.
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EFFECTS OF LONG-TERM RHGH SUPPLEMENTATION ON BONE 
METABOLISM IN GHD ADULTS: In Chapter 13, we assessed the effects 
of 5, 10 and 15 years of rhGH replacement on bone markers, BMC and 
BMD in a well-characterized cohort of 230 adult GHD patients. We 
further studied fracture incidence during rhGH suppletion. We found a 
sustained increase in lumbar spine BMD, lumbar spine BMC and T-scores 
during the first 10 years, with stabilization thereafter. Highest effects were 
found in men, which is in accordance to the results of several other studied 
investigating the bone response to rhGH suppletion. No effects on femoral 
neck BMD were found. Concomitant bisphosphonate use did not have 
additional beneficial effects on BMD in these patients. Clinical fracture 
incidence during long-term rhGH suppletion was 20.1 / 1000 py and 
seemed to be low in these patients. In conclusion, these findings from our 
cohort study of GHD patients demonstrate ongoing beneficial effects on 
bone metabolism of long-term rhGH replacement therapy, particularly in 
men, with relatively low clinical fracture incidence. Sex-specific differences 
in bone response to rhGH replacement and the long-term beneficial 
effects of bisphosphonates on fracture risk warrant further studies in adult 
GHD patients, and therefore, protocolled prolonged follow-up of these 
patients is mandatory.
GENERAL DISCUSSION AND FUTURE 
PERSPECTIVES
Part A. Long-term effects of acromegaly on joints 
and bone
In acromegaly, appropriate treatment by surgery, radiotherapy, medical 
therapy, or a combination of these treatment modalities, considerably 
improves many systemic co morbid conditions. Unfortunately, it has 
become apparent that despite biochemical control, many manifestations 
of acromegaly remain detectable during prolonged follow-up, being the 
consequence of previous (transient) GH excess. Patients suffer from severe 
skeletal manifestations, significantly affecting QoL and mortality. In 
this respect, arthropathy and VFs are common invalidating (irreversible) 
complications of acromegaly. 
The studies described in this thesis describe the characteristics 
and disease course of acromegalic arthropathy, (partly) by using new 
validated techniques. Acromegalic arthropathy was shown not to have an 
unequivocal phenotype: it is characterized by osteophytosis and wide joint 
spaces in most patients, however, in a minority of patients JSN is observed. 
Cartilage imaging by MRI showed that especially joint cartilage differs 
between acromegaly patients and primary OA subjects. Pathologically GH 
secretion was found to be associated not only with thicker joint cartilage, 
but also with changes in biochemical cartilage composition, as reflected 
by changes in T2 cartilage relaxation times. Furthermore, we reported 
that acromegalic arthropathy is a IGF-1 dependent progressive joint 
disease, both clinically and radiographically, which is not merely halted 
by biochemical disease control. Arthopathy progression seemed to be 
associated with insufficient GH control. Further studies have to confirm 
whether more aggressive therapy, for example by addition of Pegvisomant, 
can optimize disease control and thereby can improve joint symptoms. In 
clinical practice, a combination of clinical and radiographic arthropathy 
assessment is essential in these patients. In addition, further investigation 
has to focus on acromegalic-specific intervention therapies to improve OA 
symptoms in these patients. Finally, there is a need for acromegaly-specific 
scoring methods and imaging techniques, such as the semi-quantitative 
measurement developed by Van ‘t Klooster et al. and the MRI techniques 
described in this thesis to fully characterize acromegalic arthropathy. 
Another highly prevalent skeletal complication of acromegaly is the 
presence of vertebral fractures. We found impressively high vertebral 
fracture prevalence in long-term controlled acromegalics not treated with 
bisphosphonates, in the presence of normal BMD values and normal 
Vitamin D levels. Progression of vertebral fractures was shown in 20% 
of patients, indicating that the occurrence of vertebral fractures is an 
irreversible process. A possible explanation for the high vertebral fracture 
risk acromegaly is a diminished bone quality, which should be investigated 
in future studied, by performing bone biopsies. Further research should 
focus on an optimal treatment strategy for vertebral fractures, since, 
currently, the benefit of bishosphonates in this specific patient group is yet 
unestablished.   
Part B. The role of the GH / IGF-1 axis in primary 
osteoarthritis
Primary OA is a debilitating common disease, characterized by progressive 
degradation of articular cartilage and bone remodeling. Despite the 
increase in molecular knowledge accrued during the last years, the 
exact pathogenesis of the destructive process remains unknown. OA is 
considered to be a multifactorial disease in which age, BMI, hormonal 
and local biomechanical factors together with genetic predisposition play a 
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role. Several lines of research suggest a role of the GH / IGF-1 axis in OA 
pathogenesis. 
The studies described in this thesis further support the evidence for 
involvement of the GH / IGF-1 axis in primary OA onset and progression. 
We reported that patients with familial primary OA at multiple joint sites 
from the GARP Study had, overall, higher serum IGF-1 concentrations 
than expected. These findings are in line with the results of our genetic 
meta-analysis comprising 2175 cases and 2623 controls, in which we 
found an association between the common d3-GHR polymorphism, being 
associated with an enhanced GH responsiveness of the GHR, and primary 
OA in females. Largest effect was found in cases with hip OA. Together, 
these studies indicate that increased activity of the GH / IGF-1 axis 
accelerates the OA process in susceptible patients, and is thereby associated 
with an increased OA risk. Future large controlled studies should confirm 
whether OA patients indeed have higher IGF-1 concentrations compared 
to patients without any signs of OA. For clinical practice, the increased 
activity of the GH / IGF-1 system as a risk factor for primary OA (onset) 
could be a potential target for therapeutic approaches. In this respect, it 
would be interesting to study whether administration of GH-lowering 
lowering medication can be effective in inhibiting OA progression.
Part C. Long-term outcome of rhGH replacement in 
GHD adults
GHD in adults is a clinical entity associated with an adverse metabolic 
profile that includes abdominal obesity and dyslipidemia, decreased bone 
mass, decreased QoL and an increased mortality risk. Short-term follow-
up studies have shown consistent beneficial effects of rhGH replacement 
on body composition and lipid metabolism, and in selected patients, also 
positive effects on QoL and general well-being were described. Based on 
these positive short-term effects, rhGH replacement has become widely 
accepted as chronic therapy in adult GHD. These effects were reported to 
be sustained for the first 5 years of rhGH treatment; however, long-term 
efficacy and safety data are very limited and frequently uncontrolled for 
the effect of ageing.  
The studies described in this thesis report the long-term effects of 
rhGH replacement in a large well-defined cohort of adult GHD patients, 
proposed to be stringently controlled. We reported ongoing beneficial 
effects on the lipid profile after 10 years of rhGH replacement, but, on the 
other hand, significant increases in waist circumference, BMI and fasting 
glucose levels. Despite improvement of several cardiovascular risk factors, 
MS prevalence increased significantly during rhGH replacement and was 
significantly higher than in age-, sex- and BMI-matches controls from the 
general population. In addition, there were differences in the metabolic 
profile between rhGH-treated GHD adults and controls. Incidence of 
major cardiovascular events during long-term rhGH supplementation 
was low. With respect to bone metabolism, rhGH suppletion seems to be 
beneficial on BMD in the long-term, especially at the lumbar spine and in 
men, in the presence of low fracture incidence.
Based on these data, we propagate that in the context of increasing 
evidence for, on the one hand, a role of GH and IGF-1 in cancer, 
longevity and cardiovascular disease, and, on the other hand, the limited 
evidence for benefit of rhGH substitution in the elderly GHD population, 
structural follow-up and continuous monitoring of rhGH treatment is 
necessary. In this respect, new, more sensitive biomarkers to monitor 
disease activity are needed. 
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Dit proefschrift beschrijft studies naar de lange termijn complicaties 
van acromegalie op gewrichten en botten in een cohort met gecureerde 
acromegalie patiënten (Deel A). Daarnaast is de rol van de groeihormoon 
(GH)/insulineachtige groeifactor-1 (IGF-1) as onderzocht in patiënten 
met primaire artrose (Deel B). Ten slotte zijn de lange termijn effecten 
van rhGH therapie in kaart gebracht in een groep volwassen patiënten 
met groeihormoon deficiëntie (GHD). Hierbij ligt de focus op de 
cardiovasculaire effecten van recombinant humaan GH (rhGH) therapie 
en de effecten op het botmetabolisme (Deel C). 
Deel A. Lange termijn effecten van acromegalie op 
gewrichten en bot
Acromegalie is een endocriene ziekte die in de meeste gevallen wordt 
veroorzaakt door een hypofyseadenoom. Dit adenoom produceert 
overmatige hoeveelheden GH, wat resulteert in sterk verhoogde GH en 
IGF-1 spiegels in het bloed. De klinische, vaak aspecifieke symptomen 
ontstaan langzaam, waardoor de diagnose acromegalie vaak pas na 6 tot 
9 jaar na het ontstaan van de eerste klachten wordt gesteld. Adequate 
behandeling middels transsfenoïdale operatie, radiotherapie, medicatie 
of een combinatie van deze behandelopties geeft een sterke verbetering 
van een aantal systemische effecten van acromegalie. Echter zelfs na het 
bereiken van langdurige biochemische remissie blijven veel manifestaties 
van de ziekte bestaan en ervaart een groot deel van de patiënten een 
sterk verminderde kwaliteit van leven. In dit opzicht zijn de skeletale 
manifestaties van acromegalie één van de meest voorkomende en 
invaliderende complicaties. 
In Deel A worden de lange termijn effecten van acromegalie op 
gewrichten en botten beschreven in een goed gekarakteriseerd cohort van 
patiënten met acromegalie in langdurige remissie. In het bijzonder is er 
gekeken naar het beloop van gewrichtsafwijkingen en wervelinzakkingen 
en naar risicofactoren voor een slecht beloop van deze afwijkingen. Om 
deze vragen te beantwoorden werd een prospectieve follow-up studie 
uitgevoerd met een gemiddelde vervolgtijd van 2.5 jaar. 
Artropathie is één van de meest voorkomende complicaties van 
acromegalie en heeft een hoge prevalentie onder zowel patiënten met 
actieve ziekte als patiënten die gecureerd zijn. In eerdere studies is 
aangetoond dat een verhoogde GH en IGF-1 activiteit geassocieerd is 
met het ontstaan van gewrichtsklachten bij acromegalie. Voornamelijk 
patiënten met zeer hoge IGF-1 spiegels ten tijde van het stellen van de 
diagnose en met het veelvoorkomende exon 3 deletie GHR (d3-GHR) 
polymorfisme, dat is geassocieerd met een versterkte sensitiviteit voor 
GH, hadden een verhoogde kans op het ontwikkelen van artropathie. 
Hoewel artropathie bij acromegalie gelijkenissen vertoont met de 
gewrichtsafwijkingen zoals deze gezien worden bij patiënten met primaire 
artrose, verschillen de radiologische karakteristieken duidelijk. Artrose in 
acromegalie patiënten wordt gekenmerkt door een ernstige osteofytose 
in combinatie met verwijde gewrichtsspleten. Dit in tegenstelling 
tot de vernauwde gewrichtsspleten die kenmerkend zijn voor het 
kraakbeenverlies bij patiënten met primaire artrose. Recent werd middels 
een nieuwe kwantitatieve semiautomatische methode de karakteristieke 
gewrichtsspleetverwijding in acromegalen gemeten en deze methode bleek 
sensitief genoeg om de gewrichtsspleetdikte te relateren aan markers van 
ziekteactiviteit in acromegalie patienten.  
Het beloop van artropathie na behandeling voor acromegalie is 
onbekend. Daarnaast bestaat er geen literatuur over risicofactoren voor 
een ongunstig beloop van gewrichtsafwijkingen. In Hoofdstuk 2 en 
Hoofdstuk 3 is het beloop van artropathie bij acromegalie patiënten en 
risicofactoren voor een slechte uitkomst bestudeerd in een prospectieve 
follow-up studie met een gemiddelde follow-up duur van 2.5 jaar. In 
deze studie werden 58 acromegalie patiënten geïncludeerd, welke allen 
gemiddeld 17.6 jaar in biochemische remissie waren na een transsfenoïdale 
operatie, radiotherapie en/of medicamenteuze behandeling. 
Hoofdstuk 2 beschrijft het radiologische beloop van artropathie bij 
behandelde acromegalen. Er werd gevonden dat ondanks biochemische 
ziektecontrole meer dan 70% van de acromegalie patiënten progressieve 
osteofytose en gewrichtsspleetvernauwing heeft. Een hogere leeftijd 
en een toegenomen GH/IGF-1 activiteit gedurende de studie waren 
geassocieerd met progressieve gewrichtsziekte. Opvallend was een sterk 
verhoogd percentage radiologische progressie in patiënten door middel 
van behandeling met somatostatine (SMS) analogen in remissie waren 
in vergelijking met operatief gecureerde patiënten, onafhankelijk van 
leeftijd, geslacht, BMI en IGF-1 waarden. Deze bevindingen zijn in 
overeenstemming met eerdere studies die aantoonden dat, in vergelijking 
met operatief gecureerde patiënten, patiënten behandeld met SMS 
analogen ongunstigere uitkomsten hadden op het gebied van kwaliteit 
van leven en diastolische hartfunctie. Daarnaast is eerder aangetoond dat 
gedurende behandeling met SMS analogen de GH secretie niet volledig 
normaliseert. De bevindingen van de hier beschreven studie impliceren 
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dat er een indicatie bestaat voor agressievere therapie, wellicht door 
toevoeging van Pegvisomant. Toekomstige studies zullen moeten uitwijzen 
of een combinatiebehandeling met Pegvisomant de ziektecontrole in 
acromegalie patiënten kan optimaliseren. Een alternatieve verklaring voor 
een toegenomen progressie van artrose in patiënten behandeld met SMS 
analogen is de mogelijkheid van een IGF-1 onafhankelijk effect van SMS 
analogen op gewrichtsstructuren. Daarnaast hebben met SMS behandelde 
patiënten over het algemeen een ongunstiger ziektebeloop. Gezien het feit 
dat behandeling met SMS analogen de voorkeur geniet als additionele 
therapie na een incomplete operatie en als primaire behandeling wordt 
beschouwd als een goed alternatief voor operatie, hebben de bevindingen 
van deze studie implicaties voor de huidige behandelstrategieën.
Hoofdstuk 3 beschrijft het klinische beloop van artropathie bij 
acromegalie patiënten in langdurige remissie en de relatie tussen het 
klinische en radiologische beloop van artrose. Klinische artrose werd 
vastgesteld middels gevalideerde vragenlijsten naar gewrichtsklachten 
(pijn, stijfheid en functiebeperking) van de hand, knie en heup. Daarnaast 
werd gestructureerd lichamelijk gewrichtsonderzoek verricht en werden 
functietesten van de gewrichten uitgevoerd. Deze studie toonde een 
grote variatie in klinisch beloop van artrose tussen patiënten onderling. 
Echter, gemiddeld genomen werd een verslechtering waargenomen van 
de gewrichtsfuncties van de hand, knie en heup ondanks langdurige 
biochemische remissie. Gewrichtspijn was daarentegen stabiel. Veel pijn 
en functiebeperkingen bij aanvang van de studie waren voorspellend voor 
een toename in pijnklachten en functiebeperking in de hand gedurende 
de onderzoeksperiode. Daarnaast was een hoger BMI een risicofactor voor 
een toename van functiebeperkingen in de knie en heup. Klinische en 
radiologische progressie van artrose waren niet aan elkaar gerelateerd, zoals 
ook in de primaire artrose beschreven is. 
Uit Hoofdstuk 2 en Hoofdstuk 3 volgt dat artropathie bij acromegalie 
patiënten een progressieve ziekte is welke niet gestopt wordt door 
biochemische ziektecontrole. Dit onderstreept de irreversibiliteit van 
een eerder GH overschot. Gezien het ontbreken van een relatie tussen 
klinische en radiologische progressie van artrose, is het in de klinische 
praktijk belangrijk een combinatie van klinische en radiologische 
gewrichtsbeoordeling te hanteren. Toekomstig onderzoek zal moeten 
uitwijzen wat de optimale behandelstrategie is voor artropathie in deze 
specifieke patiëntengroep en of specifieke interventiebehandelingen, zoals 
fysiotherapie, in dit opzicht zinvol zijn.
In Hoofdstuk 4 werden kniegewrichten van 26 acromegalie patiënten 
nader gekarakteriseerd middels 3.0 Tesla MRI scans. Tot op heden zijn 
gewrichtsafwijkingen bij acromegalen alleen gekarakteriseerd middels 
röntgenfoto’s en in het verleden is door één onderzoeksgroep met behulp 
van echografie gekeken naar gewrichtsafwijkingen. MRI verschaft 
additionele informatie ten opzichte van conventionele röntgenfoto’s, 
voornamelijk over kraakbeendefecten, maar ook over andere structurele 
afwijkingen zoals cysten, beenmerglaesies en meniscusschade. In deze 
studie werden structurele gewrichtsafwijkingen onderzocht middels 
de gevalideerde KOSS score voor knie MRI’s. Daarnaast werd de 
kraakbeendikte gemeten en werden T2 relaxatietijden in het kraakbeen 
gemeten, welke informatie verschaffen over de biochemische compositie 
van kraakbeen. Allereerst werden patiënten met actieve en gecureerde 
acromegalie vergeleken en daarnaast werden als controlegroep patiënten 
met primaire knieartrose geïncludeerd van de geMstoan studie. Er 
werd reeds in de actieve fase van acromegalie een hoge prevalentie van 
structurele gewrichtsafwijkingen gezien. Tevens werd gevonden dat 
patienten met actieve acromegalie dikker gewrichtskraakbeen hadden dan 
gecureerde acromegalie patienten en tevens verhoogde T2 relaxatietijden. 
Dit laatste wijst op een veranderde biochemische samenstelling van 
kraakbeen met een toegenomen hoeveelheid water. In vergelijking 
met primaire artrose patiënten hadden acromegalie patiënten minder 
cystes, maar een gelijke prevalentie van kraakbeendefecten, osteofyten 
en beenmerglaesies. De acromegalie-groep had gemiddeld een verdikt  
gewrichtskraakbeen en verhoogde T2 relaxatietijden in de knie. Op basis 
van huidige bevindingen is de hypothese dat in actieve acromegalen het 
verdikte gewrichtskraakbeen bestaat uit twee componenten: een structurele 
component van kraakbeenhypertrofie, welke (partieel) irreversibel is, en 
een oedemateuze component, welke afneemt na succesvolle behandeling. 
Een afname van deze laatste component verklaart mogelijk waarom 
gecureerde acromegalen in vergelijking met controles een verdikt 
gewrichtskraakbeen hebben, maar minder dik dan in de actieve fase 
door een afname van de oedemateuze component. Geconcludeerd werd 
dat de artrosekenmerken verschillen tussen acromegalie patiënten en 
patiënten met primaire artrose. Bovendien suggereren de resultaten van 
deze studie dat naast een dikker gewrichtskraakbeen het kraakbeen van 
acromegalie patiënten een andere biochemische samenstelling heeft dan 
het kraakbeen van primaire artrose patiënten. Geconcludeerd werd dat de 
artrose kenmerken verschillen tussen acromegalie patienten en patienten 
met primaire artrose, voornamelijk op het gebied van gewrichtskraakbeen. 
De relevantie van de verschillen op kraakbeenniveau dient in toekomstige 
studies verder uitgezocht te worden.
In een klein percentage behandelde acromegalie patiënten wordt 
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op röntgenfoto’s in plaats van de voor acromegalie karakteristieke 
gewrichtsspleetverwijding juist een versmalde gewrichtsspleet gezien. 
Het is onbekend of dit een eindstadium is van artropathie bij 
acromegalie of dat dit een proces is dat zich onafhankelijk van de ziekte 
acromegalie ontwikkelt. In Hoofdstuk 5 werden knieën en heupen 
van 89 behandelde acromegalie patiënten radiologisch onderzocht op 
de aanwezigheid van gewrichtsspleetversmalling. Daarnaast werden 
risicofactoren voor gewrichtsspleetversmalling onderzocht en de 
relatie tussen gewrichtsspleetvernauwing en klinische symptomen. 
Gewrichtsspleetversmalling werd gezien in 10.3% van de heupen en 
15.4% van de knieën. Bekende risicofactoren zoals leeftijd en het 
vrouwelijk geslacht waren geassocieerd met gewrichtsspleetversmalling. 
Daarnaast waren er acromegalie-specifieke risicofactoren voor 
gewrichtsspleetversmalling, welke verschilden voor de knie en heup. In 
de heup werd een relatie gevonden met meer actieve ziekte, gereflecteerd 
door hogere GH en IGF-1 spiegels voor de start van behandeling, 
langere GH expositie en minder curatie na operatie en/of radiotherapie. 
In de knie waren voornamelijk eerdere knieoperaties en niet zozeer 
acromegalie-specifieke kenmerken, voorspellend voor het krijgen van 
gewrichtsspleetversmalling. Patiënten met gewrichtsspleetversmalling 
rapporteerden meer gewrichtsklachten. Deze studie laat zien dat 
gewrichtsspleetversmalling weinig voorkomt bij acromegalie patiënten, 
maar desondanks geassocieerd is met een toename van klachten. Daarnaast 
toont deze studie aan dat excessieve GH/IGF-1 activiteit niet alleen een 
rol speelt in de vroege fase, maar dat ook in de late fase van arthropathie, 
gereflecteerd door gewrichtsspleetversmalling, een associatie bestaat met 
ziekteactiviteit. 
Een andere veel voorkomende complicatie van acromegalie is het 
optreden van wervelfracturen. In eerdere studies werd in 60% van de 
acromegalie patiënten, ondanks langdurige biochemische remissie, 
wervelfracturen gevonden, vaak in multipele wervels. In de meeste 
patiënten is de botmassa (BMD) normaal en dit is hiermee een slechte 
predictor voor fracturen in deze specifieke patiëntengroep. Het lijkt erop 
dat in acromegalie het verhoogde fractuurrisico berust op afwijkingen 
in de botkwaliteit en niet zozeer in de botkwantiteit, gezien de normale 
BMD. Op dit moment is onbekend of het bereiken van biochemische 
remissie het risico op (wervel)fracturen normaliseert of dat patiënten in 
langdurige remissie een persisterend verhoogd risico op fracturen hebben. 
In Hoofdstuk 6 werd het natuurlijk beloop van wervelfracturen 
en potentiële determinanten van progressie onderzocht in behandelde 
acromegalie patiënten. Patiënten met bisfosfonaten werden uitgesloten van 
deelname, waarna 49 patiënten geschikt bevonden werden voor inclusie. 
De prevalentie van wervelfracturen was 63% bij de start van de studie en 
was het hoogst in mannelijke acromegalen. Er bestond geen relatie met 
BMD. Gedurende een periode van 2.5 jaar vervolgtijd in biochemische 
remissie progressieve wervelfracturen gezien in 20% van de patiënten. 
Voornamelijk mannen en patiënten met 2 of meer fracturen bij de start 
van de studie toonden progressieve wervelinzakkingen gedurende de 
vervolgperiode. Progressie was niet gerelateerd aan BMD waarden bij 
aanvang van de studie of BMD veranderingen in de tijd. Geconcludeerd 
werd dat bij patiënten met acromegalie wervelfracturen niet alleen tijdens 
de actieve fase van de ziekte ontstaan, maar dat deze patiënten nieuwe 
fracturen ontwikkelen en bestaande fracturen ernstiger worden gedurende 
de periode van remissie. De bevinding dat deze wervelfracturen ontstaan 
ondanks een normale BMD wijst op een probleem in de botkwaliteit. 
Toekomstige studies moeten zich richten op (persisterende) veranderingen 
in de botkwaliteit in deze patiëntengroep met het oog op het identificeren 
van acromegalie patiënten met een verhoogde kans op toekomstige 
fracturen. Tevens dient onderzoek gedaan te worden naar de juiste 
behandelstrategie van fracturen bij deze specifieke patiëntenpopulatie.  
Deel B. De rol van de GH/IGF-1 as in primaire 
artrose
Deel B richt zich op de betrokkenheid van de GH/IGF-1 as bij 
het ontstaan en de progressie van primaire artrose. Artrose is een 
veelvoorkomende verouderingsgerelateerde ziekte, welke wordt 
gekenmerkt door progressieve slijtage van gewrichtskraakbeen en bot 
remodelling. Artrose leidt tot gewrichtspijn, stijfheid en functiebeperking 
van de gewrichten. Ondanks dat de laatste jaren de kennis betreffende het 
ontstaan van artrose is toegenomen, is de exacte pathogenese onbekend. 
Artrose wordt gezien als een ziekte met een multifactoriële etiologie, 
waarin naast genetische predispositie, leeftijd, body mass index (BMI), 
hormonale factoren en lokale biomechanische factoren een rol spelen.
Verschillende onderzoekslijnen suggereren de betrokkenheid 
van de GH/IGF-1 as in de pathogenese van artrose. Ten eerste is 
aangetoond dat IGF-1 in normaal kraakbeen zorgt voor stimulatie 
van de chondrocytproliferatie en proteoglycaan- en collageensynthese 
van chondrocyten, ook tijdens expositie aan cytokinen. Deze anabole 
en beschermende kenmerken van IGF-1 wijzen op een mogelijke 
betrokkenheid bij kraakbeenherstel. Ten tweede is bij acromegalie 
patiënten een duidelijke relatie gevonden tussen de GH/IGF-1 activiteit 
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en het risico op het ontwikkelen van arthropathie. De prevalentie en de 
ernst van de radiologische artrose nemen toe bij een langere duur van 
onbehandelde acromegalie en hogere IGF-1 spiegels bij de diagnose. 
Ten slotte werd eerder aangetoond dat genen die de aanmaak, afbraak en 
herstel van gewrichtskraakbeen en de remodelling van het subchondrale 
bot reguleren betrokken zijn in de pathogenese van artrose. Hierbij wordt 
in het bijzonder het proces van endochondrale ossificatie genoemd (zie 
onder). 
In Hoofdstuk 7 zijn de resultaten van studies naar de associatie tussen 
serum IGF-1 spiegels en polymorfismen in het IGF-1 gen en primaire 
artrose samengevat in een systematisch literatuuroverzicht. In totaal 
werden elf studies geschikt bevonden voor inclusie. Aan de hand van een 
gestandaardiseerde set met kwaliteitscriteria werd de methodologische 
kwaliteit van elke individuele studie beoordeeld. Samenvattend 
impliceren in vitro studies, genetische associatiestudies en het hoge 
risico op secundaire artrose in acromegalie allen een relatie tussen het 
GH/IGF-1 systeem en het ontstaan van artrose. Hoewel in de grootste 
cross-sectionele studie en de enige prospectieve studie een associatie werd 
gezien tussen hoge IGF-1 spiegels en artrose, werd in het systematische 
literatuuroverzicht geen overtuigend bewijs gevonden voor een associatie 
tussen IGF-1en het ontwikkelen van radiologische artrose. Echter, omdat 
een invloed van kleine patiëntenaantallen, methodologische beperkingen 
en publicatie bias op de resultaten niet uitgesloten kan worden en 
slechts in enkele studies is gecorrigeerd voor leeftijd, geslacht en BMI 
in de interpretatie van de IGF-1 spiegels, is verder onderzoek in grote 
prospectieve studies noodzakelijk is om hier een uitspraak over te doen. 
Gezien de inconsistente resultaten van het kleine aantal beschikbare 
epidemiologische studies naar de relatie tussen serum IGF-1 en primaire 
artrose, zoals beschreven in Hoofdstuk 7, werd in Hoofdstuk 8 de relatie 
tussen serum IGF-1 en het ontstaan en progressie van primaire artrose 
onderzocht in een groot cohort van patiënten met een ernstige familiaire 
vorm van artrose. Deze patiënten zijn afkomstig van de GARP (Genetics 
osteoARthritis and Progression) Studie, een prospectieve follow-up studie 
onder 384 patiënten uitgevoerd in het LUMC. Gemiddeld genomen werd 
een significant verhoogde IGF-1 SD score gezien in GARP patiënten ten 
opzichte van beschikbare referentiewaarden. Er werd echter geen dosis-
respons relatie gevonden met de kans op het ontstaan of de progressie van 
radiologische artrose. In dit opzicht is het van belang om op te merken 
dat alle GARP patiënten een ernstig fenotype van symptomatische 
artrose hebben in meerdere gewrichten met een familiaire component, 
wat het lastig maakt een dosis-respons relatie te detecteren met ernst van 
artrose. Daarnaast is de meting van serum IGF-1 erg complex gezien 
de gevoeligheid van IGF-1 voor temporaire variaties en de substantiële 
invloed van leeftijd, oestrogenen en BMI. Geconcludeerd werd dat een 
hoog serum IGF-1 geassocieerd is met het ontstaan van artrose, maar niet 
met de radiologische progressie van artrose.
Genetische factoren spelen een grote rol in de pathogenese van primaire 
artrose. Inmiddels zijn in genetische studies associaties gevonden met 
verschillende polymorfismen in genen die allen betrokken lijken te zijn 
bij de endochondrale ossificatie, dat het belangrijkste proces is in de 
lengtegroei van het skelet. Chrondrocyten in de groeischijf spelen de 
hoofdrol in dit proces, die door een combinatie van proliferatie, secretie 
van extracellulaire matrix componenten en hypertrofie resulteren in 
lengtegroei van het bot. Het kraakbeenmodel wordt uiteindelijk vervangen 
door bot. Het gedrag van de chondrocyten wordt in elk van de genoemde 
fases gereguleerd door een complex netwerk van circulerende hormonen, 
lokale groeifactoren en extracellulaire matrixcomponenten. Eén van de 
sterkste stimulatoren van de chondrocytproliferatie is GH, voornamelijk 
via secretie van IGF-1. Dit maakt de betrokkenheid van de GH/IGF-1 
as in het ontstaan van artrose aannemelijk en kwalificeert polymorfismen 
in GH/IGF-1 genen als potentiële kandidaten voor genetische 
associatiestudies. 
De effecten van GH op doelweefsels worden gemedieerd door de GHR. 
In 2004 werd voor het eerst door Dos Santos e.a. een veelvoorkomend 
polymorfisme van de GHR (30-35% van de populatie) beschreven. 
De deletie van exon 3 (d3-GHR) resulteert in een verkorte GHR en is 
geassocieerd met een verhoogde responsiviteit van de GHR voor GH 
vanwege een toegenomen signaaltransductie. Binnen patiëntengroepen 
met verschillende klinische aandoeningen, zoals vertraagde lengtegroei 
bij kinderen en in acromegalen, zijn de functionele effecten van het d3-
GHR polymorfisme reeds aangetoond. Zo werd in acromegalie patiënten 
een relatie gevonden tussen het d3-GHR polymorfisme en het vaker en 
ernstiger voorkomen van radiologische artrose. De associatie tussen het 
d3-GHR polymorfisme en primaire artrose is nooit eerder onderzocht. 
In Hoofdstuk 9 werd de associatie van het d3-GHR polymorfisme 
bekeken in patiënten met (symptomatische) primaire artrose in 
vergelijking met controlepersonen zonder artrose. De GARP 
studie, waarin patiënten met familiaire primaire artrose in meerdere 
gewrichten zijn geïncludeerd, was gekozen als uitgangsstudie, omdat 
deze studie informatie verschaft over meerdere gewrichtslokalisaties 
in genetisch verrijkte artrose patiënten. Alle GARP patiënten werden 
gegenotypeerd voor 7 Single Nucleotide Polymorphisms (SNPs) rondom 
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het d3-GHR polymorfisme (rs4590183, rs13354167, rs7721081, 
rs7701605, rs4242116, rs6878512, rs10941583), die vanwege een 
hoog linkage disequilibrium als marker konden dienen voor het d3-
GHR polymorfisme. Deze methode is voor grote cohorten efficiënter 
dan de arbeidsintensieve conventionele polymerase chain reaction 
(PCR) techniek. De SNP rs4590183 werd geselecteerd als marker voor 
het d3-GHR polymorfisme. In de GARP studie werd een associatie 
gevonden tussen het d3-GHR polymorfisme en artrose in vrouwen, 
echter niet in mannen. Ter replicatie werd de bovengenoemde SNP in 
3 additionele patiëntencohorten bepaald, te weten de PAPRIKA/RAAK 
studie, Rotterdam studie en de ACRO studie, waarin allen patiënten zijn 
geïncludeerd met symptomatische artrose. De hierboven genoemde studies 
werden samen met de GARP studie in een meta-analyse geanalyseerd. 
Alleen vrouwen werden in de analyse meegenomen, gezien het effect 
van het d3-GHR polymorfisme in de GARP studie alleen in vrouwen 
werd gevonden. In totaal werden 2175 OA patiënten en 2623 controles 
geanalyseerd. In de meta-analyse werd de associatie tussen het d3-GHR 
polymorfisme en artrose bevestigd (OR=1.17 (1.04-1.32), ook na exclusie 
van de GARP studie. De sterkste relatie werd gevonden met heupartrose 
(OR=1.34 (1.11-1.62). De resultaten van deze studie verschaffen 
additioneel bewijs voor de betrokkenheid van de GH/IGF-1 as bij het 
ontstaan van artrose. Er werd geconcludeerd dat overactiviteit van de GH/
IGF-1 as het artroseproces versnelt in patiënten die hiervoor gevoelig zijn 
en daarmee het risico op artrose verhoogt. Toekomstige studies moeten 
uitwijzen of een toegenomen activiteit van de GH/IGF-1 as therapeutische 
consequenties heeft. 
Deel C. Lange termijn effecten van recombinant 
humaan GH (rhGH) therapie bij volwassenen met GH 
def iciëntie (GHD)
Deel C beschrijft de lange termijn effecten van rhGH therapie bij 
volwassen patiënten met GHD. GHD bij volwassen patiënten is 
geassocieerd met een ongunstig metabool profiel en wordt gekenmerkt 
door abdominale obesitas, dislipidemie en een verhoogde mortaliteit. 
Daarnaast is GHD geassocieerd met een afgenomen botmassa en een 
verhoogd fractuurrisico. In eerdere studies is aangetoond dat rhGH 
therapie op korte termijn een verbetering van de lichaamssamenstelling en 
het vetmetabolisme geeft, met een afname van lichaamsvet, een toename 
van de vetvrije lichaamsmassa en een verlaging van zowel het totaal 
cholesterol als het LDL-cholesterol. Daarnaast leidt rhGH therapie tot 
een toename van de botdichtheid. Tevens werd in enkele studies daarnaast 
een gunstig effect beschreven op de kwaliteit van leven. Gebaseerd op 
deze positieve korte termijn resultaten, is rhGH suppletie sinds 1994 
in Nederland geregistreerd als behandeling voor GHD bij volwassenen. 
Eerdere studies toonden aan dat de positieve effecten van rhGH therapie 
op metabool gebied, maar ook op de botmassa, blijven bestaan gedurende 
de eerste 5 jaren van rhGH suppletie. Gegevens over de effecten van rhGH 
therapie op langere termijn zijn echter schaars.  
In Hoofdstuk 10 zijn in een systematisch literatuuroverzicht de 
effecten van chronische rhGH suppletie, gedefinieerd als ten minste 5 
jaar, bij volwassen patiënten met GHD op een rij gezet. In dit overzicht 
werden 21 studies opgenomen die de effecten van rhGH suppletie op 
biochemische en antropometrische parameters, kwaliteit van leven, 
botmetabolisme, spierkracht, serious adverse events (SAEs) en mortaliteit 
hebben onderzocht. De studies opgenomen in het literatuuroverzicht 
suggereerden dat rhGH behandeling ook op de lange termijn leidt 
gunstige effecten heeft op de lichaamssamenstelling, het lipidenprofiel 
en de intima-mediadikte van de carotiden. Echter, de prevalentie van 
het metabool syndroom, glucose spiegels en BMI werden niet of zelfs 
negatief beïnvloed door langdurig rhGH gebruik. Hierbij moet worden 
opgemerkt dat in de meeste studies nauwkeurige data over het gebruik 
van vetverlagende middelen en antidiabetica ontbraken. Wat betreft 
spiermassa werden slechts in de eerste 5 jaar van rhGH therapie gunstige 
effecten waargenomen. Daarnaast werd in een selecte groep patiënten 
een verbetering van de kwaliteit van leven gevonden. Mortaliteit was in 
verschillende studies licht verhoogd gedurende rhGH suppletie, echter 
dit kon, mogelijk gezien de heterogeniteit van studies, in andere studies 
niet bevestigd worden. Geconcludeerd werd dat de beschikbare literatuur 
over de lange termijn effecten van rhGH therapie bij volwassenen met 
GHD inconsistente resultaten laat zien met betrekking tot de verwachte 
gunstige effecten, in de aanwezigheid van verschillende beperkingen, welke 
hierna worden genoemd. Allereerst waren de meeste lange termijn studies 
ongecontroleerd voor het effect van veroudering. Ten tweede hadden 
slechts een beperkt aantal centra hun resultaten gepubliceerd, waardoor 
de helft van de geïncludeerde studies (deels) hetzelfde patiëntencohort 
beschreef. Op basis van de resultaten van dit literatuuroverzicht kan 
geconcludeerd worden dat nader onderzoek naar het effect en de veiligheid 
van langdurige rhGH therapie bij volwassenen met GHD geïndiceerd 
is. Daarnaast is het in de klinische praktijk van belang de indicatie voor 
langdurige rhGH suppletie bij elke patiënt zorgvuldig afgewogen dient te 
worden. 
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Gezien het ontbreken van voldoende studies naar de effecten van 10 
jaar rhGH suppletie of langer bij volwassenen met GHD, waarbij de 
beschikbare studies veelal kleine patiëntengroepen beschreven, zijn in 
Hoofdstuk 12 de metabole effecten van 10 jaar rhGH behandeling 
onderzocht in ons eigen GHD cohort. In 98 volwassen GHD patiënten 
werd gekeken naar het effect van rhGH therapie op biochemische en 
antropometrische parameters, de prevalentie van metabool syndroom 
en de incidentie van ernstige cardiovasculaire gebeurtenissen. In een 
subgroep van 49 patiënten werden de 15-jaars effecten van rhGH 
therapie beschreven. IGF-1 spiegels werden in alle GHD patiënten strikt 
gecontroleerd om fysiologische rhGH suppletie te bewaken. De gunstige 
effecten op het lipidenprofiel werden na 10 jaar rhGH therapie nog 
steeds gezien, met  een significante verlaging van het totale cholesterol en 
LDL-cholesterol en een toename van het HDL-cholesterol in vergelijking 
met de onbehandelde situatie. De gemiddelde middelomtrek, BMI en 
nuchtere glucose spiegels, daarentegen, namen significant toe gedurende 
rhGH therapie. In de groep patiënten met ten minste 15 jaar rhGH 
therapie werden dezelfde effecten gevonden. Ondanks verbetering van 
enkele cardiovasculaire parameters, nam de prevalentie van het metabool 
syndroom, als maat voor het algehele cardiovasculaire risico, significant 
toe gedurende rhGH therapie, van 32.7% bij de start van rhGH 
therapie tot 57.1% na 10 jaar behandeling. Dit was het meest evident 
in mannen. De incidentie van ernstige cardiovasculaire gebeurtenissen 
was laag (1.5/1000 patiënten jaren). Geconcludeerd werd dat gezien het 
feit dat op dit moment verbetering van het cardiovasculaire risico en 
verbetering van de kwaliteit van leven de belangrijkste doelen zijn van 
rhGH therapie bij volwassenen, grotere gecontroleerde studies essentieel 
zijn om de netto cardiovasculaire winst van langdurige rhGH suppletie 
vast te stellen. Daarnaast dienen ook de kosten van langdurige rhGH 
therapie meegenomen te worden. In dit opzicht is een vergelijking met 
statines, die bewezen effectief zijn gebleken in secundaire cardiovasculaire 
risicopreventie, zinvol. 
Een beperking van de studie beschreven in Hoofdstuk 11 is het 
ontbreken van een niet-behandelde controlegroep. Gezien de vastgestelde 
gunstige effecten van rhGH therapie op korte termijn, worden alle 
patiënten met vastgestelde GHD zonder contra-indicaties met rhGH 
gesuppleerd. Dit maakt het onmogelijk een langdurige vervolgstudie 
op te zetten met een gerandomiseerde gecontroleerde opzet, waarin 
patiënten met GHD zonder rhGH therapie geïncludeerd zijn. Recent 
is in het LUMC een grote populatiestudie uitgevoerd met de focus op 
de pathofysiologie van obesitas (NEO, Nederlandse Epidemiologie 
van Obesitas Studie). Hiermee zijn grootschalige recente controledata 
beschikbaar gekomen van zowel controlepersonen met een normaal 
gewicht als controlepersonen met obesitas, welke als alternatief, bij gebrek 
aan een niet-geselecteerde controlegroep van GHD patiënten zonder 
rhGH therapie, gebruikt kan worden. 
In Hoofdstuk 12 werden de metabole effecten van chronische rhGH 
therapie (gedefinieerd als 5 jaar),  beschreven in 161 GHD patiënten 
van middelbare leeftijd. Deze data werden vergeleken met gezonde 
controlepersonen met een normaal gewicht van het Leiderdorp cohort 
van de NEO studie. GHD patiënten hadden, ondanks chronische rhGH 
therapie, een 1.3 keer verhoogde prevalentie van metabool syndroom dan 
controles, onafhankelijk van leeftijd, geslacht en BMI (53.4% vs 30.3%). 
Daarnaast werd in behandelde GHD patiënten een ander metabool profiel 
gezien dan bij controlepersonen met een gelijk BMI, gekenmerkt door een 
verhoogd prevalentie van hypertriglyceridaemie en laag HDL-cholesterol, 
maar minder vaak hyperglycaemie. Het is opvallend dat ondanks dat 
het beschreven GHD cohort verondersteld wordt adequaat gesuppleerd 
te zijn, het metabool profiel na chronische rhGH therapie lijkt op het 
profiel van een patiënt met onbehandelde GHD, met in het bijzonder 
afwijkingen in het lipidenprofiel. Deze bevindingen plaatsen vraagtekens 
bij de eerder gepropageerde gunstige effecten van rhGH therapie op 
metabool gebied. Het is van belang dat in de context van, aan de ene 
kant, het toenemende bewijs voor een (negatieve) rol van GH en IGF-1 
in kanker, veroudering en cardiovasculaire ziekten, en, aan de andere kant, 
het beperkte bewijs voor een gunstig effect van rhGH substitutie in de 
oudere GHD populatie, een kritische re-evaluatie van de indicatie voor 
langdurige rhGH suppletie bij GHD volwassenen noodzakelijk is. 
In Hoofdstuk 13 werden de effecten van chronische rhGH therapie 
(≥5 jaar) op de botmassa en botmetabolisme onderzocht in 230 volwassen 
patiënten met GHD. Patiënten werden nauwkeurig gemonitord 
gedurende de rhGH therapie en overige hormonale deficiënties werden 
adequaat gesuppleerd. Er werd een persisterende toename van de 
BMD in de lumbale wervelkolom gezien, echter niet op het niveau van 
femurnek, gedurende 15 jaar rhGH suppletie. Lumbale wervelkolom 
BMC en T-scores namen gedurende de eerste 10 jaar rhGH behandeling 
toe en stabiliseerden hierna. De grootste stijging in BMD en BMC in 
de lumbale wervelkolom werd gezien in mannen, zoals reeds in eerdere 
studies is beschreven. In patiënten die naast rhGH suppletie bisfosfonaten 
gebruikten werd geen additioneel effect van bisfosfonaten op de BMD 
gevonden. Een lagere BMD op baseline, bisfosfonaatgebruik en een hogere 
GH dosis op 1 jaar waren van invloed op de botrespons tijdens langdurige 
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rhGH suppletie. De incidentie van klinische fracturen van gedurende 
langdurige rhGH suppletie was 20.1 / 1000 persoonsjaren en leek laag 
in dit cohort GHD patiënten. Geconcludeerd werd dat in volwassen 
GHD patiënten rhGH suppletie een persisterend gunstig effect heeft op 
de botmassa, voornamelijk in mannen, en dat de incidentie van klinische 
fracturen laag is. Het verschil in de botrespons op rhGH suppletie tussen 
mannen en vrouwen is een onderwerp voor nader onderzoek. Tevens 
dient er in toekomstige studies aandacht te zijn voor het fractuurrisico 
gedurende langdurige rhGH suppletie in een gecontroleerde setting en de 
rol van additionele behandeling met bisfosfonaten hierin. 
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APPENDICES
APPENDIX 1: Comment in Nature Reviews 
Endocrinology 2012; 8: 447 (Research Highlight) 
on ‘Progression of acromegalic arthropathy 
despite long-term biochemical control: a 
prospective, radiological study (European Journal of 
Endocrinology 2012; 167(2): 235-244)’
pituitary function
Arthropathy in acromegaly
Long-term biochemical control of acromegaly does not prevent 
progression of acromegalic arthropathy in many patients, report 
researchers from The Netherlands. 
Arthropathy is a complication of acromegaly that impairs quality of life 
both physically and psychologically. Cross-sectional studies had previously 
shown a high prevalence of arthropathy in patients with long-term 
biochemical control of acromegaly.
“However, the disease course of acromegalic arthropathy during 
prolonged follow-up is unknown in treated patients,” explains lead author 
Kim Claessen of Leiden University Medical Center. “Therefore, the aim of 
the present study was to assess the course of acromegalic arthropathy in a 
cohort of long-term control patients and to identify potential risk factors 
for progression over 2.6 years of prospective follow-up.” 
The researchers studied 58 patients with acromegaly who had been 
in biochemical remission of the disease for a mean duration of 15 years. 
The investigators obtained radiographs of the knees, hips and hands 
of the patients at two study visits a mean interval of 2.6 years apart. 
Radiographic progression of arthropathy from baseline to follow-up was 
defined as a ≥1 point increase in the score for osteophytes or joint space 
narrowing according to the Osteoarthritis Research Society International 
atlas. 
Radiographic progression of osteophytes and joint space narrowing 
at any joint site was observed in 42 (72%) and 43 (74%) patients, 
respectively. Surprisingly, patients whose disease was biochemically 
controlled by somatostatin analogues had a higher risk of osteophyte 
progression than patients cured by surgery or additional radiotherapy.
The findings might indicate insufficient control of growth hormone 
in patients treated with somatostatin analogues, the researchers suggest. 
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“Further studies, preferably randomized controlled trials, with longer 
follow-up duration are required to explore whether more aggressive 
treatment is beneficial for the outcome of acromegalic arthropathy,” 
concludes Claessen. 
Carol Wilson 
Original article Claessen, K. M. et al. Progression of acromegalic arthropathy despite long-
term biochemical control: a prospective, radiological study. Eur. J. Endocrinol. doi:10.1530/
EJE-12-0147
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APPENDIX 2: Comment in Reuters Health (2013, 
Nov 30th) on ‘Metabolic prof ile in growth hormone 
def icient (GHD) adults after long-term recombinant 
human growth hormone (rhGH) therapy ( Journal of 
Clinical Endocrinology and Metabolism 2013;98(1): 
352-361)’
Long-term growth hormone treatment ups risk of 
metabolic syndrome 
Nov 30, 2012  | Reuters Health News 
By Anne Harding
NEW YORK (Reuters Health) – Adults with growth hormone deficiency 
(GHD) who take recombinant human growth hormone (rhGH) for 10 
years or more are at increased risk of metabolic syndrome, a new study in 
98 patients shows. 
Given that improving cardiovascular risk is one of the major targets 
of rhGH therapy for adults with GHD, “the effects of long-term rhGH 
therapy on overall cardiovascular profile needs to be established in a larger 
GHD cohort and should also be compared to healthy controls to control 
for the effect of aging,” Dr. Kim M. J. A. Claessen of Leiden University 
Medical Center in The Netherlands, one of the study’s authors, told 
Reuters Health.
In the short term, the researchers note, rhGH therapy improves several 
cardiovascular risk factors, such as low-density lipoprotein (LDL) levels 
and body fat. However, they add, there is some evidence that rhGH 
therapy could actually increase cardiovascular risk. 
To better understand the cardiovascular effects of long-term rhGH 
therapy in adults with GHD, the researchers looked at several efficacy 
parameters in patients who had been treated at their center for 10 years or 
longer. They recorded patients’ data at baseline and after five, 10 and 15 
years of therapy with rhGH, and reported the findings online November 
15 in the Journal of Clinical Endocrinology and Metabolism.
The mean age of patients in the study was nearly 60 years. Total 
cholesterol and LDL cholesterol were significantly lower than at baseline, 
while high-density lipoprotein levels were higher, the researchers found. 
However, at 10 years, waist circumference, body mass index, and fasting 
plasma glucose levels were all higher than at baseline. 
And the prevalence of metabolic syndrome nearly doubled, showing 
a greater increase than would have been expected based on aging alone. 
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“This was mainly due to a gradual increase in abdominal obesity, 
hypertriglyceridemia, and hyperglycemia,” the researchers wrote.
At baseline, 32.7% of patients had metabolic syndrome, while after 10 
years on rhGH, 57.1% did. While men and women were equally likely to 
have the metabolic syndrome at baseline, the prevalence at 10 years was 
44.9% in women and 69.4% in men. 
“Since the profile of GHD patients changes over time, critical re-
evaluation of the net benefit of long-term rhGH therapy is of paramount 
importance,” Dr. Claessen said via email. “Therefore, at present, the 
indication for long-term rhGH therapy should be established in every 
individual patient, and critically be re-evaluated during long term 
treatment.”
It is also important to look at the cost-benefit ratio of rhGH therapy 
compared to other widely available medications, such as statins, that 
have proven effectiveness in secondary cardiovascular risk prevention, the 
researcher added. 
SOURCE: Journal of Clinical Endocrinology and Metabolism, online November 15, 2012.
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APPENDIX 3: Comment in: Lancet Diabetes 
& Endocrinology 2013 (Research in Brief ) on 
‘Progression of vertebral fractures despite long-term 
biochemical control of acromegaly: a prospective 
follow-up study ( Journal of Clinical Endocrinology 
and Metabolism 2013, in press)’
Progressive vertebral fractues in acromegaly 
Written by Iley Ozerlat-Gunduz
In a prospective study including 49 patients with mean age of 61.3±11.1 
years having controlled acromegaly for a mean of 17 years the natural 
course of vertebral fractures was assessed over a follow-up of 2.5 years. 
Remission of acromegaly was achieved by surgery, radiotherapy and/
or medical therapy and patients did not use bisphosphonates. In these 
patients, baseline prevalence of vertebral fractures was 63%, and at 
the end of the follow up period, progressive fractures were found in 
20% of patients despite adequate biochemical remission of acromegaly. 
Progression rate was highest in patients with 2 or more fractures at 
baseline and in men, but was independent of bone mineral density. 
The data of the present study suggest that despite long-term 
biochemical remission acromegaly patients are at risk for progressive 
vertebral fractures, indicating persisting abnormalities in bone quality 
in these patients, possibly related to pretreatment long-term exposure 
to high circulating levels of GH. Further research has to elucidate the 
pathophysiological basis of the changes in bone quality leading to the high 
vertebral fracture risk and whether acromegaly patients require treatment 
for these fractures.
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